ORLANDO, FL, USA GAYLORD PALMS RESORT JANUARY 12-16, 2013 AND CONVENTION CENTER
Short Courses: January 12-13 Conference: January 14-16 Exhibition: January 13-15 Scan the code with your smartphone to go directly to SLAS2013.org.
Premier Sponsor:
Final Program & Podium Abstracts SLAS2013 is Tablet Friendly SLAS2013.org is optimized for the convenience of mobile devices. Access everything you need when you want, from wherever you are for a fantastic conference experience!
Plan to Find What You’re Looking for in San Diego Questions are the foundation of science and SLAS2014 will be the foundation for laboratory science and technology answers. From compelling and applicable world-class scientific programming to a comprehensive and energizing exhibition, you will find what you need to further your scientific goals. So, plan now to join your fellow scientists, engineers, researchers, technologists and others from academic, government and commercial laboratories at SLAS2014 in San Diego. 5,000 of your colleagues from around the globe will be there, along with the relevant answers you need.
Keynote Presenters Eric J. Topol, M.D.
Jad Abumrad
Director, Scripps Translational Science Institute Chief Academic Officer, Scripps Health Professor of Genomics, The Scripps Research Institute
Co-host and Creator, Radiolab
Robert Krulwich Co-host, Radiolab
SLAS2014 Program Committee Chairs:
Short Courses: January 18-19
Michele Cleary, Ph.D. Merck & Co.
Conference: January 20-22
David T. Eddington, Ph.D. University of Illinois at Chicago
SLAS2014.org
Exhibition: January 19-21
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
SLAS2013 Table of Contents SLAS2013 Annual Conference Program Committee, SLAS Scientific Program Advisory Committee, SLAS Board of Directors
page 4
Welcome to SLAS2013
page 5
SLAS Member Center
page 8
Celebrate Excellence
page 9
page 10
General Information
page 12
Tony B. Academic Travel Award Winners
page 14
SLAS2013@Night
page 15
Conference Floor Plan
page 16
Keynote Speaker Series
page 18
Conference-at-a-Glance
page 20
Short Course Program
page 22
Conference Schedule
page 27
Strategic Alliances
page 38
Destination Drug Discovery (Satellite Symposium)
page 38
Special Interest Groups (SIGs)
page 40
SLAS Corporate Members
page 44
Poster Program
page 47
Podium Abstracts
page 65
Exhibitor Workshops and Tutorials
page 134
New Product Launches
page 148
Innovation AveNEW
page 149
Exhibitor List
page 150
Exhibit Hall Floor Plan
page 154
Exhibitor Descriptions
page 156
Exhibitor Product Categories and Booth Numbers
page 229
Advertisers
page 241
Sponsors and Media Partners
page 242
Speaker Index
page 244
SLAS Career Connections
SLAS2013 is Tablet Friendly SLAS2013.org is optimized for the convenience of mobile devices. Access everything you need when you want, from wherever you are for a fantastic conference experience!
SLAS2013.org
I
1
Visit us at booth 834!
What — You Don’t ™ Dip and Read ?!
Do less and get more from your ELISAs • Quantitate 96 protein samples in 15 minutes, not hours • Take advantage of a 4-log dynamic range and dilute less • Run automated assays without wash steps or overnight incubations • Analyze crude samples with less prep • Get information-rich direct binding data, not end-point results • Develop new assays in a few hours, not weeks
The Octet® Platform
Octet Systems with Dip and Read assays. No hassle, label-free ELISAs.
www.fortebio.com
Fast. Accurate. EASY.
Visit us at booth 834!
Little Genius
BLItz brilliantly packs the power of Dip and Read™ label-free analysis into a personal assay system. Give BLItz a drop of your sample and it does the rest! • Protein presence/absence in seconds • Binding kinetics assays at your bench • Protein quantitation in seconds • Develop immunoassays in minutes • Easily analyze crude samples Cleverly priced so you can have your own little genius. Want to try BLItz in your lab? Visit BlitzMeNow.com or call 855.BLITZ.ME.
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
SLAS2013 Annual Conference Program Committee, SLAS Scientific Program Advisory Committee, SLAS Board of Directors SLAS2013 Annual Conference Program Committee Chairs Jonathan O’Connell, Ph.D.
Aaron Wheeler, Ph.D.
Bristol-Myers Squibb Company Wallingford, Connecticut
University of Toronto Toronto, Ontario Canada
Drug Target Biology Track
Assay Development and Screening Track
Haian Fu, Ph.D., Chair Emory University
Andrew Napper, Ph.D., Chair Nemours Center for Childhood Cancer Research
Douglas Auld, Ph.D., Associate Chair Novartis Institutes for Biomedical Research
Paul Johnston, Ph.D., Associate Chair Pittsburgh University
High-Throughput Technologies Track
Bioanalytical Techniques Track
Paul Taylor, M.S., Chair Boehringer-Ingelheim
Thomas Perroud, Ph.D., Chair Tecan Group
Peter Hodder, Ph.D., Associate Chair The Scripps Research Institute
Sam Forry, Ph.D., Associate Chair National Institute of Standards and Technology
Informatics Track James M. Gill II, Ph.D., Chair Bristol-Myers Squibb Company
Diagnostics Track
Scott Weiss, Ph.D., Associate Chair IDBS
John Robinson, Ph.D., Chair Abbott Laboratories David Ostrow, Ph.D., Associate Chair Force Diagnostics
SLAS Scientific Program Advisory Committee William Janzen, Ph.D., Chair University of North Carolina Michele Cleary, Ph.D. Merck & Co. David Eddington, Ph.D. University of Illinois at Chicago Frank Fan, Ph.D. Promega Corporation Jonathan O’Connell, Ph.D. Bristol-Myers Squibb Company Daniel G. Sipes, M.S. Genomics Institute of the Novartis Research Foundation Aaron Wheeler, Ph.D. University of Toronto
Micro/Nano Technologies Track Elliot Hui, Ph.D., Chair University of California, Irvine Dino DiCarlo, Ph.D., Associate Chair University of California, Los Angeles
SLAS Board of Directors
Frank Fan, Ph.D. Promega Corporation
Robyn Rourick, M.S. Genentech, Inc.
Dave Dorsett Bristol-Myers Squibb Company
Dean Ho, Ph.D.* University of California, Los Angeles; Peking University
Daniel G. Sipes, M.S. Genomics Institute of the Novartis Research Foundation
Richard Ellson, M.S.* Labcyte Inc.
Jeff Paslay, Ph.D. Paslay Consulting Group
Mary Jo Wildey, Ph.D. Merck Research Labs
Joshua Bittker, Ph.D.* The Broad Institute of MIT and Harvard
4
* Newly elected board members.
I
SLAS2013.org
Short Short Courses: Courses: January January 12-13 12-13
I
Conference: Conference: January January 14-16 14-16
I
Exhibition: Exhibition: January January 13-15 13-15
Welcome to SLAS2013 Welcome to Orlando and SLAS2013! Congratulations and thank you for joining us this week. By way of your participation, you are among an esteemed collection of scientists, engineers, researchers and technologists from academic, government and corporate laboratories around the world. On behalf of the Society for Laboratory Automation and Screening, we hope you enjoy our Second Annual Conference and Exhibition, themed “Repeatable Inspiration Through Scientific Education, Laboratory Technology and Intelligent Network Building.” Conference highlights include: Scientific Program Expanded for 2013 We have a tremendous core program on tap for you, all chosen by practicing scientific professionals, for scientific professionals. With over 130 peer-reviewed podium presentations, 300+ poster presentations, 20 master short courses and a Nobel Prize-winning keynote speaker, your SLAS2013 experience is bound to be memorable and impactful. Among other improvements this year, the Program Committee is proud to deliver an expanded Informatics Track featuring 24 renowned scientists addressing such topics as: Extracting Meaning From Complex Data Laboratory Informatics Success Stories Collaborative Discovery in the Internet Age Informatics in Highly Integrated Systems Integrating Laboratory Information Into a Global Discovery Solution • High Performance Computing for Laboratory Data Analysis • • • • •
SIGs Help You Make the Connection – Pages 40-43 Meet face-to-face with others in your area of interest and expertise. Special Interest Groups (SIGs) offer you a unique, in-person experience that helps all of us discover new ways to leverage laboratory science and technology in an effort to advance scientific exploration. New this year, we are proud to debut the Phenotypic Drug Discovery SIG. In addition, the Automation Quality Control (AQC) SIG is focused on a discussion of automation lifecycle management, and led by Craig Schulz, Principal Scientist at Amgen. Both of these SIGs take place Wednesday beginning at 8 am. Visit the Exhibition to Complement Your Conference Experience – Page 133 See, hear, touch, feel and engage with the most innovative laboratory technologies and services from around the world when you explore the SLAS2013 Exhibition. Located in the Florida Exhibition Hall and open additional hours this year, the exhibition features the latest technologies, products and services from nearly 300 multinational companies. Beyond the exhibit booths, you can gain valuable insights and experience by attending information-rich exhibitor tutorials and workshops that begin Monday afternoon.
The Power Formula for LinkedIn Success – Page 10 New this year, Wayne Breitbarth helps professionals successfully market themselves through LinkedIn. Breitbarth, author of The Power Formula for LinkedIn Success: Kick-Start Your Business, Brand and Job Search, presents two workshops and will also grant a limited number of personal counseling sessions. For information on these and other career development opportunities taking place over the conference, visit the SLAS Member Center in the Florida Exhibition Hall. The Art and Science of Networking: SLAS2013@Night – Page 15 SLAS2013 presents opportunities day and night for intelligent network building. After the intense rush of scientific sessions and exploring the exhibition, step-out and into SLAS2013@Night to relax, engage and continue the conversation with your colleagues. This year’s highlights include: • Open CityWalk Sunday!
– Sunday, January 13, Universal Studios CityWalk • Molecular Monday!
– Monday, January 14, Osceola Ballroom AB, Gaylord Palms Resort • Vortex Tuesday! – Tuesday, January 15, House of Blues Note: There is complimentary and continuous shuttle service (every 15 minutes) from the Gaylord Resort to CityWalk on Sunday and the House of Blues on Tuesday. SLAS and Social Responsibility From conservation to charitable efforts, social responsibility is a high priority for SLAS. In both our own practices and what we require of our partners, SLAS exercises diligent care to ensure minimal wastefulness and a strong appreciation for both local and global resources. Please know that a host of healthy, sustainable and socially-conscious practices are in place for SLAS2013. If you have any additional suggestions for how those can be improved in the future, please let a member of the SLAS Professional Team know.
Enjoy your conference! SLAS2013.org
I
5
The Official Journals of the Society for Laboratory Automation and Screening Call for Papers
Both JBS and JALA accept previously unpublished manuscript submissions on an ongoing basis from SLAS members and nonmembers. Complete details, including instructions for authors and links to online submission systems are available at slas.org/publications/journals.cfm. Editor: Robert M. Campbell, Ph.D. Eli Lilly and Company 2011 Impact Factor: 2.049 The Journal of Biomolecular Screening (JBS) seeks scientific and technical applications and advances in quantitative biomolecular sciences. Regular topics include target identification/validation; high-throughput screening; lead generation/ optimization; virtual screening and chemoinformatics; diagnostic assays; assay development; assay technologies (novel applications and comparisons); data/ image analysis, statistics and information technologies/methods; high content screening and imaging platforms; sample management; biological reagent production, characterization and management for drug discovery; genomic, proteomic screening; biomarkers, high-throughput approaches to PK, ADME and predictive toxicology.
Editor: Dean Ho, Ph.D. University of California Los Angeles 2011 Impact Factor: 1.420 The Journal of Laboratory Automation (JALA) accepts method-focused manuscripts covering a wide range of technologies, which include but are not limited to sample processing (liquid handling, sample storage, sample analysis and system integration); microfluidics (design, applications and integration); informatics (LIMS, data acquisition and management, electronic laboratory notebooks and integration). JALA does not limit the industries or research areas in which these technologies might be used to increase productivity, elevate data quality, reduce lab process cycle times or enable experimentation that otherwise would be impossible.
Now accepting manuscript proposals for special issues on 1) Phenotypic Drug Discovery; 2) Advancements in Biomedical Micro/Nano Tools and Technology; 3) New Developments in Global Health Technologies; and 4) Data Management.
Visit www.slas.org/publications/journals.cfm for details.
it’s time. (and all about your time)
See how Gilson takes PIPETMAN® to the MAX. Come to SLAS booth 1601 for the unwrapping.
www.gilson.com
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Welcome to the SLAS Member Center SLAS Member Center and Career Connections Location: Florida Exhibition Hall
The SLAS Member Center is THE place for members (and non members) to find out everything they might want to know about the many benefits and services available through SLAS. Stop-by, relax and talk with us and fellow members.
SLAS Member Center, includes the following activities: •
Take Advantage of Free Career Services - Page 10 The SLAS Member Center is the headquarters for career services at SLAS2013. Job seekers and employers are invited to: • Browse job postings • Post resumes • Sign-up for one-on-one career coaching session with a professional career counselor (See Carol Brady in the SLAS Member Center)
•
Student and Early Career Professionals Mixer Sunday, January 13, 5:30 - 6:30 pm SLAS welcomes its student attendees and Tony B. Academic Travel Award winners to SLAS2013 with this social event designed to help students connect with each other and with SLAS Volunteer Leaders. Drinks and snacks are served.
•
Journals Unveil New Cover Designs SLAS publishes two peer-reviewed scientific journals in partnership with SAGE Publications - the Journal of Biomolecular Screening (JBS) and the Journal of Laboratory Automation (JALA). Meet members of the publishing team, learn more about the journals’ new cover designs and editorial scope. Plus, find out: • How to search, secure and manage information via JALA Online and JBS Online • How to submit an original scientific manuscript to JALA or JBS • How to increase awareness, discoverability and citations of published manuscripts
•
Student Poster Award Winners Announcement Monday, January 14, 5 pm More than 60 undergraduate, graduate and postdoctoral students participate in the SLAS2013 Student Poster Competition. The winners are announced at the Member Center on Monday at 5 pm. The top three are featured in The Lab Man podcast live in the Member Center.
•
SLAS2013 Passport to Prizes Tuesday, January 15, 5 pm Play the Passport to Prizes game and you could win. Prizes include an iPad, Bose headphones, Bose stereo, American Express and Amazon.com gift cards. Official game cards were distributed in registration tote bags and are available at the SLAS Member Center and SLAS2013 Registration desk.
Live Podcasts! Meet The Lab Man SLAS Director of Education Steve Hamilton, Ph.D. (AKA The Lab Man) records podcasts live from the SLAS Member Center. Meet the SLAS2013 Student Poster Winners Monday, January 14, 5 pm Interview with Dean Ho of UCLA, about the SLAS Endowed Fellowship at UCLA and Beckman Coulter’s Contribution to the SLAS Endowment Fund Tuesday, January 15, 10:30 am Talk with Representatives from the Three Companies Honored with SLAS2013 New Product Award Designations Tuesday, January 15, 4 pm
•
•
Interact with Florida’s Elite FIRST Competition Teams (Near the SLAS Member Center) FIRST® (For Inspiration and Recognition of Science and Technology) was founded in 1989 by inventor Dean Kamen to inspire an appreciation of science and technology in young people. FIRST® provides a suite of sequentially progressive STEM education programs for youth in grades K-12. Our global FIRST Family of Programs give youth an opportunity to work with professional mentors and the business community to gain a firsthand appreciation of the value of education and careers in science, technology, engineering, and math. SLAS is proud to welcome FIRST® as a partner at SLAS2013. This year we feature Exploding Bacon FRC Team 1902, Orlando, FL; Lyman Robotics FRC Team 2757 and FTC Teams 3045 and 4228, Longwood, FL; Hillsborough HHS FRC Team 2425 and FTC Team 2425, Tampa, FL; Rockledge FTC Teams 233 and 6323 (The Pink Team), Rockledge, Cocoa Beach, and Viera, FL; and Davinci Learning Academy Brickschoolers FLL and Jr. FLL teams from Orlando.
8
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Celebrate Excellence $10,000 SLAS Innovation Award The SLAS Innovation Award recognizes the work behind one conference podium presentation that proves to be exceedingly innovative and contributes to the exploration of technologies in the laboratory. Attend the closing session on Wednesday, January 16 at 3:45 pm in the Osceola CD Ballroom to see who receives the 2013 SLAS Innovation Award. The SLAS Innovation Award finalists are: • David Beebe, University of Wisconsin-Madison – Kit-On-A-Lid-Assay: Self-Contained Microfluidic Cell-Based Assays
for the Masses; Page 130 • Amy Herr, University of California, Berkeley – Talking About a (Proteomics) Revolution: Microfluidic Frameworks for
High-Throughput Protein Analysis; Page 123 • Thomas Hughes, Montana Molecular – A Multiplexed Fluorescent Assay for Independent Second Messenger
Systems: Decoding GPCR Activation in Living Cells; Page 67 • Darren Link, RainDance – Genomic Applications of Droplet Microfluidics; Page 121 • Kelly Owens, University of Washington – Phenotypic Screening in Zebrafish Identifies Compounds That Protect
Mechanosensory Hair Cells From Drug-Induced Cell Death: A Model for Hearing Protection; Page 93 • Brian Paegel, The Scripps Research Institute – Building the Foundation of Next-Generation Distributed Drug
Discovery; Page 122 • Leo Price, Leiden-Amsterdam Center for Drug Research – A 3D Cell Culture Based Platform for Phenotypic Screening
and Multi-Parametric Profiling of Compounds; Page 74 • Kristine Schauer, Institut Curie – A Novel “Organelle Map” Framework for the Automatic Detection of Cellular
Morphology Changes; Page 110 • Andrea Weston, Bristol-Myers Squibb Company – Making a Quantum Leap in Mass Spectrometry Throughput:
Applying the NextVal MassInsight Technology to Monitor Cytochrome P450 Enzyme Inhibition in Human Liver Microsomes; Page 105
Young Scientist Awards Program Recognizes Best Student Poster Presentations From Around the World This program rewards achievement in student poster presentations from strategically aligned sister organizations, institutions and educational forums. Meet the 2012 Young Scientist Delegate winners who present their work at SLAS2013 on Monday, January 14 (presenters available 1 - 3 pm): • Aurore Lejuene, Molecular Pharmacology Department, Cancer Research Technology Development Laboratory,
Wolfson Institute for Biomedical Research, University College London, England (European Laboratory Robotics Interest Group, United Kingdom) MP056 - A Novel Cell-Based Screening Approach for the Identification of FOXA 1 Pathway Inhibitors for the Treatment of Tamoxifen-Resistant Breast Cancer • Lin Lu, Department of Molecular Biosciences and Bioengineering, University of Hawaii, Manoa, Hawaii (Institute of
Food Technologists, United States) MP049 - Electrochemical Impedance Spectroscopic Technique with a Functionalized Microwire Sensor for Rapid Detection of Foodborne Pathogens • Alexander Daschner and Kamran Honarnejad, German Centre for Neurodegenerative Diseases (DZNE), Ludwig-
Maximilians-Universitat, Munich, Germany (MipTec, Switzerland) MP041 - Development and Implementation of a High-Throughput FRET-Based Calcium Imaging Assay for Alzheimer’s Disease Drug Screening
SLAS2013.org
I
9
Join us for these FREE career development workshops. SLAS Career Connections is a highly discreet, automated employment program that brings together online professional services with respected career center and development sessions at SLAS2013. For more information about Career Connections, visit SLAS2013.org/conference/career.cfm.
The Power Formula for LinkedIn Success Room: Naples 1 Instructor: Wayne Breitbarth, Author Monday, January 14, 7 am and 12:30 pm (box lunch provided) Once a skeptic and now an outspoken proponent of LinkedIn, Wayne Breitbarth is passionate about helping professionals successfully market themselves with this innovative tool. Breitbarth, author of The Power Formula for LinkedIn Success: Kick-Start Your Business, Brand and Job Search, presents two workshops along with a limited number of personal counseling sessions at SLAS2013. Participants will learn how to maximize the potential of LinkedIn; create a powerful personal profile that delivers returns on strategic objectives; and discover pathways to new job opportunities.
Committed Networking Room: Gainesville 1-2 Instructor: Daniel J. Eustace, Ph.D., University of Connecticut Tuesday, January 15, 7 - 8:15 am (breakfast is served) Committed Networking is an example of what Charles Duhigg, author of The Power of Habit: Why We Do What We Do in Life and Business calls a “keystone habit.” Keystone habits result from identifying cues, modifying routines that change our habits, and allow us to achieve desired outcomes. This workshop covers networking conversations, interviews and elevator speeches, and weaves them into positive, proactive habits for your practical use on a daily basis.
Career Counseling In addition to workshops, SLAS2013 provides one-on-one personal counseling sessions. Contact Carol Brady at
[email protected] or stop by the SLAS Member Center to book your appointment now. Appointments are limited and assigned on a first-come, first-served basis.
Job Seekers Job Seekers may submit resumes to SLAS Career Connections online through SLAS.org and on paper at the SLAS Member Center. During SLAS2013 in Orlando, browse the job boards, meet one-on-one with a career coach, and network with recruiting professionals.
Human Resource Professional and Recruiters With 4,500 participants gathering for SLAS2013, SLAS Career Connections substantially narrows the applicant pool to very qualified prospects. Start the search for new positions and new talent at SLAS2013.org/conference/career.cfm.
JALA & JBS Author Workshop: How to Get Your Work Published Instructor: Edward Chow, Ph.D., National University of Singapore (professor, author and member of the JALA Editorial Board)
Wednesday, January 16, 11:45 am - 1:15 pm, Room: Sarasota 1-3
Congratulations to the 2013 SLAS Journal Achievement Award Winners!
2013 Readers' Choice Awards
Reflecting popularity among readers throughout 2012. 2013 JALA Readers’ Choice Award A Review of Electronic Laboratory Notebooks Available in the Market Today By Michael Rubacha, Anil Rattan and Stephen Hosselet From JALA Volume 16, Issue 1, February 2011, Pages 90-98 2013 JBS Readers’ Choice Award Sirtuin 1 (SIRT1): The Misunderstood HDAC By Walter Stunkel and Robert Campbell From JBS Volume 16, Issue 10, December 2011, Pages 1153-1169
2013 Authors' Choice Awards
Reflecting popularity among authors (citations) throughout 2012. 2013 JALA Authors’ Choice Awards Microfluidic Immunoassays By Chun-Che Lin, Jung-Hao Wang and Gwo-Bin Lee From JALA Volume 15, Issue 3, June 2010, Pages 253-274 2013 JBS Authors’ Choice Award Automated Image Analysis for High-Content Screening and Analysis By Aabid Shariff, Joshue Kangas, Luis Pedro Coelho, Shannon Quinn and Robert F. Murphy From JBS Volume 15, Issue 7, August 2010, Pages 726-734
2013 JBS Reviewer Excellence Awards
Reflecting review quality, timeliness and volunteer service to JBS in 2012. Robert Talanian of Abbott Laboratories, Worcester, MA Yichin Liu of Genentech, South San Francisco, CA Eric Goedken of Abbott Laboratories, Worcester, MA Martin Brandt of GlaxoSmithKline, Collegeville, PA
2013 JALA & JBS Art of Science Grand Prize Winner Yi Zhang and Cyrus Beh of Johns Hopkins University School of Medicine, Baltimore, MD
The Society for Laboratory Automation and Screening publishes two award-winning, peer-reviewed scientific journals. For more information, visit www.slas.org/publications/journals.cfm
I
SLAS2013
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
General Information Attire Casual business attire is recommended during all conference sessions, special events and in the exhibit hall. Some restaurants may require a sports coat and/or tie. You may also want to wear a light jacket or sweater, as it is chilly at night and meeting rooms are air conditioned.
Conference Location Gaylord Palms Resort and Convention Center 6000 W. Osceola Parkway, Kissimmee, Florida 34746 +1.407.586.0000 www.gaylordhotels.com/gaylord-palms
Conference Badges Your SLAS2013 badge represents your admission ticket to the conference, special events and the exhibit hall. The Society policy is firm. We ask that attendees display their badge prominently upon entering all SLAS and conference functions.
Beckman Coulter Cyber Café Location: Florida Exhibition Hall The Cyber Café offers free internet access within the SLAS exhibit hall. The Cyber Café is located in the back of the 800 aisle and is sponsored by Beckman Coulter. All SLAS2013 reservations at the Gaylord Palms include wireless internet access in guest rooms, atriums and at the pool.
Parking Parking is available at the Gaylord Palms Resort. The rates range from $15-22 per day, plus tax.
Posters Location: Florida Exhibition Hall
FedEx Office
Poster Viewing • Monday, January 14 • Tuesday, January 15
Location: Across from the “Jump for Joy” Dolphin Fountain, Gaylord Convention Center
While posters remain up throughout the day of presentation, they are only staffed by the authors as noted below:
• Open everyday, 6 am - 9 pm; 24-hour Internet access
FedEx Office offers large document reproduction, offset printing and bindery services.
First Aid If first aid services are required, please report your need to the SLAS2013 registration desk or one of the SLAS Professional Team members in black shirts, who will contact the Gaylord’s Safety Services team members to assist.
10 am - 6:30 pm 10 am - 6 pm
Monday Poster Session (MP) • 1–3 pm (presenters are available) Tuesday Poster Session (TP) • 1–3 pm (presenters are available) To see the entire collection of posters, abstracts and author submissions, visit the Online Poster Gallery at www.SLAS2013.org. A mobile app is also available. See details on SLAS2013.org.
Press Conferences Location: Tampa 1
Information Desk Location: Florida Exhibition Hall, SLAS Member Center Information regarding the conference, SLAS or the Gaylord Convention Center is always nearby at the SLAS Member Center in the back of the exhibit hall.
Internet Access Hamilton Company WiFi Lounge Location: The Rotunda on the Ballroom Level Sponsored by Hamilton Company, the WiFi Lounge offers wireless Internet access exclusively for SLAS2013 attendees in the immediate vicinity of the lounge. WiFi Lounge Access: SSID: SLASHamilton; Password: Hamilton2013
12
I
SLAS2013.org
Press conferences are open to registered media attendees only. For an updated schedule of press conferences, stop by the SLAS2013 Media Office located in the Vero room. As of December 3, 2012, scheduled press conferences include: Monday, January 14 • 9 - 10 am; Labcyte, Inc. • 11 am - Noon; Agilent Technologies Inc. • 2:30 - 3:30 pm; AMRI
Printed Program and Abstracts The titles and abstracts, as well as the exhibitor descriptions printed in this program are entered online by the authors and exhibitors. It is not possible to fully edit this material. Information is subject to change.
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Receptions
Ribbons
Exhibit Hall Receptions
Location: SLAS2013 Registration Desk, Florida Exhibition Hall Foyer Thank you for being involved with SLAS! SLAS volunteers are encouraged to pick up a ribbon at the ribbon kiosk next to the SLAS2013 Registration Desk and to wear on their badges to identify their roles in the Society.
Welcome Reception Sunday, January 13
5:30 - 7 pm
Reception Celebrating the 2013 SLAS Journal Achievement Award Honorees Monday, January 14 5:30 - 6:30 pm Closing Reception Tuesday, January 15
5 - 6 pm
SLAS2013@Night* Sunday, January 13 Open CityWalk Sunday – Location: Universal CityWalk SLAS provides complimentary and continuous shuttle service – every 15 minutes from 6:30 - 11:30 pm between the Gaylord Palms and CityWalk (15 min. travel time).
Security At the Gaylord Palms Resort and Convention Center, in case of a NON LIFE-THREATENING emergency, use a house phone (located throughout the center) to dial Security at extension 62080. In case of a LIFE THREATENING emergency, dial extension 33. Be prepared to provide the location and nature of the emergency along with your name.
Monday, January 14 8 pm Molecular Monday – Location: Gaylord Palms Resort, Osceola Ballroom AB
SLAS Mobile
Tuesday, January 15 7 - 10 pm Vortex Tuesday – Location: House of Blues 1490 East Buena Vista Drive
SLAS provides complimentary and continuous shuttle service – every 15 minutes from 6:45 - 10:15 pm – between the Gaylord Palms and House of Blues (10 min. travel time).
*All guests on Monday and Tuesday must have an SLAS2013 badge and be 21 or older. Participation in CityWalk Sunday is at attendee’s own expense. Shuttle service to Universal CityWalk is provided free-of-charge.
Continental Breakfast For registered conference participants, light continental breakfasts are served in the Osceola Ballroom Foyer on Monday, January 14 from 8 - 8:30 am; Tuesday, January 15 from 8:30 - 9 am; and Wednesday, January 16 from 9 - 9:30 am.
Lunches For registered conference participants, boxed lunches are available in the exhibit hall on Monday and Tuesday, January 14 and January 15 at 12:30 pm; and for Full Conference registrants only in the Osceola Ballroom Lobby on Wednesday, January 16 at 11:30 am.
Registration Location: Florida Exhibition Hall Lobby • Saturday, January 12 7:30 am - 5 pm • Sunday, January 13 7:30 am - 7 pm • Monday, January 14 7:30 am - 6 pm • Tuesday, January 15 7:30 am - 6 pm • Wednesday, January 16 8:30 am – 1:30 pm
SLAS
electronic library neighborhood
• • • • • •
Check out SLAS.org and SLAS2013.org on your smartphone or tablet to view SLAS mobile websites (sponsored by SLAS Electronic Laboratory Neighborhood). Look for these convenient mobile-friendly tools and much more:
SLAS2013 event scheduler Full scientific program Electronic poster gallery Exhibitor list and interactive floor plan Exclusive Gaylord Palms Resort benefits Career Connections
Use your smartphone or tablet on-site at SLAS2013 for maximum convenience!
Smoking There is no smoking permitted anywhere in the convention center.
Tape Recording/Video Recording Policy Please observe the SLAS policy which prohibits operation of tape recorders, video recorders, cameras, or camera phones, except for official association equipment, at all conference sessions, committee meetings, in the exhibit hall and during the keynote sessions. Note: Throughout SLAS2013 we are videotaping and taking photographs to be used for future SLAS promotions. If you do not wish to appear on camera, please notify the videographer or photographer and your request will be honored.
SLAS2013.org
I
13
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Tony B. Academic Travel Award Winners SLAS has selected 45 students from 12 different countries as SLAS2013 Tony B. Academic Travel Award recipients.
Congratulations Tony B. Academic Travel Award Winners: AUSTRALIA
• Iman Azimi, University of Queensland, Brisbane,
Australia
• Maojun Gong, Wichita State University, Wichita,
Kansas USA
• Victoria Holderby, The University of Texas at Dallas,
Richardson, Texas USA
BRAZIL
• Fabricio Ribeiro De Souza, Federal University of
Goiás, Goiânia, Brazil
CANADA
• Steve Shih, University of Toronto, Toronto, Canada
GERMANY
• Dong Liang, Institut für Mikro- und
Informationstechnik, Freiburg, Germany • Laurent Tanguy-Imtek, University of Freiburg, Freiburg, Germany
INDIA
• Michael Jacobs, The University of Texas at Dallas,
Richardson, Texas USA
• Kalyani Jambunathan, SRI International,
Harrisonburg, Virginia USA
• Chatura Jayakody, University of North Carolina at
Chapel Hill, Chapel Hill, North Carolina USA
• Gregory Linshiz, Joint BioEnergy Institute, Emeryville,
California USA
• Yanli Liu, Sandia National Labs, Livermore, California
USA
• Andrew MacConnell, The Scripps Research Institute,
Jupiter, Florida USA
• Krishnakumar Duraisamy, The Tamil Nadu Dr. M.G.R.
• Sourav Mukherjee, University of Wisconsin-
• Jawahar Natarajan, JSS College of Pharmacy, Ooty,
• Coleman Murray, University of California, Los Angeles,
Medical University, Erode, India Tamil, Nadu, India
ITALY
• Rosaria Benedetti-Sun, University of Naples,
Naples, Italy
POLAND
• Karolina Blaszczyk, Warsaw University of Technology,
Warsaw, Poland
• Elzbieta Jastrzebska (Jedrych), Warsaw University of
Technology, Warsaw, Poland
• Kamil Zukowski, Warsaw University of Technology,
Warsaw, Poland
SINGAPORE
• Edward Chow, National University of Singapore,
Singapore
SOUTH KOREA
• Olufemi Adeluyi, Computer Systems Lab, Gwangju,
South Korea
SWITZERLAND
• Benjamin Rappaz, École Polytechnique Fédérale de
Lausanne, Lausanne, Switzerland
THE NETHERLANDS
• Tijmen Booij, Universiteit Leiden, Leiden, The
Netherlands
• Leo Price, Leiden-Amsterdam Center for Drug
Research, Leiden, The Netherlands
USA
• Maria Aitken, The Scripps Research Institute, Jupiter,
Florida USA
• Ahmet Arslan, University of Illinois at Chicago,
Chicago, Illinois USA
• Narahara Chari Dingari, Massachusetts Institute of
Technology, Cambridge, Massachusetts USA
14
I
SLAS2013.org
Milwaukee, Milwaukee, Wisconsin USA Los Angeles, California, USA
• Samila Nasrollahi, University of Akron, Akron, Ohio USA • Kelly Owens, University of Washington, Seattle,
Washington USA
• Vineet Padia, National Institutes of Health National
Center for Advancing Translational Science, Rockville, Maryland USA • Dhara Patel, Washington University in St. Louis, St. Louis, Missouri USA • Amit Paul, University of Illinois at Chicago, Chicago, Illinois USA • Adam Roberts, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina USA • Tim Ruckh, Northeastern University, Boston, Massachusetts, USA • Michael Santillo, U.S. Food and Drug Administration, Laurel, Maryland USA • Kristen Schexnayder, University of New Orleans, New Orleans, Louisiana USA • Anjan Panneer Selvam, The University of Texas at Dallas, Richardson, Texas USA • Anand Srinivasan, The University of Texas at San Antonio, San Antonio Texas, USA • Krishna Mohan Vattipalli, The University of Texas at Dallas, Richardson Texas, USA • Uma Vempati, University of Miami, Miami, Florida USA • Cameron Wood, University of North Carolina, Chapel Hill, North Carolina USA • Yang Wu, University of New Mexico, Albuquerque, New Mexico USA • Jie Xu, Washington State University, Vancouver, Washington USA
SLAS2013 offers opportunities day and night for intelligent network building, so keep your business cards in your pocket as you step out of the classroom and into SLAS2013@Night.* Every evening begins with a reception in the SLAS2013 Exhibit Hall.
Universal CityWalk Start your SLAS2013 experience by reacquainting yourself with friends old and new. Following a reception in the Exhibition, feel free to venture over to Universal CityWalk, which is home to dozens of dining and entertainment options to suit a variety of tastes and budgets. While participation is at attendee’s own expense, SLAS provides complimentary and continuous shuttle service – every 15 minutes from 6:30 - 11:30 pm between the Gaylord Palms and CityWalk.
MOLECULAR
GROOVE
8 pm - Gaylord Palms Resort - Osceola Ballroom AB Rockin’ the Revolution for Personalized Healthcare They’re back and better than ever! Join PerkinElmer as it presents everybody’s favorite scientific house band, Molecular Groove. This year’s Diamond Groove-athon will rock you out in the Gaylord Palm’s Osceola Ballroom. Be your casual self. No worries, man, it’s all good when it’s with The Groove.
7 - 10 pm - House of Blues - 1490 East Buena Vista Drive SLAS takes over the entire House of Blues for Vortex2013 sponsored by Agilent Technologies. Three venues, three bands, all under one roof: Slippery When Wet (the Ultimate Bon Jovi Tribute Band) rocks the house from the main stage; guitar soloist Matt Shenk mellows out on the front porch; and HOB’s own Dueling Pianos amuse in the Main Dining Room. Plus, plenty of foosball tables, ping pong and air hockey in the Voodoo Lounge. Awesome dining and open bar. Come hungry for down south favorites like crab cakes, shrimp and grits, BBQ, jambalaya, key lime pie and much more! SLAS provides complimentary and continuous shuttle service – every 15 minutes from 6:45 to 10:15 pm between the Gaylord Palms and House of Blues (10 min. travel time). *All guests on Monday and Tuesday must have an SLAS2013 badge and be 21 or older.
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Conference Floor Plan
CONVENTION CENTER
Wreckers Sports Bar
POOL ENTRANCE
Relâche Spa (Lower Level)
Wireless internet access available in all guestrooms and hotel atrium areas.
HOW TO FIND YOUR ROOM
X 345
FLOOR
ROOM #
DIRECTIONS TO... HEMMINGWAY and SANCHEZ BOARDROOMS: Level 4, via Emerald Bay Elevator B
EMERALD MEETING ROOMS: Lower Level, via Emerald Bay Elevator A
16
I
SLAS2013.org
Exhibition: January 13-15
I Conference: January 14-16
6 5
D
B
1
2
3
4
C
Sun Ballroom A
Sun Lobby
SUN BREAKOUT ROOMS
Tallahassee 1 2 3
1
2
1
Tampa 2 3
2
2
Naples 2 3
Sarasota 1 2 3 1
1
1
OSCEOLA BREAKOUT ROOMS
Osceola Foyer Escalator Up
Gainesville
Destin
Hamilton Company WiFi Lounge
Daytona
Miami 2 3
Sanibel 1 2 3 1
2 1 Captiva
Sun Foyer
Down One Level to Bridge to Hotel Escalator Down to • Florida Exhibition Hall • SLAS2013 Registration • Convention Center Entrance
6 5 4 3 2 1
B
D
C
Osceola Ballroom A
Osceola Lobby
Guest Elevators
Restrooms
Stage
I Short Courses: January 12-13
Ballroom Level (Level 2)
17
I
SLAS2013.org
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Keynote Speaker Series
Sponsored by:
Live Streaming Session Monday, January 14, 9 am | Room: Osceola Ballroom CD #SLAS2013
Mehmet Toner, Ph.D.
Founding Director of the NIH BioMEMS Resource Center and the Helen Andrus Benedict Professor of Surgery (Biomedical Engineering), and Health Sciences and Technology, Harvard Medical School; Massachusetts General Hospital (MGH) Topic: Bioengineering and Clinical Applications of the Circulating Tumor Cell Microchip Mehmet Toner’s presentation shares his integrated strategy to simultaneously advance the engineering and microfluidics of CTC-Chip development, the biology of these rare cells and the potential clinical applications of circulating tumor cells.
Tuesday, January 15, 9 am | Room: Osceola Ballroom CD Sir Harold Kroto, Ph.D.
#SLAS2013
Department of Chemistry and Biochemistry The Florida State University 1996 Nobel Prize in Chemistry Topic: Science and Society in the 21st Century Sir Harold “Harry” Kroto is a Francis Eppes Professor of Chemistry at Florida State University, where he is conducting research in nanoscience and cluster chemistry. In 1996, Dr. Kroto was one of three recipients of the Nobel Prize for Chemistry, an honor that resulted from his 1985 laboratory experiments that uncovered the existence of C60 Buckminsterfullerene, a new form of carbon.
Wednesday, January 16, 3:45 pm | Room: Osceola Ballroom CD Charles Sabine Emmy-Award Winning Television Journalist and Scientific Advocate
#SLAS2013
Topic: The Pursuit of Hope and Dignity: Why Every Link of the Medical Chain Matters Charles Sabine is an Emmy-award-winning television journalist who witnessed wars and revolutions as a correspondent for NBC News. Today, he is a spokesperson for patients and families who suffer from neurodegenerative disease. Sabine’s presentation shares the importance of work that occurs within laboratories and the need for scientists to realize how any research is valued by patients and their families.
SLAS Electronic Laboratory Neighborhood E-Zine WELCOME TO THE NEIGHBORHOOD! This people focused and people sourced e-zine at SLAS.org shares member ideas and perspectives on what’s happening throughout the laboratory science and technology community. Related discussion forums encourage conversation and collaboration.
18
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Conference-at-a-Glance (Schedule Subject to Change) SPECIAL NOTE: SLAS@Night Events: Participants must be over 21 years old to attend the SLAS@Night Events on Monday and Tuesday. Sunday, January 13, 2013 (Short Course only registration is available.) 7:30 am - 7:00 pm
Registration Open - Florida Exhibition Hall Lobby, Lower Level
1:00 - 5:00 pm
Sanford Burnham Satellite Symposium - Lake Nona, Florida
1:30 - 4:30 pm
Exhibitor Workshop - see page 136
4:30 - 7:00 pm
Exhibition Open - Florida Exhibition Hall
5:30 - 6:30 pm
Student and Early Career Professionals Mixer - SL AS Member Center in the Florida Exhibition Hall
5:30 - 7:00 pm
Welcome Reception - Florida Exhibition Hall Open CityWalk Sunday (6:30 - 11:30 pm Continuous Shuttle Service to Universal Studios CityWalk; shuttle service is located in Gaylord Transportation Lobby.) - Universal Studios CityWalk
Monday, January 14, 2013 7:00 am 7:00 - 8:00 am 7:30 am - 6:00 pm
SLAS Career Connections’ Workshop: The Power Formula for LinkedIn Success - Naples 1 Laboratory Products Association (LPA) Special Session - Emerald 4 Registration Open - Florida Exhibition Hall Lobby, Lower Level
8:00 - 8:30 am
Continental Breakfast - Osceola Ballroom Foyer
8:30 - 9:00 am
Opening Remarks - Osceola CD
9:00 - 10:00 am 10:00 - 10:30 am
Opening Keynote Speaker: Mehmet Toner, Ph.D., Founding Director of the NIH BioMEMS Resource Center and the Helen Andrus Benedict Professor of Surgery (Biomedical Engineering), and Health Sciences and Technology, Harvard Medical School; Massachusetts General Hospital (MGH) Sponsored by Thermo Scientific Live Streaming Session! Osceola Ballroom CD Coffee Break - Florida Exhibition Hall
10:00 am - 6:30 pm
Exhibition Open - Florida Exhibition Hall
10:00 am - 6:30 pm
Poster Viewing - Florida Exhibition Hall Assay Development and Screening Sun Ballroom B
High-Throughput Technologies Sun Ballroom A
Micro/Nano Technology Sun Ballroom D
Cell-Based Assay Development
High-Throughput Chemistry and Analytics
Droplet Microfluidics
InformaticsSun Ballroom C
Bioanalytical Techniques Miami 1-3
Extracting Meaning From Complex Data
Novel Approaches to Bioanlytical Techniques
Session 1 10:30 am - 12:30 pm
12:30 pm
SLAS Career Connections’ Workshop: The Power Formula for LinkedIn Success - Naples 1
12:30 - 1:15 pm
Exhibitor Tutorials - see page 136
12:30 - 1:30 pm
Lunch - Florida Exhibition Hall Sponsored by Laboratory Products Association (LPA) (box lunch provided)
12:30 - 1:45 pm
Exhibitor Tutorials - see pages 137 - 138
1:00 - 3:00 pm
Poster Presentations (Monday Posters) - Florida Exhibition Hall
2:00 - 2:45 pm
Exhibitor Tutorials - see pages 139 - 141
Session 2 3:00 - 5:00 pm
Chemical Probes for Target Validation and Pathway Analysis
Compound and Biologics HighThroughput Sample Management
Technology Development Takes Aim at Simplifying Cellular Processes
Informatics in the Laboratory: Success Stories
BioAnalytical Methods for Next-Gen Sequencing
3:00 - 5:00 pm
Special Session: HTS and Early Drug Discovery in Industry and Academia. Collaboration: Is the Sum Greater Than the Two Parts? Live Streaming Session! - Osceola CD
5:30 - 6:30 pm
Reception Celebrating the 2013 SLAS Journal Achievement Award Honorees - Florida Exhibition Hall
7:00 - 9:00 pm
Late Night With LRIG-Rapid Fire Innovation Session - Sun Ballroom A
8:00 pm
Molecular Monday: Rockin’ the Revolution for Personalized Healthcare — PerkinElmer’s Band Performs at The Gaylord Palms Resort Sponsored by PerkinElmer - Osceola Ballroom AB
Tuesday, January 15, 2013 7:00 - 8:15 am
SLAS Career Connections’ Workshop: Committed Networking - Gainesville 1- 2
7:00 - 9:00 am
Analytical, Life Science & Diagnostics Association (ALDA) Special Session (Invitation Only)- Emerald 2
7:30 am - 6:00 pm
Registration Open - Florida Exhibition Hall Lobby, Lower Level
8:00 - 8:45 am
Special Interest Group Meetings - see pages 40 - 43
8:00 - 8:45 am
Exhibitor Tutorials - see pages 141 - 142
20
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Tuesday, January 15, 2013 Continued 8:30 - 9:00 am 9:00 - 10:00 am 10:00 - 10:30 am
Continental Breakfast - Osceola Ballroom Foyer Keynote Speaker: Sir Harold Kroto, Ph.D., Department of Chemistry and Biochemistry; The Florida State University; 1996 Nobel Prize in Chemistry Sponsored by Thermo Scientific - Osceola Ballroom CD Coffee Break - Florida Exhibition Hall
10:00 am - 6:00 pm
Exhibition Open - Florida Exhibition Hall
10:00 am - 6:00 pm
Poster Viewing - Florida Exhibition Hall Assay Development and Screening Sun Ballroom B
High-Throughput Technologies Sun Ballroom A
Biochemical Assay Technologies and Screening
Cutting Edge Technology Developments
Micro/Nano Technology Sun Ballroom D
Informatics Sun Ballroom C
Bioanalytical Techniques Miami 1-3
Collaborative Discovery in the Internet Age
Isolation and Analysis of Rare Cells Track Ends
Session 3 10:30 am - 12:30 pm
NextGen Nanomedicine Platform Technologies
12:30 - 1:15 pm
Exhibitor Tutorials - see page 143
12:30 - 1:30 pm
Lunch - Florida Exhibition Hall Sponsored by Analytical, Life Science & Diagnostics Association (ALDA) (box lunch provided)
12:30 - 1:45 pm
Exhibitor Tutorials - see pages 144 - 145
1:00 - 3:00 pm
Poster Presentations (Tuesday Posters) - Florida Exhibition Hall
2:00 - 2:45 pm
Exhibitor Tutorials - see pages 145 - 147
2:30 - 3:00 pm
Coffee Break - Florida Exhibition Hall
Session 1
Session 4
3:00 - 5:00 pm
5:00 - 6:00 pm 7:00 - 10:00 pm
Assay Development and Screening Sun Ballroom B
High-Throughput Technologies Sun Ballroom A
Micro/Nano Technology Sun Ballroom D
Informatics Sun Ballroom C
Diagnostics Miami 1-3
Drug Target Biology Tallahassee 1-3
High Content Screening
New Developments and Applications in HighThroughput Screening Technologies and Automation
Tissues and Organs on Chip
Informatics in Highly Integrated Systems
Advances in Near Patient Testing Devices Track Begins
Emerging and Challenging Targets for Interrogation Track Begins
Closing Reception - Florida Exhibition Hall Vortex Tuesday @ The House of Blues, 1490 East Buena Vista Drive Sponsored by Agilent Technologies
Wednesday, January 16, 2013 8:00 - 9:15 am 8:30 am - 1:30 pm 9:00 - 9:30 am
Special Interest Group Meetings - see pages 40 - 43 Registration Open - Florida Exhibition Hall Lobby, Lower Level Continental Breakfast - Osceola Ballroom Foyer
Session 5 Screening Libraries
9:30 - 11:30 am
11:30 am - 12:30 pm
Non Plate-Based High-Throughput Technologies
Next - Generation Microanalytical Systems
Session 2 Integrating Laboratory Information Into a Global Discovery Solution
Diagnostics Tests and Personalized Medicine
Lunch - Osceola Ballroom Lobby (For Full Conference Registrants Only)
11:45 am - 1:15 pm
JALA & JBS Author Workshop: How to Get Your Work Published - Sarasota 1-3
11:45 am - 1:15 pm
Special Interest Group Meetings - see pages 40 - 43
Session 3
Session 6 1:30 - 3:30 pm
From Cellular Pathways to Drug Targets
Assays for Diverse Applications: Biologics, Diagnostics, and Toxicology
Automated Screening Applications Using Primary Cells, Stem Cells or Phenotypic Approaches
On-Chip Imaging
High Performance Computing for Laboratory Data Analysis
Identification of Diagnostic Biomarkers With Novel Clinical Application
Navigating Neurodegenerative Disease Research to Patient Therapies
Closing Keynote and Awards Ceremony 3:45 - 5:00 pm
Keynote Speaker: Charles Sabine, Emmy-Award Winning Television Journalist and Scientific Advocate; and Announcement of $10,000 Innovation Award Winner Sponsored by Thermo Scientific Osceola Ballroom CD
SLAS2013.org
I
21
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Short Course Program
Master Short Courses Bolster Expertise The SLAS2013 Short Course Program provides in-depth instruction on topics, issues and techniques related to laboratory science and technology.
Saturday, January 12, 8:30 am - 4:30 pm Automating Scientific Data Analysis and Visualization With Excel and VBA (Computer-Based) – Naples 1....... Page 23 Automation for In Vitro Diagnostics – Osceola 2................................................................................................... Page 23 Establishing Cell-Based Assays for Screening – Osceola 1................................................................................. Page 23 Getting Started With Excel and VBA (Computer-Based) – Naples 2.................................................................... Page 25 LIMS in the Organization – Osceola 5................................................................................................................... Page 23 Liquid Handling Boot Camp (Hands-On) – Osceola 3/4....................................................................................... Page 23 Microfluidics I/II – Naples 3................................................................................................................................... Page 25 Pharmacokinetics and Pharmacodynamics in Drug Discovery – Osceola 6........................................................ Page 23 Quantitative Evaluation of Screening Assays for Drug Discovery & Biomarker Applications – Sarasota 1/2...... Page 23 Sample Management: Best Practice, Trends and Challenges – Tampa 3............................................................ Page 23
Sunday, January 13, 8:30 am - 4:30 pm 3D Cell-Based Assays for Drug De-Risking – Osceola 5...................................................................................... Page 24 Applied Information Technology for the Laboratory – Osceola 1......................................................................... Page 24 Automated Liquid Handling in Accredited or Forensic Environments – Osceola 2.............................................. Page 24 Getting Started With Excel and VBA (Computer-Based) – Naples 2.................................................................... Page 25 High Content Screening: Instrumentation, Assay Development, Screening, Image and Data Analysis – Osceola 6..................................................................................................................................... Page 24 Introduction to Design of Experiments (Computer-Based) – Naples 1................................................................. Page 24 Introduction to Laboratory Automation – Destin................................................................................................... Page 24 Label-Free/Biophysics Methods for Screening – Tampa 2/3................................................................................ Page 24 Microfluidics I/II – Naples 3................................................................................................................................... Page 25 Next Generation Sequencing Technology Fundamentals and Applications – Sarasota 1/2................................ Page 24 Technical Project Management – Osceola 3......................................................................................................... Page 24 Writing Testable and Verifiable User Requirements – Osceola 4.......................................................................... Page 24
22
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Saturday, January 12, 8:30 am - 4:30 pm Automating Scientific Data Analysis and Visualization With Excel and VBA (Computer-Based) Room: Naples 1 Mark F. Russo, Bryn Mawr College Stephen Carafello, Green Iguana Productions LLC This course explores advanced features of Excel 2007 and Excel 2010 useful to scientists and engineers. Topics covered include importing and processing experimental data, handling of data arrays, creation of custom user interfaces, curve fitting, and automatic generation of charts.
Automation for In Vitro Diagnostics Room: Osceola 2 Angelika Niemz, Keck Graduate Institute In vitro diagnostics (IVD) entails the diagnosis, screening, and monitoring of human diseases based on identification and quantification of small molecules, proteins, nucleic acids, or cells obtained from patient specimens. Automation has fundamentally changed the IVD industry, and continues to play an important role in the move towards disseminated testing and personalized medicine.
Establishing Cell-Based Assays for Screening Room: Osceola 1
Pharmacokinetics and Pharmacodynamics in Drug Discovery Room: Osceola 6 Terry Kenakin, University of North Carolina School of Medicine This course is designed to increase understanding of the fundamental concepts governing drug pharmacokinetics (ADME studies), safety pharmacology and therapeutic pharmacodynamics as they are utilized in new drug discovery.
Terry Riss, Promega Corporation Lisa Minor, In Vitro Strategies, LLC Geoffrey Bartholomeusz, UT M.D. Anderson Cancer Center Eric Johnson, Merck & Co.
Quantitative Evaluation of Screening Assays for Drug Discovery & Biomarker Applications Room: Sarasota 1/2
This course describes developing standard procedures for handling cultured cells to set up cell-based assays, techniques for measuring cell health and the pathways leading to cytotoxicity, developing siRNA screening assays, and an overview of various GPCR screening methods.
This course provides an overview of methods useful for optimizing, evaluating, and analyzing in vitro screening assays for drug discovery and biomarker applications.
LIMS in the Organization Room: Osceola 5 Robert D. McDowall, McDowall Consulting This course provides an overview of the system development lifecycle of a LIMS and the identification of the common issues and problems associated with a project.
Liquid Handling Boot Camp (Hands-On) Room: Osceola 3/4 Petar Stojadinovi, National University Benjamin Mendoza, Thoratec Corporation Learn about lab automation in a hands-on environment. One third of the class time is lecture and two thirds is hands-on work with the robots.
V. Devanarayan, Abbott Laboratories Eric Goedken, Abbott Laboratories
Sample Management: Best Practice, Trends and Challenges Room: Tampa 3 Sue Holland Crimmin, GlaxoSmithKline Karen Billeci, Genentech, Inc. Ioana Popa-Burke, GlaxoSmithKline Kevin R. Oldenburg, Matrical Bioscience This course provides current status and considered best practice in the discipline of sample management. It focuses on the traditional aspects of compound management but covers the synergies and differences in managing biologics. Consideration is given to key challenges and future directions. With the growth and interest in biological sample management the course has been expanded to cover this discipline.
SLAS2013.org
I
23
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Sunday, January 13, 8:30 am - 4:30 pm NEW! 3D Cell-Based Assays for Drug De-Risking Room: Osceola 5 Ursula Graf-Hausner, University of Applied Sciences Jens M. Kelm, InSphero AG Terry Riss, Promega Corporation Lisa Minor, In Vitro Strategies, LLC 3D cell culture receives increasing attention to produce models for more predictive and biologically relevant cellbased compound testing. Recent technological advances have improved the automation-capability and robustness of 3D cell culture, which is now ready for drug screening. This course provides an introduction into technology and applications of 3D cell culture and related assays.
Applied Information Technology for the Laboratory Room: Osceola 1 Burkhard Schaefer, BSSN Software This course provides decision makers and practitioners from biopharma, healthcare, and academia with a comprehensive overview of IT topics and trends in laboratory automation, data management, and systems integration.
Automated Liquid Handling in Accredited or Forensic Environments Room: Osceola 2 Michael Stangegaard, University of Copenhagen Laboratories are increasingly challenged to be standardized, certified or even accredited. This course presents an introduction to the process of standardizing, validating and accrediting automated liquid handling instruments and processes in both conventional and forensic environments.
High Content Screening: Instrumentation, Assay Development, Screening, Image and Data Analysis Room: Osceola 6 Stephan Schürer, University of Miami Medical School Vance Lemmon, University of Miami James G. Evans, Anon Consulting This course provides a state-of-the-art overview of the components of HCS (instrumentation, reagents, HC assay development, automated image analysis and multiparametric data analysis, and data standards) together with some showcases of small molecule and RNAi high-content screens in industry and academia.
Introduction to Design of Experiments (Computer-Based) Room: Naples 1 Wayne J. Levin, Predictum Inc. This interactive, hands-on course allows students to exploit Design of Experiments (DOE) as soon as they get back to their workplace. The course uses Excel for the essentials and JMP software for more advanced, yet accessible, methodologies.
24
I
SLAS2013.org
Introduction to Laboratory Automation Room: Destin Steven D. Hamilton, SLAS Director of Education James M. Gill II This course presents a broad introduction to laboratory automation in the R&D laboratory environment (i.e. nonclinical). A general understanding of a laboratory environment is helpful.
Label-Free/Biophysics Methods for Screening Room: Tampa 2/3 Johannes Ottl, Novartis Pharma NIBR Delphine Collin, Boehringer Ingelheim Pharmaceuticals, Inc. This course focuses on those “biochemical” biophysics technologies with highest impact and applicability for screening and lead finding. This short course also focuses on biochemical assay applications and the detection, quantification and qualification of ligand/protein binding events.
Next Generation Sequencing Technology Fundamentals and Applications Room: Sarasota 1/2 Dawei Lin, University of California, Davis Genome Center Ryan Kim, University of California, Davis Genome Center This course teaches key concepts and applications of major sequencing technologies (Illumina, 454, SOLiD, Ion Torrent and PacBio) including their technology basics, sample preps, data analysis and associated IT supports.
Technical Project Management Room: Osceola 3 Brian Hanrahan, Invetech Pty Ltd Simon English, Invetech Pty Ltd Course objectives include mapping the phases of a project; introducing specific project management tools; and discussing and demonstrating the application of these tools in the development and implementation of new technologies and processes for diagnostics, manufacturing and drug discovery.
Writing Testable and Verifiable User Requirements Room: Osceola 4 Robert D. McDowall, McDowall Consulting This short course teaches a methodology for specifying the user needs of the instrument and software elements that enable selection of the most appropriate system and end user testing to meet business and/or regulatory (e.g. GLP or GMP) requirements.
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Two-Day Short Courses Saturday, January 12, 8:30 am - 4:30 pm Sunday, January 13, 8:30 am - 4:30 pm Getting Started With Excel and VBA (Computer-Based) Room: Naples 2 William Neil Martin Echols, Forest Laboratories Excel is widely used in scientific laboratories to automate tedious data manipulation and presentation tasks. This course reviews many of the tools built into Excel for handling problems commonly encountered in the laboratory. It also introduces the Visual Basic for Applications scripting language as a way to customize Excel and expand upon its functionality.
Microfluidics I/II Room: Naples 3 Jörg P. Kutter, Technical University of Denmark Johan Nilsson, Lund University Sabeth Verpoorte, University of Groningen This course is an introduction to microfluidics and the application of this technology in the life sciences. It is designed to give a compact overview of the main important aspects of working with liquids in confined spaces as well as handling of minute amounts of chemicals, highlighting the essential differences between microfluidic-based approaches and more traditional biochemical analysis systems. Attendees receive a broad “first glimpse” impression of all the different bits and pieces (technological, physical and chemical) that are necessary to arrive at functional lab-on-a-chip devices.
SLAS2013.org
I
25
SLAS2013
26
I
I
Repeatable Inspiration
SLAS2013.org
I
Through Scientific Education and Laboratory Technology
E-mail
[email protected] with ideas and feedback. Interested in sponsorship advertising? Contact
[email protected].
Short Courses: January 12-13
I
Conference: January 14-16
Conference Schedule (Schedule Subject to Change)
I
Exhibition: January 13-15
New in 2013! Keynote and live streaming session speakers accept questions via Twitter at four sessions, time permitting. Look for the logo #SLAS2013.
Saturday, January 12, 2013
Short Courses 8:30 am – 4:30 pm
Automating Scientific Data Analysis and Visualization With Excel and VBA (Computer-Based) – Naples 1
Page 23
Automation for In Vitro Diagnostics – Osceola 2
Page 23
Establishing Cell-Based Assays for Screening – Osceola 1
Page 23
Getting Started With Excel and VBA (Computer-Based) – Naples 2
Page 25
LIMS in the Organization – Osceola 5
Page 23
Liquid Handling Boot Camp (Hands-On) – Osceola 3/4
Page 23
Microfluidics I/II – Naples 3
Page 25
Pharmacokinetics and Pharmacodynamics in Drug Discovery – Osceola 6
Page 23
Quantitative Evaluation of Screening Assays for Drug Discovery & Biomarker Applications – Sarasota 1/2
Page 23
Sample Management: Best Practice, Trends and Challenges – Tampa 3
Page 23
Sunday, January 13, 2013
Short Courses 8:30 am – 4:30 pm
3D Cell-Based Assays for Drug De-Risking – Osceola 5
Page 24
Applied Information Technology for the Laboratory – Osceola 1
Page 24
Automated Liquid Handling in Accredited or Forensic Environments – Osceola 2
Page 24
Getting Started With Excel and VBA (Computer-Based) – Naples 2
Page 25
High Content Screening: Instrumentation, Assay Development, Screening, Image and Data Analysis – Osceola 6
Page 24
Introduction to Design of Experiments (Computer-Based) – Naples 1
Page 24
Introduction to Laboratory Automation – Destin
Page 24
Label-Free/Biophysics Methods for Screening – Tampa 2/3
Page 24
Microfluidics I/II – Naples 3
Page 25
Next Generation Sequencing Technology Fundamentals and Applications – Sarasota 1/2
Page 24
Technical Project Management – Osceola 3
Page 24
Writing Testable and Verifiable User Requirements – Osceola 4
Page 24
SLAS2013 Live Streaming Brings Worlds Together SLAS offers the exclusive opportunity to participate in SLAS2013 via live streaming of select sessions — completely free. These sessions allow the global scientific community to unite in person and online through live video webcasts and real-time networking. You will be able to ask questions and get direct answers from the presenters and panelists who are live at SLAS2013. To participate via live streaming, simply go to SLAS2013.org to log-in at the times noted below for each session. There is no need to pre-register. And be sure to encourage colleagues back at the office to log-in and participate live with you: Monday, January 14 9 - 10 am, U.S. Eastern Standard Time Osceola Ballroom CD Keynote Speaker: Mehmet Toner, Ph.D. Bioengineering and Clinical Applications of the Circulating Tumor Cell Microchip
Monday, January 14 3 - 5 pm, U.S. Eastern Standard Time Osceola Ballroom CD Special Session: HTS and Early Drug Discovery in Industry and Academia. Collaboration: Is the Sum Greater Than the Two Parts?
Live streaming is compatible with iPhone, iPad and other mobile devices. Sessions will be available on-demand for a limited time following SLAS2013.
SLAS2013.org
I
27
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Conference Schedule (Schedule Subject to Change)
Sunday, January 13, 2013 7:30 am - 7:00 pm
Florida Exhibition Hall Lobby Lower Level
1:30 - 4:30 pm
See page 136
4:30 - 7:00 pm
Florida Exhibition Hall
Exhibition Open
5:30 - 6:30 pm
Florida Exhibition Hall
Student and Early Career Professionals Mixer in the SLAS Member Center
5:30 - 7:00 pm
Florida Exhibition Hall
Welcome Reception
Registration Open Exhibitor Workshop
Open CityWalk Sunday (6:30 - 11:30 pm Continuous Shuttle Service to Universal Studios CityWalk)
Universal Studios CityWalk
Monday, January 14, 2013 7:00 am
Naples 1
7:00 - 8:00 am
Emerald 4
7:30 am - 6:00 pm
Florida Exhibition Hall Lobby Lower Level
8:00 - 8:30 am 8:30 - 9:00 am
SLAS Career Connections’ Workshop: The Power Formula for LinkedIn Success Laboratory Products Association (LPA) Special Session Registration Open
Osceola Ballroom Foyer Continental Breakfast Osceola Ballroom CD
Opening Remarks
9:00 - 10:00 am
Osceola Ballroom CD
Live Streaming Session! Opening Keynote Speaker: Mehmet Toner, Ph.D., Founding Director of the NIH BioMEMS Resource Center #SLAS2013 and the Helen Andrus Benedict Professor of Surgery (Biomedical Engineering), and Health Sciences and Technology, Sponsored by: Harvard Medical School; Massachusetts General Hospital (MGH) Topic: Bioengineering and Clinical Applications of the Circulating Tumor Cell Microchip
10:00 - 10:30 am
Florida Exhibition Hall
Coffee Break
10:00 am - 6:30 pm
Florida Exhibition Hall
Exhibition Open
10:00 am - 6:30 pm
Florida Exhibition Hall
Poster Viewing
10:30 am - 12:30 pm
Sun Ballroom B
10:30 am
Page 67
Assay Development and Screening Cell-Based Assay Development; Session Chair: Petr Bartunek, Institute of Molecular Genetics A Multiplexed Fluorescent Assay for Independent Second Messenger Systems: Decoding GPCR Activation in Living Cells; Thomas Hughes, Montana Molecular FINALIST
11:00 am
Page 67
Screening for Synthetic Lethalities With Chromatin Factors; Stefan Kubicek, Austrian Academy of Sciences
11:30 am
Page 68
Reporters in Cell-Based Assays: Understanding Fact From Fiction; Doug Auld, Novartis Institutes for BioMedical Research
12:00 pm
Page 68
Primary Cells in High-Throughput Screening: Lessons From Human Blood; Petr Bartunek, Institute of Molecular Genetics
Join the SLAS Social Media Communities #SLAS2013
28
I
SLAS2013.org
Our online communities are growing every day. Stay up-to-date and join in the discussions. Sign-up now!
Short Courses: January 12-13
I
Conference: January 14-16
Conference Schedule (Schedule Subject to Change)
I
Exhibition: January 13-15
Monday, January 14, 2013 (continued)
High-Throughput Technologies High-Throughput Chemistry and Analytics; Session Chair: Alex Godfrey, Eli Lilly and Company
10:30 am - 12:30 pm
Sun Ballroom A
10:30 am
Page 97
Continuous Flow Multi-Step Synthesis; Timothy Jamison, Massachusetts Institute of Technology
11:00 am
Page 97
High-Throughput Chemistry Platform at Abbott; Kevin Woller, Abbott Laboratories
11:30 am
Page 98
The Virtual MedChem Lab: New Research Paradigms in Drug Discovery; Alex Godfrey, Eli Lilly and Company
12:00 pm
Page 98
Object Oriented Workflow Design – Virtually Unrestricted Combination of Sequential and Parallel Processing in HT Workflows; Rolf Gueller, Chemspeed Technologies
10:30 am - 12:30 pm
Sun Ballroom D
10:30 am
Page 121
11:00 am
Page 121
Micro/Nano Technologies Droplet Microfluidics; Session Chair: Darren Link, Raindance Technologies High-Throughput Screening of Small Molecules and Proteins in Droplets; Andrew Griffiths, Institut de Science et d'Ingénierie Supramoléculaires Genomic Applications of Droplet Microfluidics; Darren Link, RainDance FI NALIST
11:30 am
Page 122
Building the Foundation of Next-Generation Distributed Drug Discovery; Brian Paegel, The Scripps Research Institute FINALIST
Combining Picoliter-Scale Droplet Sampling With Proximity Immunoassays for Direct Measurement of Hormone Secretion From Small Amounts of Endocrine Tissue; Christopher Easley, Auburn University
12:00 pm
Page 122
10:30 am - 12:30 pm
Sun Ballroom C
10:30 am
Page 109
Making Sense of High-Throughput Genomic Sequencing; Chris Bizon, RENCI
11:00 am
Page 109
Exploration and Analysis of Complex Data Using Topological Data Analysis; Pek Lum, Ayasdi Inc.
11:30 am
Page 110
Extracting Complexity From High Content Screening Assays; J. Paul Robinson, Purdue University
12:00 pm
Page 110
Informatics Extracting Meaning From Complex Data; Session Chair: Dana Vanderwall, Bristol-Myers Squibb Company
A Novel “Organelle Map” Framework for the Automatic Detection of Cellular Morphology Changes; Kristine Schauer, Institut Curie FI NALIST
Bioanalytical Techniques Novel Approaches to Bioanalytical Techniques; Session Chair: Peter Grandsard, Amgen, Inc.
10:30 am - 12:30 pm
Miami 1-3
10:30 am
Page 79
High-Resolution CryoEM: A New Method for Atomic Modeling of Macromolecular Complexes; Hong Zhou, University of California, Los Angeles
11:00 am
Page 79
Nanodiscs as a Bioanalytical Platform for Understanding Membrane Protein Structure and Function; Michael Marty, University of Illinois at Urbana-Champaign
11:30 am
Page 80
switchSENSE – An Electro-Switchable Biointerface for the Label-Free Analysis of Molecular Interactions; Ulrich Rant, Dynamic Biosensors GmbH and Technical University Munich
12:00 pm
Page 80
On-Line Nano-Pore Optical Interferometry (NPOI) Mass Spectrometry (MS) for Screening and Quantifying Small Molecule-Protein Interactions; Paul Schnier, Amgen, Inc.
12:30 pm
Naples 1
SLAS Career Connections’ Workshop: The Power Formula for LinkedIn Success
12:30 - 1:15 pm
See page 136
12:30 - 1:30 pm
Florida Exhibition Hall
Exhibitor Tutorials Lunch
Sponsored by:
(box lunch provided)
SLAS2013.org
I
29
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Conference Schedule (Schedule Subject to Change)
Monday, January 14, 2013 (continued)
Exhibitor Tutorials
12:30 - 1:45 pm
See pages 137-138
1:00 - 3:00 pm
Florida Exhibition Hall
2:00 - 2:45 pm
See pages 139-141
2:30 - 3:00 pm
Florida Exhibition Hall
3:00 - 5:00 pm
Sun Ballroom B
3:00 pm
Page 69
A Focus on Robust Target Choice to Address Pipeline Attrition: Tool Compounds for Novel Targets; Cathy Tralau-Stewart; Drug Discovery Centre, Imperial College
3:30 pm
Page 69
Selective Targeting of Epigenetic Effector Domains of the Bromodomains Family; Stefan Knapp, SGC Oxford
4:00 pm
Page 70
A Comprehensive Survey of Kinase Inhibitor Selectivity; Haiching Ma, Reaction Biology Corporation
4:30 pm
Page 70
In Search of Physiological Relevance: Adventures in Molecular Pharmacology; Fabien Vincent, Pfizer
3:00 - 5:00 pm
Sun Ballroom A
3:00 pm
Page 99
Building Quality Biological Collections; Katheryn Shea, International Society for Biological and Environmental Repositories (ISBER)
3:30 pm
Page 99
Executing Collaborations and Acquisitions – A Behind the Scenes Look at the Role of a Sample Management Group; Rosalia Gonzalez, Pfizer
4:00 pm
Page 100
Real Time Droplet Detection for Low Volume Dispensing; Sam Michael, National Center for Advancing Translational Sciences (NCATS)
4:30 pm
Page 100
Rethinking Compound Pooling: “Just in Time Duplexing” is an Innovative and Cost Effective Solution to Double High-Throughput Screening Capacity; David Harden, Bristol-Myers Squibb Company
3:00 - 5:00 pm
Sun Ballroom D
3:00 pm
Page 123
Poster Presentations (Monday Posters) Exhibitor Tutorials Coffee Break Assay Development and Screening Chemical Probes for Target Validation and Pathway Analysis; Session Chair: Cathy Tralau-Stewart; Drug Discovery Centre, Imperial College
High-Throughput Technologies Compound and Biologics High-Throughput Sample Management; Session Chair: Sue Holland Crimmin
Micro/Nano Technologies Technology Development Takes Aim at Simplifying Cellular Processes; Session Chair: Dana Spence, Michigan State University Talking About a (Proteomics) Revolution: Microfluidic Frameworks for High-Throughput Protein Analysis; Amy Herr, University of California, Berkeley FI NALIST
3:30 pm
Page 123
A Microfluidic-Based In Vitro PK /PD System: Advantages and Challenges; Dana Spence, Michigan State University
4:00 pm
Page 124
Massively Parallel Nanoparticle Manipulation With Micro-Magnetic Ratcheting System for Biological Exploration; Coleman Murray, University of California, Los Angeles
4:30 pm
Page 124
Directed Secretion of Mast Cells Revealed by Selective Stimulation in a Laminar Flow-Based Microfluidic Device; Yanli Liu, Sandia National Labs
3:00 - 5:00 pm
Sun Ballroom C
3:00 pm
Page 111
In Vivo Workflow Optimization; Viral Vyas, Bristol-Myers Squibb Company
3:30 pm
Page 111
Implementation of an Integrated Data System to Support Academic Drug Discovery; William Janzen, University of North Carolina
4:00 pm
Page 112
PaR-PaR: Programming a Robot Laboratory Automation Platform; Gregory Linshinz, Joint BioEnergy Institute
4:30 pm
Page 112
A High-Throughput Phenotypic Assay for Modulators of Taste Response Utilizing Trained Rats; R. Kyle Palmer, Opertech Bio, Inc.
30
I
SLAS2013.org
Informatics Informatics in the Laboratory: Success Stories; Session Chair: James Gill, Bristol-Myers Squibb Company
Short Courses: January 12-13
I
Conference: January 14-16
Conference Schedule (Schedule Subject to Change)
I
Exhibition: January 13-15
Tuesday, January 15, 2013 (continued)
Bioanalytical Techniques BioAnalytical Methods for Next-Gen Sequencing; Session Chair: Gary Schroth, Illumina, Inc.
3:00 - 5:00 pm
Miami 1-3
3:00 pm
Page 81
Molecular Analysis With Next Generation Sequencing; Gary Schroth, Illumina, Inc.
3:30 pm
Page 81
Challenges and Solutions for Benchtop Sequencing Sample Prep; Andrew Barry, PerkinElmer
4:00 pm
Page 82
Using RNA-Binding Proteins and microRNA Targeting to Study the Human Regulatory Code; Scott Tenenbaum, The State University of New York
4:30 pm
Page 82
Millions of DNA Sequences to a Handful of Compounds: Enabling Decision-Making for Encoded Library Technology Chemists; Jeff Messer, GlaxoSmithKline
3:00 - 5:00 pm
Osceola Ballroom CD
Special Session Session Chairs: Ricardo Macarron, GlaxoSmithKline and Peter Hodder, The Scripps Research Institute
Page 66
HTS and Early Drug Discovery in Industry and Academia. Collaboration: Is the Sum Greater Than the Two Parts?; Ricardo Macarron, GlaxoSmithKline; Peter Hodder, The Scripps Research Institute; Martyn Banks, Bristol-Myers Squibb Company; Barbara Slusher, The Johns Hopkins University Live Streaming Session! #SLAS2013
5:30 - 6:30 pm
Florida Exhibition Hall
Reception Celebrating the 2013 SLAS Journal Achievement Award Honorees
7:00 - 9:00 pm
Page 39 Sun Ballroom A
8:00 pm
The Gaylord Palms Resort, Osceola Ballroom AB
Late Night With LRIG-Rapid Fire Innovation Session Moleular Monday: Rockin’ the Revolution for Personalized Healthcare – PerkinElmer's Band Performs at The Gaylord Palms Sponsored by:
Tuesday, January 15, 2013 7:00 - 8:15 am
Gainesville 1-2
7:00 - 9:00 am
Emerald 2
7:30 am - 6:00 pm
Florida Exhibition Hall Lobby Lower Level
8:00 - 8:45 am
8:00 - 8:45 am 8:30 - 9:00 am
SLAS Career Connections’ Workshop: Committed Networking Analytical, Life Science & Diagnostics Association (ALDA) Special Session (Invitation Only) Registration Open Special Interest Group Meetings
Page 40
Informatics - Tallahassee 1-3
Page 40
Labware Leachables - Sun 3-4
Page 40
Microplate Standards - Sun 1-2
Page 40
Technology Transfer and CRO/CMO Project Management - Miami 1-3
Page 40
Women Professionals in Science and Technology - Naples 1
See pages 141-142
Exhibitor Tutorials
Osceola Ballroom Foyer Continental Breakfast Keynote Speaker: Sir Harold Kroto, Ph.D., Department of Chemistry and Biochemistry; The Florida State University; 1996 Nobel Prize in Chemistry Topic: Science and Society in the 21st Century
9:00 - 10:00 am
Osceola Ballroom CD
10:00 - 10:30 am
Florida Exhibition Hall
Coffee Break
10:00 am - 6:00 pm
Florida Exhibition Hall
Poster Viewing
10:00 am - 6:00 pm
Florida Exhibition Hall
Exhibition Open
#SLAS2013 Sponsored by:
SLAS2013.org
I
31
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Conference Schedule (Schedule Subject to Change)
Tuesday, January 15, 2013 (continued)
Assay Development and Screening Biochemical Assay Technologies and Screening; Session Chair: Yuhong Du, Emory University
10:30 am - 12:30 pm
Sun Ballroom B
10:30 am
Page 71
Development of a Multiplexed HTS Assay for Simultaneous Monitoring of More Than Two Bimolecular Interactions in One Well to Maximize the Efficiency of Small Molecule Discovery; Yuhong Du, Emory University
11:00 am
Page 71
(NCATS)/NIH Enzyme Assays for Large-Scale HTS: Challenges, Compromises, Opportunities; Anton Simeonov, National Center for Advancing Translational Sciences
11:30 am
Page 72
Measuring Enzymatic Modification of DNA Using High-Throughput Mass Spectrometry; Peter Rye, Agilent Technologies
12:00 pm
Page 72
Free-Solution, Label-Free Analysis of Membrane Protein Targets by Back-Scattering Interferometry; Scot Weinberger, Molecular Sensing, Inc.
10:30 am - 12:30 pm
Sun Ballroom A
10:30 am
Page 101
Self-Imaging Petri Dishes for Direct Image Streaming From the Incubators; Changhuei Yang, California Institute of Technology
11:00 am
Page 101
Development and Application of DNA Editing Technology; Tuval Ben Yehezkal, Weizmann Institute
11:30 am
Page 102
A Dielectrophoretic Approach for Cancer Stem Cell Separation; Victoria Holderby, The University of Texas at Dallas
12:00 pm
Page 102
Digital Microfluidics With Impedance Sensing for Integrated Cell Culture and Analysis; Steve Shih, University of Toronto
10:30 am - 12:30 pm
Sun Ballroom D
10:30 am
Page 125
Nano-Devices for Next Generation Stem Cell Therapeutics, Medical Adhesives, and Drug Delivery Systems; Jeff Karp, Harvard University
11:00 am
Page 125
Assessing Cellular Toxicities Upon Exposure to Different Types of Nanomedicines: A High Content Analysis Approach; Dan Peer, Tel Aviv University
11:30 am
Page 126
Engineering of Polymeric Nanoparticles for Medical Applications; Omid Farokhzad, Harvard Medical School
12:00 pm
Page 126
Targeted Nanomedical Approach to Screening and Enhanced Treatment of Cancer Stem Cell-Driven Tumors; Edward Chow, National University of Singapore
10:30 am - 12:30 pm
Sun Ballroom C
10:30 am
Page 113
The Impact of Tablet PCs and Social Networking on Laboratory Informatics; Scott Weiss, IDBS
11:00 am
Page 113
Collaboration in the Age of Research Externalization; Michael Elliot, Atrium Research
11:30 am
Page 114
Foldit and Games for Scientific Discovery; Seth Cooper, University of Washington
12:00 pm
Page 114
Approach to an Information Management Framework to Support External Business Collaboration; Robert O’Hara, ResultWorks, LLC
10:30 am - 12:30 pm
Miami 1-3
Bioanalytical Techniques (Track Ends) Isolation and Analysis of Rare Cells; Session Chair: Sam Forry, National Institute of Standards and Technology
10:30 am
Page 83
Capture of Rare Cells From Whole Blood; Sam Forry, National Institute of Standards and Technology
11:00 am
Page 83
A New Platform for Cell Fractionation and its Application in Processing Forensic Samples; Dan Mueth, Arryx (a Haemonetics Company)
11:30 am
Page 84
Analysis and Isolation of Rare Cells by Flow Cytometry; Diether Recktenwald, BD Biosciences
12:00 pm
Page 84
Second Generation Cellular Imaging Analysis; Wendy Gough, Eli Lilly and Company
32
I
SLAS2013.org
High-Throughput Technologies Cutting Edge Technology Developments; Session Chair: Marc Feiglin, Tecan
Micro/Nano Technologies NextGen Nanomedicine Platform Technologies; Session Chair: Jeff Karp, Harvard University
Informatics Collaborative Discovery in the Internet Age; Session Chair: Scott Weiss, IDBS
Short Courses: January 12-13
I
Conference: January 14-16
Conference Schedule (Schedule Subject to Change)
I
Exhibition: January 13-15
Tuesday, January 15, 2013 (continued)
12:30 - 1:15 pm
See page 143
Exhibitor Tutorials
12:30 - 1:30 pm
Florida Exhibition Hall
Lunch Sponsored by:
12:30 - 1:45 pm
See pages 144-145
Exhibitor Tutorials
1:00 - 3:00 pm
Florida Exhibition Hall
2:00 - 2:45 pm
See pages 145-147
2:30 - 3:00 pm
Florida Exhibition Hall
3:00 - 5:00 pm
Sun Ballroom B
3:00 pm
Page 73
Development, Optimization and Validation of a HCS Biosensor Assay to Identify Compounds That Disrupt AR-TIF2 Protein-Protein Interactions; Paul Johnston, Pittsburgh Molecular Libraries Screen Center
3:30 pm
Page 73
Improving Predictive Drug and Chemical Safety Using High Content Imaging Phenotypic Screening and Pharmacogenetics to Determine Toxicity Pathways; Oscar Joe Trask, The Hamner Institutes for Health Sciences
4:00 pm
Page 74
(box lunch provided)
Poster Presentations (Tuesday Posters) Exhibitor Tutorials Coffee Break Assay Development and Screening High Content Screening; Session Chair: Paul Johnston, Pittsburgh University
A 3D Cell Culture Based Platform for Phenotypic Screening and Multi-Parametric Profiling of Compounds; Leo Price, Leiden-Amsterdam Center for Drug Research FI NALIST
4:30 pm
Page 74
Dynamic Approaches to High Content Screening; Edward Ainscow, GNF High-Throughput Technologies New Developments and Applications in High-Throughput Screening Technologies and Automation; Session Chair: Malcolm Crook, Process Analysis and Automation
3:00 - 5:00 pm
Sun Ballroom A
3:00 pm
Page 103
STEP - A Fully Automated HTS System That is Adaptable to Meet Today’s and Future Needs of Drug Discovery; Geoffrey Cutler, Novartis Institute for Biomedical Research
3:30 pm
Page 103
Developing an Automated Multi-System Compatible Screening Platform at the Novartis Institutes for Biomedical Research Designed for Flexible and Rapid Assay Development and Screening With Direct Compound Addition; Chun-Hao Chiu, Novartis Institute for Biomedical Research
4:00 pm
Page 104
Conception Through Build of Automated Compound Dissolution and Distribution Systems for Compound Management in a Low Humidity Environment; Richard Belval, Boehringer Ingelheim
4:30 pm
Page 104
High-Throughput Manufacturing of Human Epidermal Models Using a Novel Tissue Culture Plate; Andreas Traube, Fraunhofer IPA
3:00 - 5:00 pm
Sun Ballroom D
3:00 pm
Page 127
Microfluidic Models of the Body and Microfluidic Biomarker Analysis; Shu Takayama, University of Michigan
3:30 pm
Page 127
Engineered Models of Liver Disease; Salman Khetani, Colorado State University
4:00 pm
Page 128
Microfluidic Oxygenated Substrates for Cells and Tissues; David Eddington, University of Illinois at Chicago
4:30 pm
Page 128
A Bjerknes Force Based Microfluidic Platform for On-Chip Trapping, Enriching, Sorting and Manipulating Caenorhabditis Elegans; Jie Xu, Abbott Laboratories
Micro/Nano Technologies Tissues and Organs on Chip; Session Chair: Dan Huh, Harvard University
SLAS2013.org
I
33
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Conference Schedule (Schedule Subject to Change)
Tuesday, January 15, 2013 (continued)
Informatics Informatics in Highly Integrated Systems; Session Chair: Yan Song, Abbott Laboratories
3:00 - 5:00 pm
Sun Ballroom C
3:00 pm
Page 115
Bio-Analytical Lab Workflow and Information Systems Integration; Yan Song, Abbott Laboratories
3:30 pm
Page 115
Fully Automated Sample Preparation for Forensic Toxicology Analysis – Handling of Various Sample Types Including Whole Blood Samples; David Andersen, University of Copenhagen
4:00 pm
Page 116
Integrated Informatics Solution for Biologics Discovery Research; Geetha Vasudevan, Bristol-Myers Squibb Company
4:30 pm
Page 116
A Remotely Guided Chemical Synthesis System for Discovery Chemistry; Jeff Gygi, Eli Lilly and Company
3:00 - 5:00 pm
Miami 1-3
Diagnostics (Track Begins) Advances in Near Patient Testing Devices; Session Chair: John McDevitt, Rice University
3:00 pm
Page 85
The Programmable Bio-Nano-Chip: A Fully Automated Platform That Bridges From Biomarker Discovery to Clinical Application; John McDevitt, Rice University
3:30 pm
Page 85
Image-Based CBC Solution for Near-Patient Care; Douglas Olson, Abbott Laboratories
4:00 pm
Page 86
Point-of-Care Nucleic Acid Testing for Infectious Diseases; Angelika Niemz, Keck Graduate Institute
4:30 pm
Page 86
Performance Comparison of Nanomonitor Against ELISA on Patient Pool Samples; Krishna Mohan Vattipalli, University of Texas at Dallas
3:00 - 5:00 pm
Tallahassee 1-3
3:00 pm
Page 91
Protein-Protein Interaction Interfaces as Drug Targets; Haian Fu, Emory University
3:30 pm
Page 91
Challenges to Congenital Genetic Disorders With “RNA-Targeting” Chemical Compounds; Masatoshi Hagiwara, Kyoto University
4:00 pm
Page 92
The Human SET1/MLL Family of Histone Methyltransferase Complexes – The Challenges of Developing Robust Biochemical Assays for Identification of Discovery Tool Compounds; Konrad Howitz, Reaction Biology Corporation
4:30 pm
Page 92
A Systematic Approach to the Identification of Biased Agonists of the Apelin Receptor (APJ) Via High-Throughput Screening; Layton Smith, Sanford Burnham Medical Research Institute
5:00 - 6:00 pm
Florida Exhibition Hall
7:00 - 10:00 pm
1490 East Buena Vista Drive
House of Blues
Drug Target Biology (Track Begins) Emerging and Challenging Targets for Interrogation; Session Chair: Haian Fu, Emory University
Closing Reception in the Exhibit Hall Vortex Tuesday @ The House of Blues
Wednesday, January 16, 2013 8:00 - 9:15 am
8:30 am - 1:30 pm 9:00 - 9:30 am
34
I
Special Interest Group Meetings Page 41
ADMET - Sun 5-6
Page 41
Automation Quality Control - Sun 1-2
Page 41
Phenotypic Drug Discovery - Sarasota 1-3
Page 42
Screen Design and Assay - Sanibel 1
Florida Exhibition Hall Lobby Lower Level
Registration Open
Osceola Ballroom Foyer Continental Breakfast
SLAS2013.org
Sponsored by:
Short Courses: January 12-13
I
Conference: January 14-16
Conference Schedule (Schedule Subject to Change)
I
Exhibition: January 13-15
Wednesday, January 16, 2013 (continued)
Assay Development and Screening Screening Libraries; Session Chair: Donna Huryn, University of Pittsburgh, University of Pennsylvania
9:30 - 11:30 am
Sun Ballroom B
9:30 am
Page 75
Are We Closer to Building a Perfect Screening Library?; Donna Huryn, University of Pittsburgh, University of Pennsylvania
10:00 am
Page 75
Generation and Characterization of a GABABR-Focused Allosteric Modulator Library: From a PAM to a NAM With Biased and Orthologue Selective Behavior; Emmanuel Sturchler, The Scripps Research Institute
10:30 am
Page 76
Screening Natural Product Extracts in Cell-Free and Cell-Based Assay Systems; Barry O’Keefe, Frederick National Laboratory for Cancer Research
11:00 am
Page 76
From Heterocyclic Libraries to Biological Probes; Peter Wipf, University of Pittsburgh
9:30 - 11:30 am
Sun Ballroom A
9:30 am
Page 105
High-Throughput Technologies Non Plate-Based High-Throughput Technologies; Session Chair: Adam Hill, Novartis Biomedical Research Institute Making a Quantum Leap In Mass Spectrometry Throughput: Applying the NextVal MassInsight Technology to Monitor Cytochrome P450 Enzyme Inhibition in Human Liver Microsomes; Andrea Weston, Bristol-Myers Squibb Company FINALIST
10:00 am
Page 105
Droplet-Based Microfluidics for High-Throughput Experimentation; Andrew deMello, Institute for Chemical and Bioengineering Department of Chemistry and Applied Biosciences ETH
10:30 am
Page 106
Cellular Microarrays for Applications in Antimicrobial Drug Discovery; Anand Ramasubramanian, University of Texas at San Antonio
11:00 am
Page 106
The Evolution of Flow Cytometry as a High-Throughput Drug Screening Platform; Robert Jepras, GlaxoSmithKline
9:30 - 11:30 am
Sun Ballroom D
9:30 am
Page 129
Autonomous Screening of C. Elegans Using Advanced MIcrofluidics and Machine Vision; Hang Lu, Georgia Institute of Technology
10:00 am
Page 129
Paper-Based Agricultural and Clinical Point-of-Care Diagnostics for Resource Limited Settings; Matthew Stewart, Diagnostics For All
10:30 am
Page 130
Picoliter-Scale Compound Library Distribution and Assays; Alexander Price, The Scripps Research Institute
Page 130
Kit-On-A-Lid-Assay: Self-Contained Microfluidic Cell-Based Assays for the Masses; David Beebe, University of Wisconsin-Madison
11:00 am
Micro/Nano Technologies Next-Generation Microanalytical Systems; Session Chair: Amy Herr, University of California, Berkeley
FI NALIST
Informatics Integrating Laboratory Information Into a Global Discovery Solution; Session Chair: Andreas Matern, Thomson Reuters
9:30 - 11:30 am
Sun Ballroom C
9:30 am
Page 117
Now, Where Did I Put That? The Future of Search and Findability in Scientific Data; Andreas Matern, Thomson Reuters
10:00 am
Page 117
Drug Repurposing Through the Analysis of Large Corporate Chemoinformatic/ Bioinformatic Databases; Will Loging, Boehringer Ingelheim
10:30 am
Page 118
Challenges in Designing, Integrating, and Delivering a Chemical and Biological Database and Query Portal to Stakeholders Across Multiple Organizations, Locations, and Disciplines: Case Histories From Pharma and the NIH Roadmap; Thomas Chung, Sanford-Burnham Medical Research Institute
11:00 am
Page 118
How Can We Reduce the Cost of Drug Discovery?; Elizabeth Iorns, ScienceExchange
SLAS2013.org
I
35
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Conference Schedule (Schedule Subject to Change)
Wednesday, January 16, 2013 (continued)
Diagnostics Diagnostics Tests and Personalized Medicine; Session Chair: John Robinson, Abbott Laboratories
9:30 - 11:30 am
Miami 1-3
9:30 am
Page 87
Companion Diagnostics Enabling Personalized Medicine; ALK Gene Rearrangement in Non-Small Cell Lung Cancer; Klara Abravaya, Abbott Molecular
10:00 am
Page 87
Next Generation Sequencing Based Clinical Diagnostics in Molecular Oncology; Eric Duncavage, Washington University Association for Molecular Pathology (AMP) Presentation
10:30 am
Page 88
Kinase Cell-Based Assays for Selectivity Assessment and Personalized Medicine; Deborah Moshinsky, Cell Assay Innovations
11:00 am
Page 88
Circulating Tumor Cells as a Biomarker to Monitor Cancer; Martin Fleisher, Memorial Sloan-Kettering Cancer Center Association for Molecular Pathology (AMP) Presentation
9:30 - 11:30 am
Tallahassee 1-3
9:30 am
Page 93
10:00 am
Page 93
Drug Target Biology From Cellular Pathways to Drug Targets; Session Chair: Kelvin Lam, Blue Sky BioServices Hit Concordance Between the TDA (Template Directed Assembly) and Phenotypic HCS (High Content Screening) Assays; Kelvin Lam, Blue Sky BioServices Phenotypic Screening in Zebrafish Identifies Compounds That Protect Mechanosensory Hair Cells From Drug-Induced Cell Death: A Model for Hearing Protection; Kelly Owens, University of Washington FI NALIST
10:30 am
Page 94
Integrating Novel Technologies to Identify Small-Molecules That Drive Translational Research and Therapeutics in Cardiovascular Disease; Michelle Palmer, Broad Institute of MIT and Harvard
11:00 am
Page 94
High Content Screening Strategy for the RNA Binding Protein TDP-43; Marcie Glicksman, Harvard Center for Neurodegeneration and Repair
11:30 am - 12:30 pm Osceola Ballroom Lobby Lunch (For Full Conference Registrants Only) 11:45 am - 1:15 pm
Sarasota 1-3
11:45 am - 1:15 pm
JALA & JBS Author Workshop: How to Get Your Work Published Special Interest Groups
Page 42
Academic Drug Discovery - Sun 3-4
Page 42
Drug Repurposing - Sanibel 1
Page 42
Sample Management - Sanibel 2
Page 43
Standards Initiatives - Sun 1-2
Page 43
Stem Cells - Sun 5-6 Assay Development and Screening Assays for Diverse Applications: Biologics, Diagnostics, and Toxicology; Session Chair: Christopher Moxham, Imclone Systems
1:30 - 3:30 pm
Sun Ballroom B
1:30 pm
Page 77
Cell-Based Assays for Biologics Drug Discovery; Christopher Moxham, Imclone Systems
2:00 pm
Page 77
Platform Technology for Identifying Stem Cell Sub Populations for Tumor Classification in Lung and Breast Cancer; Shalini Prasad, The University of Texas at Dallas
2:30 pm
Page 78
Label-Free Bioanalytical Investigation of Long-Term Glycemic Markers; Narahara Chari Dingari, Massachusetts Institute of Technology
3:00 pm
Page 78
Multiplexed Drug Assessment in Multi-Cell Type 3D Microtissues; Jens Kelm, InSphero AG
1:30 - 3:30 pm
Sun Ballroom A
1:30 pm
Page 107
Human Induced Pluripotent Stem Cell Derived Cardiomyocytes are a More Relevant Model Than H9C2 Cells for Assessing Mitochondrial Function in Drug Discovery and Toxicity Screens; Blake Anson, Cellular Dynamics International
2:00 pm
Page 107
High-Throughput Multiplexed Transcriptional Profiling, Coupled With High-Content Cellular Analysis, Identifies Disease-Related Targets in a Newly Characterized Pediatric Hypomyoplasia; John Westwick, Odyssey Thera, Inc.
2:30 pm
Page 108
PhenomicScreen and PhenomicTD in Drug Discovery at IP-Korea; Veronica Soloveva, Pasteur Institute Korea
3:00 pm
Page 108
Elucidation of Potent, Dimeric Inhibitors of HCV NS5A in Replicon; Jeff Romine, Bristol-Myers Squibb Company
36
I
SLAS2013.org
High-Throughput Technologies Automated Screening Applications Using Primary Cells, Stem Cells or Phenotypic Approaches; Session Chair: Jonathan Lee, Eli Lilly and Company
Short Courses: January 12-13
I
Conference: January 14-16
Conference Schedule (Schedule Subject to Change)
I
Exhibition: January 13-15
Wednesday, January 16, 2013 (continued)
Micro/Nano Technologies On-Chip Imaging; Session Chair: Aydogan Ozcan, University of California, Los Angeles
1:30 - 3:30 pm
Sun Ballroom D
1:30 pm
Page 131
Cancer Therapeutics Based on Smart Nanoparticles; Sadik Esener, University of California, San Diego
2:00 pm
Page 131
Lens-Free On-Chip Microscopy and Tomography Toward Telemedicine Applications; Aydogan Ozcan, University of California, Los Angeles
2:30 pm
Page 132
Silicon Photonic Bio-Sensing Detection Platform; Martin Gleeson, Genalyte
3:00 pm
Page 132
Interactions Between Biomolecules Driven by Femtosecond UV Laser Pulses; Rosaria Benedetti, SUN, University of Naples
1:30 - 3:30 pm
Sun Ballroom C
1:30 pm
Page 119
The Collaborative Drug Discovery Paradigm; Barry Bunin, Collaborative Drug Discovery (CDD), Inc.
2:00 pm
Page 119
Enabling Hit Identification With Data Mining and Advanced Computing Infrastructure; Brian Claus, Bristol-Myers Squibb Company
2:30 pm
Page 120
Computing in Cloud: Challenges in Managing Logistics of Big Data and High Transaction Applications; Mohammed Shaikh, Bristol-Myers Squibb Company
3:00 pm
Page 120
1:30 - 3:30 pm
Miami 1-3
1:30 pm
Page 89
Single-Cell Mass Cytometry Delineates Clinically and Mechanistically Relevant Leukemic Differentiation Substructures; Garry Nolan, Stanford Medical School
2:00 pm
Page 89
EGIR for Non-Invasive Genomic Detection and Assessment of Melanoma; William Wachsman, University of California, San Diego School of Medicine Association for Molecular Pathology (AMP) Presentation
2:30 pm
Page 90
Transformative Technology Support From The NCI: The Innovative Molecular Analysis Technologies Program; Tony Dickherber, National Cancer Institute
3:00 pm
Page 90
1:30 - 3:30 pm
Tallahassee 1-3
1:30 pm
Page 95
A Perspective on Living With Huntington’s Disease; Charles Sabine, Emmy-Award Winning Television Journalist
2:00 pm
Page 95
Developing Therapies for Huntington’s Disease: A Prototype for all Neurodegenerative Drug Discovery?; Robert Pacifici, CHDI Foundation, Inc.
2:30 pm
Page 96
3:00 pm
Page 96
3:45 - 5:00 pm
Osceola Ballroom CD
Informatics High Performance Computing for Laboratory Data Analysis; Session Chair: Mohammed Shaikh, Bristol-Myers Squibb Company
Dispensing Processes Impact Computational and Statistical Analysis; Sean Ekins, Collaborations in Chemistry Diagnostics Identification of Diagnostic Biomarkers With Novel Clinical Application; Session Chair: Thomas Kodadek, The Scripps Research Institute
Discovery of Serum Antibody Biomarkers Via Screening Libraries of Synthetic Antigen Surrogates; Thomas Kodadek, The Scripps Research Institute Drug Target Biology Navigating Neurodegenerative Disease Research to Patient Therapies; Session Chair: Doug Auld, Novartis Institutes for BioMedical Research
A New Therapeutic Discovery Strategy for Alzheimer’s Disease: Treating Vascular Deficits Through the Inhibition of Amyloid-Fibrinogen Interactions; J. Fraser Glickman, Rockefeller University Targeting Inherited Genetic Diseases of the Peripheral Nervous Systems for Drug Discovery: A Case Study for the Gene-Dosage Disorder CMT1A; Jim Inglese, National Institutes of Health (NIH) Closing Keynote Speaker: Charles Sabine, Emmy-Award Winning Television Journalist and Scientific Advocate Topic: The Pursuit of Hope and Dignity: Sponsored by: Why Every Link of the Medical Chain Matters
#SLAS2013
Announcement of $10,000 Innovation Award Winner
JALA & JBS Authors Workshop Wednesday, January 16, 11:45 am - 1:15 pm, Room: Sarasota 1-3 How to Get Your Work Published
There is no magic bullet, but there are important tips that every prospective author should know before submitting a scientific manuscript for consideration by a peer-reviewed journal. Edward Chow, Ph.D., of National University of Singapore (an accomplished author and member of the JALA Editorial Board) shares step-by-step advice on how to design and write scientific research papers more clearly and effectively to improve their chances for successful publication. Attendees learn what editors want, what they don’t want, and how reviewers evaluate manuscripts.
SLAS2013.org
I
37
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Strategic Alliances Bring Special Sessions to SLAS2013
Destination Drug Discovery, Sunday, January 13, 1 - 5 pm EST A Satellite Symposium at the Lake Nona (FL) Facility of the Sanford Burnham Medical Research Institute SLAS, in close concert with the Sanford Burnham Medical Research Institute (SMBRI), with support from DiscoveRx and HighRes Biosolutions, presents Destination Drug Discovery, a free satellite symposium for SLAS2013 participants. The program includes a tour of Sanford-Burnham’s ultra-high throughput screening facility, presentations by top researchers from the Institute, and a reception with informal networking. The source of tomorrow’s medicines is of great concern to policy makers, scientists, physicians, and patients. The high rate of attrition and enormous costs requires a smarter approach to drug discovery, especially in the early stages of target and lead identification, validation, and optimization. This program will feature multiple internationally renowned scientists from SBMRI presenting their cutting-edge research, application of novel technologies, and approaches to discovering new medicines faster, cheaper, and better.
Laboratory Products Association (LPA), Monday, January 14, 7 – 8 am
Room: Emerald 4 LPA and SLAS host a special session to announce the preliminary results of the annual North American Laboratory Equipment Purchasing Trends Study.
International Society for Biological and Environmental Repositories (ISBER) Monday, January 14, 3 – 3:30 pm
Room: Sun Ballroom A New this year ISBER delivers a special presentation within the High-Throughput Technologies Track Focusing on “Building Quality Biological Collections.”
Analytical, Life Science & Diagnostics Association (ALDA), Tuesday, January 15, 7 – 9 am
Room: Emerald 2 This exclusive invitation-only breakfast provides an informal forum for dialogue among the senior executives attending SLAS2013 and features presentations from leading academics and users on global trends in laboratory automation technologies and applications and the strategic implications.
Association for Molecular Pathology (AMP), Wednesday, January 16, 10 am, 11 am, 2 pm
Room: Miami 1-3 New this year AMP delivers a series of special presentations within the Diagnostics Track focusing on Next Generation Sequencing Based Clinical Diagnostics in Molecular Oncology (10 am); Circulating Tumor Cells as a Biomarker to Monitor Cancer (11 am); and EGIR for Non-Invasive Genomic Detection and Assessment of Melanoma (2 pm).
38
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Late Night With LRIG-Rapid Fire Innovation, Monday, January 14, 7 – 9 pm
Room: Sun Ballroom A An interactive forum weaving together a selection of up to 17 highly innovative companies participating at SLAS2013. The goal of this session is to discuss and learn about the latest innovations in technology products and services impacting laboratory science and technology.
Complimentary refreshments are served. Seating is limited and on a first-come, first-served basis. Admission is FREE.
The following companies are expected to participate: • Labcyte Inc., Sunnyvale, California USA
• Agilent Technologies, Santa Clara, California USA
Echo 525 Liquid Handler
Introduction to the Encore Multispan Liquid Handling System
• Microfluidic ChipShop, Jena, Germany
• Artel, Westbrook, Maine USA
Artel MVS: Liquid Handler Performance Measurement in 100 percent DMSO
• BSSN Software, Mainz, Germany
Next Generation Bioprocess Development and Execution Platform
Valves & Blisters; Latest Additions to the Microfluidic Toolbox
• Nano Discovery, Inc., Orlando, Florida USA
Innovation AveNEW Participant NDS1200: Label-Free Biomolecule Detection and Analysis in Homogeneous Solution
• OcellO 3D Screening, Leiden, The Netherlands
• Biocartis, Lausanne, Switzerland
Innovation AveNEW Participant 3D Compound Screening and Profiling Services
Biocartis Multiplex Detection Platform
• BioTek Instruments, Winooski, Vermont USA
• PerkinElmer, Inc., Downers Grove, Illinois USA
405™ Touch and 405 LS Microplate Washers with Verify™ Technology
NGS Express - Library Prep for Benchtop Sequencers
• Brooks Life Science Systems, Poway, California USA
Brooks Plate Auditor™
• Genalyte, Inc., San Diego, California USA
Maverick™ Rapid Multiplex Detection System
• Genometry, Inc., Cambridge, Massachusetts USA
Innovation AveNEW Participant L1000™ Expression Profiling
• SAMDI Tech, Inc, Chicago, Illinois USA
Innovation AveNEW Participant SAMDI Label-Free Assay Solutions
• Sandstone Diagnostic, Inc., Livermore, California USA
Innovation AveNEW Participant Sandstone One™
• TTP Labtech, Melbourne, UK
• Integra Biosciences, Hudson, New Hampshire USA
VIAFLO 384 - 384 Channel Handheld Pipetting Made Easy and Affordable
Maximise Sample Integrity at -80°C: arktic®, the Affordable Biostore Automated with Air
SLAS Point-to-Point E-News Brief This mobile-friendly weekly e-mail news brief keeps you up to date with SLAS news announcements, deadline reminders and selected industry headlines. Visit SLAS.org to sign up for a free subscription and browse the archives.
SLAS2013.org
I
39
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Special Interest Groups (SIGs)
SIGs afford participants a unique, in-person experience to help find new ways to leverage laboratory science and technology in an effort to advance scientific exploration. SLAS2013 features the following organized SLAS Special Interest Groups (SIGs):
Tuesday, January 15, 8 - 8:45 am • Informatics, Viral Vyas, Chair
Room: Tallahassee 1-3 The SLAS Informatics SIG is being developed to provide software developers an opportunity to better understand and influence the state of informatics in the laboratory. The focus of this SIG is on systems architecture from the board to the user interface and thus includes topics such as hardware/software interfaces, data management, metadata management, asynchronous coding and operating systems, networking and “big data issues.” The Informatics SIG involves developers from academia, industry and the vendor community, and looks forward to partnering with other SIGs both inside and outside SLAS. • Labware Leachables, Lynn Rassmussen, Chair
Room: Sun 3-4 A Suppliers’ Perspective on the Impact of Labware Leachables Presenter: Sammy Datwani, Ph.D., Labcyte, Inc. Chemical additives are routinely used in plastic manufacturing processes and have the ability to leach from labware (pipette, tips and tubing) and impact biological assay activity. This presentation highlights plausible mechanisms, the impact to data quality and solutions to measure and monitor this phenomenon. • Microplate Standards, Amer El-Hage and Michael Shanler, Co-Chairs
Room: Sun 1-2 This is an open forum to discuss the recent Standards 1-4 Re-certification as well as the Standard 6 approval by ANSI. The new ANSI endorsed Standards Management plan, detailing how SLAS will be handling re-certification moving forward is discussed. We will also establish new Chairperson(s) to replace Amer El-Hage and Michael Shanler, as well as confirm committee membership for the Standards Committee. Note: in accordance with ANSI requirements, this committee will meet every five years to re-certify Standards 1-4 and 6. • Technology Transfer and CRO/CMO Project Management, Liming Shi, Chair
Room: Miami 1-3 This SIG focuses on technology transfer this year. In biopharmaceutical industry, technology transfer is composed of manufacturing science, analytical techniques, purification, process science, fill/finish and packaging, etc. In general, the business flowchart includes technology transfer from innovative research to industry and from industry to CRO. There are several challenges and pitfalls during technology transfers. The following topics will be discussed: Technology transfer landscape; advantages and benefits of technology transfer; intellectual management during technology transfer; challenges and strategies for efficient technology transfer; regulations for technology transfer in emerging markets, etc. • Women Professionals in Science and Technology, Robyn Rourick, Chair
Room: Naples 1 The goal of this forum is to establish a collaborative opportunity for Women Professionals in Science and Technology to connect and create a diverse network for sharing experiences and tools for development and success. Do you ever wonder how you can intentionally engineer your career by designing and executing a networking and advancement plan? This session provides a networking opportunity for SLAS members members and is a premier catalyst to share experiences and exchange ideas. This round table discussion with attendees will identify topics of interest and preferred formats for delivery and interaction. All are invited to attend and participate.
40
I
SLAS2013.org
Short Short Courses: Courses: January January 12-13 12-13
I
Conference: Conference: January January 14-16 14-16
I
Exhibition: Exhibition: January January 13-15 13-15
Special Interest Groups (SIGs) continued Wednesday, January 16, 8 - 9:15 am • ADMET, David M. Stresser, Chair
Room: Sun 5-6 Drug Interaction Investigations: Impact of Recent Guidance for Industry on Early ADME Testing In Vitro In 2012, the USFDA issued the updated draft “Guidance for Industry: Drug Interaction Studies —Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations” and the European Medicine Agency issued its final “Guideline on the Investigation of Drug Interactions.” These documents provide specific and general guidance for conducting in vivo and in vitro investigations of drug interaction potential and also serve to reduce uncertainty among practitioners when sending information to these agencies for review. In this discussion, the ADME SIG highlights guidelines pertaining to in vitro studies and discusses what modifications, if any, are indicated for early ADME testing programs to better position developmental drug candidates for later stage drug-interaction testing. • Automation Quality Control, John Thomas Bradshaw, Chair
Room: Sun 1- 2 The Automation Quality Control Special Interest Group (AQC SIG) brings together peers from the pharmaceutical/ biotechnology industries to discuss automation lifecycle management. The intent of this new forum is to discuss current corporate strategies for the acquisition, implementation and support of laboratory automation. It will also address the organization of laboratory automation specialists and highlight success stories as well as potential pitfalls in automation management. Leading this initiative is Amgen’s Craig Schulz, Ph.D., principal scientist, who shares Amgen’s current policies and practices around automation management. An open discussion with audience participants shares perspectives and insights regarding the journey from equipment acquisition to retirement within their organizations. This SIG aims for an open and ongoing dialogue regarding current best practices and lessons learned on key topics such as budgeting, vendor selection/management, outsourcing, and both internal and external support models for automation. The objective of this open forum is for participants to share current approaches, strategies and key learnings about their personal, and their organizations’, automation management practices so that we all benefit from the group’s collective wisdom. Attendee input and participation here would be of great benefit to our greater SLAS community. SIG organizers hope the ideas exchanged and peer connections provide significant help in guiding well-informed automation lifecycle decisions in participants’ organizations. • Phenotypic Drug Discovery, Jonathan Lee, Chair
Room: Sarasota 1-3 An Open Discussion on Phenotypic Drug Discovery (PDD) The majority of modern drug discovery efforts incorporate reductionist views of biology where identification and validation of specific molecular targets form the foundation of the research strategy. In contrast, recent analysis indicates that the majority of first in class NMEs were discovered by target agnostic approaches relying on phenotypic strategies. Significantly, the disconnect between the prevalent use of TDD and the historical productivity of PDD comes at a time when the pharmaceutical industry is experiencing issues with research innovation and productivity. The PDD SIG serves as a forum for the global research community to share, discuss and debate topics related to PDD research. The format is an open forum with a short introduction and definition of terminology. Participants are free to share their experiences, perceptions and thoughts on PDD and issues facing the field.
SLAS2013.org
I
41
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Special Interest Groups (SIGs) continued • Screen Design and Assay Technology, Kenda Evans, Chair
Room: Sanibel 1 Speakers: - Barry O’Keefe, Ph.D., National Cancer Institute, NIH - Paul Johnston, Ph.D., University of Pittsburgh - Douglas Auld, Ph.D., Novartis Institutes for Biomedical Research - Lisa Minor, Ph.D., In Vitro Strategies, LLC Screening in This Economy….What Makes ‘Cents’? The SDAT SIG focuses on the high cost of screening and how to determine the path forward for the new early phase drug discovery economy. Some of the questions addressed include: • What techniques and processes have been put in place to be able to have a viable screening campaign? • Are different screening techniques and applications employed depending on the target of the screen? • Are specific assay technologies used to reduce the cost of the primary vs. secondary screens?
Wednesday, January 16, 11:45 am - 1:15 pm • Academic Drug Discovery, Andrew Napper
Room: Sun 3-4 The Academic Drug Discovery SIG is a forum to discuss the challenges of chemical probe and lead discovery in universities and not-for-profit research centers. It welcomes active participation from vendors, pharmaceutical and biotech companies. This SIG’s goal is to maximize the impact of collaborative efforts to advance target validation and chemical probe and lead discovery projects originating in academic labs. To address widely publicized doubts regarding the reliability of findings reported by labs outside the for-profit pharmaceutical industry, the questions posed at the SLAS2013 are: “Can industry trust the results of academic drug discovery? What are the best strategies to ensure that academic labs are recognized as significant contributors in the field of drug discovery?” A panel discussion to explore these issues are followed by a demonstration of BARD, a new data mining tool designed to facilitate extraction of useful information from screening and hit-to-lead data residing in PubChem and other freely accessible databases. • Drug Repurposing, Roger Bosse and Mathieu Arcand, Co-Chairs
Room: Sanibel 1 Best Strategies to Undertake a Drug Repurposing Initiative • How can we reconcile target-based drug discovery with phenotypic assays in the context of drug repurposing? • What are the best practices in assay and screen be design? • How should compounds be tackled? This format is an open discussion to address considerations and issues when embarking on a drug repurposing endeavor. • Sample Management, Tim Dawes and Richard Kuo, Co-Chairs
Room: Sanibel 2 Listed below are the invited speakers and abstracts: Introduction to the CM SIG, Snehal Bhatt, Sample Management Technologies In a world of globalization, outsourcing, off-shoring and external partnerships, today’s pharmaceutical R&D organization is faced with increasing logistical and regulatory challenges to move research samples across an international network of companies to support the discovery pipeline. Speakers share their experiences (best practices and challenges) in performing cross-border transportation of small molecules and associated regulatory compliances and risks. In addition, there is a round table discussion covering the following topics: • Compliance, risk and mitigation of import/export laws and regulations • Material identification and valuation methodology • Management of prohibited compounds • Software and records retention
42
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
• Sample Management continued
Compound Logistics in a Global Drug Discovery Environment: Challenges and Opportunities, Marybeth Burton, Merck Research Laboratories Externalization of both compound synthesis and screening efforts requires optimized and harmonized processes for compound preparation, import/export, and tracking. This presentation explores challenges in these areas and reviews steps that have been taken at Merck Research Laboratories to stabilize and optimize compound management workflow in a global environment. Topics include compound workflow, product handling for international shipments and IT tracking tools. Global Shipping and Tracking in Sample Management, Rachael Holmes, Novartis Institutes for Biomedical Research In response to the growing need for advanced sample transfer and tracking logistics due to increasing global nature of compound management operations, Novartis has developed an application (Global Shipping and Tracking, GST) to track and automate both inter- and intra- site sample transfers. The need for this tool arose from the desire to streamline and globalize our sample transfer processes and automate (where possible) our compliance with regulatory practices across nations. While the software was developed with internal resources at the Cambridge site, the requirements were developed and improved with input from global team members. Development and release is taking place in several phases, allowing us to both test and refine our needs. Global release will see six sites adopting the software. The development and implementation of this project has been a successful collaboration between global and multi-disciplinary teams. GST provides several types of functionality that enable end-to-end request tracking and performance metrics. Some examples include: tracked and validated transfer of new chemist-created samples to compound management; the ability to create and distribute tracked and validated “packages” (groupings of items destined for a specific recipient and assay); shipment creation – grouping several packages destined for the same site into a shipping box; and reflection of real-time status information back to the global sample request system (allowing the requestor to view the exact status of their item at any time); linking the shipments to courier databases when possible to enhance the tracking features. Tying all of these functionalities together are a set of sample inventory and request databases that were recently developed to replace older infrastructure. These state-of-the-art systems allow us to efficiently store and mine our request and sample transfer data – we can now evaluate bottlenecks, create live metrics to share with stakeholders and quickly and easily research any issues that arise during the sample request and delivery cycle. The linking of numerous related data sources such as shipping and tracking, ordering and corporate compound databases and potential linking with regulatory data banks, allow us to easily create reports for internal purposes and going forward to meet external demands such as shipment valuations and management of prohibited compounds. Additionally, this new infrastructure has been developed with room for improvement and expansion, so we can easily update the software as we add new services, make improvements in best practices and adapt to changes in the regulatory environment. • Standards Initiatives, Burkhard Schaefer, Chair
Room: Sun 1-2 The Standards Initiatives SIG promotes standardization and interoperability of instruments and data systems in the laboratory. The purpose of this session is to raise awareness of community-driven standardization efforts currently underway. It also provides a forum to foster collaboration between standards initiatives to ensure greater impact and better utilization of community resources. This session kicks off with a showcase of a number of current standards efforts that are in varying stages of development. Each group presents a quick summary of their activities, current status and an application example. Afterwards, the presenters are available in a panel discussion format. • Stem Cells, Marcie Glicksman and Sitta Sittampalam, Co-Chairs
Room: Sun 5-6 A special issue on stem cells in drug discovery was published in the October 2012 edition of the Journal of Biomolecular Screening. This is a rapidly expanding field encompassing elements of promise together with challenge. The papers featured in this special issue represent a variety of topics on the use of stem cells for drug discovery, including methods for proliferation and differentiation of stem cells, as well as results from high throughput screens using stem cells. A number of key papers were selected representing advancements in the production and use of stem cells for drug discovery that will likely further our understanding of disease and biology. The 2013 Stem Cell SIG reaches out to a subset of the authors to present a brief talk on their work and lead a discussion on what the results and challenges have been for their studies and future directions.
SLAS2013.org
I
43
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
SLAS Welcomes its Corporate Members
Sterling Corporate Members Agilent Technologies (www.chem.agilent.com)
BMG Labtech (www.bmglabtech.com)
Agilent Technologies is a leading manufacturer of automation platforms and benchtop instrumentation for laboratory processes. Agilent’s suite of innovative products and commitment to service provide a winning combination for complete automation solutions. To learn more about our innovative instruments and how we can meet your automation needs today and in the future, please contact an Agilent sales representative.
BMG Labtech is a leading developer and global manufacturer of microplate reader instrumentation with a wide range of measurement methods. Microplate readers are used in the pharmaceutical and biotech industries, as well as in academic research establishments, for both basic research analysis and High-Throughput Screening. BMG Labtech focuses solely on microplate readers and offers the most diverse selection of optical detection systems in conjunction with integrated liquid handling equipment..
Art Robbins Instruments (www.artrobbins.com)
Art Robbins Instruments (ARI), a privately held company, was founded in 2003 by a team with over 75 years of experience in developing life science. ARI is dedicated to developing and providing instruments and consumables that enable automated, flexible liquid handling for drug discovery, protein crystallography, and tissue typing applications. ARI Gryphon, Intelli-Plate® and Phoenix platforms are used by more than 1500 laboratories worldwide. ARI is headquartered in Sunnyvale, California with distributors around the world.
Computype (www.computype.com/laboratory)
Computype is a leading manufacturer of labels designed for use in with laboratory automation. Computype offers Barcode and Data Matrix identification products for your plates, tubes, slides, and other labware that allow you to focus on the task at hand. Computype works with you to build solutions tailored to fit your needs using pre-printed and blank labels, label printers, automatic label applicators, software, and our Label Ease pre-labeled labware service.
Corning (www.corning.com/lifesciences)
BioTek Instruments, Inc. (www.biotek.com) ®
BioTek® Instruments, Inc. is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
44
I
SLAS2013.org
Corning Incorporated is a leading developer, manufacturer and global supplier of scientific laboratory products for more than 90 years and is the trusted partner of researchers seeking new approaches to increase efficiencies, reduce costs and compress timelines in the drug discovery process. Using our unique expertise in the combined fields of optics, materials science, surfaces, and biology, we provide a full range of innovative solutions that improve productivity and enable breakthrough discoveries.
Short Courses: January 12-13
I
Conference: January 14-16
Douglas Scientific (www.douglasscientific.com)
Revolutionary High-Throughput Screening on a patented, continuous Array Tape platform. Our patented tape automation has transformed traditional microplate processing by delivering disruptive throughput and cost savings for our laboratory clients. Our modular platform enables the flexibility to address various screening processes and chemistries.
INHECO GmbH (www.inheco.com)
INHECO GmbH is a leading manufacturer of innovative and high precision thermal management products for LabAutomation and Medical Lab Applications. Our standard and OEM solutions include temperature controlled shakers, heated and cooled positions, thermal cyclers, incubators, temperature controllers and verification tools.
Labcyte Inc. (www.labcyte.com)
We move liquids with sound! Labcyte Echo systems are powered by acoustic droplet ejection, using sound energy to transfer ultra-low volumes of liquids. This “touchless” technology provides better results by eliminating pipette tips and compound loss on surfaces, while saving consumables costs. Accuracy is maintained from the first drop through the last for a wide variety of fluids. Prepare assay plates for siRNA screening, compound screening with biochemical and cell-based assays, PCR reactions and more all on a single liquid handling platform, with no tips and no cross-contamination. Labcyte Echo, POD and Deerac liquid handling systems are the leaders for miniaturizing biological assays.
MagneMotion Inc. (www.magnemotion.com)
MagneMotion provides Linear Synchronous Motors (LSMs) and advanced transport solutions for high performance assembly and manufacturing automation based on our advanced electro-magnetic technology and controls. The systems are ideal for applications such as assembly automation, lab automation, pharmaceutical manufacturing,
I
Exhibition: January 13-15
packaging, food and beverage and medical device manufacturing to name a few. MagneMotion systems offer higher throughput and production capacity through independent and bi-directional payload propulsion and control, moving payloads at varying speeds to positions along a guideway system, also suitable for cleanroom environments (IP 65). MagneMotion’s next generation transport systems replace outdated technologies, such as belt and chain conveyors. MagneMotion’s LSM technology is embodied in two product lines, MagneMover LITE, for payloads less than 2kg and the QuickStick line, for payloads up to metric tonnes.
METTLER TOLEDO (http://www.mt.com/quantos)
QUANTOS is the world’s first bench top system for automatically dispensing small sample quantities of powders. At its heart is an intelligent dispensing head including storage container for dispensing highly potent or hazardous powdery substances. Thanks to the highprecision mechanism and intelligent electronics, the dispensing heads are perfectly adapted to the dispensing instrument. Each dispensing step moves closer to the target weight without exceeding tolerances. The dispensing instrument is based on proven METTLER TOLEDO weighing technology, which controls and monitors the entire dispensing process. QUANTOS dispenses with highest precision up to 20 times faster than by hand — and with greatly improved safety! At the touch of a button QUANTOS dispenses directly, accurately, and automatically into a great variety of containers. Even highly experienced hands struggle to attain this precision: QUANTOS dispenses to 0.5 mg with 0.005 mg readability.
Molecular Devices, LLC (www.moleculardevices.com)
Molecular Devices, a division of Danaher Corporation, is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics.
SLAS2013.org
I
45
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Tecan (www.tecan.com)
Tecan is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment
manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries.
Bronze Corporate Members Invetech Pty Ltd (www.invetech.us)
Bluechiip Ltd. (www.bluechiip.com)
bluechiip® is the only way to electronically track with surety healthcare laboratory consumables and samples stored in low temperatures, especially cryogenic temperatures. bluechiip® can: •
survive and operate in low storage temperatures, down to cryogenic temperatures (-196°C)
•
survive high temperature, including autoclave and moulding into plastic, without the need for extra protective packaging
•
survive gamma irradiation
•
passively track and monitor the temperature of cryopreserved samples in biobanks, cordblood banks and other tissue related banks.
bluechiip® offers a number of advantages over traditional labels, barcodes and RFID technologies for storing and tracking valuable and irreplaceable samples.
Invetech provides innovative contract development and manufacture for devices, instruments, consumables and custom automation. For more than 20 years, Invetech has worked with leading in-vitro diagnostics, life sciences, drug discovery and pharmaceutical companies.Our team of 200+ professionals use systematic ISO 9001, QSR compliant development processes and FDA registered manufacturing facilities, to deliver high-quality, fast-tomarket results.
UNIconnect (www.uniconnect.com)
Auditors and inspectors often say, “If it isn’t documented, it didn’t happen”. Every lab is different and has many unique requirements that drive success in the organization. UNIConnect empowers labs to document every last detail that is important to their organization (and to auditors) by using its own powerful software platform called UNIFlow™. This platform provides the most adaptable and flexible laboratory process management software in the world and takes a lab far beyond conventional LIMS software. It is used by both small start-up labs processing just a few hundred samples, and by large, established labs that process millions of samples.
SLAS2013 Collector's Pin Attend the SLAS2013 Opening Keynote Session on Monday, January 14 and receive the second in a series of limited edition SLAS Annual Conference and Exhibition commemorative pins. This is the one and only opportunity to receive the complimentary SLAS2013 pin, so don’t miss out!
46
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
Poster Program
I
Exhibition: January 13-15
Location: Florida Exhibition Hall
QR Codes on Posters SLAS2013 poster presenters were invited to include a QR (Quick Response) Code on their poster. If you scan the code with your mobile device, you will be automatically taken to the online poster gallery where you can view the abstract and other details the author submitted with their poster. If you would like to download a QR code reader specific to your mobile device, go to: www.mobile-barcodes.com/qr-code-software
MP001
Candida Albicans Biofilm Chip (CaBChip) – A Cellular Array of 3D Nano-Biofilms for High-Throughput Drug Discovery Anand Srinivasan, The University of Texas at San Antonio
MP002
Digital Holographic Microscopy: A Label-Free Technology for Image-Based Screening Benjamin Rappaz, École Polytechnique Fédérale de Lausanne
MP003
Laser Printing of Toner-Based Devices for Clinical Assays With Colorimetric Detection Fabricio Ribeiro De Souza, Federal University of Goiás; Co-Authors: Karoliny Oliveira, Wendell Karlos Tomazelli, Federal University of Goiás
MP004
Design of an On-the-Fly Optical Detection System for Multi-Tip High-Throughput Reagent Dispensing Vineet Padia, NIH National Center for Advancing Translational Sciences
MP005
Mesoporous Silica Beads Coded With Multiple Quantum Dots for Multiplex Detection of Cancer Biomarkers Kristen Schexnayder, University of New Orleans
MP006
High-Throughput Screening and Development for Next-Generation Antiviral Drugs Dhara Patel, Washington University in St. Louis
MP007
A Robust and Cost Effective Platform for Infectious Disease Monitoring Anjan Panneer Selvam, The University of Texas at Dallas
MP008
A Novel Polymeric Aqueous Biphasic System for High-Throughput Screening of Cancer Cell Migration Samila Nasrollahi, University of Akron
MP009
A 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Identify Selective Inhibitors of cMet Tijmen Booij, Universiteit Leiden; Co-Authors: Di Zi, Rob Roovers, Bob van de Water, Leo Price, Leiden University
MP010
Development of a Fluorescent Imaging Plate Reader (FLIPRTETRA) Based Screen to Identify Regulators of Store Operated Calcium Entry in Breast Cancer Cells Iman Azimi, University of Queensland; Co-Authors: Gregory Monteith, Sarah Roberts-Thomson, University of Queensland
MP011
Development of Novel Therapeutics That Target Splicing Machinery in Ovarian Cancer Ahmet Arslan, University of Illinois at Chicago; Co-Authors: Xiaolong He, Minxiu Wang, Emily Rumschlag-Booms, Sam Bettis, Rita Grantner, Lijun Wong, William Beck, University of Illinois at Chicago
MP012
Enhancement of DNA Fragmentation for Biospecimen Processing Cameron Wood, University of North Carolina at Chapel Hill
MP013
High-Throughput Screening for Bacterial β-glucuronidase Inhibitors to Alleviate Drug Toxicity Adam Roberts, University of North Carolina at Chapel Hill
MP014
Predictive Modeling and Biomechanical Microengineering of Mesenchymal Stem Cells to Enhance Differentiation Amit Paul, University of Illinois at Chicago; Co-Authors: David Franz, Sumaira Yahya, Shan Sun, Michael Cho, University of Illinois at Chicago
MP015
A Novel Nanotexturing Approach for Enhanced Biomarker Detection Michael Jacobs, The University of Texas at Dallas
MP016
Formaldehyde Assisted Isolation of Regulatory Elements Used to Screen a Novel Epigenetic Library Against EWS-FLI1 Chatura Jayakody, University of North Carolina
MP017
Smart Pressure Driven and Regulated Dispenser for the Nanoliter and Microliter Range Laurent Tanguy, Laboratory for MEMS Applications, IMTEK - University of Freiburg
MP018
Novel Automated Multi-Principle Volume Calibration System for Non-Contact Micro and Nano Liter Liquid Handling Devices Dong Liang, HSG-IMIT - Institut für Mikro- und Informationstechnik
MP019
GABAb Receptor Allosteric Ligands Exhibit Pathway-Selective and Species-Dependent Effects: Implications for Drug Screening Maria Aitken, The Scripps Research Institute
SLAS2013.org
I
47
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
MP020
Ebselen and Mitoxantrone Function as Antivirals by Displacing Viral Helicases and Similar Proteins From Nucleic Acids Sourav Mukherjee, University of Wisconsin-Milwaukee
MP021
DNA Encoded Solid-Phase Compound Synthesis Andrew MacConnell, The Scripps Research Institute
MP022
Discovery of Regulators of Receptor Internalization by High-Throughput Flow Cytometry Yang Wu, University of New Mexico
MP023
An mRVI Assay for High Throughput Detection of a CVD Biomaker Olufemi Adeluyi, Chosun University
MP024
BioAssay Ontology (BAO): A Standard to Report Screening Assays and Results Uma Vempati, University of Miami
MP025
Red-Emitting Sodium Nanosensors: A New Tool for Electrophysiology Tim Ruckh, Northeastern University
MP026
Evaluation of Bivalent Mucoadhesive Nasal Vaccine Krishnakumar Duraisamy, The Tamilnadu DR.MGR Medical University
MP027
Automated, Modular Microsystem for Non-Enzymatic Determination of Carbohydrates Concentration Kamil Zukowski, Warsaw University of Technology Faculty of Chemistry
MP028
An Integrated System for Multiple-Location Monitoring of Neurotransmitters Maojun Gong, Wichita State University
MP029
Design and Evaluation of Solid Lipid Nanoparticles Containing Olanzapine for Brain Targeted Drug Delivery Jawahar Natarajan, JSS College of Pharmacy
MP030
Development of In Vitro Assays for Neurochemical Screening of Dietary Supplements Michael Santillo, U.S. Food and Drug Administration
MP031
Application of CombiFluor™ Technology in Molecular Diagnostics Kalyani Jambunathan, SRI International
MP032
New Microtools for Cell Culture Monitoring – Medium Analysis Elzbieta Jastrzebska (Jedrych), Warsaw University of Technology, Department of Microbioanalytics
MP033
Contactless Conducitivity Detector With Two Different Location of Electrodes in Microfluidic Device Karolina Blaszczyk, Warsaw University of Technology
MP034
Multiplexed Screening of Lipid Production in Algae Cells Using Digital Microfluidics Steve Shih, University of Toronto; Co-Author: Aaron Wheeler, University of Toronto
MP035
An Optimization Based Study of Equivalent Circuit Models for Representing Recordings at the Neuron-Electrode Interface Vaibhav Thakore, Department of Physics and NanoScience Technology Center, University of Central Florida
MP036
Selective Isolation of Cancer Cells in an Aptamer-Mediated Microfluidic Device Weian Sheng, University of Florida
MP037
Challenges of Contactless Dispensing Systems for IVD Applications Caused by Reagent Properties Nadine Losleben, Roche Diagnostics GmbH
MP038
Action of Glycosidase Inhibitors on the Human Ether a-Go-Go-Related Gene (hERG) Channel: A Computational Analysis N.S. Hari Moorthy, University of Porto
MP039
Flexible Automation of RNA Sample Preparation for NGS Sequencing Sebastian Schoening, Fraunhofer IPA
MP040
A Calibration-Free, Disposable, Non-Contact Reagent Dosing Cartridge for the Sub-µl Range Stefan Bammesberger, Department of Microsystems Engineering - IMTEK
MP041
Development and Implementation of a High-Throughput FRET-Based Calcium Imaging Assay for Alzheimer’s Disease Drug Screening Kamran Honarnejad, University of Munich (LMU); Co-Authors: Alexander Daschner, André Gehring, Franz Bracher, University of Munich
MP042
Identifying the Selectivity and Potency Determinants of Polo-Like Kinase 1 for Lead Optimization by Mining Known Kinase Inhibitor Binding Modalities Kavitha Bharatham, St. Jude Children’s Research Hospital; Co-Authors: Gregory Miller, Anang Shelat, St. Jude Children’s Research Hospital
48
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
MP043
Improved Methods for Reprogramming Human Dermal Fibroblasts Using Fluorescence Activated Cell Sorting David J. Kahler, The New York Stem Cell Foundation; Co-Authors: Faizzan Ahmad, Weill Cornell Medical College in Qatar; Anita Ritz, Haiqing Hua, Dorota Moroziewicz, Andrew Sproul, Carmen Dusenberry, Linshan Shang, Daniel Paull, Matthew Zimmer, Keren Weiss, The New York Stem Cell Foundation
MP044
Modeling Phenotypic Signatures for the Development of Active Small Molecules Gregory Miller, St. Jude Children’s Research Hospital; Co-Authors: Jonathan Low, Taosheng Chen, Anang Shelat, St. Jude Children’s Research Hospital
MP045
Nanoparticle-Enabled Dynamic Light Scattering Assay: The Most Advanced Label-Free Technology for Protein Detection and Analysis Shiyun Zhang, University of Central Florida
MP046
Automated Droplet Microfluidic System for High-Throughput Microbiological Screens From Microliter Samples Krzysztof Churski, Institute of Physical Chemistry of the Polish Academy of Sciences; Co-Authors: Slawomir Jakiela, Tomasz Kaminski, Piotr Garstecki, Institute of Physical Chemistry of the Polish Academy of Sciences
MP047
Automated Gravity-Driven Flow Microfluidic System for Mapping Entrainment Window of Islets of Langerhans Tuan M. Truong, Florida State University; Co-Authors: Raghuram Dhumpa, Michael Roper, Florida State University
MP048
Determination of a Synchronization Mechanism of Islets of Langerhans Using a Feedback Interaction System Raghuram Dhumpa, Florida State University; Co-Authors: Tuan Truong, Michael Roper, Florida State University
MP049
Electrochemical Impedance Spectroscopic Technique With a Functionalized Microwire Sensor for Rapid Detection of Foodborne Pathogens Lin Lu, University of Wisconsin, Madison; Co-Author: Soojin Jun, University of Hawaii at Manoa
MP050
Gene Expression Profiling of Primary Human Cell Populations Within a Multi-Dimensional Microfluidic Platform Vinay Abhyankar, Sandia National Labs; Co-Authors: Meiye Wu, George Buffleben, Anson Hatch, Sandia National Labs
MP051
Loading of Gold Nanoparticles and Nanoshells Into Human Serum Albumin Nanoparticles for Targeted Drug Delivery Donna Peralta, University of New Orleans; Co-Authors: Matthew Tarr, Tina Trosclair, Marta Sans, University of New Orleans
MP052
Microfluidic Screening Platform for Screening Host-Pathogen Interactions Schudel Benjamin, Sandia National Laboratory; Co-Authors: Brooke Harmon, Vinay Abhyankar, Oscar Negrete, Anup Singh, Sandia National Laboratory
MP053
Workflow Simulation for Life Science Automation Laboratories Yanfei Li, Celisca, University of Rostock, Germany; Co-Authors: Steffen Junginger, Norbert Stoll, Kerstin Thurow, Celisca, University of Rostock
MP054
Combinatorial Inverse Drug Screen Pipeline to Probe Epithelial Wound Healing in a Model Genetic Organ Culture System Miranda Burnette, University of Notre Dame; Co-Authors: Jonathan Chen, Jeremiah Zartman, University of Notre Dame
MP055
Feasibility of Pinto Beans to Protect Against Cellular Oxidation Cristiane Camara, University of Nebraska-Lincoln; Co-Authors: Qin-Yin Shi, Richard Zbasnik, Vicki Schlegel, University of Nebraska-Lincoln
MP056
A Novel Cell-Based Screening Approach For The Identification Of FOXA1 Pathway Inhibitors for the Treatment of Tamoxifen-Resistant Breast Cancer Aurore Lejeune, Cancer Research Technology; Co-Authors: Julie Stock, Cancer Research Technology; Kelly Holmes, Cancer Research UK; Stephen Myatt, Susan Young, Matthew Rushbrooke, Cristina Alli, Ai Ching Wong, Cancer Research Technology; Ason Carroll, Jon Roffey, Cancer Research UK
MP057
Identification of Promiscuous Inhibitors in Screening Libraries With the Use of an Intrinsically Fluorescent Probe: High-Throughput Screening Approach Premchendar Nandhikonda, University of Wisconsin-Milwaukee; Co-Authors: Megan McCallum, Jonathan Temmer, Alexander Arnold, University of Wisconsin-Milwaukee
MP058
Development and Implementation of an Orthogonal High-Throughput Screen for Inhibitors of Trypanosoma Brucei Methionyl-tRNA Synthetase (MetRS) Laura Pedró-Rosa, The Scripps Research Institute; Co-Authors: Franck Madoux, Christina Eberhart, The Scripps Research Institute; Ranae Ranade, Wim Hol, Frederick Buckner, University of Washington; Peter Hodder, The Scripps Research Institute
MP059
High-Throughput Screening for Inhibitors of Mucosa-Associated Lymphoid Tissue lymphoma Translocation Protein 1 (MALT1) Emily A. Smith, National Cancer Institute; Co-Authors: Lauren Krumpe, SAIC-Frederick, Inc.; Vu Ngu, Kian-Huat Lim, Louis Staudt, James McMahon, NCI; Barry O’Keefe, Frederick National Laboratory for Cancer Research, NCI
MP060
Performance Comparison of Nanomonitor Against ELISA on Patient Pool Samples Krishna Vattipalli, University of Texas at Dallas; Co-Authors: Steve Kazmierczak, Thomas Barrett, Oregon Health Sciences University; Shalini Prasad, The University of Texas at Dallas
SLAS2013.org
I
49
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
MP061
A Novel Rapid In Vitro High-Throughput Screening (HTS) Assay for Detection of the Anti-tuberculosis Activity of Liver Enzyme-Derived Metabolites Nan Zhang, University of Illinois at Chicago; Co-Authors: Scott Franzblau, Larry Klein, Institute for Tuberculosis Research/ University of Illinois at Chicago; Yang Song, ChemoCentryx, Inc.; Sang Hyun Cho, Institute for Tuberculosis Research/University of Illinois at Chicago
MP062
A Multiplexed Matrix Metalloproteinase (MMP) Assay for Wound Healing Studies Nesia Zurek, University of New Mexico; Co-Authors: Andrew Shreve, Steven Graves, University of New Mexico; Thomas Howdieshell, University of New Mexico Health Sciences Center; Paul McGuire, University of New Mexico
MP064
A Faster, Reusable Electrochemical Proximity Assay for Direct Protein Quantitation Jiaming Hu, Auburn University
MP076
Combining Liquid Handling and Microfluidics: Chip and Instrument Platforms to Perform Immunological Assays in a Microfluidic Format Holger Becker, microfluidic ChipShop GmbH
MP077
Fluorescent 2-Hybrid Assay: Fully Reversible Protein-Protein Interaction Assay in Living Cells for HCA and Drug Screening Kourosh Zolghadr, ChromoTek GmbH
MP078
Novel Photoreactive Diazide Based Benzamide Probes for Mapping the Binding Site of Histone Deacetylase 2 Aditya S. Vaidya, University of Illinois at Chicago
MP079
Target Based Drug Activity and Post-Translational and Transcriptional Analysis using Ex Vivo Alvetex Three Dimensional Cell Culture Technology Sumeer Dhar, Oncotest GmbH - Institute for Experimental Oncology; Co-Authors: Anne-Lise Peille, Oncotest GmbH; Susanne Braum, Tecan Schweiz AG; Richard Rowling, Reinnervate Limited; Torsten Giesemann, Vincent Vuaroqueaux, Oncotest GmbH; Stefan Przyborski, Reinnervate Limited; Heiner Fiebig, Oncotest GmbH
MP080
“SmartTip” Approach to Automated Genomic DNA Extraction Using Akonni TruTip Technology on Hamilton Microlab STAR Liquid Handling Workstations Dane Brady, Akonni Biosystems; Co-Authors: Tinsley Stokes, Rebecca Holmberg, Akonni Biosystems
MP081
A New Method for Increasing Versatility Within the Automated Processes of High Content/High-Throughput Screening Technologies: Thomas Noonan; EMD Serono Research Institute, Inc.; Co-Authors: Bill Griffin, Jennifer Jackson, Vikram Shankar, Dusica Santos, Jared Head, Gaianne Berrios, Mei Zhang, Mohanraj Dhanabal, Brian Healey, EMD Serono Research Institute, Inc.
MP082
A High-Throughput Robotic Platform for Illuminating Gene Function Carleen Klumpp-Thomas, NIH/NCATS; Co-Authors: Pinar Tuzmen, Scott Martin, Rajarshi Guha, Yu-Chi Chen, Eugen Buehler, Christopher Austin, NIH/NCATS
MP083
A Low-Cost DNA Purification System Designed for Use in De-Centralized Laboratories Jeffrey Helfer, Diffinity Genomics, Inc.; Co-Authors: Robin Hodownes, George Diaz, Holly Reynolds, Rhiannon Gaborski, Corey Scala, Jacqueline Zaengle, Diffinity Genomics, Inc.
MP084
A New Method: Automated Processing and Cultivation of 3D Cell Cultures - Alginate Beads Ricarda Lehmann, celisca; Co-Authors: Thomas Roddelkopf, Steffen Junginger, Grit Koch, Kerstin Thurow, celisca
MP085
A New Powerful System for Automated Processing of Immunofluorescence and ELISA Tests Sabine Merx, STRATEC Biomedical AG
MP086
A Novel High-Throughput DNA Purification System for Improving Core Lab Productivity Jeffrey Helfer, Diffinity Genomics, Inc.; Co-Authors: George Diaz, Robin Hodownes, Rhiannon Gaborski, Holly Reynolds, Corey Scala, Jacqueline Zaengle, Diffinity Genomics, Inc.
MP087
A Novel Process Utilizing Pin Tool Transfer From Acoustically Dispensed Low Volume Compound Source Plates Provides a Solution for High-Throughput Screening Hit list Follow-Up Michael Paolucci, Novartis Institutes for Biomedical Research; Co-Authors: Dave Farley, Simona Gokhin, John Davies, Matt O’Brien, Damien MacDougall, Carl Ristaino, Zhan Deng, Chun-Hao Chiu, David Fletcher, Novartis Institutes for Biomedical Research
MP088
An Automated Profiling Application Using a Direct, Cell-Based, Target-Compound Interaction Assay for G9a Histone Methyltransferase and Bromodomain Proteins Ellaine Abueg, BioTek Instruments, Inc.; Co-Authors: Brad Larson, Peter Banks, BioTek Instruments, Inc.
50
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
MP089
An Automated System for Precise and Accurate Dispensing of Powders and Liquids Justin Fisher, Freeslate, Inc.; Co-Authors: Bob Busacca, Adam Tanner, Jeff Maag, Sourav Saha, Milind Deshpande, David Yamane, Freeslate, Inc.
MP090
An Automated, High-Throughput Method for the Quantification of Endogenous Cellular Kinase Activity Jason Greene, BioTek Instruments, Inc.; Co-Authors: Brad Larson, BioTek Instruments, Inc.; Nicolas PIERRE, Suzanne Graham, Cisbio US; Laurence Jacquemart, Francois Degorce, Cisbio Bioassays; Peter Banks, BioTek Instruments, Inc.
MP091
An Integrated Solution for Automated Nanolitre Hit-Picking at BioFocus Richard Kim, TTP Labtech; Co-Authors: Joby Jenkins, Chloe Carter, Stephen Starkie, TTP Labtech; Serge Parel, Biofocus
MP092
An RT-qPCR Automated Platform: Validation Methods for the Access™ Workstation, the Echo® Liquid Handler, and Real-Time Ready™ Reagents Celeste Glazer, Labcyte Inc.; Co-Authors: Joseph Barco, Sammy Datwani, Maria Sonntag, Randy Dyer, Labcyte Inc.
MP093
Apply Plasma Technology to High-Throughput Drug Discovery Workflow Jean Shieh, IonField Systems, Co-Author: Paul Hensley
MP094
Automated Isolation of Genomic DNA From Large Volume Blood Fractions Sydnor Withers, Promega Corporation; Co-Authors: Mary Dressler, Steven Krueger, Christine Newton, Eric Vincent, Cristopher Cowan, Promega Corporation
MP095
Automation of Assay Optimisation Studies: Efficient and Rapid Set-Up for a Wide Range of Biological Applications Joby Jenkins, TTP Labtech; Co-Authors: Gary Cochrane, Wayne Bowen, Wendy Gaisford, TTP Labtech
MP096
Broadening Applications for Bulk Lateral Ultrasonic™ Energy In Genomics/Next Gen Sequencing Workflows Vibhu Vivek, Microsonic Systems Inc.; Co-Author: William Beckwith, Microsonic Systems Inc.
MP097
Comparative Study for Sensitive Determination of Total Mercury in Organic Matrices Using Microwave Assisted Digestion and ICP-MS as Well as ICP-OES With Mercury Cold Vapor Heidi Fleischer, celisca - Center for Life Science Automation; Co-Author: Kerstin Thurow, celisca - Center for Life Science Automation
MP098
Comparison of ADP Detection Methods Used for High-Throughput Screening Robert G. Lowery, BellBrook Labs; Co-Authors: Meera Kumar, Karen Kleman-Leyer, Tom Zielinski, BellBrook Labs
MP099
Connecting High-Throughput to High Content in Screening David Lorenz, Wako Automation; Co-Authors: Sam Michael, Jim Inglese, Sunits Shukla, Samuel Hasson; Steve Titus, NIH Chemical Genomics Center; Rajarshi Guha, Douglas Auld, NCATS, NIH
MP100
The Use of MicroCal™ Auto-iTC200 in a Fragment Based Drug Design Campaign to Identify Compounds That Reduce Resistance to Cancer Drugs Eric Roush, GE Healthcare; Co-Author: Ronan O’Brien, GE Healthcare
MP101
Development of a 100 Percent DMSO Sample Solution for Liquid Handler Performance Verification Rachel M. Parshley, ARTEL; Co-Authors: John Bradshaw, George Rodrigues, Keith Albert, Karl Olson, Doreen Rumery, ARTEL
MP102
Development of a HTS Compatible Three-Dimensional Cell Culture System Kazuya Arai, SCIVAX Corporation; Co-Authors: Manabu Itoh, SCIVAX Corporation Miura Hiromi, SCIVAX USA, Inc.
MP103
Development of an Ultra High-Throughput Screen to Identify Antagonists for GluK1 Kelli Solly, Merck & Co.; Co-Authors: Carissa Quinn, Rebecca Klein, Darrel Henze, Eric Johnson, Michael Finley, Merck & Co.
MP104
Development of High-Throughput, Label-Free Analytical Methods to Determine Transporter Inhibition Using RapidFire™-MS/MS Andrew Wagner, Bristol-Myers Squibb Company; Co-Authors: Lisa Elkin, Kathy Mosure, Matt Soars, Wilson Shou, Bristol-Myers Squibb Company
MP105
Dialysis and Electrodialysis Into Microplate Stefan Kreusch, SCIENOVA GMBH; Co-Authors: Katharina Pfohl, Raffael Rubick, SCIENOVA GMBH
MP106
Digital Dispensing for Direct Dilution: New Flexibility in Dose-Response Analyses Jeff Nielsen, Hewlett-Packard Company; Co-Authors: Ken Ward, Christie Dudenhoefer, David Ochs, Joshua Yu, Hewlett Packard; Kevin Peters, Hewlett-Packard High-Performance Dispensing
MP107
Financial and Environmental Analysis for Four High-Throughput Liquid Handling Methods Jean Shieh, IonField Systems; Co-Author: Paul Hensley, IonField Systems
MP108
Forensic Considerations for Automating a Large-Scale mtGenome Databasing Project Kimberly Sturk-Andreaggi, American Registry of Pathology, Armed Forces DNA Identification Laboratory; Co-Authors: Rebecca Just, Melissa Scheible, Spence Fast, American Registry of Pathology; Jodi Irwin, Federal Bureau of Investigation
MP109
High Throughput Aliquoting of Urine Specimens for Diagnostic Testing as Part of the CDC’s Rapid Toxic Screen Ernest Mcgahee CDC; Co-Author: Rudolph Johnson, CDC
SLAS2013.org
I
51
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
MP110
High-Throughput Miniaturized PCR Using the Echo® Liquid Handler Celeste Glazer, Labcyte Inc.; Co-Authors: Joseph Barco, Brent Eaton, Sammy Datwani, Labcyte Inc.
MP111
How Rapid Prototyping Helps to Investigate the In-Vitro Performance of Inhaled Investigational Products Stephen Trowbridge, GlaxoSmithKline; Co-Authors: Melanie Hamilton, Tony Reeves, GlaxoSmithKline
MP112
Implementation of Cisbio’s HTRF M1 Muscarinic Receptor Related Assays on CyBio Liquid Handling Solutions for Small, Medium and High Throughput Iris Pribilla, Cisbio Bioassays; Co-Authors: A. Jean, J.-L. Tardieu, M. Préaudat, F. Degorce, Cisbio Bioassays; K. Undisz, M. Beil-Peter, CyBio AG
MP113
Integration of Compound Storage Into the Automated Laboratory Workflow Simon Tullett, TTP Labtech; Co-Authors: James Craven, Wendy Gaisford, TTP Labtech
MP114
Low Cost, Low Footprint Automated Biobanking Ensuring Efficient Laboratory Workflow James Craven, TTP Labtech; Co-Authors: Simon Tullett, Wendy Gaisford, TTP Labtech
MP115
Mobile Robots in Life Science Automation Steffen Junginger, celisca - Center for Life Science; Co-Authors: Automation Hui Liu, Kerstin Thurow, Norbert Stoll, celisca
MP116
Mosquito® HTS HV: Bridging the Gap for Automated Low Volume Liquid Handling Joby Jenkins, TTP Labtech; Co-Authors: Rob Lewis, Wendy Gaisford, TTP Labtech; Sarah Caunt,Viral Patel, Novartis Pharmaceuticals UK Ltd
MP117
Mosquito®: Automated Liquid Handling of Low Volumes for Biological Assay and Screen Set-Up Richard Kim, TTP Labtech; Co-Authors: Joby Jenkins, Rob Lewis, Wendy Gaisford, TTP Labtech
MP118
Next Generation Sequencing Sample Preparation Utilizing the Echo® Liquid Handler Howard Lee, Labcyte Inc.; Co-Authors: Danny Lee, Kelvin Chan, SeqMatic
MP119
Optimal Luminometers for Getting the Most Out of Ultrasensitive Luciferase Reporter Assays Reija-Riitta Harinen, Thermo Fisher Scientific; Co-Authors: Jorma Lampinen, Arto Perälä, Thermo Fisher Scientific
MP120
Performance and Refurbishment of Cassette Based Dispensing Systems Eric Jones, National Center for Advancing Translational Sciences; Co-Author: Timothy Mierzwa, National Center for Advancing Translational Sciences
MP121
QIAxcel®: Novel 12-Channel Capillary Electrophoresis System for High-Throughput Protein Separation Mirjana Kozulic, QIAGEN Instruments; Co-Authors: AG Marion Egli, QIAGEN Instruments AG; Udo Roth, Karen Kowalewski, QIAGEN GmbH
MP122
Self-Imaging Petri Dishes for Direct Image Streaming From the Incubators Changhuei Yang, California Institute of Technology
MP123
Semi-Automated High-Throughput Analytical Analysis and Queuing of Secondary Assays Using UPLC/ MS-ToF/ UV in Support of Monitoring the Merck Compound Collection Navin Varshney, Merck & Co.; Co-Authors: Wilfredo Pinto, Michelle Ayer, Connie Lee, James Maloney, Marybeth Burton, Merck & Co.
MP124
SNP Assay Multiplexing Using Barcoded Magnetic Beads in Array Tape® Terry Rusch, Douglas Scientific; Co-Authors: Nathan Westad, Andrew Haug, Douglas Scientific
MP125
Speeding up Process Development With an Automated, Microtiter Plate Based System for Suspension Cell Culture Sven Markert, Roche Diagnostics GmbH; Co-Author: Klaus Joeris, Roche Diagnostics GmbH
MP126
Sub Micro-liter Quantitative Real-Time PCR From Whole Blood Using Acoustic Transfer With the Echo® Liquid Handler Ghislain Luke, Labcyte Inc.; Co-Authors: Celeste Glazer, Richard Ellson, Sammy Datwani, Labcyte Inc.
MP127
Temperature Control of High-Speed Mixing Platforms Using Electronic Heating Optimization Olaf Hoyer, QUANTIFOIL Instruments GmbH Andreas Vester, QUANTIFOIL Instruments GmbH Ralf Pätzold, QUANTIFOIL Instruments GmbH
MP128
TTP Labtech’s ComPOUND Provides Efficient Biobanking for High Quality Antibody Storage James Craven, TTP Labtech; Co-Authors: Wendy Gaisford, TTP Labtech; Maud Godfrey, Danielle Miller, Abcam
MP129
Unparalleled Nucleic Acid Purification and Downstream Analyses Using Thermo Scientific KingFisher Magnetic Particle Processor and PikoReal Real-Time PCR Instrument Sini Suomalainen, Thermo Fisher Scientific; Co-Authors: Marika Suomalainen, Eva Tas, Ossian Saris, Arja Lamberg, Thermo Fisher Scientific
MP130
Use of Shear Valves to Improve Results in Laboratory Automation Applications Michael Keller, IDEX; Co-Authors: Corey Phipps, Darren Lewis, IDEX
MP131
Using High Speed Vision of the Brooks Tube Auditor™ to Evaluate Sample Volume and Precipitates of Source Tubes Sue Holland-Crimmin, GSK; Co-Authors: Stacey Barto, Brian Lupotsky, Joann Coleman, GEmma Harbert, Steve Vitale, GSK
52
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
MP132
Volume Determination in Microplates Using Pressure Measurement Bill Gigante, Stratec Biomedical US; Co-Authors: Walt Caldwell, Ryan Caldwell, Leslie Walling, Stratec Biomedical US
MP133
Acoustic Dispensing Technology: Beyond DMSO Dispensing (Exploring the Benefits of Protein Crystallography and DNA Dispensing) Sue Holland-Crimmin, GSK; Co-Authors: Thomas Foley, Genaro Scavello Jr, Jeffrey Gross, Nestor Concha, William Bonnette, Angela Smallwood, Brian Lupotsky, GSK
MP134
Studies of Proliferation and Viability of Adherent Cells Cultured With Continuous Medium Flow in Microsystem Ilona Grabowska-Jadach, Warsaw University of Technology; Co-Authors: Ewelina Majewska, Elzbieta Jastrzebska, Michal Chudy, Artur Dybko, Zbigniew Brzozka, Warsaw University of Technology
MP135
High-Throughput Assays to Study the Chemical Biology of Acetyllysine Binding Proteins Levi Blazer, Cayman Chemical Company; Co-Authors: Daniel Bochar, Rana Sidhu, Jeffrey Johnson, Cayman Chemical Company
MP136
New Cell-Based HTRF Total ERK, Stat3 and MEK1 Assays to Help Phosphorylation Assessment Normalization and Support Exploration of Cell Signaling Pathways Fabienne Charrier-Savournin, Cisbio Bioassays; Co-Authors: Cedric Chouvet, Julie Vallaghe, Francois Degorce, Eric Trinquet, Cisbio Bioassays
MP137
Physiologically Relevant Tools and Assays for Ubiquitin Drug Discovery: A Novel Fluorescence Lifetime Isopeptide-DUB Assay Platform Graham Cotton, Almac Group; Co-Authors: Colin Dunsmore, Beatrice Maltman, David Anderson, Almac Group
MP138
Transcreener ® High-Throughput Screening Assays for Glycosyltransferases Karen Kleman, BellBrook Labs; Co-Author: Robert G. Lowery, BellBrook Labs
MP139
Screening for Use-Dependent Inhibitors of Human Nav1.1 Channel Using the IonWorks Quattro Automated Patch Clamp System Yuri A Kuryshev, ChanTest Corporation; Co-Authors: Hung Lee, Cory Stebal, Michael Fraifogl, Peter Hawryluk, Glenn Kirsch, Arthur Brown, Emir Duzic, ChanTest Corporation
MP140
Rapid Screening of a Cell-Based Assay for GLP-1 Receptor Using a Natural Product Library Brad Larson, BioTek Instruments, Inc.; Co-Authors: Nicolas Pierre, Suzanne Graham, Cisbio US; Jean-Luc Tardieux, Francois Degorce, Cisbio Bioassays; Peter Banks, BioTek Instruments, Inc.
MP141
Development of Radioligand Membrane Binding Assays for Compound Screening Helena Mancebo, Multispan Inc.; Co-Author: Miao Tan, Multispan Inc.
MP142
Improved Efficiency and Automation of a 384-Well Real-Time PCR Taqman® Assay to Quantify HCV RNA Replication Laura Rokosz, Merck; Co-Authors: Agrawal Sony, Asra Malikzay, Erik Aponte, Deborah Barbey, Merck; Ellen Barrabee; Christine Brideau, Steven Cifelli, Merck; Cherrie Cornisha; Boris Feld; Emily Frank
MP143
Two Novel HTRF® Phospho-Protein Assays to Monitor JNK Signaling Pathway Julie VALLAGHE, Cisbio Bioassays; Co-Authors: Fabienne Charrier-Savournin, Vincent Morcillo, Franois Degorce, Eric Trinquet, Cisbio Bioassays
MP144
Screening for Inhibitors of BRD4 Bromodomain 1 Using a Homogeneous Proximity Assay Peter J. Brescia, Jr., BioTek Instruments, Inc.; Co-Authors: Peter Banks, Brad Larson, BioTek Instruments, Inc.; Daniel Bochar, Levi Blazer, Cayman Chemical Company
MP146
A Method to Identify Multi-Serotype HRV Inhibitors in a High-Throughput Screen Gary Lee, Gilead Sciences; Co-Authors: Chris Mello, Gabriel Birkus, Robert Jordan, Tomas Cihlar, Nikos Pagratis, Helen Yu, Gilead Sciences
MP147
A Novel Assay Platform for the Detection of Kinase-Inhibitor Binding in Intact Mammalian Cells Tom Wehrman, DiscoveRx Corporation; Co-Authors: Daniel Bassoni, Will Valencia, Uyen Le, Kai Rehder, DiscoveRx Corporation
MP148
BROMOscan – A High-Throughput, Quantitative Ligand Binding Platform Identifies Best-In-Class Bromodomain Inhibitors From a Screen of Mature Compounds Targeting Other Protein Classes Elizabeth Quinn, DiscoveRx Corporation; Co-Authors: Mark Floyd, Elyssa Pickle, Lisa Wodicka, Pietro Ciceri, Gabriel Pallares, Adam Torrey, DiscoveRx Corporation
MP149
Developing Parallel Functional Assays for Opioid Receptors Helena Mancebo, Multispan Inc.; Co-Authors: Miao Tan, Radhika Venkat, Multispan Inc.
MP150
Development of a Novel Assay Suitable for the High-Throughput Screening of Human 5’-tyrosyl DNA Phosphodiesterase (Tdp2) Graeme Thomson, Paterson Institute for Cancer Research; Co-Authors: Paul Depledge, Syntaxin Ltd; Nicola Hamilton, Gemma Hopkins, Ali Raoof, Paterson Institute for Cancer Research; Matthew Rushbrooke, Fabrice Turlais, Cancer Research Technology; Ian Waddell, Donald Ogilvie, Paterson Institute for Cancer Research
SLAS2013.org
I
53
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
MP151
EU-OPENSCREEN, Chemical Keys for Life’s Locks Bahne Stechmann, EU-OPENSCREEN/FMP
MP152
InCELL Hunter ®: A Novel Cellular Assay Platform for the Direct Measurement of Compound Binding to Intracellular Targets in Intact Mammalian Cells Pyare Khanna, DiscoveRx Corporation; Co-Authors: Tom Wehrman, Jennifer Lin-Jones, Will Valencia, Judy Leon, Albert Doan, DiscoveRx Corporation
MP153
Metal Impurities Cause False Positives in High-Throughput Screening Campaigns Qing-Fen Gan, Hoffmann-La Roche Inc.; Co-Authors: Yingsi Chen, Charles Wartchow, Hoffman-LaRoche Inc.
MP154
Screening of a Novel Chiral Library at High Concentration Using Complementary Biophysical Methods Joshua A. Bittker, Broad Institute; Co-Authors: Jeremy Duvall, Broad Institute; Martin Drysdale, Justin Bower, Andrew Pannifer, Duncan McArthur, Ken Cameron, Beatson Institute for Cancer Research; Michelle Palmer, Michael Foley, Broad Institute
MP155
Validation of a Cell-Based Phospholipidosis Assay in a 1536-Well Plate Format Sampada Ajay Shahane, Tox21-NCATS-NIH; Co-Authors: Ruili Huang, Menghang Xia, NCATS-NIH
MP156
Improved Protocol for Stable Recombinant Cell Line Generation Through Nanofluidic Single Cell Technology Clarisa Salado, Innoprot; Co-Authors: Danel Kortazar, Rosa Maria Mella, Meritxell Roura, Patricia Villacé, Innoprot
54
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
TP001
A Multiport Metering Valve Technology for On-Chip Valving Holger Becker, microfluidic ChipShop GmbH; Co-Authors: Richard Klem, Renee Sewart, Claudia Gärtner, microfluidic ChipShop GmbH
TP002
Wall-Less, Patterned Planar Plates for Miniaturizing Immunoassays Jianyong Wang, Genentech
TP003
Influence of Infectious Disease and Diet on Circulating Biological Nanoparticles and miRNA Profiles Kenneth Witwer, Johns Hopkins University
TP004
Accelerating Development of Highly Sensitive Diagnostics Using In Silico Powered Design Richard Del Mastro, IntelligentMDx
TP005
Multivariate Analysis of HTS Data to Predict Production Potential of Genetically Engineered Microbes Amoolya H. Singh, Amyris, Inc.
TP006
Utilizing Design of Experiment Statistical Models to Improve Assay Development in High-Throughput Biology Diana Ballard, Predictum
TP007
Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation Kun Bi, Life Technologies
TP008
Detection of Cardioactive Drug Effects Using a Plate-Based Impedance Reader Andrew Bruening-Wright, ChanTest Corporation
TP010
A World of Pain: Physiologically Relevant Assays Darren Cawkill, Neusentis (a Pfizer research unit)
TP011
Integration of a Large-Scale Genetic Screening Assay Development Pipeline for Genotypic Analysis With Scheduling and Control Elements Colin Cox, Genentech
TP012
Multiplexed High Content Hepatotoxicity Assays Using Induced PluripotentStem Cell Derived Hepatocytes Evan Cromwell, Molecular Devices; Co-Authors: Oksana Sirenko, Jayne Hesley, Molecular Devices, LLC; Shannon Einhorn, Vanessa Ott, Cellular Dynamics International
TP013
Discovery and Application of EZH2 Inhibitors Rich Cummings, Constellation Pharmaceuticals
TP014
Full Automation of Pharmacokinetic and Anti-Drug Antibody Assays in Support of Clinical Trials Parul Jhunjhunwala, Regeneron Pharmaceuticals
TP015
Development of an Electric Field Stimulation Assay for the Identification of Compounds Modulating the “Pain Response” in Sensory Neurons Paul Karila, Cellectricon
TP016
A Case Study: Maximizing the Precision and Accuracy of a Multi-Channel Pipettor to Optimize Inhibition Data From a Kinase Assay. Development of a Low-Cost Liquid Handling Solution Alan H. Katz, Hudson Robotics, Inc.
TP017
Using the xCELLigence System for Screening and Multi-Dimensional Profiling of G-Protein Coupled Receptors Ning Ke, ACEA Biosciences Inc.
TP018
A Data Driven Computer Model of a Single Neuron for High-Content Drug Discovery With Novel Electrophysiological Readout Aditya Reddy Kolli, University of Central Florida
TP019
Novel Single Step Dual Luciferase Reporter Gene Assays Using Spectral Resolution Jorma Lampinen, Thermo Fisher Scientific; Co-Authors: Jae Choi, Megan Dobbs, Janaki Narahari, Douglas Hughes, Reija-Riitta Harinen, Marika Raitio, Brian Webb, Thermo Fisher Scientific
TP020
Assessment of New Developments in ADCC Assays Brad Larson, BioTek Instruments, Inc.
TP021
Development of the Semi-Automated Method Isolation of Functional Mitochondria From Mammalian Tissues Alexander Lazarev, Pressure BioSciences, Inc.
TP022
Ultrasensitive Assay Development and Analysis of Serum and Plasma Cytokines in Normal and Disease-State Subjects Using a Novel Non-optical Detection Technology Charles Lee, BioScale, Inc.
TP023
A new Revolution in Soil Metagenomics: Large-insert BAC Libraries for the Discovery of Natural Products and Drugs David Mead, Lucigen Corporation
TP024
2D+: in vitro cell biology upgraded Lisa Minor, CYTOO; Co-Author: Alexandra Fuchs, Pauline Menager, CYTOO
SLAS2013.org
I
55
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
TP025
Novel Cell-Based Real-Time Platform for Drug Discovery Saurabh Sen, Lucigen Corporation
TP026
A Ligand Titration Based Ca Flux Assay for High-Throughput High Content In-Vitro Pharmacological Investigation of MrgX1 Modulators Meng Wu, HTS Facility, University of Iowa
TP027
Assessment of hERG Channel Function Including Overt, Covert and Trafficking Inhibitors Using xCELLignece RTCA Cardio Instrument Siaoyu Zhang, Acea Biosciences
TP028
Real-Time Cell Cycle Analysis in Mammalian Cells Using Chromobodies Kourosh Zolghadr, ChromoTek GmbH
TP029
Feedback Control of Microfluidic Droplet Formation for Continuous ProteinAssays in Picoliter Volumes Kennon Deal, Auburn University; Co-Authors: Joonyul Kim, Louis Jackson, Christopher Easley, Auburn University
TP030
A Novel QCM Flow Cell Instrument for the Characterization of Molecular Interactions, Surface Layer Systems and Fluid Properties Carsten Haber, 3T GmbH & Co. KG
TP031
Democratizing Automated Sample Prep - Low Cost Automation of Next Gen Sequencing Library Prep for Moderate Throughput Laboratories Curtis Knox, Lucigen Corporation
TP032
Long-Span, Mate-Pair NGS Library Construction Technology David Mead, Lucigen Corporation
TP033
Primuline Derivatives That Stimulate Hepatitis C Virus NS3 Helicase Catalyzed ATP Hydrolysis David Frick, University of Wisconsin- Milwaukee
TP034
Cardiotoxicity of Kinase Inhibitors: Integrated Cross-Platform Surveillance Ina hESC-Derived Cardiomyocyte Model Liz Roquemore, GE Healthcare
TP035
Expressioneering Technology Accelerates Functional Expression and Structural Biology of Membrane Proteins Eric Steinmetz, Lucigen Corporation
TP036
A New Quantitative, Automated, Analytical Sample Preparation Platform for Characterization of PTMs Randy Bolger, Agilent Technologies; Co-Author: Steve Murphy, Agilent Technologies
TP037
Shortening the Drug Discovery Pipeline: Phenotypic Assays in Primary High Content Screening Jonathan Cechetto, Institut Pasteur Korea
TP038
Discovery of Cancer Drug Targets Using RNAi Screening With Pooled Lentiviral shRNA Libraries Alex Chenchik, Cellecta, Inc.
TP039
CMOS-Based Laser Line Confocal Technology: Principles and Benefits for HCA Applications Robert Graves, GE Healthcare
TP040
A Novel Compound Management Solution for Efficient Hit & Lead Optimization Support Brian Healey, EMD Serono Research Institute, Inc.
TP041
Advances in the Use of TipCharger Plasma Treatment Paul Hensley, IonField Systems
TP042
Implementation of a High-Throughput Screening Platform Using MALDI - MS as a Readout W. Adam G. Hill, Novartis Institutes for Biomedical Research
TP043
A High-Quality Direct NaV1.7 Assay for HTS on the Novel Automated Patch Clamp System, the Qube Knirke Jensen, Sophion Bioscience A/S
TP044
Quantitative Analysis of High-Throughput Multiple-Format In Situ Hybridization Image Data for Automated Quality Control Jayson Jochim Allen, Institute for Brain Science
TP046
Miniaturized High-Throughput Cellular Assays Using Primary Blood Cells, PBMCs and Other Suspension Cells Namyong Kim, Curiox Biosystems
56
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
TP048
A New Device for Rapid Image Acquisition, Analysis and Phenotypic Screening of Zebrafish Rock Pulak, Union Biometrica, Inc.
TP049
Multi-Parameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells Oksana Sirenko, Molecular Devices; Co-Authors: Carole Crittenden, Evan Cromwell; Molecular Devices, Blake Anson; Cellular Dynamics; Ivan Rusyn, University of North Carolina
TP050
Design-Build-Test: A High-Throughput Pipeline to Create Industrial Microbes that can Produce Renewable Commodity Chemicals Jeffrey A. Ubersax, Amyris
TP051
Engineered Tissue-Based Compound Screening for Drug Discovery Tetsuro Wakatsuki, InvivoSciences, LLC
TP052
Software Processes in Regulatory Environment Henning Bär, Infoteam Software AG; Co-Author: Uli Syré; Infoteam Softare AG
TP053
Bringing the Barcode and the LIMS/LIS Worlds Together Carl Hull, UNIConnect
TP055
Blister Techniques for On-Cartridge Reagent Storage Andrew Campitelli, MiniFAB (AUST) Pyt Ltd
TP056
Facilitating Multisite Bioprocess Transfer: Multi-Instrument and Multi-Platform Comparability and Long-Term Stability of Nova Biomedical’s BioProfile® Chemistry and Gas Analyzers Matt McRae, Nova Biomedical
TP058
Systematic Analysis of Leachables and Extractables in Liquid Handling Components Kyle T. Harris, Porex Technologies; Co-Author: Gary Mao, Porex Corporation
TP059
Three-Dimensional Tissue Dynamics Imaging for Drug Discovery and Personalized Medicine John J. Turek, Purdue University; Co-Authors: Ran An, Purdue University; Daniela Matei, Indiana University School of Medicine; David Nolte, Purdue University
TP060
Connecting Live Cell High Content Analysis With High-Throughput and High Resolution Imaging David Lorenz, Wako Automation; Co-Authors: Eugenio Fava, Philip Denner, DZNE Erika Kaneko, Yokogawa
TP061
Similarity Analysis of Spectra Obtained Via Reflectance Spectrometry in Legal Medicine Liudmila Belenki, Materials Research Center Freiburg; Co-Authors: Michael Bohnert, Vera Sterzik, University of Würzburg, Department of Legal Medicine
TP062
Analysis of Synergistic Effect of Anticancer Drugs’ Combination in the Microfluidic System Michal Chudy, Faculty of Chemistry, Warsaw University of Technology; Co-Authors: Elzbieta Jastrzebska, Warsaw University of Technology, Department of Microbioanalytics; Sylwia Flis, National Medicine Institute; Aleksandra Rakowska, Warsaw University of Technology; Zenon Jastrzebski, National Medicine Institute; Artur Dybko, Warsaw University of Technology; Zbigniew Brzozka, Warsaw University of Technology
TP063
New and Highly Effective Automated Solutions for Sample Preparation for Next-Generation Sequencing Salim Essakali, QIAGEN GmbH; Co-Authors: Dominic O’Neil, Heike Glowatz, Joerg Dennig, Peter Hahn, Nan Fang, QIAGEN GmbH
TP064
IgG Quantification and Correlation in Cell Culture Media With the BioProfile ® FLEX Automated Cell Culture Analyzer Brian Goulart, Nova Biomedical
TP065
Optimization of a Novel Sample Storage and Delivery System Tanya Knaide, ARTEL; Co-Authors: Gordon Robertson, G. Steven Bova, Archivex; Matt Wilkinson, Wilkinson Communications Ltd.
TP066
An Automation-Assisted Solid Phase Extraction Method Development System Ming Li, Biogen Idec; Co-Authors: Judy Chou, Kristopher King, Liyu Yang, Biogen Idec
TP067
The ÄKTA™ Ready Gradient Controller Aleksandar Alex Mladenovic, Amgen Inc.; Co-Authors: Craig Schulz, Michael Johnson, Amgen Inc.
TP068
Competition Based Screening and Characterisation of Fragments With SPR and ITC Michael Murphy, GE Healthcare; Co-Author: Tomoya Mitani, GE Healthcare
SLAS2013.org
I
57
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
TP069
Exploration of Utilizing Low Volume Transcriptomics Solutions With Acoustic Technology Sue Holland-Crimmin, GSK; Co-Authors: Zining Wu, Genaro Scavello Jr., Xin Zeng, Michael Platchek, Brian Lupotsky, Ashka Patel, Tina Shah, Sandy Chang, GSK
TP070
Microdevice for Cell Coculture - Procedure of Cell Pattering and Cell Migration Monitoring Ilona Grabowska-Jadach, Warsaw University of Technology; Co-Authors: Ewelina Majewska, Elzbieta Jastrzebska, Michal Chudy, Artur Dybko, Zbigniew Brzozka, Warsaw University of Technology
TP071
Picoliter Liquid Handling for Sub-Microliter Reagent Dispensing Claude Dufresne, Scienion
TP072
A Windows .NET Service for Parsing Instrument File Outputs Into a Common .XML Format for Informatics Platforms Jason Burbank, Broad Institute of MIT and Harvard; Co-Authors: Gil Walzer, Jacob Asiedu, Michelle Campo, Clint Beilman, David Gregoire, Broad Institute of MIT and Harvard
TP073
Advanced Software Solutions for Enantiomeric Excess Determination of Chiral Compounds Using ESI-MS in High-Throughput Screening Processes Heidi Fleischer, celisca - Center for Life Science Automation; Co-Author: Kerstin Thurow, celisca - Center for Life Science Automation
TP074
Enabling an HTS Workflow in the Academic Lab Through MScreen Martha J. Larsen, University of Michigan; Co-Authors: Paul Kirchhoff, Richard Neubig, Renju Jacob, Jason Gestwicki, University of Michigan
TP075
Global Shipping and Tracking in Sample Management Rachael Holmes, Novartis; Co-Authors: Aaron Hohos, Robert Smith, Kai Chan, Brendan Hannigan, Michel Erb, Daniel Baeschlin, Marc Andreae, Manori Turmel, Novartis
TP076
Software System Used to Automate Equipment Performance Investigations and Improve Monitoring of Equipment at XDx, Expression Diagnostics Inc. Rebecca Butler XDx, Expression Diagnostics; Co-Author: Dave Wexler, XDx, ExpressionDiagnostics
TP077
TRIER: A Tool Supporting HTS Hit Triage John Braisted NIH/NCATS; Co-Authors: Dac-Trung Nguyen, Tyler Peryea, Raj Guha, NIH/NCATS; Noel Southall, NIH; Ajit Jadhav, NIH/NCATS
TP078
Utilization of High-Throughput Mass Spectrometry to Eliminate False Positives in Protease uHTS Screens Gregory Adam, Merck & Co., Inc.; Co-Authors: Juncai Meng, Joseph Rizzo, Adam Amoss, Angela Jaramilllo, Jeffrey Lusen, Amita Patel, Daniel Riley, Kenneth Ellsworth, Peter Nizner, Anthony Kreamer, Merck & Co., Inc.
TP079
Optimize Volume Transfer Methods to Avoid Reagent Concentration Errors of > 40 Percent Keith J. Albert, ARTEL
TP080
The Power of an Integrated Discovery Platform for the Exploitation of “Synthetically Engineered Macrocycles” against Challenging Therapeutic Targets Sethu L. Alexander, Ensemble Therapeutics; Co-Authors: Julian Bond, Sarah Jensen, Nathan Walsh, Kelley Shortsleeves, Cheri Snedeker, Timothy Briggs, David Livingston, Stephen Hale, Ensemble Therapeutics
TP081
Introduction of a High-Throughput Automated Multi-Assay Processing System (MAPS) for Viral and Immunological Assays in a BSL4 Laboratory Using the Tecan Freedom EVO® Platform Cindy M. Allan, MRIglobal/NIH; Co-Authors: Catherine Jett, Tunnell Government Services Inc./NIH; Jon Smith, Kenny Ung, Tecan US, Inc., Jason Paragas, Defense Threat Reduction Agency; Peter Jahrling, NIAID-IRF Fort Detrick
TP082
Live-content Imaging: Multiplexed, quantitative, Kinetic Assays Enabled by CellPlayer ® Reagents and IncuCyte ZOOM® Daniel Appledorn, Essen BioScience
TP083
Comparison of Endogenous Methyl Marks on Histone H3 in Cancer-Derived Cell Lines Using AlphaLISA® Mathieu Arcand, PerkinElmer; Co-Authors: Jean-Francois Michaud, PerkinElmer Biosignal, Inc.; Jean-Philippe Levesque-Sergerie, Nancy MacDonald, Philippe Bourgeois, Lucille Beaudet, Nathalie Rouleau, PerkinElmer Biosignal, Inc.
TP084
Live-Cell Biosensor Assay Used to Interrogate GPCRs: Comparative Analysis of Biosensor Variants Peter Banks, BioTek Instruments, Inc.; Co-Authors: Peter Brescia, Jr., BioTek Instruments, Inc.; Brock Binkowski, Mei Cong, Pete Stecha, Promega Corporation
TP085
Development of AlphaLISA Assays for Characterization of Monoclonal Antibody Biotherapeutics Jimmy Barbee, PerkinElmer; Co-Authors: Genevieve Pinard, Valerie Paquet, Claire Normand, Wolfgang Reintsch, Julie Bédard, Veronique Brechler, Francesco Lipari, PerkinElmer
TP087
Miniaturized and Automated Cisbio HTRF Assays With the Echo® Liquid Handler and BMG PHERAstar FS Joseph Barco, Labcyte Inc.; Co-Authors: Bonnie Edwards, Labcyte, Inc.; Nga Tang, Cisbio; Maggie Nakamura, BMG Labtech; Brent Eaton, Sammy Datwani, Joseph Barco, Labcyte Inc.
58
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
TP088
Comparison of GLP-1 Detection Technologies James R. Beasley, Venenum Biodesign; Co-Authors: Melissa Donigan, Christina Gallo-Ebert, Venenum Biodesign
TP089
Screening for Isoform-Selective HDAC Inhibitors Maureen H. Beresini, Genentech; Co-Authors: Linda Orren, Steven Jones, Peter Thana, Jiansheng Wu, Yvonne Franke, Tim Dawes, Christopher Heise, Rebecca Turincio, Richard Rodriguez, Genentech
TP090
Phenotypic Approaches Defining Toxicity Mechanisms Ellen L. Berg, BioSeek, LLC; Co-Authors: Mark Polokoff, Alison O’Mahony, Jennifer Melrose, Dat Nguyen, Jian Yang, BioSeek, LLC
TP091
High-Throughput Analysis of Methyl-DNA Binding Proteins MBD2 and MeCP2 Levi Blazer, Cayman Chemical Company; Co-Authors: Daniel Bochar, Adam Driscoll, Rana Sidhu, Jeffrey Johnson, Cayman Chemical Company
TP092
Application of Real-Time Decay Curve Analysis to Fluorescence Lifetime Assays - An Attractive Addition to Drug Discovery Technologies Wayne Bowen, TTP Labtech; Co-Authors: Uliana Bastanova, TTP Labtech; Colin Dunsmore, Graham Cotton, Almac Sciences
TP093
Automation of a Homogeneous Proximity Assay for Immunogenicity Testing of Biological Drug Products Peter J. Brescia, Jr., BioTek Instruments, Inc.; Co-Author: Peter Banks, BioTek Instruments, Inc.
TP094
Rapid Profiling of Multiple Toxicity Indicators Using a Laser Scanning Imaging Cytometer Diana Caracino, TTP Labtech; Co-Authors: David Onley, Paul Wylie, TTP Labtech; Nicholas Dolman, Life Technologies
TP095
Extracting Rich Information From Biological Images to Tackle World Health Problems Anne Carpenter, Broad Institute of Harvard and MIT
TP096
Do all Cell-Based Kinase Assays Perform Similarly? A Side-by-Side Comparison of HTRF®, Western Blot, Elisa and AlphaScreen® Fabienne Charrier-Savournin, Cisbio Bioassays; Co-Authors: Julie Vallaghe, Nathalie COSTY, Stéphanie Douzon, Cedric Chouvet, Chloé Boisseau, Francois Degorce, Eric Trinquet, Cisbio Bioassays
TP097
Identification of Anti-Infectious Disease Agents and Introduction of Nation-Wide HTS Service in Taiwan Rachel Cheng, Academia Sinica; Co-Author: Yih-Shyun Edmond Cheng, Academia Sinica
TP098
X-MAN™ NanoLuc™ Reporter Cell Lines: Tools for High-Throughput Screening Lowe Chris, Horizon Discovery Ltd; Co-Authors: Holly Astley, Suzanne Grooby, Annette Little, Sue Griffin, Christine Schofield, Rebecca Foster, Kyla Grimshaw, Horizon Discovery Ltd
TP099
Novel Histone Reagents and Fluorescence Lifetime Assays for Epi-enzyme and Epi-reader Targets Graham Cotton, Almac Group; Co-Authors: Colin Dunsmore, Beatrice Maltman, Jennifer Thom, David Anderson, Antonio Marques, Gillian Gray, Almac Group
TP100
Cell Based Assays on the FLIPR® Tetra System: Comparison of a Novel FLIPR® Calcium Assay System to Other Fluorescence Based Calcium Flux Assays Carole Crittenden, Molecular Devices LLC; Co-Authors: Yen-Wen Chen, Debra Gallant, Molecular Devices
TP101
Accurate and Precise Acoustic Transfer of Venom Discovery Arrays Using the Echo® Liquid Handler Sammy Datwani, Labcyte Inc.; Co-Author: Steve Trim, Venomtech Limited; Rich Ellson, Labcyte Inc.
TP102
RoboLector ® Family From Automated Media Preparation to Fed-Batch Fermenation in Shaken Microbioreactors Elizabeth Dierickx, m2p-Labs, Inc.; Co-Authors: Johannes Hemmerich, Pamela Wenk, Frank Kensy, m2p-labs GmbH
TP103
A High-Throughput In-Cell Assay for Identification of Compounds Which Increase SMN Protein Levels Svetlana V. Dobritsa, AMRI; Co-Authors; Midori Clarke, Michele Luche, AMRI
TP104
Where Phenotypic Screening Meets Target-Based Drug Discovery: Multiplexing Label-Free Cellular measurements With DiscoveRx Assays on the Same Cells to Aide Mode of Action Studies – Two Bangs for One Buck! Kathy Dodgson, Aurelia Bioscience Limited; Co-Authors: Kevin Hart, Aurelia Bioscience Limited
TP105
A Novel Duplex Assay to Detect Phosphorylated and Total Tau Protein in Human Cells Using Alpha® Technology Pat Escaron, PerkinElmer; Co-Authors: Christian Fafard, PerkinElmer; Chantal Illy, PerkinElmer Biosignal
TP106
HTS Performance and High-Content Analysis of Antimigratory Compound Phenotypes Using the Oris™ Pro 384 Cell Migration Assay Jennifer Fronczak Platypus Technologies; Co-Authors: Laura Vollmer, Andreas Vogt, University of Pittsburgh Drug Discovery Institute; Gopal Krishnan, Platypus Technologies
TP107
Analysis of a New High-Throughput Screening Detection Technology for Rapid hERG Safety Testing using a Fluorescence Polarization Assay Wendy Goodrich, BioTek Instruments, Inc.; Co-Authors: Mark Koeppel, Life Technologies; Peter Banks, Xavier Amouretti, BioTek Instruments, Inc.
SLAS2013.org
I
59
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
TP108
Automated, High Throughput, HTRF®-Based Detection of Histone Methylase and Demethylase Enzyme Activity Jason Greene, BioTek Instruments, Inc.; Co-Authors: Brad Larson, BioTek Instruments, Inc.; Nicolas Pierre, Suzanne Graham, Cisbio US; Francois Degorce, Cisbio Bioassays; Peter Banks, BioTek Instruments, Inc.
TP109
The Use of Novel Endogenous Reporter Technology in Large Scale siRNA Library Screens Provides a Simple System for Rapid Identification of Potential Drug Targets Sue Griffin, Horizon Discovery Ltd.; Co-Authors: Holly Astley, Suzanne Grooby, Kyla Grimshaw, Karin Schmitt, Jo Francis, Horizon Discovery Ltd.
TP110
Development of an Automated Mycoplasma Detection System Aana Hahn, The New York Stem Cell Foundation; Co-Authors: Hesed Kim, Hector Martinez, Christopher Napolitano, David Kahler, The New York Stem Cell Foundation
TP111
A FLIPR-Based HTS Assay to Identify N-Type Calcium Channel (Cav2.2) State-Dependent Blockers Peter Hawryluk, ChanTest Corporation; Co-Authors: Summer Gunn, Xiaoyi Du, Glenn Kirsch, Arthur Brown, Emir Duzic, ChanTest Corporation; Stephan Steigele, Stephan Heyse, Genedata AG
TP112
Effect of Liquid Handling QC on Biological Assay Performance Nathaniel Hentz, North Carolina State University BTEC; Co-Author: Tanya Knaide, ARTEL
TP113
Assay Optimization and Performance of a Cell-based FLISA With Laser Scanning Imaging and MicroVolume Fluorescent Detection Pei-i Ho, Novartis Institutes for Biomedical Research; Co-Authors: Wai Lee, Novartis Institutes for Biomedical Research; Diana Caracino, Ben Schenker, TTP Labtech Inc.; Adam Hill, Douglas Auld, Novartis Institutes of Biomedical Research
TP114
Ultra-High Throughput Cell Based Screen for Identifying Potential TRAIL Sensitizing Caspase 8 Activators Becky Hood, Sanford Burnham Medical Research Institute; Co-Authors: Brock Brown, Kevin Nguyen, Eigo Suyama, Fusayo Yamamoto, Darren Finlay, Sanford Burnham Medical Research Institute; Stefan Vasile, Conrad Prebys Center for Chemical Genomics at Lake Nona; Robyn Richardson, Layton Smith, Ekaterina Bobkova, Thomas D.Y. Chung, Sanford-Burnham Medical Research Institute
TP115
A Novel Sensitive and Selective Real-Time Cellular Assay for Detection of Endocrine Disruptors Using Native Endocrine Signaling Pathways Can Jin, ACEA Biosciences, Inc.; Co-Authors: Yama Abassi, Adrian Papas, Khanh Nguyen, Can Jin, ACEA Biosciences, Inc.; Alexander Seiler, Roche Diagnostics GmbH; Xiao Xu, Xiaobo Wang, ACEA Biosciences, Inc.
TP116
Development of a Methyltransferase Screening Panel Amber Jones, GlaxoSmithKline; Co-Authors: Melissa Pappalardi, Martin Brandt, Jessica Schneck, Elsie Diaz, Hong Xiang, Kelvin Nurse, Thau Ho, Carl Machutta, Paul Keller, Matt Steiginga, GlaxoSmithKline
TP117
Identification and Characterisation of Novel Positive Allosteric Modulators of the Galanin 2 Receptor Hayley Marie Jones, MRCT; Co-Authors: Paul Wright, Jamie Cartland, Catherine Kettleborough, MRCT; David Wynick, Bristol University; Jeff Jerman, MRCT
TP118
A High-Throughput Phenotypic Cell-Based Assay Modeling Cardiac Ischemia-Reperfusion Injury Ada Kane, Sanford-Burnham Medical Research Institute; Co-Authors: Alka Mehta, Becky Hood, Kevin Nguyen, Eigo Suyama, Paul Herschberger, Mahesh Peddibhotla, Patrick Maloney, Layton Smith, Stefan Vasile, Siobhan Malany, Sanford-Burnham Medical Research Institute,
TP119
Multi-Cell Type Human Liver Microtissues for Hepatotoxicity Testing Jens Kelm, InSphero AG; Co-Authors: Simon Messner, Irina agarkova, Wolfgang Moritz, InSphero AG
TP120
Selective Detection of LRRK2 GTPase Activity With the Transcreener ® GDP Assay Karen Kleman, BellBrook Labs; Co-Author: Tom Zielinski, BellBrook Labs
TP121
Predictive Cardiac Risk and the Suitability of Automated Ion Channel Patch Clamping Platforms James Kramer, ChanTest Corporation; Co-Authors: Carlos Obejero-Paz, Andrew Bruening-Wright, Yuri Kuryshev, Emir Duzic, Arthur Brown, ChanTest Corporation
TP122
Nav1.7 Ion Channel on IonWorks™ Barracuda Platform: Manual Patch Clamp Quality with High-Throughput Capability Yuri A. Kuryshev, ChanTest Corporation; Co-Authors: Cory Stebal, Weimin Pei, Michael Fraifogl, Hung Lee, Peter Hawryluk, Glenn Kirsch, Arthur Brown, Emir Duzic, ChanTest Corporation
TP123
Fragment-Based Drug Discovery: Comparison of Labeled and Label-Free Approaches to Beta-Amyloid Secretase (BACE-1) William Albino LaMarr, Agilent Life Technologies, Inc.; Co-Author: Lauren Frick, Agilent Technologies, Inc.
TP124
Determination of Endogenous Cellular Kinase Activity Through the Use of an Automated, High-Throughput, AlphaScreen®-Based Method Brad Larson BioTek Instruments, Inc.; Co-Author: Peter Banks, BioTek Instruments, Inc.
60
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
TP125
Do We Need Antibiotics in Cell Culturing? Comparison of Automated and Manual Disseminated Cell Cultures Ricarda Lehmann, celisca; Co-Authors: Thomas Roddelkopf, Steffen Junginger, celisca; Grit Koch, University of Rostock; Luisa Person, Leonie Vetter, Kerstin Thurow, celisca
TP126
Profiling MT Inhibitors With Transzyme Methyltransferase Enzyme Assay Kits Robert G. Lowery, BellBrook Labs; Co-Authors: Karen Kleman-Leyer, Meera Kumar, BellBrook Labs
TP127
Novel Cell Based PDE Assays With Cyclic Nucleotide-Gated (CNG) Channels Jimmy Lu, Codex BioSolutions, Inc.; Co-Authors: Louie Zhang, Kiho Han, Wenshan Hao, Codex BioSolutions, Inc.
TP128
Label Free Measurements of Small Molecules and Peptides Binding to Liposomes Ruben Luo, Bio-Rad Laboratories; Co-Author: Dalia Shezifi, Bio-Rad Laboratories
TP129
Liquid Handling Methods for a Cellular Metabolite Assay in a Sequentially Multiplexed 1536-Well Microplate Format Ryan MacArthur, National Institutes of Health NCATS DPI; Co-Authors: Sung-Wook Jang, National Institute of Health; James Inglese, NIH Chemical Genomics Center
TP130
Compound Screening for Opioid Family Receptors in Parallel Functional Assays Helena Mancebo, Multispan Inc. Co-Author: Miao Tan, Multispan Inc.
TP131
Different siRNA Library, Different Result. What are the Implications for RNAi Screening Strategies? Scott Martin, NIH/NCATS; Co-Authors: Eugen Buehler, Pinar Tuzmen, Carleen Klumpp-Thomas, Yu-Chi Chen, NIH/NCATS
TP132
Automated High-Throughput RNA-Seq Scott McCroskey, Stowers Institute
TP133
High Content Screen to Identify Small Molecule Agonists of the Neurotensin1 Receptor in 1536-Well Plate Format Alka Mehta, Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical Research Institute; Co-Authors: Eigo Suyama, Wilson Gray, Santosh Hariharan, Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical Research Institute; Stefan Vasile, Conrad Prebys Center for Chemical Genomics at Lake Nona; Eliot Sugarman, Kevin Nguyen, Yujie Li, Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical Research Institute; Monika Milewski, Sanford-Burnham Medical Research Institute; Palak Gosalia, Sanford-Burnham Center for Chemical Genomics at SanfordBurnham Medical Research Institute; Susanne Heynen-Genel
TP134
High-Throughput Homogeneous Histone Methyltransferase and Demethylase Assays Using HTRF® Technology and the SpectraMax® Paradigm® Microplate Detection Platform Cathy Olsen, Molecular Devices; Co-Authors: Nicolas Pierre, Arturo Gonzalez-Moya, Suzanne Graham, Francois Degorce, Cisbio
TP135
Ultra-High Throughput Screening to Identify Small Molecule Caspase-6 Inhibitors Using a Combination of Luminescence, Fluorescence and Mass Spectrometry Technologies Amita Patel, Merck & Co.; Co-Authors: Louis Locco, Samuel May, Gregory Adam, Kun Liu, Sharie Haugabook, Fiona Thomson, Rachel Hunt, Eric Johnson, Merck & Co.
TP136
Development of Non-Rad Homogeneous Assays for Histone Lysine and Arginine Methyltransferases Using Peptide, Protein and Nucleosomal Substrates Liliana Pedro, PerkinElmer; Co-Authors: Nancy Gauthier, Marie-Elaine Caruso, Anja Rodenbrock, Philippe Bourgeois, Mireille Caron, Lucille Beaudet, PKI; Roberto Rodriguez-Suarez, PerkinElmer
TP137
Small Molecule Inhibitors of Isocitrate Dehydrogenase-1 Point Mutants Alter Dimethylation Status of Histone 3 Lysine 9 in 384-Well Cell-Based Assays Melissa Porter, University of North Carolina; Co-Authors: Emily Hull-Ryde, Melissa Porter, Victoria Korboukh, University of North Carolina; Catherine Simpson, University of North Carolina at Chapel Hill; Nancy Cheng, Jing Liu, University of North Carolina; William Janzen, University of North Carolina at Chapel Hill
TP138
Evaluation of Viral ToxGlo as an Endpoint Reagent for Cell-Based, High-Throughput Anti-Viral Discovery Lynn Rasmussen, Southern Research Institute; Co-Authors: Carrie Evans, Nichole Tower, Sara McKellip, Miranda Nebane-Akah, Lucile White, Melinda Sosa, Noah, Southern Research Institute
TP139
Automation of Hydrogel-Based 3D Cell Culture Markus Rimann, Zurich University of Applied Sciences, Institute of Chemistry and Biological Chemistry; Co-Authors: Isabel Patocchi-Tenzer, Susanne Braum, Tecan; Brigitte Angres, Cellendes GmbH; Ursula Graf-Hausner, Zurich University of Applied Sciences, Institute of Chemistry and Biological Chemistry ICBC
TP140
Automation of the HCV NS3 Protease Enzyme Assay Using the Agilent BioCel 1600 System Laura Rokosz, Merck; Co-Authors: Steven Cifelli, Emily Frank, Erik Aponte, Deborah Barbey, Merck; Cornisha Cherrie; Boris Feld; Scott Greene, Merck; Frederic Masse, Beckman Coulter Canada Ltd; Cheryl Rebsch, Merck; Jonathan Schneeweis
TP141
Development of Screening Assays for Two Stem Cell Lineages Using Corning® Epic® Label-free Technology Mark Rothenberg, Corning Inc.; Co-Authors: Hilary Sherman, Hanna Gitschier, David Randle, Corning Inc.
SLAS2013.org
I
61
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
TP142
High-Throughput Homogeneous Histone H3 Methyltransferase (HMT) andDemethylase (HDMT) Enzyme Assays Using HTRF Technology: G9a, MLL1, and EZH2 Methyltransferase plus LSD1, JMJD2C and JMJD2A Demethylase Assays Thomas Roux, Cisbio Bioassays; Co-Authors: Koji Adachi, Chikashi Tokuda, Sceti Medical Labo K.K.; Eric Trinquet, Francois Degorce, Cisbio Bioassays
TP143
Development of a New Biosensor for the Measurement of the Intracellular Second Messenger Levels in Living Cells by High-Content Imaging Clarisa Salado, Innoprot; Co-Authors: Danel Kortazar, Rosa Maria Mella, Meritxell Roura, Patricia Villacé, Innoprot
TP144
Novel Screening Strategy to Address GPCR Drug-Discovery Pitfalls Stephan Schann, Domain Therapeutics; Co-Authors: Michel Bouvier, IRIC-Université de Montréal; Pascal Neuville, Domain Therapeutics
TP145
Automated Low Sample Volume Protein Assays Rozhok Sergey, NanoInk Inc.; Co-Authors: Kathy Ouyang, Pat Morgan, Javad Vakil, Jeff Rendlen, Nabil Amro, John Bussan, Mike Nelson, NanoInk Inc.
TP146
A Novel Screening Method for the Detection of Small Molecule Mimetics of Micro-RNA mir29-b to Promote Neuronal Cell Survival Catherine Simpson, University of North Carolina at Chapel Hill; Co-Authors: Mohanish Deshmukh, Vijay Swahari, Bill Janzen, Emily Hull-Ryde, University of North Carolina at Chapel Hill
TP147
Inert Surfaces for Laboratory Diagnostic Systems Plagued With Chemical Adsorptivity on Stainless Steel Substrates David A. Smith, SilcoTek Corporation
TP148
High-Throughput Screening of Combinatorial Libraries for Inhibitors of Clostridium Difficile Toxins Ilana L. Stroke, Venenum Biodesign; Co-Authors: Laurie Sturzenbecker, Jeffrey Letourneau, Jorge Quintero, Joan Sabalski, Brett Marinelli, Igor Pechik, David Diller, Venenum Biodesign; Teresa Paulish-Miller, David Hilbert, Femeris, LLC; Scott Gygax
TP149
The Development and Performance of a Novel Microtiter Plate-Based High-Throughput Assay to Measure Intracellular Triacylglyceride Accumulation Eliot Sugarman, Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute; Co-Authors: Ada Kane, Eigo Suyama, Kevin Nguyen, Manuel Ruidiaz, Conrad Prebys Center for Chemical Genomics at Sanford Burnham Medical Research Institute; Susanne Heynen-Genel, Kyungmoo Yea, Sanford-Burnham Medical Research Institute; Brock Brown, Conrad Prebys Center for Chemical Genomics at Sanford Burnham Medical Research Institute; Teresa Leone, Sanford-Burnham Medical Research Institute; Stefan Vasile, Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute; Rick Vega
TP150
Development of a Bioluminescent Cell-Based Bioassay to Measure Fc Effector Functionality in Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) Teresa Surowy, Promega Corporation; Co-Authors: Jey Cheng, Richard Moravec, Denise Garvin, Aileen Paguio, Neal Cosby, Richard Somberg, Frank Fan, Promega Corporation
TP151
A Robust Ultra-High-Throughput Screening Assay for DEK, a Structure-Specific DNA Binding Protein Robert Swanson, Venenum Biodesign; Co-Authors: Albert Uveges, Nalini Kanneganti, Elena Severinova, Denise Dimitrov, Venenum Biodesign; Antara Datta, Michael Scher, Oncoveda; Michael McQueney, Venenum Biodesign; Jason Trama, Oncoveda; Maria Webb, Venenum Biodesign
TP152
A Novel High-Throughput Screening Assay for Inhibitors of Microsomal Prostaglandin E2 Synthase-1 Hirotada Takahashi, Dainippon Sumitomo Pharma Co., Ltd.; Co-Authors: Hidetaka Nagata, Tomoya Shiro, Hideo Kase, Masanori Tobe, Manabu Shimonishi, Ryuji Hiramatsu, Dainippon Sumitomo Pharma Co., Ltd.
TP153
Assay Development for High-Content Screening of Small-Molecule Modulators on the Differentiation of Oligodendrocyte Progenitor Cells (OPCs) Hong Tang, University of Cincinnati; Co-Authors: Fadi Najm, Case Western Reserve University; Ruben Papoian, William Seibel, University of Cincinnati; Paul Tesar, Case Western Reserve University
TP154
Development of an Automated, Homogeneous Fluorescent Assay for the Identification of N-Acylethanolamine Acid Amidase Inhibitors Glauco Tarozzo, Italian Institute of Technology, Co-Authors: Luisa Mengatto, Mauro Dionisi, Mattia Pini, Anna Maddalena, Chiara Pagliuca, Fabio Bertozzi, Angelo Reggiani, Italian Institute of Technology
TP155
Efficient Discovery of Synergistic Combinations Matthew Tudor, Merck & Co.; Co-Authors: Bryan Severyn, Jing Li, Jeremy Caldwell, Jeffrey Hermes, Merck & Co.
TP156
A New HTRF® Assay for the Quantification of Active Glucagon-Like Peptide-1 (GLP-1) Julie Vallaghe, Cisbio Bioassays; Co-Authors: Sara Bdioui, Patrick Mensat, Stéphane Martinez, Francois Degorce, Eric Trinquet, Cisbio Bioassays; Chikashi Tokuda, Koji Adachi, Sceti Medical Labo K.K.
62
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
TP157
A Novel Luminescent Cell Viability Assay With Greatly Enhanced Storage Stability Michael P. Valley, Promega; Co-Authors: Dan Lazar, James Unch, Kevin Kershner, Poncho Meisenheimer, James Cali, Promega Corporation
TP158
A High-End uHTS System for the New Open-Access “Pivot Park Screening Centre” Jacques van den Broek, Pivot Park Screening Centre & LAC4LS; Co-Authors: Hans Jansen, Steven van Helden, Pivot Park Screening Centre
TP159
Novel Bioluminescent Cell Metabolism Assays Integration With HP D300 Digital Dispenser and Tecan Gas Controlled Module Equipped Infinite M200 Pro Reader Gediminas Vidugiris, Promega Corporation; Co-Authors: Donna Leippe, Mary Sobol, Sarah Duellman, Promega Corporation; Wenhui Zhou, Promega Biosciences, LLC; Jolanta Vidugiriene, Promega Corporation; Jessica Merlino, Tecan Schweiz; Michael Reitman, Tecan US; Thomas Hengstl, Tecan Austria GmbH; Poncho Meisenheimer, Promega Biosciences, LLC; Cristopher Cowan
TP160
Use of a Multiplexed Cell Assay for the Identification of Novel Selective Estrogen Receptor Downregulator (SERD) Compounds Graeme E. Walker, AstraZeneca
TP161
Application of ISFETs for Ion Channel Drug Discovery Kenneth Walsh, University of South Carolina; Co-Authors: Nicholas DeRoller, Yihao Zhu, Goutam Koley, University of South Carolina
TP162
A New Approach to Time Dependent Cytochrome P450 Inhibition Assay Using the Echo® Liquid Handler Jing Wang, Labcyte; Co-Authors: Brent Eaton, Sammy Datwani, Joseph Barco, Labcyte, Inc.; Sean Wu, Quintara Discovery; Wentao Zhang, Exelixis, Inc.; Ji Young Lee, Celsis IVT
TP163
Screening for Compounds Affecting Macrophage Polarization Shaohui Wang, GSK R&D China; Co-Authors: Phoebe Lei, Qianqian Wu, Justin Liao, Jie Luo, Azalea Du, Yihui Lin, Jerry Wang, Biao Zheng, Guohuang Fan, Zhong Zhong, GSK
TP164
A Luciferase-Based Coupled Enzyme Assay for the Discovery of Inhibitors of the Histone Methyltransferase NSD1 Venita G. Watson, Nemours Center for Childhood Cancer Research; Co-Author: Andrew Napper, Nemours Center for Childhood Cancer Research
TP165
Use of a Novel Thallium-Sensitive Fluorescent Dye Thallos™ to Support the Development of the First Potent and Selective Small-Molecule Activators of GIRK Channels Dave Weaver, Vanderbilt School of Medicine; Co-Authors: Emily Days, Kim Kwangho, Vanderbilt University; Rogelio Escamilla, Teflabs; Ian Romaine, Yu Du, Kristian Kaufmann, Craig Lindsley, Gary Sulikowski, Vanderbilt University
TP166
Development of a High-Throughput Screening Assay to Identify Inhibitors of the De Novo Purine Biosynthetic Pathway David Whalley, MRC Technology; Co-Authors: Keith Ansell, Peter Coombs, Craig Southern, Chido Mpamhanga, Michelle Newman, Zaynab Isseljee, Debbie Taylor, Andy Merritt, MRC Technology; Steve Firestine, Wayne State University; Nils Visser
TP167
The Benefits of Live Cell Kinetic cAMP Assay (GloSensor) in Screening for Positive Allosteric Modulators Martyn Wood, UCB Pharma; Co-Authors: SA Michel Gillard, Maggi Burton, Evelyne Malray, Michel Famelart, David Urbain, UCB Pharma SA
TP168
Bringing Assays and Automation Together for Lower Throughput Kinase Profiling Tracy Worzella, Promega Corporation; Co-Authors: Gediminas Vidugiris, Jacquelyn Turri, Jolanta Vidugiriene, Hicham Zegzouti, Lyndsey Helley, Promega Corporation; Jessica Merlino, Michael Reitman, Tecan
TP169
A High-Throughput Screen Using the IonWorks System to Identify Inhibitors of the Inward Rectifying Potassium Channel Kir7.1 Paul D. Wright, MRC Technology; Co-Authors: Srinivasan Kanumilli, Tim Dale, Del Tresize, Essen Bioscience; David Tickle, Catherine Kettleborough, MRC technology; Andrew Blanks, University of Warwick; Jeff Jerman, MRC Technology
TP170
Verification of High-Throughput Electrophysiology With IonWorks Barracuda Natsue Yamanada, Shionogi & Co., Ltd.; Co-Authors: Yoshihito Ishida, Nishigaki, Maki Tomari, Kazuho Kawase, Koichi Ogawa, Masahito Horiuchi, Noriko Suzuki, Shino Kikuoka, Hideki Tsujishita, Hiroshi Takemoto, Shionogi & Co., Ltd.
TP171
A New FAP-Based pH Sensor for Tracking GPCR Trafficking and pH Sensing Qi Yan, Sharp Edge Labs, Inc.; Co-Authors: Scott Sneddon, Sharp Edge Labs, Inc.; Marcel Bruchez, Brigitte Schmidt, Alan Waggoner, Carnegie Mellon University
TP172
Analyzing Polyubiquitin Chains Upon Ubiquitin Activating Enzyme Inhibition From Cell Culture and Tumor Lysates Using the Quanterix’s Single Molecule Array (SiMoA) Technology Zhong-Hua Yan, Millennium Pharmaceuticals
TP173
Automated High-Throughput Soft Agar Assay for Anticancer Compound Screening Wang Yana, Millennium Pharmaceuticals; Co-Authors: Jean Courtemanche, John Bradley, John Ringeling, Saurabh Menon, Millennium Pharmaceuticals
SLAS2013.org
I
63
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
TP174
An Integrated Approach to Study the Cellular Mechanisms of GPCR Drug Actions Using Calcium and Label-Free Based Platforms Huailing Zhong, U-Pharm Laboratories LLC; Co-Authors: Kiho Han, Wenshan Hao, Hung Cuong Louie Tran, Ye Fang, Corning Inc.
TP175
Pharma - Academic Partnerships to Enhance Lead Discovery Peter Simpson, AstraZeneca
TP177
High-Throughput Assay to Measure the Functional Activity of Transient Receptor Potential Ankyrin 1 (TRPA1) in Human Airway Smooth Muscle Cells Prasanthi Geda, Merck & Co.
TP178
How Rapid Prototyping Helps to Investigate the In-Vitro Performance of Inhaled Investigational Products Stephen Trowbridge, GlaxoSmithKline; Co-Authors: Melanie Hamilton, GlaxoSmithKline; Tony, GlaxoSmithKline
TP179
SERS-Based Detection of Chemical Ligands and Its Reactivity on the Alpha-synuclein-Mediated 2-Dimensional Array of Gold Nanoparticles Daekyun Lee, Seoul National University; Co-Author: Seung R. Paik, Seoul National University
TP180
Development of Binding and Functional Assays for mGluR2 and mGluR3 Helena Mancebo, Multispan, Inc.; Co-Authors: Miao Tan, Radhika Venkat, Multispan Inc.
TP181
scanKINETIC - A Broadly Applicable Tool for Kinetic Characterization of Interactions Between Small Molecule Inhibitors and Protein Targets From the Kinase and Bromodomain Families Elizabeth Quinn, DiscoveRx Corporation; Co-Authors: Lisa Wodicka, Gabriel Pallares, Elyssa Pickle, Dan Treiber, DiscoveRx Corporation
TP182
Multi-Parameter GPCR Screening: An Essential Tool for Uncovering GPCRMutant Penotypes Tom Wehrman, DiscoveRx Corporation; Co-Authors: Daniel Bassoni, Mong Saetern, Qumber Jafri, Phil Achacoso, Bill Raab, DiscoveRx Corporation
“Unlike research scientists, we don’t sequence full genomes; we leverage existing research knowledge and apply it to clinical practice,” explains Eric J. Duncavage, Washington University School of Medicine. “We’re trying to identify mutations that have known prognostic significance in patients—and we want the genes to be targetable by existing drugs to help clinicians in therapeutic decision making.” Read more at www.ELN.SLAS.org
64
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Podium Abstracts
Special Session
page 66
Room: Osceola Ballroom CD
Assay Development and Screening
page 67
Room: Sun Ballroom B
Bioanalytical Techniques
page 79
Room: Miami 1-3
Diagnostics
page 85
Room: Miami 1-3
Drug Target Biology
page 91
Room: Tallahassee 1-3
High-Throughput Technologies
page 97
Room: Sun Ballroom A
Informatics
page 109
Room: Sun Ballroom C
Micro/Nano Technologies
page 121
Room: Sun Ballroom D
SLAS2013 Live Streaming Brings Worlds Together New in 2013: Speakers accept questions via Twitter for these two sessions, time permitting.
#SLAS2013.
SLAS offers the exclusive opportunity to participate in SLAS2013 via live streaming of select sessions — completely free. These sessions allow the global scientific community to unite in person and online through live video webcasts and real-time networking. You will be able to ask questions and get direct answers from the presenters and panelists who are live at SLAS2013. To participate via live streaming, simply go to SLAS2013.org to log-in at the times noted below for each session. There is no need to pre-register. And be sure to encourage colleagues back at the office to log-in and participate live with you: Monday, January 14 9 - 10 am, U.S. Eastern Standard Time Room: Osceola Ballroom CD Keynote Speaker: Mehmet Toner, Ph.D. Bioengineering and Clinical Applications of the Circulating Tumor Cell Microchip
Monday, January 14 3 - 5 pm, U.S. Eastern Standard Time Osceola Ballroom CD Special Session: HTS and Early Drug Discovery in Industry and Academia. Collaboration: Is the Sum Greater Than the Two Parts?
Live streaming is compatible with iPhone, iPad and other mobile devices. Sessions will be available on-demand for a limited time following SLAS2013.
SLAS2013.org
I
65
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Special Session
New in 2013: Speakers accept questions via Twitter for this special session, time permitting. #SLAS2013.
3 pm, Monday, January 14 (Live Streaming Session) Room: Osceola Ballroom CD Ricardo Macarron, GlaxoSmithKline, Peter Hodder, Scripps; Co-Authors: Martyn Banks, Bristol-Myers Squibb Company; Barbara Slusher Johns Hopkins University
HTS and Early Drug Discovery in Industry and Academia. Collaboration: Is the Sum Greater Than the Two Parts? Large pharma pioneered High-Throughput Screening (HTS) in the early ‘90s. The 2000s saw a rapid increase in investment in HTS as well as in corporate compound collection size, with many companies developing collections of 2-5 million entities. Driven by a desire to seek out novel tool molecules for neglected diseases and cutting edge research, academic institutions developed their own HTS infrastructure in the early to mid 2000s and started to accumulate and screen their own libraries. In the latter half of the decade, the NIH initiated a significant translational research effort across multiple academic and federal institutes, in which HTS played a significant role,. So what have we got from all of this investment and effort? What do the pharmaceutical industry and academia do well and what are the advantages of partnering? Many examples of collaboration between the two already exist, what has been the outcome and what lessons have been learned? Is there a new public-private hybrid model that could be established to enhance drug discovery? How has HTS developed drug discovery programs in these settings and how could we do better? In a time where industry focus on HTS has been reducing, academic-industry partnerships for drug discovery are increasing, the challenge of finding novel targets is getting harder and the emphasis is now increasingly focused on epigenetics, translational medicine and black-box phenotypic screens. What can be learnt from the past and leveraged to develop partnerships that will increase our success in the future? Where will HTS be conducted in the future? Are academic groups wasting taxpayer money dreaming of becoming industrial drug discovery engines and will pharmaceutical companies ever open up their HTS collections? This session aims to be a provocative discussion addressing these questions. There will be two presentations, one from academia and one from the pharmaceutical industry. This will then be followed by a lively panel discussion hosted by experts from the field.
“I want researchers to realize just how important the work they do is from day to day,” SLAS2013 keynote speaker Charles Sabine stresses. “While they may feel several degrees of distance from the patient; the fact is that collaboration across the fields is what has brought us to this point. We see light at the end of the tunnel for people like me.” Read more at www.ELN.SLAS.org
66
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Assay Development and Screening 10:30 am, Monday, January 14 Room: Sun Ballroom B FI NALIST
Thomas Hughes, Montana Molecular
A Multiplexed Fluorescent Assay for Independent Second Messenger Systems: Decoding GPCR Activation in Living Cells There is a growing need in drug discovery and basic research to measure multiple second messenger components of cell signaling pathways in real time and in relevant tissues and cell types. Many signaling pathways are activated by cell surface GPCR receptors that couple to the heterotrimeric protein, Gq, which activates phospholipase C (PLC). PLC produces two-second messengers: diacylglycerol (DAG), which remains in the plasma membrane, and inositol triphosphate (IP3), which diffuses through the cytosol to release stores of intracellular calcium ions (Ca2+). This coordinated increase, in both DAG and cytosolic Ca2+, triggers the activation of conventional isoforms of protein kinase C (cPKC) which then phosphorylate many different targets. Although there are no assays for detecting increases in DAG that are robust enough for screening GPCRs in living cells, there are a number of live cell assays that detect increases in Ca2+. The problem is that there are multiple sources of intracellular Ca2+, so these readouts are ambiguous. We created a robust live cell assay for DAG (Z’ > .5) based on a single circularly permuted green fluorescent protein. In contrast to previous sensors for DAG based on Förster resonance energy transfer (FRET), this assay produces an unprecedented 80 percent increase in fluorescence in response to DAG signaling. The sensor design places a circularly permuted green fluorescent protein between the pseudo substrate domain and the C1 domain of the novel PKC isoform PKCδ, PKCδ does not respond to Ca2+, and the C1 domain has a high affinity for DAG. 64 fusion proteins of this design were built and tested by activating the M1 acetylcholine receptor with carbachol. Ten of the candidate sensors produce changes in fluorescence. Two of these sensors produce large ( > 40 percent) changes in fluorescence intensity. One produces a 45 percent increase in fluorescence in response to GPCR activation, and a second produces a 40 percent loss in fluorescence. Changes in the linker composition can produce large differences in the response properties of circularly permuted sensors. We tested an additional 91 candidate sensors that varied in the length and composition of the linker between the fluorescent protein and the PKC, and identified a sensor with an 80 percent increase in fluorescence and a second sensor with a 50 percent decrease. We fused these improved DAG sensors to the 2A peptide and a robust red circularly permuted Ca2+ sensor, R-GECO. The DAG and Ca2+ sensors simultaneously produce robust changes in fluorescence in real time in response to Gq pathway activation. This assay is homogeneous, does not require lysis, and can be used in virtually any cell type to unambiguously monitor GPCR signaling in biologically relevant tissues.
11 am, Monday, January 14 Room: Sun Ballroom B Stefan Kubicek, Austrian Academy of Sciences
Screening for Synthetic Lethalities With Chromatin Factors Chromatin modifying enzymes have emerged as key targets in cancer, and many of these factors act as oncogenes and tumor suppressor genes. Accordingly, small molecules targeting histone deacetylases and DNA methyltransferases are now approved drugs, and compounds for many more of the approximately 200 chromatin modifying enzymes are currently in preclinical development. In addition to cancers with genetic mutations in chromatin genes, these drugs may also be beneficial for exploiting synthetic lethalities and non-oncogene addictions. As the central structure that regulates access to DNA, chromatin integrates all signaling pathways to ensure tightly regulated gene expression. Therefore, chromatin pathways are hubs, which are highly enriched in genome-wide synthetic lethality screens in fly and worn. In cancer, non-oncogene addiction means that overexpression of an oncogene or loss of a tumor suppressor gene makes tumor cell viability and proliferation dependent on certain other factors. To systematically identify such factors, we use small molecule and shRNA screening in a breast cancer model. The isogenic cell lines we use are all derived from the non-tumorigenic precursor MCF10A and differ only be the over expression of a single oncogene or knock-down of one tumor suppressor. In these cell lines we test proliferation differences and alterations in histone modifications following modulation of chromatin modifiers. A variety of readouts including next-generation sequencing, imagebased assays, FACS, and Luminex methods are implemented to measure these effects. The data we have generated have identified first genes and compounds that might be used for prioritizing chromatin targets, patient stratification and novel therapeutic applications.
SLAS2013.org
I
67
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Assay Development and Screening 11:30 am, Monday, January 14 Room: Sun Ballroom B Doug Auld, Novartis; Co-Authors: Adam Hill, Pei-i Ho, NIBR
Reporters in Cell-Based Assays: Understanding Fact From Fiction Understanding the underlying mechanisms of compound activity in cell-based assays is of central importance in chemical biology or drug discovery efforts. Compound activity in cell-based assays can be governed by a variety of mechanisms including desired on-target activity, off-target activity, cell-health effects, compound cell penetration/ solubility, and direct effects on the assay reporter itself. To construct improved reporter-gene-assay (RGAs) systems we have investigated eight reporter enzymes including common reporter enzymes such as firefly luciferase (Photinus pyralis), Renilla reniformis luciferase and β -lactamase as well as mutated forms of R. reniformis luciferase emitting either blue- or green-shifted luminescence, a mutated form of Gaussia princeps luciferase (ThermoFisher), and an optimized luciferase derived from the luminescent sea shrimp Oplophorus gracilirostris (NanoLuc, Promega). This talk describes these studies as well as the use of additional approaches to address cell-based assays where we have employed high-content approaches to understand the basis of compound activity in cell-based assays.
12 pm, Monday, January 14 Room: Sun Ballroom B Petr Bartumek, Institute of Molecular Genetics
Primary Cells in High-Throughput Screening: Lessons From Human Blood Differentiation of hematopoietic stem cells and progenitors into various lineages is controlled by a complex array of extrinsic and intrinsic factors. We use small molecules to affect cell fate by interfering with important regulatory pathways within the cell. One of the advantages of using phenotype-based screens is their focus on disease and/or particular cell fate. Such non-target approach might eventually lead to identification of new mechanism of action and novel therapeutical targets. In addition, the use of the “real” cells in primary HTS campaigns could dramatically reduce the number of compounds that fail later in the drug development. During last couple of years we have developed couple of assays that are amenable for high-throughput screening. We have been using hematopoietic stem cells (CD34+) or progenitor cells (SCF/Epo-dependent) derived from peripheral blood, bone marrow and umbilical cord blood. We are presenting examples of HTS assays from simple homogenous assays to multiplexed high-content screening using FACS. To be able to immediately validate primary hits in vivo, we have recently established a robust platform based on transgenic zebrafish. Challenges and opportunities of assay development using primary cells are also discussed.
68
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Assay Development and Screening 3 pm, Monday, January 14 Room: Sun Ballroom B Cathy Tralau-Stewart, Drug Discovery Centre, Imperial College, London; Co-Authors: Caroline Low, Imperial College London; Albert Jaxa-Chamiec, Independent; Hayley Cordingley, Katie Chapman, Imperial College London
A Focus on Robust Target Choice to Address Pipeline Attrition: Tool Compounds for Novel Targets There are many reasons for the current fragmentation and decline of R&D in the Pharmaceutical Industry but the overall drivers are unsupportable rising costs coupled to declining productivity. Industry data suggests that each viable clinical candidate is the product of detailed investigation in over 25 individual projects. Often these clinical candidates fail in Phase II/III. Thus, the focus at this juncture must be to choose the best targets as early as possible to reduce project attrition, increase the probability of clinical success and change the cost and risk profile of drug discovery. Key to this is greater clarity of disease understanding and analysis of the importance of targets and mechanisms in human disease. Over 5 years, the Imperial College Drug Discovery Centre evaluated and progressed over 40 novel approaches to therapeutics in Oncology, Cardiovascular, Inflammation and Infection. The aim was to combine Industry knowhow and expertise with academic and clinical disease knowledge to create robust target validation and optimization packages. An important step in achieving this was generating appropriate tools and probes for these novel approaches. Pharma’s default practice of screening large numbers of compounds in engineered synthetic systems and non-human models is costly and results are very dependent on the assay and compound library used. This is clearly not a viable approach for multiple targets with the limited budgets available within academia. Thus, alternative strategies were explored, which used existing knowledge of targets and tool compounds to derive appropriate chemical starting points. We successfully examined the pharmacology of existing commercial compounds in parallel with biological probes (siRNA, monoclonal antibodies) in robust, ideally human, assay systems. Computational modeling, virtual screening and target homology modeling played an important part in generating novel medicinal chemistry. This presentation discusses examples of approaches used, the challenges of such work in the current environment and the importance of academic-industrial collaborations in the future.
3:30 pm, Monday, January 14 Room: Sun Ballroom B Stefan Knapp, SGC Oxford
Selective Targeting of Epigenetic Effector Domains of the Bromodomains Family Bromodomains (BRDs) are evolutionary conserved protein interaction modules that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. The human proteome encodes 61 of these highly diverse domains present in 41 mainly nuclear proteins. To establish a solid platform for screening and the rational design of specific inhibitors we cloned all human BRDs into bacterial expression systems, an effort that led to the development of more than 40 efficacious expression systems and the determination of more than 30 novel crystal structures. The acetyl-lysine binding pocket has been identified as an attractive binding site for the development of inhibitors. Recently, a number of highly specific and potent inhibitors for BET bromodomains have been reported by us and other laboratories. For instance, we developed in collaboration with other laboratories the pan-BET inhibitors JQ1 and PFI-1. We are now interested to develop highly specific chemical probe molecules for bromodomains outside the BET family. Evaluation of the rich body of structural information on bromodomains enabled detailed family-wide structural analysis of the human BRD family, the structural mechanisms of specific substrate recognition and its “druggability”. Using pharmacophore searches, shape based and 2D similarity searches and docking together with high throughput structure determination and fragment based screening we identified several diverse and versatile acetyl-lysine mimetic compounds. These chemical starting points are currently used for the development of inhibitor libraries and for the identification of selective lead compounds. Recent progress developing selective BRD inhibitors for a number of diverse bromodomain targets and the potential targeting these protein modules for the validation of new targets as drug targets are discussed.
SLAS2013.org
I
69
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Assay Development and Screening 4 pm, Monday, January 14 Room: Sun Ballroom B Haiching Ma, Reaction Biology Corporation
A Comprehensive Survey of Kinase Inhibitor Selectivity Small-molecule protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents. However, majority of the kinase inhibitors in the public domain are lacking systematic studies for their selectivity across the human kinome, therefore, their values in research are weakened. Trying to make these tool compounds more valuable for the research community and drug discovery industry, we recently have tested 178 compounds against 300 recombinant human protein kinases in functional phosphorylation assays, reported the largest-scale analysis of kinase inhibitor selectivity based on these experiments (Anastassiadis et al., Nat Biotech, 2011). The compound collection included FDA-approved drugs, compounds in the clinical pipeline, and research tool compounds. Quantitative analysis revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity. Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases. The results have implications for drug development, drug repurposing, and provide a resource for selecting compounds to elucidate kinase function. This approach reveals the full spectrum of kinase targets early in the process, thus reducing late stage compound attrition due to unknown off-target activities. Furthermore, this approach will greatly facilitate the identification of “multi-targeted” inhibitors which are currently of great interest. The presentation covers the key findings of this study in more details. Recently we have continued this studies with more disease related mutant kinases and atypical kinases, not only make the data base more complete, but more importantly reaching to the kinases that are less studied in the kinase community. We’ll release these data first time in this presentation.
4:30 pm, Monday, January 14 Room: Sun Ballroom B Fabien Vincent, Pfizer
In Search of Physiological Relevance: Adventures in Molecuar Pharmacology As in vitro pharmacologists, our mission is to provide drug discovery project teams with assays predictive of in vivo pharmacology in patients. To better ensure the clinical translation of pre-clinical hypotheses, the Primary Pharmacology Group at Pfizer has a strong focus on the physiological relevance of its vitro assays. Examples of ongoing work and strategies encompassing phenotypic screening, as well as primary cell and biochemical screening will be discussed. Specifically, the results of a phenotypic screen aimed at discovering novel mechanisms for the treatment of Alzheimer’s Disease (AD) is presented. A strong genetic link exists between the ApoE4 genotype and AD with homozygous ApoE4 carriers being 12 fold more likely to contract the disease. Despite some uncertainty regarding the biological function of ApoE, a loss of function hypothesis is gaining credence based on the lower ApoE levels detected in ApoE4 carriers and the diminished ability of ApoE4 to carry out neuroprotective functions such as A-beta clearance and stimulation of synaptogenesis. Accordingly, mechanisms leading to increased production and secretion of ApoE may be therapeutically beneficial, regardless of genotype. A medium throughput ELISA assay was established, allowing the screening of compound libraries to identify compounds and mechanisms enhancing ApoE secretion. To that end, a proprietary library termed the Chemogenomics Library was used. The design of this library, encompassing 6,000 compounds addressing >1,200 molecular mechanisms, are presented as well. Besides known mechanisms such as RXR and LXR agonism, the screen revealed HDAC inhibition as a novel mechanism for enhanced ApoE secretion. Pharmacological experiments further suggested HDAC inhibition to be located upstream of RXR/LXR activation. Most importantly, oral administration of HDAC inhibitor MS275 to mice led to a significant increase in ApoE levels in both plasma and the hippocampus, thus validating this novel mechanism in vivo.
70
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Assay Development and Screening 10:30 am, Tuesday, January 15 Room: Sun Ballroom B Yuhong Du, Chemical Biology Discovery Center, Emory University
Development of a Multiplexed HTS Assay for Simultaneous Monitoring of More Than Two Bimolecular Interactions in One Well to Maximize the Efficiency of Small Molecule Discovery The network of protein-protein interactions (PPIs) controls the diverse physiological and pathological processes in living organisms such as cell proliferation and death. PPIs have emerged as a class of under-developed, challenging, but highly promising cancer targets for therapeutic development. To monitor molecular interactions, a number of assay technologies, particularly in homogenous format, have been extensively used in high-throughput screening (HTS) campaigns for the identification of new chemical entities in the drug discovery field and chemical biology studies. However, the networks of signaling pathways often involve the interaction of multiple proteins, which poses a major challenge to identify selective modulators in a simple HTS format. To enhance and maximize the efficiency of HTS campaigns, we have designed and developed a novel information-enriched HTS (iHTS) technology that allows simultaneous monitoring of more than two bimolecular interactions in the same well with multiple readouts. Utilizing the principle of conventional TR-FRET technology, this iHTS assay provides a mix-and-read homogenous format without the requirement of separation, which is readily adaptable for a 1536-well uHTS format. Such a multiplexed assay format permits the initial identification of selective protein-protein interaction modulators from a single HTS campaign. An uHTS case study with three pairs of PPIs will be presented.
11 am, Tuesday, January 15 Room: Sun Ballroom B Anton Simeonov, National Center for Advancing Translational Sciences; Co-Authors: Thomas Dexheimer, Dorjbal Dorjsuren, Timothy Leyden Foley; Jennifer Kouznetsova, Wendy A. Lea, Amy M. Quinn, Adam Yasgar, Ajit Jadhav, David J. Maloney, NIH Chemical Genomics Center
(NCATS)/NIH Enzyme Assays for Large-Scale HTS: Challenges, Compromises, Opportunities The extraordinary diversity of targets being pursued by the NIH Molecular Libraries network of screening and probe development centers stems from its mission to make accessible the technologies of high throughput screening and chemistry optimization, developed primarily in the biopharmaceutical industry, to academic investigators. This diversity, the focus on targets and diseases that are currently “undrugged” (i.e., for which no chemical modulator exists), and the need to generate large datasets for public use has had a considerable impact on the selection of assay technologies and has frequently resulted in de novo assay design in order to address previously inaccessible targets. Case studies will be presented which include enzyme assays for targets implicated in genome maintenance and DNA repair, posttranslational modifications, and metabolic regulation/signaling. An overview of strategies for detection of false positives and validation of hits will be provided along with examples from our recent work on alternative means to evaluate inhibitor mode of action.
SLAS2013.org
I
71
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Assay Development and Screening 11:30 am, Tuesday, January 15 Room: Sun Ballroom B Peter Rye, Agilent Technologies
Measuring Enzymatic Modification of DNA Using High-Throughput Mass Spectrometry Enzymes that act on DNA are promising targets for anticancer therapeutics. For example, the DNMT1 enzyme is inhibited by 5-azacytidine, causing DNA hypomethylation and enhancing the function of tumor suppressor genes. Similarly, APE1, a key enzyme in DNA base excision repair, can be inhibited by Lucanthone to sensitize glioma cells to radiation therapy. In concordance, the development of accurate and user-friendly assays to study DNA modifications has become pivotal to drug discovery. Traditional in vitro assays have utilized radioactivity, antibodies, and/or fluorescent substrates to relate the extent of reaction. However, each of these approaches has drawbacks that limit its practicality for large sample numbers. This work describes the advantages of developing label-free assays for DNA-modifying enzymes using high-throughput mass spectrometry (HTMS). The RapidFire/TOF-MS system couples microfluidic solid phase extraction with TOF-MS detection, circumventing the need for compound-specific method development. The platform routinely sustains a sample-to-sample cycle time of ~8 seconds (50 percent of all anti-cancer compounds currently used in the clinic, the National Cancer Institute has pursued screening its large repository of crude natural product extracts against molecular targets of interest. This talk discusses the practical considerations of screening natural product extracts in HTS and provide numerous examples of successful screening programs.
11 am, Wednesday, January 16 Room: Sun Ballroom B Peter Wipf, University of Pittsburgh
From Heterocyclic Libraries to Biological Probes Many biologically active natural products and pharmaceuticals favor heterocyclic substructures, most likely due to their rigid array of polarizable π-electron clouds, hydrogen donors and acceptors that facilitate strong binding to protein targets, as well as their relatively high stability toward metabolic degradation. However, the number of unique scaffolds of carbo- and heterocycles in current use is quite limited. Pyridines, indoles, imidazoles, thiazoles, thiophenes, quinolines, quinazolines, pyrazoles, pyrimidines, and triazoles rank among the most common heterocycles in pharmaceutical collections, while the breadth of oxygen-, nitrogen- and sulfur-containing ring systems is far greater in natural products. Ease of commercial or synthetic access, scope of literature functionalizations, and precedence for biological activity play an important role in perpetuating the status quo and limiting an increase in the diversity of the stable of available pharmaceutical building blocks. Drug candidates reflect high-throughput screening (HTS) libraries, featuring prominently these “privileged” heterocycles and their close congeners. Recent studies point out the dearth of diverse scaffolds in the medicinal chemistry toolset, and the challenges to improve the quality of compounds in HTS, lead identification, and lead optimization campaigns. While improvements in the methodology to access privileged scaffolds remain a major effort in the synthetic chemistry community, the serendipitous or systematic discovery of fundamentally new reactions to access novel hetero- and carbocyclic scaffold would be most desirable. New structural diversity will likely increase the number and utility of small molecule modulators of biological functions, access new intellectual property (IP) space, and stimulate a more creative deployment of the organic chemistry toolset to solve challenges in biology and medicine. While initial hits might be more rapidly identified in HTS assays of libraries rich in privileged chemotypes, novel scaffolds showcase the value of an innovative chemistry program, increase the opportunities for the discovery of new biological phenotypes, and convey greater IP value for a platform approach.
76
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Assay Development and Screening 1:30 pm, Wednesday, January 16 Room: Sun Ballroom B Christopher Moxham, Imclone Systems
Cell-Based Assays for Biologics Drug Discovery Biologics predominantly target cell surface proteins. Thus in vitro cell-based assays to identify and characterize biologics for therapeutic use must encompass the array of biological processes associates with cell surface proteins. This presentation discusses the various state-of-the-art technologies that can be employed to monitor cell surface target engagement, receptor internalization and degradation as part of the biologics drug discovery process.
2 pm, Wednesday, January 16 Room: Sun Ballroom B Shalini Prasad, University of Texas at Dallas
Platform Technology for Identifying Stem Cell Sub Populations for Tumor Classification in Lung and Breast Cancer The goal of the project is the demonstration of a new paradigm in cancer diagnosis, which is identification and quantification of cancer stem cells in the tumor that are hypothesized to be the instrumental for tumor self renewal and heterogeneity. Problem Statement: In cancer diagnostics, technologies that detect and quantify cancer stem cells are currently unavailable. The existence of such a technology will enable customization of a patient’s therapy. Identifying the presence and the number of cancer stem cells in a tumor mast is an important diagnostics challenge in designing next generation cancer diagnostics tools. Project Goal: The goal of this project is the design and demonstration of a nanotechnology enabled platform technology for (a) screening and quantifying aldehyde dehydrogenase (ALDH) activity and (b) correlating this activity to the number of cancer stem cells present in a test sample. The technology performance has been evaluated by determining (i) functional sensitivity, (ii) inter and intra assay variability and (iii) designing a mathematical construct to quantify cell count based on ALDH activity. Lung and breast cancer samples have been selected as test samples. Methods and Results: Based on recent research in evaluating cancer stem cell markers for lung and breast cancer, ALDH activity was selected as the stem cell marker of interest for the project. Two isozymes of ALDH have been evaluated, they are ALDH1A1 and ALDH1A3. The platform technology comprises of a silicon microelectronic chip integrated with a nanoporous alumina membrane that is packaged with a microfluidic manifold. The design of the technology generates a high density array of nanoscale confined spaces that can be electrically addressed through the silicon microchip. The platform leverages the principle of size based confinement for detecting ALDH activity at the ultra low concentrations (in femtogram/mL regime). Detection and quantification of ALDH activity is achieved by measuring dose related impedance changes from the platform. Cross reactivity minimization is achieved by tuning the measured electrical impedance signal to distinguish between specific and non-specific binding. Statistical analysis has been performed to determined the limit of detection, inter and intra-assay variability. Using the platform calibration a mathematical construct has been designed to quantify the number of cancer stem cells based on ALDH isozymes activity specific to each test sample. Significance and Impact: This project offers the cancer clinical diagnostics community an electrical platform assay technology for quantifying cancer stem cell activity and correlating it to the quantity of cancer stem cells in a tumor mast. This technology can be potentially used to design custom therapy for patients. This technology will be a new paradigm in cancer diagnostics to enable the classification of tumors.
SLAS2013.org
I
77
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Assay Development and Screening 2:30 pm, Wednesday, January 16 Room: Sun Ballroom B Narahara Chari Dingari, Massachusetts Institute of Technology
Label-Free Bioanalytical Investigation of Long-Term Glycemic Markers Good glycemic control is an important goal of diabetes care. Much evidence suggests that many of the long-term complications of diabetes, especially the microvascular complications, result from the lack of glycemic control. Therefore, long-term glycemic control is imperative in proper management and potential prevention of the metabolic disorder. The essential examination that has usually been performed in a clinical chemistry laboratory is the measurement of blood HbA1c and fructosamine levels as a functional metric of glycemic control over the past three months and three weeks, respectively. In my presentation, we show the first demonstration of non-enhanced Raman spectroscopy as a novel analytical method for qualitative and quantitative detection of HbA1c and glycated albumin. By using the drop coating deposition Raman (DCDR) technique, we observe that the non-enzymatic glycosylation of these proteins results in subtle, but consistent, changes in vibrational features, which with the help of multivariate classification techniques can be used to distinguish the glycated proteins from their unglycated variants with 100 percent. The acquired Raman spectra demonstrate excellent reproducibility of spectral characteristics at different locations in the drop and show a linear dependence of the spectral intensity on the analyte concentration. Furthermore, the developed multivariate calibration models show a high degree of prediction accuracy even at substantially lower concentrations than those typically encountered in clinical practice. The excellent accuracy and reproducibility accomplished in this proof-of-concept study opens substantive avenues for basic investigations of glycated proteins as well as in high-throughput glycemic marker sensing in multi-component mixtures and potentially even in serum and whole blood samples. Finally, we also discuss the caveats in determining these two glycemic markers in patients with diabetic complications and how they correlate with the development of diabetic complications. We believe that the proposed approach can provide a uniquely powerful tool for glycemic marker determination in routine clinical diagnostics in the near future. The proposed method can be readily extended to the point of care diagnostics by taking the advantage of currently advancing microfluidic technologies.
3 pm, Wednesday, January 16 Room: Sun Ballroom B Jens Kelm, InSphero AG
Multiplexed Drug Assessment in Multi-Cell Type 3D Microtissues Cell-based assays, being a highly versatile tool to assess cell response to biological and chemical stimuli, have become a powerful tool in the research lab. They can be tailored to evaluate many cellular and biochemical functions. On an industrial level they are used to discover and develop new drugs and test the toxicity of new and old chemicals. To further improve the biology of cells grown in vitro, cell technologies which allow a 3-diemensional structure towards a more organotypic “tissue” model are being used more intensively. These culture systems are becoming increasingly complex being composed not only of a single cell type but, similar to native tissue, incorporating several cell populations to mimick native tissue as close as possible. The increasing use of more physiological 3-dimensional cell model systems for drug and substance testing entails the development of more sophisticated analysis systems which allow parallel multiplexing of several read outs. It becomes especially intricate if a drug response has to be correlated to a specific cell population in a multi-cell type system. Here we demonstrate combinations of a novel size-reduced Luciferase and fluorescent reporter proteins to measure drug effects on specific cell populations in multi-cell type tumor spheroid models. Tumor spheroids were generated from a cancer cell lines harboring the Luciferase of fluorescent proteins and mouse fibroblasts expressing a red fluorescent protein. With a multi plate reader drug effects on the different cell populations were assessed combining high sensitive luminescence quantification, representing the impact on the cancer cell population, and fluorescence read out, signifying the impact on the stroma cell population. Non-disruptive and analysis technologies have to be adapted to gain the full benefit of more complex organotypic multi-cell type models. The combination of fluorescent reporter and secreted luciferase allows to tailor high-throughput-compatible analysis according to the spheroid system applied, to detect drug efficacy on cancer and stroma cell populations within the same model.
78
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Bioanalytical Techniques 10:30 am, Monday, January 14 Room: Miami 1-3 Hong Zhou, University of California, Los Angeles
High Resolution CryoEM: A New Method for Atomic Modeling of Macromolecular Complexes Single-particle cryo-electron microscopy (cryoEM) is a technique for determining three-dimensional (3D) structures from the projection images of molecular complexes preserved in their “native”, non-crystalline state. Recently, atomic or near-atomic resolution structures of several viruses and protein assemblies have been determined by single-particle cryoEM, allowing ab initio atomic model building by following the amino acid side chains or nucleic acid bases identifiable in their cryoEM density maps. In particular, these cryoEM structures have revealed extended arms contributing to molecular interactions that are otherwise not resolved by the conventional structural method of x-ray crystallography at similar resolutions. High-resolution cryoEM requires careful consideration of a number of factors, including proper sample preparation to ensure structural homogeneity, optimal configuration of electron imaging conditions to acquire high-resolution cryoEM images, accurate determination of image parameters to minimize image distortions through correction, efficient refinement and computation to obtain a converged 3D density map, and finally appropriate choices of modeling tools to construct correct atomic models for functional interpretation. Automation in both image acquisition and processing has significantly reduced the amount of sample required to be about a few micrograms and structure determination within a few days. This progress illustrates the power of cryoEM and ushers it into the arsenal of structural biology, alongside conventional techniques of x-ray crystallography and NMR, as a major tool (and sometimes the preferred one) for the studies of molecular interactions in supramolecular assemblies or machines.
11 am, Monday, January 14 Room: Miami 1-3 Michael Marty, University of Illinois at Urbana-Champaign; Co-Author: Stephen G. Sligar, University of Illinois Urbana-Champaign
Nanodiscs as a Bioanalytical Platform for Understanding Membrane Protein Structure and Function Membrane proteins play an important role in biology and pharmaceuticals. However, analysis of membrane protein structure and interactions is challenging due to their poor expression and insolubility in aqueous systems. Nanodiscs, nanoscale lipid bilayers surrounded by an amphipathic membrane scaffold protein belt, have emerged as a robust platform for solubilizing and studying membrane proteins. This presentation will discuss the characterization of Nanodisc complexes and explore the interfacing of Nanodiscs with advanced bioanalytical techniques. Interesting recent results show that intact Nanodisc complexes can be analyzed by native mass spectrometry to characterize their precise composition and lipid distributions. Advances in mass spectrometry of Nanodiscs also facilitate the direct analysis of full-length membrane proteins in Nanodiscs. Coupling of Nanodiscs to label-free biosensors such as photonic microring resonators provides a multiplexed platform for quantitating protein-lipid and protein-protein interactions. Nanodisc libraries formed from a population of membrane proteins enable the application of pull-down assays for target identification and enable high-throughput drug screens in cases where the target is not known or easily expressed.
SLAS2013.org
I
79
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Bioanalytical Techniques 11:30 am, Monday, January 14 Room: Miami 1-3 Ulrich Rant, Dynamic Biosensors GmbH and Technical University Munich
switchSENSE - An Electro-Switchable Biointerface for the Label-Free Analysis of Molecular Interactions A novel biosensing principle, switchSENSE, which employs an electrically actuated bio-interface is introduced. Short end-tethered DNA molecules are driven to oscillate (switch their conformation) on microelectrodes by the application of ac voltages. The induced molecular motion is monitored in real-time on a sub-microsecond timescale by fluorescence energy transfer. The conformation switching amplitude and the dynamics of the actuated DNA-levers not only reveal the mere presence of biomolecular targets on the sensor surface, but also permit the simultaneous analysis of the target molecule size, shape, and charge in a single experiment. The mechanism of swaying molecules atop of DNA levers are described and how kon, koff, KD values are quantitatively determined from the DNA’s switching behavior are discussed. The method features a very high sensitivity, which is demonstrated by the affinity ranking of monoclonal antibodies in the one-digit pM concentration range (detection limit in the fM range). DNA targets can be discriminated with single base mismatch specificity, which is exemplified at hand of a SNP in the p53 gene. The size of the target is inferred from a molecular dynamics measurement and analysed with a theoretical model that accounts for the molecule’s hydrodynamic friction. The analysis yields the molecule’s effective diameter with 0.2 nm accuracy. Dynamic switching measurements are also applied to the analysis of antibodies, where fragmentation states and agglomerates are readily identified. The implications of switchSENSE as a high information content (affinity, reaction rates, size, shape, charge) analytical platform technology is highlighted for the discovery process of biological drugs.
12 pm, Monday, January 14 Room: Miami 1-3 Paul Schnier, Amgen, Inc.
On-line Nano-Pore Optical Interferometry (NPOI) Mass Spectrometry (MS) for Screening and Quantifying Small Molecule-Protein Interactions The discovery of small molecules that bind to protein targets is an essential first step in the design of novel therapeutic agents. Label free biosensor technologies such as surface plasmon resonance spectroscopy have become routinely used techniques to discover and quantify protein-ligand interactions. One drawback to biosensor technologies is that the detector does not provide structural information about the ligand, making direct screening of mixtures a challenge. Here we demonstrate the utility of NPOI biosensors interfaced to mass spectrometry for small molecule drug screening. A target of interest is immobilized to the NPOI surface (Silicon Kinetics, San Diego, CA) and mixtures of ligands flow across the surface; the eluent from the biosensor surface is directly injected onto a reversed phase column for LCMS analysis. A switching valve has also been constructed such that the sample and reference eluents can be collected and independently sampled by LC-MS. We will show how LC-MS sampling time-point determination during the dissociation phase are critical to minimize any false-positive binding results and how parameters may vary depending on which system is studied. How this system can be used to screen mixtures of compounds against a variety of protein targets, to directly measure binding kinetics and affinity parameters is illustrated. The advantages of exact mass measurement, MS/MS, and ion mobility, to unambiguously identify a “hit” in a complex mixture are discussed. A significant advantage of the NPOI-MS system is that traditionally MS-incompatible buffers can be utilized for the screening, since coupling to an LC-MS system provides for a rapid and efficient means of desalting the ligand(s) of interest.
80
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Bioanalytical Techniques 3 pm, Monday, January 14 Room: Miami 1-3 Gary Schroth, Illumina, Inc.
Molecular Analysis With Next Generation Sequencing Next generation sequencing (NGS) technology has revolutionized genome biology. In addition to genome sequencing many new bioanalytical methods have been developed to study gene expression, RNA structure and function, and protein-nucleic acid interactions. These bioanalytical methods take advantage of the billions of digital reads, or counts, that NGS sequencers produce to create new quantitative assays. Some of the methods that our group has developed to study the structure, function and expression of RNA using high throughput sequencing platforms are discussed.
3:30 pm, Monday, January 14 Room: Miami 1-3 Andrew Barry, PerkinElmer
Challenges and Solutions for Benchtop Sequencing Sample Preparation Advances in next generation sequencing technologies provide unprecedented access to genomic information. These advances have rendered these technologies tractable towards understanding the critical genetic factors underpinning disease. More recently, the emergence of so-called “benchtop sequencers,” scaled down versions of the high throughput powerhouses, has made it feasible for greater numbers of researchers to harness next-generation sequencing technology due to the reduction in infrastructure investment. These instruments are extremely powerful in their ability to produce large amounts of high-quality data with rapid turnaround times for a number of scientific applications. The result is a need for a sample preparation device for specific applications and sample throughputs that are correctly impedance matched for benchtop sequencer data output. These specific applications include targeted re-sequencing panels, small and micro RNA, and whole genome assembly of prokaryotic genomes. Here we discuss the specific challenges associated with the variety of applications and protocols that have been explored to maximize efficiency of sample preparation for benchtop sequencers, and solutions that have been employed to overcome them.
SLAS2013.org
I
81
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Bioanalytical Techniques 4 pm, Monday, January 14 Room: Miami 1-3 Scott Tenenbaum, The State University of New York
Using RNA-Binding Proteins and microRNA Targeting to Study the Human Regulatory Code Unlike DNA, RNA has tremendous potential to form complex and elegant structures. This may be one of the most important attributes of RNA that permits it to both serve as a template for the genetic code while simultaneously containing essential regulatory information that determines where, when and how much of the encoded gene will be expressed. It is very unlikely that mRNA, or any cellular RNA for that matter, exists in a truly naked state, but rather, is likely bound by multiple molecules, existing as RNA-protein complexes (mRNPs). Many of these molecules including microRNAs and RNA-binding proteins (RBPs) can regulate gene expression most notably through their actions with the untranslated-regions (UTRs) of mRNA. Accordingly, eukaryotic organisms depend integrally on the actions of RBPs for successful post-transcriptional control of gene expression. We are using methods for purifying endogenously formed RNP complexes and identifying the associated RNA targets with microarray and next-gen sequencing technologies (RIP- Seq profiling). This approach has enabled the genomic-scale identification of targets of RBPs. This advance has enabled the large-scale identification of many mRNA targets of RBPs and provides new insight into the principles governing post-transcriptional gene regulation. Our studies reveal that analogous to transcriptional regulation, groups of functionally related RNAs are coordinately regulated in a combinatorial manner by distinct classes of RBPs targeting related cis-regulatory elements located in the transcripts. Our data also suggests that non-coding RNA such as miRNAs are modulating RBP binding sites in a dynamic manner, which implies that the cis-regulatory code targeted by miRNAs is at least in part, the same as that read by mRNA-binding proteins. This model predicts that miRNAs indirectly or directly binding to RBP binding sites and multiple regulatory elements could simultaneously be influenced by miRNA-mRNA contacts. Consequently, binding of one or more miRNA could result in conformational changes in mRNA structure, thereby revealing or masking a other regulatory elements. By using RIP-Chip/Seq profiling to explore the post-transcriptional infrastructure of the cell, our studies reveal that many of the non-coding RNAs expressed from the genome also appear to have an interesting regulatory association with RBPs in a specific and selective manner and could modulate RNA-binding protein binding sites in a dynamic manner. Further, we are pioneering an RNA-based Nano-switch technology termed structurally interacting RNAs (sxRNA), which utilizes post-transcriptional gene regulation as a reporter of non-coding RNA expression such as miRNA. Unlike other reporter systems that decrease gene expression upon miRNA induction, our system results in an increase in reporter gene expression upon miRNA induction. The sxRNA platform is based on trans-acting RNA complexes that can enhance or disrupt RBP interactions.
4:30 pm, Monday, January 14 Room: Miami 1-3 Jeff Messer, GlaxoSmithKline
Millions of DNA Sequences to a Handful of Compounds: Enabling Decision-Making for Encoded Library Technology Chemists Encoded Library Technology (ELT) is a novel approach to lead discovery based upon the creation of large (our biggest library has over a trillion components!) encoded libraries of novel, drug-like structures that can be rapidly interrogated to identify families of compounds with affinity for a macromolecular target. The utility of libraries assembled by combinatorial chemistry to molecular discovery has been constrained due to deconvolution limitations: ELT addresses this issue by encoding each molecule with a covalently attached DNA sequence. The resulting libraries are screened by “selection” on the basis of affinity, any “hits” identified by Next Generation Sequencing. I will describe the process of translating NextGen data to actionable chemical synthesis with an emphasis on heuristics to choose what from very large datasets are most likely to yield value as individual “off DNA” molecules.
82
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Bioanalytical Techniques 10:30 am, Tuesday, January 15 Room: Miami 1-3 Sam Forry, National Institute of Standards and Technology; Co-Authors: Jason Kralj, Chanda Arya, Matt Munson, Thomas Forbes, National Institute of Standards and Technology
Capture of Rare Cells From Whole Blood Whole blood is a complex matrix and presents a heterogeneous mixture of many different types of cells. Rare cells of interest, such as circulating tumor cells (CTCs) or stem cells, are often present at just 1 part in 10^7 red and white blood cells. Various experimental platforms have been developed that enable capture of these rare cells using microfabricated systems. Typically, time consuming surface chemistries and complicated device fabrication steps are required. In our work, we have focused on lowering the barrier-to-entry for rare cell capture by designing a capture system that uses simple and commercially available components. Using large avidin-functionalized beads, we prepare a packed bed in a simple microfluidic device containing a wier. Model CTC samples were prepared by spiking breast cancer (MCF-7) cells into whole blood from healthy donors. The blood samples were pumped through the packed bed, which allowed fluids and cells to pass easily and provided multiple opportunities for cell-bead surface interactions. Biotinylated antibody to highly expressed proteins on the surface of cancer cells (anti-EpCAM) led to immobilization and capture of these rare cells. The rate of capture exhibited a linear response across the physiologically relevant range of cell densities. Good reproducibility was observed for samples prepared using blood from a single donor, but significant variability arose when blood samples from different healthy donors were considered. Overall, the use of a simple geometry and commercially available components provided similar advantages to other rare cell capture approaches while requiring minimal microfabrication or surface chemistry expertise.
11 am, Tuesday, January 15 Room: Miami 1-3 Dan Mueth, Arryx (a Haemonetics Company)
A New Platform for Cell Fractionation and its Application in Processing Forensic Samples Isolating individual cells of interest from a solution containing a mixed population is an ongoing challenge in situations where samples are small and have high value and in cases where cell morphology or staining patterns are part of the sorting criteria. Processing and DNA analysis of criminal forensic samples is one example where existing cell fractionation methods are inadequate as samples often comprise very small quantities of two or more cell types and have contributions from multiple individuals. We have developed a method for automated isolation of cells using fluorescent video microscopy, holographic optical trapping (HOT), and active microfluidic liquid handling. Fluorescent video microscopy enables the use of cell morphology and fluorescent labeling for the sorting criteria, while the advanced HOT optical trapping method enables manipulation of multiple cells at once and movement in 3D such as away from surfaces or other cells. Microfluidics provides the critical interface between the microscopic scale of HOT-based cell sorting and the macroscopic scale of the lab bench and automated liquid handling systems. We report on the design of the cell isolation system, its performance in processing mock sexual assault evidence samples, and its compatibility with downstream DNA analysis methods.
SLAS2013.org
I
83
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Bioanalytical Techniques 11:30 am, Tuesday, January 15 Room: Miami 1-3 Diether Recktenwald, BD Biosciences
Analysis and Isolation of Rare Cells by Flow Cytometry Today’s high end flow cytometers enable the analysis of suspended particles like biological cells at rates approaching 100,000 per second. The analysis is performed on a cell by cell basis using optical parameters. High levels of cell characterization are obtained by using highly specific reagents e.g. antibody-labeled conjugates, which make cells fluoresce. Ten and more different fluorophors can be analyzed simultaneously and specific cell subpopulations can be sorted at rates of up to 50,000 per second. Recently a element label-based cytometer with ICP mass spectrometry detection of more than 30 elements has been described for analysis only. The analysis of very rare cells requires a careful selection of the parameters for the identification of the rare populations of interest, because background from cell autofluorescence, other fluorescent particles in the sample, and non-specific interactions with the labels influence the limit of detection. Taking those limitations into account cell populations at a frequency of one in 10 million have been successfully measured by flow cytometry. Pre-enrichment methods can improve the workflow and the performance of a rare cell analysis and isolation even further. Some newer cytometers integrate a magnetic pre-enrichment with flow cytometric analysis.
12 pm, Tuesday, January 15 Room: Miami 1-3 Wendy Gough, Eli Lilly and Company
Second Generation Cellular Imaging Analysis Automated cellular imaging and high content analysis (HCA) has become an important methodology in Academic and Pharma research with broad impact on multiple therapeutic and target platforms. Practical limitations of HCA include adequate description of complex cellular phenotypes, analytical errors introduced by small changes in gating, and imaging/analysis of large multi-cellular structures. This presentation summarizes our efforts to address these HCA issues through the use of whole well scanning and the development of quantitative methods for object level analysis and the description of complex network morphologies. Population Binning (PB) is a method which quantitatively describes differences in object level population distributions and is thus differentiated from methods using KolmogorovSmirnov statistics. Comparison of validated assay data using conventional gating techniques indicates that PB is as statistically robust as conventional approaches but has the operational advantage that event gates are not utilized and thereby reduces day to day or operator variation. In conjunction with whole well imaging techniques, two methods were developed to describe morphologically distinct endothelial cell networks which were not differentiated by existing angiogenesis algorithms. Network Analysis (NA) was facilitated by the development of an Image J algorithm which captures 99 network features including segment, branch point, and network hole metrics in addition to nuclei and pericyte associated features. A second NA method using an artificial intelligence approach quantitatively discriminates between distinct endothelial network morphologies derived by various pro-angiogeneic growth factors.
84
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Diagnostics 3 pm, Tuesday, January 15 Room: Miami 1-3 John McDevitt, Rice University
The Programmable Bio-Nano-Chip: A Fully Automated Platform That Bridges From Biomarker Discovery to Clinical Application Clinical analysis remains one of the most important frontiers in measurement science today as an ever-increasing understanding of living systems places evolving demands on the bioanalysis laboratory. One important trend is toward miniaturized designs-for clinical systems, this can lead to medical results at the point-of-need (i.e. bedside, ambulance, pharmacies and rural locations in resource scarce settings). Medical costs consume a stageringly large fraction of the global economic output, accounting now for about 17 percent of the total US gross demostic product and growing at a rate of 7 to 8 percent each year. Further complicating the situation is the fact that diagnostic tools, so critical to healthcare, have not kept pace with medical knowledge. The fields of proteomics, genomics, and bioinformatics have enjoyed explosive growth, but precious few of the biomarkers found here are translated into widespread clinical practice. More than 20,000 scientific-discovery papers for cancer and 6,000 for cardiac disease have been published, yet only about one biomarker per year for ALL diagnostics areas received US Food and Drug Administration approval from 1995 to 2005. Unless these biomarkers receive approval from medical regulatory bodies they cannot move into widespread clinical practice. These statistics are sobering, but they also illustrates tremendous opportunity for new technologies that will enhance greatly global healthcare. Stated succinctly, today our society faces a severe technology bottleneck where we are unable to access information related to health and wellness status, much of which is encoded in biomarker signatures. Rich biomarker data combined with microfabrication techniques can provide the means to deploy quick, affordable point-of-need diagnostics for a wide variety of ailments. Over the past 15 years the McDevitt group has pioneered the development of the Programmable Bio-Nano-Chip Sensor Systems, a universal platform that serves to extract the information content of biomakers. This platform and the information derived there from is now being used to establish a “biomarker highway”. Advanced diagnostic tools of this type show strong potential to impact healthcare both in developed countries as well as in resource scarce settings through the identification and monitoring of diseases early when they are easier and less costly to treat. This presentation features the design, fabrication and clinical testing of the Programmable Bio-Nano-Chip Sensor technology. The use of this universal detection modality in the context of 6 major clinical trials for the areas of HIV immune function (one of the most important global humanitarian issues), cardiac heart disease (number one killer on a global basis) and three types of cancers (oral, ovarian, prostate) are discussed.
3:30 pm, Tuesday, January 15 Room: Miami 1-3 Douglas Olson, Abbott Laboratories
Image-Based CBC Solution for Near-Patient Care The rapid advancement of technology has made it increasingly possible to provide critical diagnostic tests at the point of patient care (POC). Instead of waiting for test results for hours or even days, clinicians can perform diagnostic tests in minutes while the patient is present. This is especially important in situations where rapid test turnaround is essential for positive patient outcomes. While POC tests are increasingly available, there are as yet no satisfactory complete blood count (CBC) and white blood cell (WBC) differential solutions for near patient testing. Various hematology solutions based on automated impedance and flow cytometry or other traditional technologies have been developed, but none of them fully satisfy the demand for rapid, accurate sample analysis, fluid-free processing, reliability, compactness, low cost and ease of operation. All of these are important requirements for POC diagnostic systems. We report on a new technology for POC hematology testing that makes use of digital imaging to produce a CBC and a five-part WBC differential. The primary challenges for a comprehensive CBC solution are accurate blood volume measurement and formation of a cell monolayer for imaging. The POC hematology analyzer described in this presentation uses an inexpensive disposable chamber of precisely-defined height for specimen imaging that is integrated into a consumable incorporating all required reagents, in dry form. In contrast to traditional fixed and stained blood smears, the cellular components presented for analysis in our system are stained, but are live rather than fixed cells. The chamber height constrains the blood cells into a monolayer for imaging, and the blood volume can be precisely calculated from the measured blood smear area and the known chamber height. This imaging chamber technology enables a hematology solution that satisfies key requirements for POC diagnostic systems. The application of imaging technology to hematology has many advantages. With imaging, platelet clumps in the specimen can be correctly identified and the platelets can then be enumerated. Conversely, conventional technologies may misidentify such clumps as unrelated cell types, and/or substantially underestimate the platelet count. Another advantage lies in cell identification. Unlike flow cytometric methods that employ impedance and multi-channel light scattering measurements to classify cells by size and complexity, the described image-based cell classifier system utilizes 2D images from multiple color channels to classify cells based on morphological and measured features. The information in cell images is far richer and more directly related to cell structure than that obtained using conventional techniques. Further, the cell images may be used to review and confirm results. Several cell classification examples are provided, including five-part WBC differential, nucleated red blood cells (nRBCs), reticulocytes and immature granulocytes.
SLAS2013.org
I
85
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Diagnostics 4 pm, Tuesday, January 15 Room: Miami 1-3 Angelika Niemz, Keck Graduate Institute
Point-of-Care Nucleic Acid Testing for Infectious Diseases Rapid cost-effective sample-to-answer diagnosis of infectious diseases in point-of-care settings can greatly improve the accessibility of health care in developed and developing countries. Our goal is to enable timely diagnosis of active pulmonary tuberculosis by integrating nucleic acid sample preparation, isothermal DNA amplification, and nucleic acid lateral flow (NALF) detection within a compact system. The system consists of a disposable cartridge containing a miniaturized bead blender, active and passive valves, flexible pouches, and electrolysis-driven pumps, in conjunction with an instrument that automates blender motor activation, valving, pumping, heating, and timing. The disposable cartridge is manufactured using low-cost and scalable techniques and forms a closed system to prevent workplace contamination by amplicons. Using an early prototype of the amplification and detection unit, we have demonstrated identification of Mycobacterium tuberculosis (M.tb) genomic DNA in 60 min via two different isothermal DNA amplification reactions coupled to lateral flow: an established and clinically validated loop-mediated amplification (LAMP) reaction or an in-house developed assay based on the Exponential Amplification Reaction (EXPAR). Nucleic acid amplification occurs in a two-layer pouch that facilitates fluid handling and appropriate thermal control. We herein present a refined design of the amplification and detection unit, and the characterization of thermal and fluidic control and assay execution within this system. Our next step is to couple this amplification and detection unit to a sample preparation unit, which performs mechanical lysis of mycobacteria and DNA extraction from liquefied and disinfected sputum. The final integrated cartridge and device will enable fully automated sample-in to answer-out diagnosis of active tuberculosis in primary care facilities of low-resource and high-burden countries. We are applying the same system concept to facilitate rapid point-of-care diagnosis of sexually transmitted diseases and hospital acquired infections.
4:30 pm, Tuesday, January 15 Room: Miami 1-3 Krishna Mohan Vattipalli, University of Texas at Dallas
Performance Comparison of Nanomonitor Against ELISA on Patient Pool Samples Cardiac related events are one of the most common complaints in the human physiology. There is a high demand in the need to identify these events before their occurrence. Early diagnosis of cardiac markers may facilitate enhanced patient outcomes. Troponin-T is a representative biomarker for cardiac related events. Increasing levels of this protein has been studied well (ref) and an increased presence of this protein is correlated to the cardiac arrest or attack or stroke. Nanomonitor (NM) is an electro-chemical based setup on a 1” x 3” size printed circuit board with concentric gold patterns that would take mere drops of blood for testing. Enhancements in the signal can be attributed to the presence of a nanoporous membrane that would isolate the antibody-antigen binding resulting in a change in the applied electrical signals; change in impedance. In this study we are using a NM to rapidly screen patient samples and are compared against the standard ELISA detection methodology. NM has a much lower limit of detection in addition to its specificity. Calibration of this device is performed in Phosphate Buffered Saline (PBS) and in Human Serum (HS). Patient cohort study was performed on blood samples that were drawn pre- and post-surgery at multiple instances of time. Patient samples that were collected in a clinical environment were tested on the NMs and the data is translated into concentrations based on the profiles that were defined. Concentration results compared with ELISA fell within a less than 10 percent CV for a patient pool of 26 collected at multiple time stamps - initial visits and post-operative instances. Limit of detection in the ELISA technique was at 0.01 nanogram per mL. Such samples were further characterized using NM technique and were resolved further on the concentration profile regimes. Technique and methodology in sensing will be discussed in this presentation.
86
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Diagnostics 9:30 am, Wednesday, January 16 Room: Miami 1-3 Klara Abravaya, Abbott Molecular
Companion Diagnostics Enabling Personalized Medicine; ALK Gene Rearrangement in Non-Small Cell Lung Cancer In the era of personalized medicine where therapeutics are targeted to specific biomarkers, diagnostic tests that can reliably detect such markers are essential in identifying the patients who would most likely benefit from the treatment. The discovery and identification of the ALK gene rearrangement in Non-Small Cell Lung Cancer (NSCLC) will be discussed as one of the successful medical achievements in the treatment of patients who carry the ALK rearrangement.
10 am, Wednesday, January 16 Room: Miami 1-3 Eric Duncavage, Washington University
Next Generation Sequencing Based Clinical Diagnostics in Molecular Oncology Next Generation Sequencing (NGS) technologies have the ability to rapidly sequence a large number of genes at a cost far less than traditional Sanger sequencing. However, to date most NGS applications have been confined to the research setting and not routine clinical diagnostics. The successful application of NGS to molecular diagnostics requires robust sequencing and informatics pipelines capable of identifying variants with low observed allele frequencies as well as the full spectrum of DNA-level mutations including insertion and deletions, translocations, and copy number variation. This talk will focus on the design, implementation, and results of NGS-based diagnostics in molecular oncology.
SLAS2013.org
I
87
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Diagnostics 10:30 am, Wednesday, January 16 Room: Miami 1-3 Deborah Moshinsky, Cell Assay Innovations
Kinase Cell-Based Assays for Selectivity Assessment and Personalized Medicine Kinases represent well-established targets for drug discovery. A number of kinase inhibitors are currently on the market, however selectivity against the intended target and acquired drug resistance of tumors remain as significant issues in the field. This presentation introduces a kinase cell-based assay system that enables selectivity assessment while measuring potencies of compounds directly in the physiologically relevant environment of human cells. The development of this assay platform are presented, first in the context of a drug discovery project against the Pim (provirus integration site for Moloney murine leukemia virus) kinases. Pim kinases are therapeutic targets for oncology, however uncertainty exists regarding which Pim to inhibit for optimal therapeutic benefit. Cellular assays were developed and validated to be specific for either Pim-1, -2, or -3, thus enabling the discovery of molecules specific for one family member over the others, and those targeting all 3.The described cell-based assay system was then applied to personalized medicine by developing assays specific for drug resistant mutant kinases. Results are presented with reference inhibitors showing differential potencies against wild type vs. drug resistant mutant kinases in cells, and how this information has added value compared to that obtained with purified enzymatic assays. Screening compound libraries against wild type and drug resistant kinases should facilitate the discovery of compounds that are active against multiple forms of the kinase, and are thus less susceptible to drug resistance in patients. Furthermore, the ability to multiplex the wild type with drug resistant mutant assays are presented as a clear illustration of how this assay platform vastly increases efficiencies in the drug discovery process.
11 am, Wednesday, January 16 Room: Miami 1-3 Martin Fleisher, Memorial Sloan-Kettering Cancer Center
Circulating Tumor Cells as a Biomarker to Monitor Cancer Circulating tumor cells (CTC) detected and isolated from peripheral blood of patients with cancer may represent a real-time snapshot of the metastatic process as cancer cells shed from the primary or metastatic tumor. Monitoring CTC is less invasive than biopsy and is a valid alternative source of the cancer tissue. In addition to enumeration, CTC capture permits molecular characterization of the cancer cell and provides important information about the heterogeneity of the cancer and drugable targets in the tumor. Currently, one analytical method, the Veridex CellTrack Analyzer, is FDA approved for use in monitoring therapeutic response in patients with breast, prostate and colon cancers. The Veridex CellTrack enrichment technique and subsequent enumeration of CTC is based on expression of a cell surface antigen, EpCAM and a cytoplasmic protein, cytokeratin, both of which are essential for the identification of CTC originating from carcinomas. With the rapid technological advances in recent years, there are many approaches to detect, isolate, enumerate and characterize Circulating Tumor Cells (CTCs) from peripheral blood. CTC enrichment methods are becoming available based on morphologic or physical characteristics, such as size or density of the cancer cell. Some isolation technologies are based on negative selection and depend on mononuclear cell depletion for the isolation of CTC. The assay characteristics of these new methods must be carefully validated before being incorporated into clinical trials, as is the case for any new assay or analytical procedure used in the clinical laboratory for patient management. The Biomarker Discovery Laboratory (BDL) at MSKCC focuses on the analytical validation of new CTC enrichment techniques and on the evaluation of expression signatures in the genomic profile, ie, mRNA contained within all CTCs. The BDL has validated assay procedures that permit detection of picogram concentrations of RNA in CTC that are used to define the molecular profile or gene signature of the metastatic cancer. The successful clinical application of these emerging CTC technologies and the genomic interrogation of cancer cells are the basis for further studies into the biology of neoplastic disease and the metastatic process. Once these new biomarker assays have been rigorous validated to clinical laboratory standards, they will represent an important prognostic tool in the clinical management of patients with metastatic cancer.
88
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Diagnostics 1:30 pm, Wednesday, January 16 Room: Miami 1-3 Garry Nolan, Stanford Medical School
Single-Cell Mass Cytometry Delineates Clinically and Mechanistically Relevant Leukemic Differentiation Substructures Single cell analysis of functional cell states via flow cytometry has been an essential tool for dissecting the functional complexity of hematopoiesis. Using a next-generation single-cell “mass cytometry” platform we quantify surface and cytokine or drug responsive indices of kinase targets with 45 parameters analysis (e.g. 41 antibodies, viability, DNA content and relative cell size). We focused on dissecting the biology and improving risk stratification in human acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML). The simultaneous measurement of surface marker, cell cycle, apoptosis, and intracellular signaling parameters has revealed substantial “order” within the presumed heterogeneity in the blast populations of these diseases. Analysis indicates there exists remarkable “structure” within tumors that is suggestive of either an adulterated differentiation cascade or a pseudo-hierarchy of differentiation. Taken together, these early successes point toward a future of actionable clinical information based on single-cell assays for diverse hematological malignancies.
2 pm, Wednesday, January 16 Room: Miami 1-3 William Wachsman, University of California, San Diego School of Medicine; Co-Author: Sherman Chang, DermTech International, Inc.
EGIR for Non-Invasive Genomic Detection and Assessment of Melanoma The cure of melanoma is dependent upon its early detection. Physicians currently use visual and optical cues to evaluate pigmented lesions and determine whether a biopsy is indicated. However, only 3-5 percent of biopsied skin lesions, deemed suspicious for melanoma, are found on histopathologic examination to contain the disease. In addition, reader studies have shown that some 20-30 percent of melanoma lesions are not initially thought to be suspicious enough to warrant a biopsy. In recent work, we used adhesive sampling coupled with epidermal genetic information retrieval (EGIR) to expression profile stratum corneum overlying melanoma and nevi. These data enabled development of a class prediction model to discern melanoma from benign pigmented skin lesions, and discovery of a novel multi-gene biomarker for melanoma detection (Brit J Dermatol 164: 797-806 [2011]). Both in situ and invasive melanomas were discriminated from nevi with a sensitivity of 100 percent and a specificity of 88 percent. We have now moved these findings forward to develop a quantitative RT-PCR (qPCR) test on a high throughput platform. In subsequent work, we have used this EGIR-based technology to identify another multi-gene classifier that accurately separates invasive from in situ melanoma. These results provide the basis for genomic testing that can be used to assist with melanoma staging and clinical management. Because this approach to disease detection and staging is noninvasive, it has the potential to lower the bar for lesion assessment by the physician and improve patient acceptance for testing, thereby facilitating identification of early stage melanoma.
SLAS2013.org
I
89
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Diagnostics 2:30 pm, Wednesday, January 16 Room: Miami 1-3 Tony Dickherber, National Cancer Institute
Transformative Technology Support From the NCI: The Innovative Molecular Analysis Technologies Program The National Cancer Institute (NCI) Center for Strategic Scientific Initiatives (CSSI) has as its mission the task of planning, developing, executing, and implementing rapid strategic scientific and technology initiatives that keep the Institute ahead of the scientific curve with respect to potential new exciting areas and discoveries. This may involve the development and application of advanced technologies, synergy of large-scale and individual initiated research, and/or forging novel partnerships that emphasize innovation, trans-disciplinary teams and convergence of scientific disciplines to enable the translation of discoveries into new interventions, both domestically and in the international arena, to detect, prevent and treat cancer more effectively. In the fall of 2011, the NCI CSSI re-launched an updated Innovative Molecular Analysis Technologies (IMAT) program, dedicating $10.5 million dollar to providing unique funding mechanisms (3 year R21s and R33s) to better support investigators through both the early and advanced stages of technology development over traditional funding mechanisms for exploratory research. A variety of IMAT-supported research projects will be highlighted to demonstrate the variety and high level of innovation evident in the IMAT portfolio of supported research. Potential projects of interest and identified technology gaps will also be discussed. The IMAT program continues to represent a unique resource for highly innovative technology development, but runs alongside several active programs at the NCI for supporting cancer-relevant technologies.
3 pm, Wednesday, January 16 Room: Miami 1-3 Thomas Kodadek, The Scripps Research Institute; Co-Authors: Bindu Raveendra, Wu Hao, The Scripps Research Institute; Reddy Moola, Jennifer Busby, Chad Hopkins, John Ndungu, Opko Health, Inc.
Discovery of Serum Antibody Biomarkers Via Screening Libraries of Synthetic “Antigen Surrogates” Recently, we have discovered a relatively general approach to the discovery of serum antibody biomarkers for a variety of disease states. The method involves sequential screens large libraries of synthetic molecules against a pool of serum samples derived form control subjects to remove compounds that bind IgG antibodies present at high levels in these individuals. The denuded library is then screened against a pool of serum samples collected from patients with a particular disease of interest. Compounds that bind to antibodies present in these samples are identified and validated by subsequent testing against many individual samples. The application of this technology to neurodegenerative disease, cancer and autoimmune conditions are described.
90
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Drug Target Biology 3 pm, Tuesday, January 15 Room: Tallahassee 1-3 Haian Fu, Emory University
Protein-Protein Interaction Interfaces as Drug Targets Protein-protein interactions (PPI) dictate intricate intra- and inter-cellular signaling networks, which are essential for diverse physiological processes. Genomic alterations in cancer and other diseases are often associated with altered PPI networks, which provides molecular basis for a large number of human diseases. Thus, PPIs have emerged as a promising class of molecular targets for therapeutic interventions. Indeed, recent advances in high throughput screening, innovative chemistry, and computational technologies have accelerated the discovery of PPI inhibitors for disease-related signaling pathways. This presentation will briefly summarize recent advances in targeting PPI interfaces for therapeutic development. Case studies will be presented to illustrate challenges and promises for the discovery of small molecule PPI inhibitors.
3:30 pm, Tuesday, January 15 Room: Tallahassee 1-3 Masatoshi Hagiwara, Kyoto University
Challenges to Congenital Genetic Disorders With “RNA-Targeting” Chemical Compounds Patients of congenital diseases such as Down syndrome (DS), Duchenne muscular dystrophy (DMD), and Denys Drash Syndrome (DDS) have abnormalities in their chromosomes and/or genes. Therefore, it has been considered that drug treatments can serve to do little for these patients more than to patch over each symptom temporarily when it arises. Although we cannot normalize their chromosomes and genes with chemical drugs, we may be able to manipulate the amounts and patterns of mRNAs transcribed from patients DNAs with small chemicals. Based on this simple idea, we have looked for chemical compounds which can be applicable for congenital diseases and found that protein kinase inhibitors such as INDY, TG003, and SRPIN340 are promising as clinical drugs for DS, DMD, and DDS, respectively. Our originally developed multi-color splicing reporters enable the visualization of alternative splicing patterns at a single-cell resolution in cultured cells and living organisms, and can be applied for analyses to identify cis-elements and trans-acting factors involved in splicing regulation. We have constructed splicing reporters of target pre-mRNAs such as FGFR2, PML, PKM, and IKBKAP, and carried out a genome-wide, high-throughput cDNA overexpression screen to identify the splicing regulatory factors. The dual-color splicing reporters are also applicable for screen of small chemicals which affect the splicing patterns of mRNAs, and may bring new therapeutics to congenital diseases.
SLAS2013.org
I
91
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Drug Target Biology 4 pm, Tuesday, January 15 Room: Tallahassee 1-3 Konrad Howitz, Reaction Biology Corporation
The Human SET1/MLL Family of Histone Methyltransferase Complexes — The Challenges of Developing Robust Biochemical Assays for Identification of Discovery Tool Compounds Histone Methyltransferases (HMTs) are emerging as new targets for drug discovery at a time when our knowledge of how these enzymes work in the cell is far from complete. In vivo, histone methyltransferases (HMTs) target specific histone lysine or arginine residues at particular locations in chromatin. However, isolated HMTs often have low activity in vitro. While activity can sometimes be enhanced by addition of their in vivo binding partners, these are not always known. An added difficulty is that few known HMT inhibitors are potent or selective enough to act as assay validation controls. In this presentation, we will describe efforts to improve the quality and activity of recombinant HMTs, to develop precise biochemical assays, and to discover tool compounds for this new area of biology. As an illustrative case study, we will focus on our efforts to produce, develop assays and discover tool compounds for the six members of the human SET1/ MLL family (MLLs 1-4, SET1A, SET1B), histone H3 lysine-4 methyltransferases with potential value as therapeutic targets for multiple cancers (e.g leukemia, breast, colon) as well as other indications (e.g. osteoarthritis). In vivo, each of these enzymes functions as a multisubunit complex, including the catalytic SET1/MLL subunit unique to each complex, and four subunits common to all six complexes (WDR5, RbBP5, Ash2L, DPY-30). Proteins in addition to the core five are found only in certain subsets of the family. Since the SET1/ MLL subunits have little activity in isolation and since some of complexes’ subunit interactions have ca. micromolar affinities, achieving robust assays at the nanomolar enzyme concentrations desirable for screening poses a particular challenge. To that end we have explored variations in the recombinant constructs, complex components, assay methods and substrates.
4:30 pm, Tuesday, January 15 Room: Tallahassee 1-3 Layton Smith, Sanford Burnham Medical Research Institute
A Systematic Approach to the Identification of Biased Agonists of the Apelin Receptor (APJ) Via High-Throughput Screening The concept of biased agonism necessitates a reassessment of the methods used for drug discovery. Biased agonists are defined by their ability to selectively activate distinct signaling pathways of a receptor. As such, they hold enormous promise for the development of novel drugs that specifically elicit only the desired therapeutic response, and avoid potential adverse effects. High throughput screening assays designed to detect signaling of seven transmembrane spanning receptors (7 TMRs) downstream of G proteins, such as an increase in intracellular cAMP, ignore compounds that selectively activate β -arrestin-mediated signaling. Similarly, assays that examine only β -arrestin recruitment and signaling ignore compounds that selectively activate G-protein-dependent signals. Thus, a comprehensive drug discovery program seeking biased agonists must employ assays that report on the activity of each compound at multiple discrete pathways. This approach requires a significant re-tooling of the early drug discovery processes, especially in the conduct of high-throughput screening campaigns. Otherwise, potentially useful compounds that exhibit biased agonism will not be discovered. Here we report a systematic approach to the identification of biased agonists of human apelin receptor (APJ). We synthesized 460 modified versions of apelin-13, the most potent form of apelin, and screened them against four validated assays of APJ function including intracellular cAMP, β -arrestin recruitment, receptor internalization and receptor recycling assays simultaneously. Each of the assays in the campaign was robust, exhibiting Z’-values of 0.6-0.7, and an average signal to noise ratio >8. Using this approach we identified 32 biased agonists of APJ (a hit rate of ~6 percent). The “hits” were potent (EC50 30x). Of the agonists identified, 8 were perfectly biased towards G-protein signaling (cAMP) and 14 were perfectly biased towards β -arrestin signaling (β -arrestin recruitment).The biased signaling of these agonists was further confirmed using siRNA targeting β -arrestin, and APJ mutants incapable of signaling through either G-protein or β -arrestin pathways. None of the hits exhibited perfect bias towards the internalization or recycling of APJ. Interestingly, a subset of the hits favoring β -arrestin signaling also favored either internalization or recycling but not both. Of the remaining hits, 4 exhibited a modest preference for signaling via cAMP over β -arrestin and while 2 exhibited the opposite preference. These biased agonists will be useful tools to probe the function and pharmacology of apelin in normal physiology and disease. Further, the identification of novel biased agonists of APJ using this approach is proof-of-concept of our systematic approach to the discovery of biased ligands. This approach is likely universally applicable to the search for biased agonists of other peptide 7 TMRs.
92
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Drug Target Biology 9:30 am, Wednesday, January 16 Room: Tallahassee 1-3 Kelvin Lam, Blue Sky BioServices; Co-Authors: Ryan Clinton, Deanna Navaroli, Esposito, Scott Gridley, Norman Garceau, Blue Sky Biotech, Inc.
Hit Concordance Between the TDA (Template Directed Assembly) and Phenotypic HCS (High Content Screening) Assays Receptor tyrosine kinases (RTKs) are single-pass transmembrane receptor proteins that play a key role in cell growth, differentiation and motility. Tropomyosin-related kinases (Trks A, B, and C) are a family of RTKs activated by neurotrophins. RTKs are shown to be implicated in many diseases including Alzheimer’s disease, depression, pain sensation and various cancers. We validated the Template Directed Assembly (TDA) assay and a phenotypic high content screening (HCS) assay against TrkA. We completed the two screens against the same compound library. The goal of the present study is to examine the concordance of the hits between target based TDA assay and the phenotypic assay. TDA is a target-based assay technology is designed to restore membrane-associated proteins to more relevant physiological conditions. This technology utilizes recombinant polyhistidine-tagged proteins bound to the surface of nickel-chelated liposomes. Recombinant HIS-tagged proteins are engineered such that the target proteins when coupled to TDA have the same polarity on the lipid scaffold as they have in the native membrane environment. The lipids in TDA are fully fluid within the surface of the liposome and associated proteins can rotate freely. Furthermore TDA promotes the formation of high-order structures such as homo- or hetro-dimers and the recruitment of accessory factors. Thus, TDA allows the HIS-tagged proteins to bind to the liposome creating an environment much like a cellular membrane. The TDA approach restores TrkA activity to a more-native environment; therefore, we hypothesize that we will be able to identify compounds that are positive in a phenotypic HCS assay.We used the Cellomics CellInsight HCS system to detect chemical effects on neurite outgrowth in PC12 cells. Nerve growth factor (NGF) can induce the differentiation of this rat pheochromocytoma cell line, endogenously expressing TrkA, into neuron like cells characterized by neurite outgrowth. We evaluated the neurite outgrowth to quantify several key parameters including neurite number, length, and the extent of branching for each cell in the image. Using this approach, the effect of TrkA agonists and antagonists on neurite outgrowth can be quantified. Here we report the concordance of the hits between the phenotypic neurite outgrowth assay and target based TDA assay.
10 am, Wednesday, January 16 Room: Tallahassee 1-3 Kelly Owens, University of Washington
FI NALIST
Phenotypic Screening in Zebrafish Identifies Compounds That Protect Mechanosensory Hair Cells From Drug-Induced Cell Death: a Model for Hearing Protection Loss of mechanosensory hair cells in the inner ear is a leading cause of hearing impairment. Like aging and noise trauma, clinical treatment with aminoglycoside antibiotics or anti-neoplastics, such as cisplatin, can induce hair cell loss. This unintended side effect is a major limitation on the use of these clinically effective drugs. We are interested in identifying drugs or drug-like molecules that prevent hair cell loss by ototoxic agents. We have adopted the zebrafish lateral line as a model system to study sensory hair cell toxicity. Hair cells of the zebrafish lateral line are homologous to mammalian inner ear hair cells, sharing most structural and molecular components and including sensitivity to these ototoxins. In addition, the external location of the lateral line hair cells allows visualization and manipulation in vivo. For chemical screening, 5 day old zebrafish are pre-labeled with the vital dye YO-PRO1 to visualize hair cell nuclei and placed in 96-well glass bottom plates. Libraries of test drugs are multiplexed to allow evaluation of 1-5 drugs in parallel typically at a final concentration of 2 µg/ mL or ~2-10 µM. Fish are then treated with potentially protective protectants for one hour, and then co-treated with an ototoxic agent and visualized for loss or protection of hair cells with an inverted fluorescent microscope. When hair cell protection is observed, we retest the individual drugs with the initial screening paradigm to identify the effective compound. Both dimensions of a “dose-response matrix” can be rapidly evaluated in the zebrafish. For these studies, we treat groups of zebrafish placing 10-50 fish in insert baskets in 6-well tissue culture plates to allow rapid transfer. In one dimension, we vary the concentration of a putative protective compound against a given concentration of ototoxin to determine the HC50 or the concentration of compound that confers 50 percent hair cell survival. In the second dimension, we vary the ototoxin concentration against an optimal of HC50 concentration of the protective drug as determined in the first dimension of the dose-response matrix. We have evaluated over 20,000 compounds from small molecule libraries and 640 FDA-approved drugs in our initial screening and confirmed 4 small molecules and 10 FDA-approved drugs that act as hair cell protectants in our dose-response matrix. We observe that some protectants are effect against single classes of toxins while others protect hair cells from loss induced by multiple classes of toxins. This may indicate commonalities and distinctions between cell death pathways. We are currently evaluating the structure-function relationship of our best lead to date, PROTO1 which protects against aminoglycoside toxicity. We have identified analogs of PROTO1, which improve the efficacy of PROTO1 by 15-fold.
SLAS2013.org
I
93
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Drug Target Biology 10:30 am, Wednesday, January 16 Room: Tallahassee 1-3 Michelle Palmer, Broad Institute of MIT and Harvard
Integrating Novel Technologies to Identify Small-Molecules That Drive Translational Research and Therapeutics in Cardiovascular Disease Advances in human genetics have lead to new drug discovery strategies that may lower the rate of attrition when translated to human trials. Molecular characterization of patient derived samples is providing new insights into the root cause of many diseases. Many of these insights point to targets that have traditionally been challenging for small-molecule therapeutics, such as transcription factors and protein protein interactions. Identification of drugs to modulate targets where knowledge of the targets function in disease is poorly understood requires innovation in chemistry, phenotypic cell-based assays and target identification studies. At the Broad Institute, we have integrated technology across all aspects of lead identification in an effort to realize the benefit of the genes to drugs approach in cardiovascular disease. Using the insights derived from genome-wide association studies (GWAS) in up to 100,000 individuals, we have identified multiple genetic loci associated with LDL-C, HDL-C, and/or triglycerides. The causal genes for two of these loci-SORT1 and TRIB1, are also strongly associated with coronary artery disease, making them highly compelling therapeutic targets. Additional experiments in mice and supporting human genetic data indicate that pharmacological upregulation of hepatic TRIB1 expression would result in decreased LDL-C, increased HDL-C, and decreased triglycerides, together resulting in decreased risk of MI in humans. We have identified novel scaffolds from our diversity oriented synthesis compound collection using a phenotypic cell based screening strategy that upregulate TRIB1 expression as well as a decrease in PCSK9 expression in liver cells. Use of the novel biomarker, Trib1, focused our phenotypic strategy to select hits with a novel mechanism that decouples PCSK9 and LDL receptor expression in hepatic cells. The unique properties of our screening collection has facilitated rapid SAR and the target ID process. Progress on this novel drug discovery target are presented.
11 am, Wednesday, January 16 Room: Tallahassee 1-3 Marcie Glicksman, Harvard Center for Neurodegeneration and Repair
High Content Screening Strategy for the RNA Binding ProteinTDP-43 The RNA binding protein TDP-43 has been found to accumulate in the cytoplasm of brain and spinal cord from patients affected with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Many mutations have been identified in TARDBP, the gene that encodes TDP-43, and they are associated with increased cytoplasmic inclusion formation in both familial and sporadic cases of ALS and FTLD. The TDP-43 protein regulates alternative splicing of RNA in the nucleus, and under stressed conditions, it forms cytoplasmic granules that co-localize with stress granule proteins in cell culture. The co-localization is also found in the brain and spinal cord of patients affected with ALS and FTLD. Under conditions of cellular stress, stress granules appear as dense aggregations and are composed of proteins and RNAs. The function of stress granules is not fully understood and may be either protective or a result of accumulated RNA molecules from failed attempts to make protein from mRNA. We developed a phenotypic high content imaging assay for the RNA binding protein TDP-43 measuring aggregate formation in cells and completed a high throughput screen. Progress of our identified compounds in additional validation assays will be described. Highlights will include the challenges and the benefits of using high content imaging and phenotypic assays for drug discovery.
94
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Drug Target Biology 1:30 pm, Wednesday, January 16 Room: Tallahassee 1-3 Charles Sabine, Emmy-Award Winning Television Journalist
A Perspective on Living With Huntington’s Disease Emmy-award winning TV journalist, Charles Sabine, worked for US network NBC news for 26 years. That career took him; via 12 wars, six revolutions, and four earthquakes; to most of the news events of Europe, the Middle East, Africa and Asia since the early 1980s. There, he learnt first-hand the extraordinary limits that the human spirit is capable of reaching, in the face of tragedy inflicted by both nature and mankind. In 2008, he decided to put the lessons of those experiences to a different use, when he became a pioneering spokesman for freedom of scientific research, and sufferers of degenerative brain illnesses - in particular, Huntington’s disease, which has ravaged his family. That role has led to Sabine speaking at prestigious venues across the world, among them; the European and British parliaments; the Royal Institution in London and the World Congress on Freedom of Scientific Research. No two presentations of Charles Sabine’s are the same, as he recognizes that no two audiences are the same; but all draw on the lessons of his travels with NBC and the stark reality of battling with one of the most devastating illnesses known to man. Charles delivers an opening talk as part of the Drug Target Biology Neurodegenerative Disease session and the closing keynote session. For the members of the Society for Laboratory Automation and Screening, the central theme of his talk is the importance to patients and their families of work that goes on within laboratories on their behalf, and the need for researchers to realize just how even unsuccessful research is of value; because; in a world of total darkness, the very faintest glimmer of light emboldens the human spirit to go on. He will also talk of his belief that the future of healthcare and research must involve greater collaboration between all key protagonists: researchers, governments, pharmaceutical companies, and patients and their families. Lastly, he explains why every aspect of research, however far it may seem to be removed from the patient, is part of a greater good of aspiring to care for the infirm; what Darwin called “the noblest part of our nature”.
2 pm, Wednesday, January 16 Room: Tallahassee 1-3 Robert Pacifici, CHDI Foundation, Inc.
Developing Therapies for Huntington’s Disease: A Prototype for all Neurodegenerative Drug Discovery? Aging Western populations have increased the burden of neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD), and despite considerable investments in time, money, and intellect by biopharmaceutical companies, precious-few drugs have been successfully developed to treat these disorders. Huntington’s disease (HD) is an orphan neurodegenerative disorder that shares many of the same clinical signs and symptoms, including motoric, behavioral, and cognitive problems. However, unlike the more prevalent neurodegenerative diseases, HD is an inherited monogenic disorder with 100 percent penetrance, making it possible (from birth) to unambiguously predict who will ultimately display the late-onset disease later in life. This ability to identify, characterize, and (eventually) treat people long before they manifest the overt disease phenotype affords HD drug-hunters with some distinct advantages. CHDI is a notfor-profit drug discovery organization that is exclusively dedicated to accelerating the development of therapeutics for HD. Over the past decade we have created a large and diverse portfolio of projects to fulfill this mission. Each individual project is predicated on an evidencebased mechanistic hypothesis as to why pharmacological intervention at a particular biological target is predicted to have a beneficial effect on HD pathophysiology, and is designed to identify a proof-of-concept molecule for in vivo testing as quickly as possible. An illustrative overview of the current programs, along with their challenges and opportunities, will be presented. We believe that many of the lessons learned from HD – correlating targets to animal models, animal models to human disease, and development of useful biomarkers – will serve as an informative prototype that can improve drug discovery efforts for other neurodegenerative diseases.
SLAS2013.org
I
95
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Drug Target Biology 2:30 pm, Wednesday, January 16 Room: Tallahassee 1-3 J. Fraser Glickman, Rockefeller University
A New Therapeutic Discovery Strategy for Alzheimer’s Disease: Treating Vascular Deficits Through the Inhibition of Amyloid-Fibrinogen Interactions Accumulating evidence suggests that vascular pathology promoted by the beta-amyloid (Aβ) peptide in Alzheimer’s disease (AD) could contribute greatly to cognitive decline. Previous published work has shown that the deposition of fibrin(ogen), the primary protein component of blood clots, plays a role in exacerbating pathology and cerebrovascular dysfunction in AD mouse models, and Aβ specifically binds to fibrin(ogen), forming an abnormal clot structure. We have used a high-throughput screening strategy to identify a compounds that disrupt the Aβ -fibrin(ogen) interaction and have demonstrated that one of these compounds improves memory in mouse AD model systems. Highthroughput assays were designed utilizing alphaLISA and fluorescence polarization to measure the interaction of purified Aβ -fibrinogen. Several additional techniques were used to confirm the mechanism of action of screening hits including surface plasmon resonance (BiaCore), “pull-down assays” and clot formation assays. Through this combined approach, we were able to identify a low molecular weight compound which binds to Aβ peptide, blocks the Aβ -fibrinogen interaction, and restores normal clot structure in vitro. Intravital imaging of clot formation showed that our lead compound restored normal thrombosis in the AD mouse model. In vivo studies showed the compound had a long half-life, a reasonable maximum tolerated dose, and was available to the brain tissue. It also showed significant positive effects after long-term administration on two memory tasks in AD mice versus littermate controls. Thus, these results further support a new molecular target for identifying bioactive lead compounds for studies applied to the understanding and therapy for AD.
3 pm, Wednesday, January 16 Room: Tallahassee 1-3 Jim Inglese, National Institutes of Health (NIH)
Targeting Inherited Genetic Diseases of the Peripheral Nervous Systems for Drug Discovery: A Case Study for the Gene-Dosage Disorder CMT1A As part of its mission to spur therapeutic discovery and development for inborn genetic and neglected diseases the NIH’s recently established National Center for Advancing Translational Sciences (NCATS) works in partnership with disease foundations, their grantees and patients to explore and facilitate the innovation of novel paradigms and approaches to drug discovery. In this presentation I will describe the initial phase of a drug discovery program for Charcot-Marie-Tooth (CMT) disease type 1A, involving the CMT Association (CMTA), leading investigators in peripheral nerve myelination, neurologists, patient advocates, and pharmaceutical companies. CMT1A is an inherited autosomal dominant neuropathy linked to the overexpression of the peripheral myelin protein 22 (PMP22). Here, in an effort to identify transcriptional inhibitors of therapeutic relevance to CMT1A, we developed a primary screening and candidate evaluation assay strategy to rapidly identify chemotypes with preferred effects on PMP22 and other key myelination genes. For the primary HTS assay we developed a cross-validating pair of non-homologous or orthogonal reporter assays capable of recapitulating PMP22 expression, utilizing the intronic regulatory element of the human PMP22 gene. Each compound from a collection of approximately 3,000 approved drugs was tested at multiple titration points to achieve a pharmacological end point in a 1536-well plate quantitative high-throughput screen (qHTS) format. In conjunction with an independent counter-screen for cytotoxicity, the design of the screening platform effectively enabled the selection and prioritization of active compounds, among which three drugs (fenretinide, olvanil, and bortezomib) exhibited marked reduction of endogenous Pmp22 mRNA and protein. Overall, the findings of this study provide a strategic approach to assay development for genedosage diseases such as CMT1A.
96
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
High-Throughput Technologies 10:30 am, Monday, January 14 Room: Sun Ballroom A Timothy Jamison, Massachusetts Institute of Technology
Continuous Flow Multi-Step Synthesis Using continuous flow techniques for multi-step synthesis enables multiple reaction steps to be combined into a single continuous operation. The current state of the art in this field and highlight recent progress and current challenges facing this emerging area are discussed. Several case studies from our own laboratory are presented.
11 am, Monday, January 14 Room: Sun Ballroom A Kevin Woller, Abbott Laboratories
High-Throughput Chemistry Platform at Abbott The High-Throughput Chemistry (HTC) platform at Abbott Laboratories has evolved over the past decade to provide synthetic support to project teams through the efficient production of SAR enabling libraries. During that time we have built the infrastructure and informatics systems to produce over 20,000 discrete and fully characterized compounds per year. As part of our ongoing efforts, we have begun the development and implementation of an integrated system to synthesize and purify libraries of compounds in flow. This presentation highlights our process for library generation from design through product registration on our traditional batch platform and introduce our nascent flow platform.
“There’s a big difference between people who take initiative and try to figure the best way forward, and people who just do what they are told,” SLAS member Daniel Sipes says. Whether testing the depths of the ocean or overseeing laboratory operations on land, Sipes’ overall advice for career and life is: always be rigorous and make time to experience life.” Read more at www.ELN.SLAS.org
SLAS2013.org
I
97
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
High-Throughput Technologies 11:30 am, Monday, January 14 Room: Sun Ballroom A Alex Godfrey, Eli Lilly and Company
The Virtual MedChem Lab: New Research Paradigms in Drug Discovery Lilly has designed and constructed a unique automated synthesis lab directed at supporting the work a medicinal chemist does at the bench. Traditionally automation technologies have been directed mainly to support parallel library synthesis generally in a plate-based format. In contrast, the approach we have taken more closely aligns with the tube-based approach many bench chemist follow allowing the pursuit singletons at >= 100 mg scale, libraries or even multi-step synthetic sequences with complete workflow automation from reagent gathering and mixing to purification and characterization. In this talk we will describe the layout of the lab, how it functions, and how it is going about impacting and transforming our approaches to doing chemical synthesis in the pursuit of drug discovery.
12 pm, Monday, January 14 Room: Sun Ballroom A Rolf Gueller, Chemspeed Technologies
Object Oriented Workflow Design – Virtually Unrestricted Combination of Sequential and Parallel Processing in HT Workflows It is the step-changing high-throughput and high-output solution for virtually unrestricted combination of sequential and parallel processing of entire (or partial) product development workflows (sample preparation, synthesis, process research, formulation, application, testing). The unrivalled design enables dramatic product development efficiency increases combined with highest quality and maximum ease of use. Several years ago, the software programming industry came to a limit. The complexity of the software that needed to be developed was such that it was becoming impossible to create stable and efficient software with the standard languages of that time. The complexity of connecting the different sub-routines was such that the applications could no longer be developed in a cost efficient manner. This is when Object Oriented Programming was introduced. By defining objects with clear interfaces, the developers were no longer limited by the complexity of interfacing the subroutines. With object oriented languages, the programmers could easily combine objects to create the needed functionality, even adapt them if needed without risking disturbing the rest of the application. Beside the simplification that this brought, other advantages derived from this development, for example:- The community of objects was steadily growing thanks to the standardization of their connection.- The objects could be exchanged in existing software - It was possible to purchase existing objects on the market- It was also possible to build custom “exclusive” objects for a specific situation and have them easily integrated in the overall software- Existing software capabilities could be expanded by adding or changing modules with new or additional functionality- It was also possible to test the objects independently of the context in which they were developed. The product development workflows have now reached a similar level of complexity that requires a similar paradigm shift. To respond to this demand, Chemspeed has developed its SpeedShuttle product line for Object Oriented Workflow Design and has defined a library of objects on which we now base workflow solutions. This brings to workflow design the same kind of advantages that it did to software:- Exchangeable Objects- Possibility to physically rearrange objects- Possibility to easily expand the workflow with existing and new objects- Standardization of objects brings reliability- Possibility to exchange an object with a similar one on loan until the initial one is upgraded or repaired (imagine the increase in up time this means)- Assurance of being able to bring new objects later on without needing to change the architecture (Upgradability)- No need to require new engineering when objects are added or exchanged- The possibility to develop custom/ exclusive objects and be certain that they will integrate with the rest of the workflow.
98
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
High-Throughput Technologies 3 pm, Monday, January 14 Room: Sun Ballroom A Katheryn Shea, International Society for Biological and Environmental Repositories (ISBER)
Building Quality Biological Collections The International Society for Biological and Environmental Repositories (ISBER) is the leading international forum for promoting consistent, high quality standards, ethical principles and innovation in biospecimen banking by uniting the global biobanking community. ISBER is a diverse community of biorepositories and supporting collaborators. We are focused on building high quality, ethical collections of human, animal and environmental specimens to fuel research in the biological sciences with benefits to many fields including healthcare, agriculture, biodiversity and the environment. Building quality biological collections begins with the incorporation of best practices into each aspect of the collection. Multiple best practice guidelines are available, such as the third edition of ISBER’s “Best Practices for Repositories”, which was published in 2012. The practical application of these best practices depends on the intended use of the specimens as the goal is to ensure the preserved specimen is fit for the purpose intended. One of the greatest challenges faced by many repositories is that the intended use is only known for a portion of the specimens to be collected, and so designers must be able to envision the potential future of the collection and build this into the design. Logistical considerations must also be taken into account in the design phase. One goal of study design must be to standardize all sample handling procedures. If the current and envisioned future biomarkers to be studied are sufficiently stable, processing all samples in a central laboratory greatly simplifies standardization. If immediate sample processing is necessary, in the variety of locations where the samples are taken, then careful documentation of all activities performed by each site and ongoing monitoring to ensure consistency in sample collection and preservation techniques across all locations is critical. Incorporating automation to promote standardization is an optimal, but difficult to justify, solution. Automation can eliminate site-to-site differences by diminishing the variable, human element of sample processing needed in each site and substituting identical automated processing. However, most studies have developed individual labeling, processing, vialing and preservation requirements for their particular study. These varied requirements reduce the utility of automation and make it difficult to justify from a financial perspective. Harmonization of repository practices remains a critical mission for the ISBER community and we welcome collaborations with other groups such as SLAS to help us achieve this mission.
3:30 pm, Monday, January 14 Room: Sun Ballroom A Rosalia Gonzalez, Pfizer; Co-Author: Chi-kin Chan, Lisa Thomasco, Pfizer
Executing Collaborations and Acquisitions – A Behind The Scenes Look At The Role of A Sample Management Group The search for targets with a high confidence in rationale has given rise to an increasing number of collaborative agreements among pharmaceutical companies and academic groups. These agreements inevitably lead to the exchange of proprietary materials between the two parties with the aim of either increasing confidence in the target, or of identifying novel compounds that hit the target, or both. That no two agreements are alike is understandable and true. This is the story of the collaboration between Pfizer and Icagen as told by the Pfizer Compound Management and Distribution group. The story illustrates the nuances involved in enabling collaborations, nurturing them to success, and following the progression of the relationship to one of the possible endings of such a story - acquisition. A multidisciplinary team of med chem designers, biologists, data and infrastructure technologists, compound management experts, and shipping logisticians worked together to ensure the cradle-to-grave tracking of samples and data. Information about Pfizer compounds going to Icagen had to conform to the terms of the collaborative agreement. Icagen compounds going to Pfizer had to be protected to limit sample access only to the specific Pfizer Project Team, while taking advantage of global screening panels. When Icagen was eventually acquired by Pfizer, a whole host of other issues related to the integration of the company had to be addressed. Six months after Day One, Icagen now functions as Pfizer Neusentis US in Durham, NC and is a fully functioning Pfizer research site supported by Compound Management and Distribution in Groton, CT.
SLAS2013.org
I
99
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
High-Throughput Technologies 4 pm, Monday, January 14 Room: Sun Ballroom A Sam Michael, NCATS
Real Time Droplet Detection System for Low Volume Liquid Dispensing Low volume multi-tip dispensing of biological reagents is a critical aspect of high-throughput screening, with a wide variety of dispensers that utilize different dispense techniques commercially available. One of the most common problems during a high-throughput screen are errors in dispensing reagents into microplates. This is typically due to a failure of the dispense instrumentation itself (often a clogged tip) or incorrect calibration of the dispenser. Calibration errors can lead to the premature depletion of reagents leaving many plates empty. Overall, these errors can cause plates to fail quality control and the need to rescreen compounds, costing additional screening resources and time. To effectively detect these dispense errors as they occur, we have developed a droplet measurement system for volumes as low as 50nL that can be used to monitor dispenses in real time, providing immediate feedback in the event of any failure. Development of the droplet monitor required the selection of an appropriate sensor capable of rapidly detecting low liquid volumes, and the design of a mechanical fixture used to house the selected sensors to allow for the simultaneous monitoring of multiple dispense tips. We have also created simple software to read the output of all connected sensors to allow for easy integration with existing commercially available dispensers. Since implementing our solution on two Beckman BioRAPTR dispensers on one of our high-throughput screening systems, we have had multiple instances where we could immediately respond to a detected dispensing error, allowing us run several thousand 1536-well plates without loss. Together, we foresee that our hardware and software combination could become a low-cost and straightforward tool to increase the robustness of high-throughput screening.
4:30 pm, Monday, January 14 Room: Sun Ballroom A David Harden, Bristol-Myers Squibb Company
Rethinking Compound Pooling: “Just in Time Duplexing” is an Innovative and Cost Effective Solution to Double High-Throughput Screening Capacity Due to recent compound acquisitions, the number of samples available for high throughput screening (HTS) at Bristol-Myers Squibb (BMS) has more than doubled in the past few years. To accommodate the number of screens required to support early phase discovery, approximately half of the current compound collection can be screened against a target under current budgetary constraints. Although knowledge-driven compound selection for a given target has been used to enrich chemical space sampling, this approach can be limited by the information available. The success of HTS is fundamentally dependent on maximizing opportunities to observe hits. Therefore, increasing the number of diverse samples tested against a target increases the probability of identifying lead molecules from multiple chemotypes and thereby increases the chances for drug discovery success. One way in which the industry has dealt with the increasing size of screening collections is compound pooling, or multiplexing multiple compounds per well during primary screening. This is a controversial approach with a long history of limited success. Many issues with this approach arise from long-term storage of library plates containing complex mixtures of compounds at high concentrations. Due to the historical difficulties with using multiplexed library plates, primary HTS at BMS employs a “one-compound-one-well” approach in a 1536 format. However, as compound collections grew and our ability for further miniaturization was maximized, innovative strategies were required to increase the capacity of primary screening campaigns without increasing screening costs. Towards this goal, we have identified a novel compound pooling method that increases screening capacity without compromising data quality. This method circumvents issues related to long-term storage of complex mixtures by “Just-in-Time” dispensation of unique compounds from two source plates into a single assay plate using an acoustic based delivery system, effectively doubling the capacity of a primary screen. We have implemented rigorous prescreen validation methods to evaluate this compound “duplexing” method relative to our standard “one-compound-one-well” approach to ensure comparable hit detection sensitivity as well as assay robustness as determined by descriptive statistics. We will present data from multiple screening campaigns encompassing multiple target classes and assay formats. Our results indicate this method can be used to vastly increase screening capacity without significant reduction in the ability to detect screening hits and ultimately identify greater number of chemically tractable starting points. This has been accomplished without additional screening costs and without additional capital investment. Overall, this approach leverages BMS’s constant focus on enabling the most flexible infrastructure to drive diverse hit identification strategies.
100
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
High-Throughput Technologies 10:30 am, Tuesday, January 15 Room: Sun Ballroom A Changhuei Yang, California Institute of Technology
Self-Imaging Petri Dishes For Direct Image Streaming From the Incubators This talk discusses our work on the implementation of self-imaging petri dishes (ePetri). The ePetri can image cell cultures at microscopylevel resolution (0.66 microns) over an area of 5 x 6 mm. The lensless imaging strategy also obviates the need to perform manual or mechanical focusing - the imaged cells are automatically in focus as long as they are in contact with the dish surface. We have demonstrated that the mug-sized ePetri prototypes are capable of streaming images of growing cultures directly out of the incubators. I will further discuss the utility of the ePetri in a broad range of applications.
11 am, Tuesday, January 15 Room: Sun Ballroom A Tuval Ben Yehezkal, Weizmann Institute
Development and Application of DNA Editing Technology DNA programming is the DNA-counterpart of computer programming. The basic computer programming cycle is to modify an existing program, test the modified program, and iterate until the desired behavior is obtained. Similarly, the DNA programming cycle is to modify a DNA molecule, test its resulting behavior, and iterate until the goal (which is either understanding the behavior or improving it) is achieved. One key difference between the two is that unlike computer programming, our understanding of DNA as programming language is very far from being perfect, and therefore trial and error are the norm rather than the exception in DNA-based research and development. Hence DNA programming is more efficient if multiple variants of a DNA program, also called a DNA library, are created and tested in parallel, rather than creating and testing just one program at a time. Hence the basic DNA programming cycle, when operating in full steam, takes the best DNA programs from the previous cycle, uses them as a basis for creating a new set of DNA programs, tests them, and iterates until the goal is achieved. The biotechnology revolution has, to a large extent, been held back by its notoriously prolonged R&D cycle compared to the computer programming cycle. A CAD/CAM technology for DNA which will bring word processor ease to DNA processing and thus support rapid DNA programming will revolutionize biotechnology by shortening the R&D cycle of DNA-based applications. This can only be accomplished by concerting the development of complex, multi layered technologies which integrate expertise from fields as varied as algorithmics, software engineering, biotechnology, robotics, microfluidics and chemistry. These are only now starting to emerge as feasible. Furthermore, Polymerase Chain Reaction (PCR) is the DNA-equivalent of Gutenberg’s movable type printing, both allowing large-scale replication of a piece of text. De novo DNA synthesis is the DNA-equivalent of mechanical typesetting; both ease the setting of text for replication. What is the DNA-equivalent of the word processor? Word processing was rapidly adopted as a replacement for the typewriter when users had discovered its revolutionary advantages in document creation, editing, formatting and saving. While the electronic representation of text in computers allows the processing of text within a simple unified framework, DNA processing – the creation of variations and combinations of existing DNA – is performed by biology labs daily using a plethora of unrelated manual labor-intensive methods. As a result, so far no universal method for DNA processing has been proposed and, consequently, no engineering discipline that further utilizes the processed DNA has emerged. We are developing technological platforms that aim to deliver a revolution in DNA processing analogous to the revolution text editing underwent with the introduction of electronic text editors.
SLAS2013.org
I
101
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
High-Throughput Technologies 11:30 am, Tuesday, January 15 Room: Sun Ballroom A Victoria Holderby, The University of Texas at Dallas
A Dielectrophoretic Approach for Cancer Stem Cell Separation Lung cancer is one of the most common cancers; more people in the United States die from lung cancer than any other type of cancer. In 2007 (the most recent numbers available) 203,536 people in the United States were diagnosed with lung cancer and 158,638 people died from the disease. The discovery of cancer stem cells has opened an important area of cancer research that could lead to substantial discoveries in the treatment and detection of cancer. Detecting cancer stem cells is vital to treating cancer. Cancer stem cells are the main source of new cancer cells with in a tumor and resist treatment, so there is an urgent need for characterization of these cells in order to create new treatment methods. In order to characterize these cells, they must be purified. Current methods for purification, typically fluorescence-activated cell sorting (FACS), take hours to complete and can be invasive to the cells. FACS requires fluorescent tagging of the cells to extract them one by one which can change the inherent properties of the cell that need to be understood. This abstract describes a new approach for separating the cancer stem cells from the cell population in a fast and non-invasive manner using a microelectrode based platform. The technique used is dielectrophoresis (DEP), which moves cells in a nonuniform electric field based on the dielectric properties that are specific to the cell and the suspending medium. DEP has been used for the isolation of rare cells, but never specifically for lung cancer stem cells. Cell separation is accomplished by applying a voltage and cell specific frequency to an electrode pattern creating an electric field that induces a DEP force that influences the movement of the targeted cell. The electrode design was a simple two by two array with alternating positive and negative terminals with a diameter of 250 microns and center to center distance of 750 microns creating an area of high electric flux between the electrodes for the cells to gather. Optimization of the electrode pattern for the desired electric field was accomplished through 3D COMSOL modeling. Without the use of microfluidics, about 50 micro liters can be sorted at a time, but with the addition of microfluidics the volume able to be sorted will increase significantly. The targeted separation efficiency for separating lung cancer stem cells is 95 percent pure. Utilizing photolithography methods to create a gold microelectrode pattern on a glass substrate allows for a versatile and inexpensive chip for fast cell sorting. Lung cancer stem cells were extracted from human serum samples with high efficacy. With this technology, research in the field of cancer stem cells can be advanced much quicker and more efficiently.
12 pm, Tuesday, January 15 Room: Sun Ballroom A Steve Shih, University of Toronto
Digital Microfluidics With Impedance Sensing for Integrated Cell Culture and Analysis Flow cytometry and fluorescence microscopy are powerful cellular analysis techniques; however, neither is perfectly suited for analysis of adherent cells in situ (flow cytometry requires enzymatic stripping of adherent cells, and fluorescence microscopy requires perturbation with dyes and fixatives). Electrical impedance analysis is thus an attractive alternative, as adherent cells can be evaluated without significant perturbation. Despite this advantage, impedance analysis is seldomly used relative to cytometry and microscopy; one reason is the limited throughput (and significant reagent use) of conventional impedance analysis systems. There is great hope that microfluidics can solve this problem; however, to date, there have been no report of multiplexed impedance analysis systems relying on the standard format for microfluidics (i.e., enclosed microchannels). Here, we report a new approach to integrating cell impedance analysis with microfluidics. This method relies on an alternative to microchannels for miniaturized analysis, known as digital microfluidics (DMF). In DMF, discrete droplets are manipulated electrostatically on an array of electrodes. DMF is well-suited for multiplexing cell culture and analysis, but all methods reported previously have used fluorescence or microscopy as a read-out. Here, we introduce the first digital microfluidic platform capable of impedance analysis of cells. The platform is driven by an automated feedback control system that enables high-fidelity, multiplexed droplet manipulation involving thousands of droplet actuations to implement assays that take place over several days. The system was validated in three assays: calibration, proliferation, and serum sensing. In the calibration, three cell lines (HeLa, CHO-K1, and NIH-3T3) were seeded at different densities to determine the relationship between impedance and cell number. In the proliferation assay, cells were grown for four days and their proliferation rates were determined by regular impedance measurements. In the serum sensing assay, a dilution series of cell media containing different concentrations of serum were generated by DMF and evaluated using impedance measurements to determine the optimum conditions for proliferation. The DMF impedance method is label-free and does not require imaging. We propose that this system will be useful for the growing number of scientists that are seeking methods other than fluorescence or cell sorting to analyze adherent cells in situ.
102
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
High-Throughput Technologies 3 pm, Tuesday, January 15 Room: Sun Ballroom A Geoffrey Cutler, Novartis Institute for Biomedical Research (Basel)
STEP – A Fully Automated HTS System That is Adaptable to Meet Today’s and Future Needs of Drug Discovery High-throughput screening is the approach that yields today the largest number of novel chemical leads for drug discovery programs at the Novartis Institutes of BioMedical Research (NIBR). Fifteen years of experience in HTS at NIBR have led to a change in paradigm. We have gone away from a highly standardized “one fits all” process to a focus on process adapability: the HTS-process is customized to every new screening project. This poses great challenges for the automation systems used in HTS. The presentation will cover the development, implementation and use of Novartis’ new automated screening platform STEP1. A system that incorporates the latest automation innovations and is designed to meet not only today’s needs of HTS, but also be adaptable to meet future requirements.
3:30 pm, Tuesday, January 15 Room: Sun Ballroom A Chun-Hao Chiu, Novartis Institute for Biomedical Research
Developing an Automated Multi-System Compatible Screening Platform at the Novartis Institutes for Biomedical Research Designed for Flexible and Rapid Assay Development and Screening With Direct Compound Addition High-throughput screening (HTS) of chemical libraries is one of the early critical steps in drug discovery and chemical biology efforts where the results populate databases used for structure activity analysis and chemical matter is discovered that could serve as starting points to launch a resource-intensive drug discovery campaign. Improving the quality of HTS data and the leads that are discovered requires new non-linear efficient models where rapid testing of ideas surrounding the biological pathway/target and technologies is performed using small focused libraries to ensure that the right assay and technologies are being applied before making a final assay selection and scale-up for full-scale HTS. To enable rapid testing of hypotheses, we designed a modular screening system that would be fast, userfriendly, robust, and flexible. The new system, composed of an offline direct compound addition station (ODCA) and reader feeder station (RF), was designed to support rapid assay development, evaluations of both biochemical and cell-based assays formats, and hypothesis testing using custom focused library sets. The nature of focused screens with small (100. Alternatively, even using 3-5 parameter data, HT screening provides a rich amount of information very quickly. Within the past couple of years, the throughput and available dimensionality provided by modern cytometry has increased well beyond the processing, mining or visualization ability offered by current analytical tools. Our overall goal is to discover relationships between molecular compositions and observable phenotypes in model cellular systems using an array of newly developed tools. Key to the success of this technology is the scalable development of a requisite analytical environment to quantify descriptors of function at a single-cell level for accurate characterization of heterogeneous populations. For example, using the complexity of the flow cytometry systems approach it is possible to build functional relationships between cell phenotypes, activation molecules, phosphorylation states and drug responsiveness all in a single assay. It is necessary to develop new tools for processing, reduction, analysis, and visualization of very high content cytometry to assist in transformation of our understanding of cellular heterogeneity, by defining the relationship between phenotype and genotype, and the nature of complex cellular responses. All data processing tools developed for this work are currently interactive, intuitive, and operate in real-time even on huge data sets and these will be demonstrated in this presentation.
12 pm, Monday, January 14 Room: Sun Ballroom C Kristine Schauer, Institut Curie
FI NALIST
A Novel “Organelle Map” Framework for the Automatic Detection of Cellular Morphology Changes Despite the central role of morphological comparisons in cellular biological approaches, few statistical tools are available that allow scientists, without a high level of statistical training, to quantify the similarity or difference of fluorescent images containing multifactorial information. Such computational imaging methods are indispensable tools for the high-throughput image acquisition capability of advanced microscopes that can acquire thousands of high-content images per day. We have developed a screening procedure that takes advantage of the cellular normalization by micropatterning and a novel quantitative “oganelle mapping” approach that allows unbiased and automated cell morphology comparison using a black-box statistical test. Micropatterns of extracellular matrix proteins force cells to take a reproducible shape avoiding strong cell-to-cell variation that is a major limitation of classical culture conditions. To measure spatial organization of intracellular structures in micropatterned cells we transform corresponding fluorescent signals from several tens of cells into probabilistic density maps that quantify their three-dimensional spatial organization. To detect changes in cell morphology induced by compound treatment, we developed a black-box test that computes a P-value to quantify the similarity or difference between corresponding density maps. This method estimates all parameters directly from the data, without any subjective decisions. We validated the performance of our organelle mapping approach in a screen for kinase-, phosphatase- and protease- inhibitors that disturb the steady-state organization of lysosomes (marked by Lamp1) and the Golgi apparatus (marked by GM130). Human RPE-1 cells were seeded in 96-well plates containing micropatterns, incubated at 10µM drug concentration for one hour and fixed and stained with specific antibodies. Images were acquired at 20X, segmented and statistically compared using the density-based test. Unlike to “state-of-the-art” high-content/high-throughput analysis on unrestricted cells having massive cell-to-cell variation, we required data from as little as 30 cells per condition for statistically significant results. Globally, kinase inhibition disturbed cell organization to a higher degree than inhibition by phosphatases or proteases. We found that the positioning of lysosomes was specifically regulated by the mTor pathway and the morphology of the Golgi apparatus by EGFR signaling. Surprisingly, the majority of kinases tested regulated the spatial organization of both lysosomes and the Golgi apparatus. These data show, for the first time, that the organization of the endocytic and secretory compartments is tightly linked by regulatory proteins. A similar screen was performed with a siRNA library against cellular motor proteins, demonstrating that siRNA screening for loss of function analysis is compatible with density mapping. We are confident that our organelle mapping platform in micropatterned cells represents a major step towards quantitative, robust and fast analysis for automated detection of cell morphology changes in high-throughput screens. We believe that this framework has the potential to become a gold-standard for cell phenotyping in HCS.
110
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Informatics 3 pm, Monday, January 14 Room: Sun Ballroom C Viral Vyas, Bristol-Myers Squibb Company
In Vivo Workflow Optimization Production and consumption of Pharmacokinetic (PK) data in preclinical species is integral to the success of discovery programs. This presentation details the implementation of an electronic work process to streamline the capture of in vivo PK data. The Pharmaceutical Candidate Optimization (PCO) organization used multiple applications to manage data generated from in-vivo studies. While the requests for in-vivo studies were electronic, the execution, analysis, and reporting of PK data were still manual processes. We identified several opportunities to optimize these processes using Lean Sigma methodology. A phased approach was used to: •
Provide request-stage tracking, prioritization and demand management across all functional aspects of PK studies
•
Integrate and automate data capture, archival, processing, approval and transfer activities
•
Provide request and data management capabilities for effective collaboration with offshore and out-source groups for all or part of the process
The resulting workflow reduced non value added activities such as cutting and pasting, and transcribing. Data quality and availability was improved. By extending the workflow to Biotransformation and toxicology studies, we have enabled better demand forecasting and prioritization of functional study resources.
3:30 pm, Monday, January 14 Room: Sun Ballroom C Bill Janzen, University of North Carolina; Co-Authors: Dmitri Kireev, University of North Carolina; Cen Gao, Eli Lilly; Duane Bronson, Screenable Solutions; Emily Hull-Ryde, Chatura Jayakody, University of North Carolina
Implementation of an Integrated Data System to Support Academic Drug Discovery While academic drug discovery centers are able to build on the processes and knowledge developed in industrial labs, they face many unique challenges. The area of data processing and interpretation exemplifies this in that many commercial packages exist to support all aspects of drug discovery but their cost combined with the additional flexibility required in an academic environment make implementation challenging. The Center for Integrative Chemical Biology and Drug Discovery (CICBDD) at the University of North Carolina was founded in 2008 to serve as a collaborative resource for UNC faculty for drug and probe development from innovative targets. As such, any supporting infrastructure systems had to be flexible enough to accommodate diverse target platforms and easy enough to use that graduate students and collaborator scientists could apply the system with minimal training. The system requirements included compound registration, sample tracking, data reduction, data visualization and long term secure data storage. Data audit trail security is usually not a requirement for academic systems, but for this application we required sufficient security and auditing to support intellectual property filings. The choice of a data system was further complicated by the need to bring the system on-line quickly to match a rapid chemistry ramp up and a requirement that the cost be kept to a minimum. This talk will describe the implementation of a system that combines a commercial LIMS system (Screenable Solutions) that was implemented as a Beta-phase/co-design project with in-house packages for compound registration and SAR analysis implemented by means of the Pipeline Pilot development kit (Accelrys). This system has been in production for over two years and currently contains over 2 million data points from 150 different assay and format combinations.
SLAS2013.org
I
111
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Informatics 4 pm, Monday, January 14 Room: Sun Ballroom C Gregory Linshiz, Joint BioEnergy Institute - JBEI
PaR-PaR: Programming a Robot Laboratory Automation Platform Many labor-intensive multistep biological tasks, such as the construction and cloning of DNA molecules, are prime candidates for laboratory automation. The flexible and biology-friendly operation of robotic equipment is key to its successful integration within biological laboratories. To make laboratory automation effective, the efforts required to operate the robots must be less than the alternative manual lab work. Laboratory robot operation should be flexible enough to promptly and easily accommodate changes in current protocols and to implement new protocols. To achieve this goal, there is a need for a simple high-level biology-friendly robot programming language for communication between biologists and laboratory robots. We have developed such a language - Programming a Robot (PaR-PaR). The syntax and compiler for the language are based on Computer Science principles and a deep understanding of biological needs. Our language allows researchers to use liquid handling robots effectively, enabling a plethora of new experiments that would not have been considered previously. After minimal training, a biologist can independently write relatively complicated protocols for a robot within an hour. PaR-PaR provides a set of high-level robotic commands, enabling the user to perform complex laboratory tasks easily. PaR-PaR’s commands are modular, generic, human-readable, and easy to modify. PaR-PaR utilizes an object oriented approach. Physical laboratory objects can be represented virtually, and entirely virtual objects can be created. Groups of several objects can then be defined as new entities, creating hierarchies of objects. PaR-PaR allows various actions to be executed on objects. Sequences of these actions can constitute procedures, which can then be used as PaR-PaR commands and deposited in external PaR-PaR modules. PaR-PaR has a web interface as well as a command-line mode. Users can write scripts in a PaR-PaR editor using intuitive visual GUI tools. The PaR-PaR compiler consists of four modules: a parser, database manager, optimizer and translator. This modular structure facilitates adaptation of PaR-PaR syntax to different user needs and its translation to different robotic or human languages. Adoption of PaR-PaR as a standard cross-platform high-level robot programming language would help to standardize biological protocols and allow for more reliable and reproducible experiments. As the PaR-PaR protocols are shared, updated and evaluated by different laboratories, the protocols would evolve, until ultimately only the most successful protocols, validated across laboratories, would be accepted as community standards.
4:30 pm, Monday, January 14 Room: Sun Ballroom C R. Kyle Palmer, Opertech Bio, Inc.
A High-Throughput Phenotypic Assay for Modulators of Taste Response Utilizing Trained Rats The sense of taste is a crucial factor influencing several aspects of health and well being. For instance, the search for low calorie sweeteners possessing the clean sweetness of sucrose has been a centuries old search that is on-going today. The obesity crisis in the USA is thought due in part to an over consumption of sucrose and related caloric sweeteners. In the past 10 years a number of groups have continued this search and have established HTS campaigns utilizing recombinant GPCRs and ion channels involved in taste chemo reception and signal transduction. To date, very few hits from this molecular approach have led to molecules with the desired taste attributes or approved products. We developed a novel automated apparatus, called the Microtiter Operant Gustometer (MOG), and methodology that combines high throughput screening technology with an operant taste discrimination paradigm where a specific taste cue indicates which of several behavioral responses will be rewarded. Rats were trained in this device to sample taste stimuli by licking solutions from a 96-well plate located beneath the floor. On each trial, the 96-well plate was moved in a randomized pattern by an x-y motion table to align a single well with an aperture in the floor. Interruption of laser beam projected across the top of the 96-well plate indicated licks as the rats tongue passed through the aperture into the well. Initial indication of a lick triggered appearance of two retractable levers from the front panel that operated a pellet dispenser. The taste of sucrose was associated with food reinforcement by presses on a sucrose-designated lever, whereas the taste of water and other essential tastes were associated by differential reinforcement of presses on the alternative lever. Using this procedure, rats were trained rats to discriminate 100 mM sucrose from water, quinine, citric acid, and NaCl with 90-100 percent accuracy. A trained animal could evaluate all 96 samples within 90 minutes enabling multiple dose-response functions within a single test session for a variety of sweeteners. Quantitative values were obtained for potency and efficacy in both taste quality and appetitveness. The discriminative power of the method enabled detection of subtle effects of two putative sweet taste inhibitors, alloxan and ZnSO4, and demonstrated that they altered taste quality and not sucrose response. This high throughput operant assay method generalized readily to other appetitve tastes namely salt- and umami-taste stimuli. A primary screen for taste properties was demonstrated with a set of known sweeteners tested at single high and low concentrations. The MOG apparatus presents an enabling technology for rapid evaluation of large numbers of novel tastants or taste-modifying compounds in an in vivo assay designed to capture both taste quality and palatability.
112
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Informatics 10:30 am, Tuesday, January 15 Room: Sun Ballroom C Scott Weiss, IBDS
The Impact of Tablet PCs and Social Networking on Laboratory Informatics Electronic laboratory notebooks (ELNs) have become commonplace in research, development and manufacturing labs. They have evolved from tools designed for IP capture, into feature-rich applications now suitable for data acquisition, sample management, complex analysis and reporting. Driven by industry pressure to improve laboratory processes and efficiency, ELN vendors continue to push their design and functionality into the role traditionally played by Laboratory Information Management Systems (LIMS), in many cases rivaling the power, features and sophistication of LIMS. However, the meteoric rise of tablet computers within the consumer market, user uptake of simple mobile “apps,” and the near ubiquitous participation in social networking via the internet are exerting a different commercial pressure: end users are demanding that software vendors produce simpler, more user friendly, accessible applications capable of running on small, hand-held devices that enable truly mobile data capture and access to laboratory information. The tablet form factor and interface has many benefits: easy to use for many routine tasks, excellent as an information and media consumption device, highly portable, and always connected through the internet to content and other users. For many end users switching from paper, a tablet computer embodies what an ELN should be. Is the future of the ELN to continue to grow in sophistication and complexity to displace LIMS, or will it become the scientist’s handheld lab companion for data entry and communication? More importantly, is the primary role of an informatics tools such as an ELN to make its users more productive, or can they also create an environment that facilitates a culture of collaboration and promote innovation? This presentation will discuss the recent market trends in laboratory informatics towards tablet and web client based tools for mobile data capture and searching, using simpler, more intuitive application designs. It will also discuss how user familiarity and acceptance of social networking outside of the laboratory environment may be leveraged by informatics tools to change behavior within the context of scientific discovery, by encouraging real time information sharing, peer review, user data markup and discussion to drive collaboration, discovery and innovation both within and between laboratories.
11 am, Tuesday, January 15 Room: Sun Ballroom C Michael Elliot, Atrium Research
Collaboration in the Age of Research Externalization The acceleration of biopharmaceutical research externalization is forcing change on traditional informatics architectures. No longer can systems designed purely for internal consumption be relied upon to communicate with a wide range of partners scattered across the globe. For effective collaboration, new models must be designed. However, the externalization movement is occurring at a pace faster than most IT organization have been able - or willing - to adapt to. The resulting data collaboration via email, paper notebooks, and DVD is “de-evolving” the millions spent on internal systems. The speaker will discuss the trends in research externalization, challenges of an integrated perspective, and some of the future models to support a distributed research environment.
SLAS2013.org
I
113
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Informatics 11:30 am, Tuesday, January 15 Room: Sun Ballroom C Seth Cooper, University of Washington
Foldit and Games for Scientific Discovery Foldit is a revolutionary game that has has shown that it is possible to crowd source human problem solving to solve very hard scientific problems. The project is a collaboration between the Center for Game Science and the Baker Biochemistry Lab at the University of Washington, and has allowed hundreds of thousands of players to participate and contribute to biochemistry research. Foldit uses game mechanics and visualizations to introduce the concepts of protein folding and protein design to novices. Through gameplay and the Foldit community, players can be brought to the point where they are able to contribute to novel scientific research. The game allows players to discover the structure of naturally occurring proteins, develop protein folding algorithms, and design entirely new and more effective proteins. This talk will discuss the motivation for creating Foldit, the development and design of the game, and what scientific results players have produced. The talk will also cover new directions we are going with Foldit - including integrating and visualizing new forms of data and interfacing with Kinect - as well as games for scientific discovery in general.
12 pm, Tuesday, January 15 Room: Sun Ballroom C Bob O’Hara, ResultWorks, LLC
Approach to an Information Management Framework to Support External Business Collaboration Many BioPharmaceutical companies are anxiously expanding partnerships with a variety of contract research and specialty organizations in order to cut costs, share risk, and streamline the business. Companies have been using partners (e.g., central labs, CRO’s, specialty labs, CMO’s) for many years in a wide variety of situations. However, as companies transition to a new paradigm for drug development, one that is less reliant on internal resources, the use of and the dependency on external partners is accelerating and broadening. So what happens with the information associated with externalized work? Who needs it? Who owns it? Where is it stored? How accessible is it for immediate and long-term collaboration to inform future investments? Organizations self-optimize based on their own business objectives, processes, and systems. Contract organizations strive to be more cost effective by performing similar functions and providing similar deliverables for all of their customers. Information generated and transferred by partners is optimized for decisions that need to be taken in the present by members of a given project team. Without a clear long-term informatics vision in this mixed environment, that information is no more likely to be available and useful in the future than it is today within the vertical structure of a Pharmaceutical company. If anything it will be more challenging because information governance across co-operating companies is often an afterthought. This paper explores information issues created by business collaboration strategies and outlines an approach for an information management framework based on a variety of work with several major Pharma companies.
114
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Informatics 3 pm, Tuesday, January 15 Room: Sun Ballroom C Yan Song, Abbott Laboratories; Co-Authors: Leiming Fan, Mario Richter, Abbott Laboratories
Bio-Analytical Lab Workflow and Information Systems Integration A typical bio-analytical laboratory workflow could be divided into four areas: (1) sample receiving and storage; (2) liquid extraction and plate preparation; (3) analytical data acquisition and (4) analytical data analysis and reporting. Traditionally, lab automation and information management systems have focused on the last two steps of the workflow. However, advances in LC/MS and data processing technologies have exposed sample and plate management as significant bottlenecks to the overall throughput of a bio-analytical lab. Our recent analysis reveals that it maybe possible to increase our bio-analytical lab capacity by 20 percent or more through redesign, automation and integration of existing workflow without adding new analytical equipments such as LC/MS. This paper describes our business strategy, workflow design, systems architecture and vendor products that have been evaluated and/or selected for implementation. The new capabilities and solutions consist of I.Sample Inventory Management System. Automated freezers and expanded sample inventory management software have been introduced as the pre-requisite of downstream automation. Each storage sample is collected, received and retrieved using standardized tubes with 2D bar-codes at the bottom. The 2D bar-codes are then used as unique identifiers of these samples throughout the analytical life cycleII.Analytical Method Library Management System. By regulation, bio-analytical labs must develop and validate methods prior to production use. In practice, emphasis is more on documentation than standardization. Internal procedures must be adjusted to minimize variations across studies and investigators and therefore achieve optimal quality and efficiencyIII. Integration with Watson LIMS and ELNWatson LIMS is an established industry standard for bio-analytical labs. However, it lacks the sophisticated sample and plate management functionality required by our business strategy. We have designed a new workflow and user interfaces for assay requests, sample selection, plate prep and other tasks while preserving the integrity of Watson’s analytical core. Electronic Lab Notebooks (ELN) is also leveraged and integrated to streamline documentation, QC and other manual steps.IV.Integration with Robotics Scheduling Software. Sample retrieval, liquid extraction and plate preparation are initiated by the users and executed via robotics and scheduling software in the background. Thus analysts are able to request multiple assays at the same time and/or overnight.
3:30 pm, Tuesday, January 15 Room: Sun Ballroom C David Andersen, University of Copenhagen, Department of Forensic Chemistry
Fully Automated Sample Preparation for Forensic Toxicology Analysis – Handling of Various Sample Types Including Whole Blood Samples Liquid chromatography-mass spectrometry (LC-MS) is one of the most important analytical methods in forensic chemistry. Numerous technological advances in recent years have increased the throughput and sensitivity of the LC-MS analysis. However, less effort has been spent on automation of the often cumbersome sample preparation, such as solid phase extraction (SPE), required before LC-MS analysis can be performed on biological samples. A major obstacle in the automation of sample preparation rises from the nature of the samples, which are often whole blood. Not only are the samples irreplaceable and often in limited amount, but the quality of whole blood varies greatly from relatively easy to handle fresh, anti-coagulated whole blood to viscous, partly coagulated and/or decomposed post mortem whole blood. Automated liquid handling of these valuable samples proves difficult as normal pipetting often does not transfer the desired volume or amount due to variations in sample volume, viscosity, clots etc. Knowing the exact amount of sample transferred and used in assays is crucial for obtaining reliable quantitative results. Even though various techniques such as liquid level detection, clot detection, and pressure monitored pipetting can provide some information about the pipetting event, they do not however give a quantitative measure of the actual transferred amount for each individual sample. Here we present a solution to quantitatively monitor the pipetting of whole blood and other matrices by weighing of each aliquot along with full automation of all steps typically involved in sample preparation for LC-MS. A Tecan Freedom Evo liquid handler was customized with several devices integrated on the deck, including a Mettler-Toledo XP203S balance modified for 96-well plates. Each transfer of valuable and irreplaceable forensic sample material from test tubes is weighed when transferred to 96-well plates, not only as a qualitative control that samples has been transferred, but also quantitatively as the mass is used in subsequent calculation of analyte concentration. Different approaches for the dealing with viscous samples and coagulates such as larger air gaps or wide bore tips could decrease the accuracy of the pipetting procedure and hereby the overall analysis. The gravimetric measurement eliminates this decrease in accuracy and thereby enables more features when pipetting problematic samples. The process is fully automated and transferal of 96 samples takes less than 20 minutes with weighing of each sample aliquot. Following e.g. protein precipitation or dilution can be processed with normal liquid handling without weighing. All other steps in the sample preparation including addition of internal standards, centrifugation, solid phase extraction, evaporation, and plate sealing are done without manual intervention yielding a less labor-intensive sample preparation method with a very high degree of traceability.
SLAS2013.org
I
115
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Informatics 4 pm, Tuesday, January 15 Room: Sun Ballroom C Geetha Vasudevan, Bristol-Myers Squibb Company
Integrated Informatics Solution for Biologics Discovery Research This abstract describes the approach to an integrated informatics solution for biologics at Biologics Discovery California-Bristol-Myers Squibb. The enterprise system design focuses on data acquisition, integration and knowledge management while keeping up with technology and process automation. This has led to workflow enhancements and lab process improvements. The architecture includes the following workflow and data management systems which are federated in data collection but integrated at the services and application tiers. Mice colony and their treatment management, Mice Genotyping system, Sample management, Screening automation workflow, Antibody Sequencing and Bioinformatics System, Antibody and Antigen purification, characterization workflow define the system in place. The systems have a request manager, sample manager, results and subsequently a report manager. The detail s about the architecture and IT infrastructure would be discussed in the presentation.
4:30 pm, Tuesday, January 15 Room: Sun Ballroom C Jeff Gygi, Eli Lilly and Company
A Remotely Guided Chemical Synthesis System for Discovery Chemistry Lilly has designed and constructed a unique synthesis lab directed at automating the work a medicinal chemist does at the bench. The system is far more than just bench equipment tied together via robotics; an extensive infrastructure of software, databases, and websites has been built to facilitate interactively using the system both locally and remotely from around the world. A graphical, object oriented, reaction workflow editor allows the chemist to construct reaction workflow templates. Experiment information from an electronic notebook (ELN) is then combined with the workflow in an experiment editor to facilitate creating a fully parameterized submission. The experiment is then submitted via network to the experiment manager. When an experiment begins running, the instrument controller software takes over. Experiment files are updated as the reactions progress with extensive results and data presented back to the user in near real time. The instrument controller executes each discrete task independently of other tasks as defined by task connectivity pattern which can vary from very simple linear paths to divergent or distinctly separated paths. The timing and execution of tasks is centrally governed by a complex prioritization logic that is designed to maximize throughput and resource utilization. Communication with the submitting chemist is critical. Three different systems are in place to facilitate this. A piece of software that each chemist can run, is tied into the experiment manager and allows remote viewing of experiment reaction progress, status, and results of completed tasks. In addition, the system provides e-mail updates of experiment status. The third communication component is a 32 camera video monitoring system that any chemist can remotely access at any time and view what is taking place on the system.
116
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Informatics 9:30 am, Wednesday, January 16 Room: Sun Ballroom C Andreas Matern, Thomson Reuters
Now, Where Did I Put That? The Future of Search and Findability in Scientific Data We are all inundated with data, both in our professional and personal lives. We think we are productive when we spend our days sifting through e-mail. We perform experiments which add Gigabytes of data to our corporate data warehouses. We’re being told that Big Data is going to change the way we work. Where is “search” really going? How does the consumerization of data consumption affect how we work today, and what we’ll expect of technology tomorrow? This talk will discuss some of the thoughts and research involved in analyzing structured and unstructured data and making it findable. Trends in the industry will be discussed, including Big Data and analytics, Semantics, Push and the growing ubiquity of mobile and cloud computing.
10 am, Wednesday, January 16 Room: Sun Ballroom C Will Loging, Boehringer Ingelheim
Drug Repurposing Through the Analysis of Large Corporate Chemoinformatic/Bioinformatic Databases The science of drug repositioning is an important consideration for any scientific organization. By using knowledge driven systems in the form of large data stores and applying rational in silico experimental design, researchers have generated workflows that are capable of indentifying novel uses for both newly marketed and established drugs. Both broadly accessible data, such as Medline and Chembank, in addition to a companies’ internal proprietary data in the form of gene chip experiments, compound screening databases, and clinical trial information play an important role in the success of drug repositioning. By reviewing how past successes have been accomplished along with the data use, important stratagems emerge that can provide a wealth of ideas for novel workflows to the area, as well as provide a guide for future discoveries.
SLAS2013.org
I
117
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Informatics 10:30 am, Wednesday, January 16 Room: Sun Ballroom C Thomas Chung, Sanford-Burnham Medical Research Institute
Challenges in Designing, Integrating, and Delivering a Chemical and Biological Database and Query Portal to Stakeholders Across Multiple Organizations, Locations, and Disciplines: Case Histories From Pharma and the NIH Roadmap In recent years, industry-academic partnerships have involved collaboration across disciplines, locations, and organizations. These research efforts require an effective integration of chemical and biological information, which presents key informatics, personnel, and organizational challenges. To address these challenges, the BioAssay Research Database (BARD) was conceived to serve as a community-wide resource of chemical biology data analysis and visualization tools. BARD will enable scientists to effectively utilize the National Institutes of Health (NIH) Molecular Libraries Program (MLP) data. This repository of data originating from publicly funded chemical biology research efforts will present such data in a contextual manner with structured assay and result annotations making use of the BioAssay Ontology (BAO) and a data dictionary. We will share how an inter-disciplinary team with public and private sector experience interacted to design and implement an effective solution. This solution builds upon industry best practices, several of the authors’ own experiences in private sector data integration projects, and incorporates feedback from multi-level stakeholders in the chemical biology community. We expect to deliver a beta-release of BARD to the public in March 2013.
11 am, Wednesday, January 16 Room: Sun Ballroom C Elizabeth Iorns, ScienceExchange
How Can We Reduce the Cost of Drug Discovery? It is now estimated that the cost of developing a single new drug has reached ~$4B. This is clearly unsustainable and a major obstacle to delivering effective new therapies to patients. One contributor to the very high cost of drug development is the quality of preclinical research produced by academic laboratories. Pharmaceutical companies base much of their drug development efforts on targets identified in academic laboratories. Unfortunately, ~70 percent of academic preclinical studies cannot be reproduced and the majority of target validation projects are abandoned by industry due to the inability to replicate the reported results. This very high rate of failure is a significant contributor to the cost of drug development. To solve this problem, Science Exchange, in partnership with the Public Library of Science, BioMed Central, and Nature Publishing Group, will launch the Reproducibility Initiative in August 2012. This initiative will incentivize scientists, institutions and funding agencies to validate their critical research findings via the Science Exchange network of experts (1,000+ core facilities and commercial scientific service providers). These experts conduct experiments on a fee-for-service basis and operate outside the problematic current academic incentive system. The initiative will provide independent validation of potential drug targets identified in academic laboratories, allowing industry to identify robust translatable drug targets that they can focus their drug development efforts on. This could significantly reduce the number of validation failures and as a result significantly reduce the cost of drug development. In the longer-term, it is hoped that the reproducibility initiative will promote a cultural change in replicating and validating research. Large funding agencies and government bodies should fund independent replications as well as novel studies to incentivize robust academic research. In addition, journals should reward independent validation of results. Eventually this will facilitate a culture shift towards impact of reproducibility as a key metric over novelty and lead to a much higher rate of industry validation of drug targets identified in academic laboratories. This will ultimately significantly reduce the cost of drug development.
118
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Informatics 1:30 pm, Wednesday, January 16 Room: Sun Ballroom C Barry Bunin, Collaborative Drug Discovery (CDD), Inc.
The Collaborative Drug Discovery Paradigm This presentation will provide perspectives on a career starting with the synthesis of the first historic 1,4-benzodiazepine libraries to the development of novel chemoinformatics tools to capture synthetic and biological structure activity relationship (SAR) data. There are currently hundreds of database and modeling technologies available to assist in the small molecule drug design and discovery process - each with its own scope and limitations. An entrepreneur’s perspective of the challenges associated with developing new technologies for chemists and biologists will be presented. Cloud computing and leveraging the Internet for secure collaborations are becoming more important. A more economical, collaborative business model for drug discovery has emerged. Representative case studies will be shared, including: •
NIH Neuroscience Blueprint consortia: Including AMRI, CDD, Southern Research Institute, and SRI International working with seven leading academic biology laboratories and the NIH as part of a 5-year contract.
•
The Bill and Melinda Gates Foundation multi-year CDD TB (Tuberculosis) Database Project: 250 users, 58 labs, 20 collaborations produced the following results: the two year project was extended to five years. Three projects supported were partnered with three big pharmas.
•
MM4TB EU funded collaboration with 25 partners in 13 countries including two large pharmas working together as if one organization using projects in a securely collaborate in a single CDD Vault.
•
UCLA screening center support for all campus-wide collaborations, and Rockefeller University high-throughput screening resource center for secure inter-campus collaborations.
•
Acetyton Pharmaceuticals: Harvard spinout company managing academic-industry and China CRO collaborations to IND for selective HDAC inhibitor and Series-B financing.
2 pm, Wednesday, January 16 Room: Sun Ballroom C Brian Claus, Bristol-Myers Squibb Company; Co-Author: Stephen Johnson, Bristol-Myers Squibb Company
Enabling Hit Identification With Data Mining and Advanced Computing Infrastructure As the size of screening collections grows and the screening data grows in complexity, hit identification activities provide ample opportunity for the application of advanced computing infrastructure (ACI) to better guide decisions in the early stages of discovery projects. From a pharmaceutical research perspective, this talk will focus on the analysis of data surrounding the high throughput screening process (HTS) and highlight several relevant applications of ACI both upstream and downstream of the HTS experiments. From an ACI perspective, this talk will consider cycle scavenging, cloud computing, storage performance, traditional clusters and high-end servers, as well as software techniques in the context of the scientific applications. The first application to be discussed is utilized in preparation for the HTS experiments and demonstrates the use of a multi-objective genetic algorithm (MOGA) to select on-demand, focused screening collections. The genetic algorithm facilitates the selection of plates for screening while taking into consideration all the available knowledge about a target. Using a multi-objective genetic algorithm alleviates the need for the user to bias the plate selection a priori with a predefined weighting scheme and allows the rapid investigation of multiple parameter configurations. As the therapeutic project continues through the hit identification process, we will discuss the application of Map/Reduce style calculations and the generation and utilization of a matched pair database to analyze the performance of the MOGA with the newly available screening data. This approach identifies pairs of molecules with minor structural modifications and facilitates comparison of their activities. Looking at pairs of molecules helps elucidate structureactivity relationship (SAR) hot spots and aids the scientist in navigating the data landscape. The matched pair technique also highlights related molecules for potential follow up experiments and helps identify opportunities for molecular modification to generate novel chemical entities. When coupled with cluster analysis, it also provides a feedback loop for evolving the models utilized by the MOGA for future screening collection selections. By focusing on these real world applications in the context of lead identification, this talk will elucidate computational challenges as well as the pivotal role ACI plays in enabling science and drug discovery.
SLAS2013.org
I
119
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Informatics 2:30 pm, Wednesday, January 16 Room: Sun Ballroom C Mohammed Shaikh, Bristol-Myers Squibb Company
Computing in Cloud: Challenges in Managing Logistics of Big Data and High Transaction Applications The first generation of scientific applications successfully leveraged burst computing paradigm to address the needs of compute intensive applications. Protein docking, Peptide docking, Trial simulations, Boot strapping and many more were quickly migrated to cloud to tap the compute power of large server farms. Then came the demands of managing large data sets and distributed transactions. Sequence data, compound libraries and drug design applications bring challenges of searching through large data sets and logistics of moving large data sets around. This presentation will review the successful use cases in Preclinical space and discuss the challenges in handling large data sets in the cloud. Some of the more complex simulations for PK/PD models will be discussed. These simulations are designed to access the impact of different sampling schemes on precision and bias of PD parameter estimates. Most simulations require multiple data sets and the batch programs processing these algorithms run over multiple days even when hundreds of servers are leveraged on the cloud. The presentation will discuss our experiences in configuring clinical modeling environments, logistics of managing large data sets and challenges of high transactional applications. Suitability of external cloud, internal cloud and hybrid cloud for scientific applications will be reviewed.
3 pm, Wednesday, January 16 Room: Sun Ballroom C Sean Ekins, Collaborations in Chemistry
Dispensing Processes Impact Computational and Statistical Analyses We have recently described how independent groups have identified errors across various internet databases used for biomedical research, including small molecule databases. Molecule structural integrity and quality of high throughput screening (HTS) data in such databases will also impact future directions of R&D. As an example, data for 14 molecules from AstraZeneca patents (WO 2009/010794 Al and US 7718653 B2) with IC50 data (half maximal inhibitory concentration measuring the effectiveness of a compound in inhibiting biological or biochemical function) derived using traditional disposable tip-based dispensing or the Echo¨ acoustic dispensing system were compared using different computational and statistical approaches. A 3D pharmacophore was developed using Accelrys Discovery Studio (v2.5.5. San Diego, CA) for each dataset. The best pharmacophore for the acoustic dispensing data included two hydrophobic features, a hydrogen bond acceptor (HBA) and hydrogen bond donor (HBD) (observed vs predicted IC50 r = 0.90). The best pharmacophore for the traditional aqueous dispensing pharmacophore consisted of two HBA and one HBD (observed versus predicted IC50 r = 0.80). All 14 IC50 values derived by each method were used to correlate with molecular descriptors using SAS JMP (v8.0.1, SAS, Cary, NC). cLogP and LogD showed a statistically significant Spearman rho ranking with the acoustically determined IC50 data only. We found no statistically significant correlation for the dispensing methods. These results suggest that the dispensing system is important and influences computational models and structure activity relationships. It appears that acoustic dispensing could improve HTS and avoid misleading computational models while increasing R&D efficiency.
120
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Micro/Nano Technologies 10:30 am, Monday, January 14 Room: Sun Ballroom D Andrew Griffiths, Institut de Science et d’Ingénierie Supramoléculaires
High-Throughput Screening of Small Molecules and Proteins in Droplets Programmable microfluidic modules have been created which can precisely make, combine, split, mix, incubate, detect fluorescence and fluorescence anisotropy, and sort microscopic droplets. All microdroplets are identical and stable, allowing for quantitative experiments, and sequential additions, which enables reactions to be started and stopped at defined times and reagents to be mixed. Integration of multiple modules onto a single microfluidics chip enables a vast number of assays (>10,000 per minute) to be performed using extremely low volumes of reagents. Each microdroplet functions as an independent microreactor separated from both the walls of the device and other microdroplets by a fluorinated carrier fluid. This technology has many potential applications in both fundamental and applied research. Here we highlight it’s application for protein engineering for industrial biotechnology applications, and high-throughput screening of small molecules and antibodies for drug discovery.
11 am, Monday, January 14 Room: Sun Ballroom D Darren Link, RainDance
FI NALIST
Genomic Applications of Droplet Microfluidics Genome sequence germline and somatic variations along with epigenomic modifications (DNA methylation) are associated with a significant proportion of human disease. As researchers drive to further understand the role of genomics in disease there is a need for new genomics tools to rapidly and precisely detect, quantify and monitor genomic loci. To meet these analytical demands, RainDance Technologies is developing droplet microfluidic technology to build new tools. The first of these tools is for targeted sequencing and provides a method for uniformly enriching up to 20,000 different target portions of an individual’s genome prior to DNA sequencing analysis. Enrichment is achieved by preparing 2.5 million parallel PCR reactions in picoliter droplets. This automated and scalable process has low amplification bias and a simple workflow enabling high-quality targeted sequencing performance. A second tool is for digital PCR and provides a means to partition each sample into 10 million 5 picoliter droplets. The large number of divisions ensures that most compartments contain one or zero copies of the genomic fragment of interest as well as sequence-specific fluorescence assays. After PCR amplification, detection of fluorescence from each droplet enables precise counting of the number of target molecules present in the original sample. This digital PCR tool provides high sensitivity and absolute quantification of one or more molecular targets in parallel. In this presentation I will introduce the basic concepts of droplet microfluidics and associated technology for targeted sequencing and digital PCR that enable the characterization and quantification of DNA samples.
SLAS2013.org
I
121
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Micro/Nano Technologies 11:30 am, Monday, January 14 Room: Sun Ballroom D Brian Paegel, The Scripps Research Institute
FI NALIST
Building the Foundation of Next-Generation Distributed Drug Discovery The NIH established the Molecular Libraries Program (MLP) and its network of HTS centers to discover small molecule probes for studying biological function and as therapeutic leads for targets spanning the newly-sequenced human genome. However, after 7 years, > $400 million invested, and < 200 probes discovered, the original vision of genome-wide probe discovery remains unattainable in light of the significant logistic and financial liabilities of centralized robotic HTS. We aim to meet this lofty challenge by inventing a next-generation distributed drug discovery platform based on (1) efficient, ultra-low-scale solid phase synthesis of portable and disposable compound libraries, and (2) a single benchtop instrument that integrates all compound management, dispensing, and screening operations. We have developed split-and-pool solid-phase synthesis methods for accessing libraries of polyketide-inspired, natural product-like structures. The compounds feature numerous sp3 centers with multiple structural and stereochemical isomers. Synthesis occurs on 10-µm-dia particles, representing one billion potential compounds per gram of resin and 100 fmol each compound/bead. The infinitesimal per-bead yield and structural complexity preclude conventional mass spectrometric structure elucidation. Instead, we have developed genetically-encoded solid-phase synthesis on bifunctional resins that support both photolabile compound coupling sites and enzymatic DNA codon ligation sites. The resulting particles each display ~1,000 copies of a unique genetic signature that is accessible via PCR and sequencing. Dropletbased microfluidic automation provides the centerpiece functional screening technology to pair with the genetically-encoded libraries. We have developed new microfluidic components capable of sedimentation-mediated loading of 100,000 beads into individual picoliter-scale droplet of assay reagent, programmable in situ photochemical droplet dosing (0.01 - 10 µM compound in a given droplet), and droplet incubators with integrated oil removal and reinjection. We coupled these advances with established fluorescence-activated droplet sorting technology in a prototype circuit and instrument that integrates compound library distribution, dosing, and screening at the fmol scale. This new mode of small molecule discovery will require neither the vast staff and space of a conventional HTS facility, nor the outrageous quantities of expensive assay reagents. The solid phase libraries obsolete current compound library quality control and maintenance infrastructure because they are disposable and managed exclusively by the microfluidic instrumentation. Droplet-based manipulation allows fmol-scale functional screening while using minute quantities of screening reagent and requiring no robotics or plate readers. This platform is potentially distributable to laboratories worldwide, raising the possibility of genome-wide probe discovery through economy of scale.
12 pm, Monday, January 14 Room: Sun Ballroom D Christopher Easley, Auburn University
Combining Picoliter-Scale Droplet Sampling With Proximity Immunoassays for Direct Measurement of Hormone Secretion From Small Amounts of Endocrine Tissue Microfluidic systems provide unique benefits for interrogating small samples of tissue. For example, our laboratory has applied microfluidic aqueous-in-oil droplet formation to the sampling and measurement of zinc secretion from murine pancreatic islets at high temporal resolution (~1 s). However, without concurrent development of small volume protein or peptide assays, these systems will find limited use. Here, we present the development of a novel proximity immunoassay for protein detection in small volumes with direct fluorescence readout. This assay, termed the proximity FRET assay (pFRET) is capable of selectively detecting insulin with a detection limit of 300 pM using only direct fluorescence readout. Further, the assay is amenable to detection of any protein with an available pair of antibodies. Importantly, pFRET is ideal for integration with microfluidic droplet sampling of endocrine tissue. Starting with aptamer-based pFRET and microfluidic droplet sampling, preliminary experiments show that we can detect 20 nM human thrombin in 100 pL droplets (= 2 amol = 72 fg) with a direct fluorescence readout. Our microfluidic secretion sampling systems have been shown capable of sampling from both pancreatic tissue (islets of Langerhans) and from 3D cultures of fat tissue (adipocytes), with ELISA-based measurement of insulin and adiponectin secretion, respectively. These systems are currently being combined with the droplet sampling systems and pFRET assays. While we are particularly interested in uncovering the nature of rapid adiponectin secretion from adipocytes, the integrated system should provide a unique and generalizable platform for interrogating the dynamics of hormone secretion from various types of tissue at small scales.
122
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Micro/Nano Technologies 3 pm, Monday, January 14 Room: Sun Ballroom D FI NALIST
Amy Herr, University of California, Berkeley
Talking About a (Proteomics)Revolution: Microfluidic Frameworks for High-Throughput Protein Analysis Technology advances have driven a genomics revolution with sweeping impact on our understanding of life processes. Nevertheless, the arguably more important “proteomics revolution” remains unrealized. Proteins are complex; meaning that multiple physicochemical properties must be assayed. Consequently, proteomic studies are resource intensive and ‘data limited’. To drive a bold transformation of biomedicine, engineering innovation in proteomics instrumentation is needed. While microfluidic technology has advanced separations science, progress lags in the multi-stage separations that are a hallmark of proteomics. This talk will summarize new microengineering design strategies for critical multi-stage protein assays. Specifically, I will introduce our tunable photopatterned materials for switchable function, microfluidic architectures for seamless integration of discrete stages, and multiplexed readouts for quantitation. In a translational example, I will detail assay and design advances from our two highly integrated Western blotting platforms. Focus will center on next-generation confirmatory HIV diagnostics. In a life sciences example, I will highlight our recent contributions to protein isoform measurements, here for new prognostic cancer biomarkers and biospecimen repository monitoring. Performance and operational gains will be discussed, including quantitation capability, total assay automation, integration of sample preparation, and workflows that require minutes not days. Ultimately, we aim to infuse engineering advances into the biological and biomedical sciences - collaboration that promises to address a range of unmet scientific, biomedical, and societal needs.
3:30 pm, Monday, January 14 Room: Sun Ballroom D Dana Spence, Michigan State University
A Microfluidic-Based In VitroPK/PD System: Advantages and Challenges A significant effort has recently been put forth by several laboratories to develop microfluidic devices that enable in vivo processes to be performed using controlled, in vitro platforms. Of course, in order to obtain meaningful data with these in vitro devices, the integration of various components (both biological and physical) into these devices is required. Biological components may include cells, tissue, and blood flow while physical components may include systems that control fluid movement, temperature, dissolved gases, and detection. Our group has had a long-standing interest in devices that enable meaningful in vitro measurements, particularly those involving communication between multiple cell types on singular devices. In accordance with recent government mandates, our group is now applying our past experiences involving cellular assays and microfluidic devices to facilitate the drug discovery process. In this presentation, data will be shown that strongly suggests microfludic devices may serve as an excellent in vitro pharmacological tool. Specifically, one of the most important measurements in the drug discovery process is the pharmacokinetic (PK) and pharmacodyanmic (PD) profile. After obtaining these profiles in animal models, in vitro models are often used to mimic the PK profile to learn more about the PD effects on the cell or tissue targets. Unfortunately, current in vitro models suffer from limitations; many of these models are static and consume large volumes of reagent (liters, in some cases). Many of the dynamic models enable a gradient-like reduction in drug concentration interacting with the cells or tissue of interest, but post-profile analysis of the biological target is difficult. Here, a microfludic in vitro PK/PD system will be described that enables a dynamic, gradient-driven generation of a PK profile. In addition, this system enables real-time evaluation of the biological target (e.g., adherent cells) and direct access to the cells for post-dosing analysis. Importantly, unlike current in vitro PK/PD systems, a microfluidic-based system is amenable to automation and enables multiple profiles to be obtained on the same device, simultaneously, thus overcoming the low throughput of current devices. Demand on synthetic chemists for high amounts of drug molecule candidate is also reduced due to the sub-milliliter volumes consumed during the generation of the PK curves.
SLAS2013.org
I
123
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Micro/Nano Technologies 4 pm, Monday, January 14 Room: Sun Ballroom D Coleman Murray, University of California, Los Angeles
Massively Parallel Nanoparticle Manipulation With Micro-Magnetic Ratcheting System for Biological Exploration Richard Feynman in his discussion of the promise of nanotechnology discussed the concept of “a hundred tiny hands” where motions at the human scale could be de-amplified to the microscopic scale, thus allowing users to interface with microscale systems. Particularly, these capabilities would aid in the spatial exploration of biological systems, such as cells and bacteria. In turn, this can further our understanding of intracellular processes of cells, such as transcription or protein production, which are often sequestered to specific locations within a cell. To address the need to explore the cell spatially, we have developed a micromanipulation system which can maneuver superparamagnetic nanoparticles with high precision for massively parallel interrogation of biological systems. The device is comprised of three main components; a solution of dextran coated superparamagnetic iron oxide nanoparticles, a microarray of coated 80/20 permalloy micro-pillars on a transparent slide, and a mechatronic system which controls the orientation of a 0.5 T rare earth magnet. When the rare earth magnet is brought within close proximity to the microarray, the permalloy pillars magnetize in alignment with the bulk field. In response to the micromagnetic field within the pillars, the superparamagnetic nanoparticles will coalesce at the micromagnetic field maxima. As the orientation of the rare earth magnet is changed the nanoparticles can be manipulated to different positions or continuously moved within the microarray with the shifting field maxima. The device was able to achieve a manipulation resolution of 1.47 ± 0.0613 µm and a speed of approximately 23.8 ±3.04 µm/s across the active substrate demonstrating a proof of concept for a massively parallel micromanipulation system. As a preliminary application of this system, we plan to internalize and then pilot the nanoparticles within living HeLa cells in order to explore the effect of localized chemical and mechanical stimuli on cellular processes. We believe this system can be developed into a powerful tool for the research community, allowing scientists and biologists to explore specific intercellular processes at high resolution and in a massively parallel manner.
4:30 pm, Monday, January 14 Room: Sun Ballroom D Yanli Liu, Sandia National Labs
Directed Secretion of Mast Cells Revealed by Selective Stimulation in a Laminar Flow-Based Microfluidic Device Polarization is a common theme in intracellular signaling. However, currently available analytical tools to decipher the mechanism of directed secretion are very limited. The hurdles include a lack of quantitative measurement of released chemical mediators and poor control of stimulating reagents at spatio-temporal dimensions with sub-cellular resolution. We proposed to use a laminar flow-based microfluidic device to partially treat live cells with chemical reagents so that the distribution of involved intracellular proteins from the stimulated regions of mast cells could be visualized and secreted chemical mediators from different regions could be compared spectrometrically. The microfluidic chip was fabricated using conventional wet-etching and photolithography. It was integrated with accessories such as electronic control valves, activated pressure controllers and digital heaters into a bench-top, automated device that maintains cell viability and enables precise delivery of reagents to specific part of cells. We patterned 20-30 rat basophile leukemia (RBL-2H3) cells on the floor of the channel in a single cell file by hydrodynamic focusing. One side of RBL cells were challenged with multivalent DNP-BSA while the other side of the cells were exposed to the stream containing Hank’s buffered saline. After 5 minutes of stimulation, we observed directed clustering of IgEFceRI complexes in the contact region. We further captured polarized tyrosine phosphorylation and directed organization of microtubule organizing center (MTOC) by intracellular immunostaining and microscopic imaging. To quantitate the released b-hexosaminidase upon 15 minutes of continuous stimulation, the supernatants were collected simultaneously from two sides of the cells. Fluorgenic enzymatic analysis of the supernatants showed that RBL cells secreted b-hexosaminidase only from the contact area. For the first time, we demonstrated a quantitative analysis of the secretory repertoire of mast cells specifically from the contact region between external stimuli and the specific region of RBL cells in real time with sub-cellular resolution.
124
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Micro/Nano Technologies 10:30 am, Tuesday, January 15 Room: Sun Ballroom D Jeff Karp, Harvard University
Nano-Devices for Next Generation Stem Cell Therapeutics, Medical Adhesives, and Drug Delivery Systems This talk will explore platform nano-technologies that are currently being developed in the KarpLab to tackle some of the most challenging medical problems. Namely, controlling and monitoring cell fate and function following transplantation, sealing tissues/closing wounds, achieving long term local drug delivery for treatment of diseases such as rheumatoid arthritis and glioblastoma, development of surfaces to separate cells for disposable point of care diagnostics and for cell therapy, and needles that sense different levels of tissue for the delivery of cells and drugs.
11 am, Tuesday, January 15 Room: Sun Ballroom D Dan Peer, Tel Aviv University
Assessing Cellular Toxicities Upon Exposure to Different Types of Nanomedicines: A High Content Analysis Approach Lipid-based nanoparticles (LNPs) are widely used for the delivery of drugs and nucleic acids. Although most of them are considered safe, there is confusing evidence in the literature regarding their potential cellular toxicities. Moreover, little is known about the recovery process cells undergo after a cytotoxic insult. We have previously studied the systemic effects of common LNPs with different surface charge (cationic, anionic, neutral) and revealed that positively charged LNPs ((+) LNPs) activate pro-inflammatory cytokines and induce interferon response by acting as an agonist of Toll-like receptor 4 on immune cells. Here, I will focuse on the response of human fibroblasts exposed to LNPs and their cellular recovery process. To this end, I will described the use of image-based high content analysis (HCA). Using this strategy, we were able to show simultaneously, in several intracellular parameters, that fibroblasts can recover from the cytotoxic effects of (+) LNPs. The use of HCA, which represent a novel concept in automated lab screening capabilities, opens new avenues in understanding cellular response and nanotoxicity and may become a valuable tool for screening safe materials for drug delivery and tissue engineering.
SLAS2013.org
I
125
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Micro/Nano Technologies 11:30 am, Tuesday, January 15 Room: Sun Ballroom D Omid Farokhzad, Harvard Medical School
Engineering of Polymeric Nanoparticles for Medical Applications A variety of organic and inorganic materials have been utilized to generate nanoparticles for drug delivery applications, including polymeric nanoparticles, dendrimers, nanoshells, liposomes, nucleic acid based nanoparticles, magnetic nanoparticles, and virus nanoparticles. The two most commonly used systems are polymeric nanoparticles and liposomes [1, 2]. Controlled release polymer technology has impacted virtually every branch of medicine, including ophthalmology, pulmonary, pain medicine, endocrinology, cardiology, orthopedics, immunology, neurology and dentistry, with several of these systems in clinical practice today such as Atridox, Lupron Depot, Gliadel, Zoladex, Trelstart Depot, Risperidol Consta and Sandostatin LAR. The annual worldwide market of controlled release polymer systems which extends beyond drug delivery is now estimated at $100 billion and these systems are used by over 100 million people each year. Polymeric nanoparticles can deliver drugs in the optimum dosage over time, thus increasing the efficacy of the drug, maximizing patient compliance and enhancing the ability to use highly toxic, poorly soluble, or relatively unstable drugs. These systems can also be used to co-deliver two or more drugs for combination therapy [3]. The surface engineering of these nanoparticles may yield them “stealth” to prolong their residence in blood [4] and the functionalization of these particles with targeting ligands can differentially target their delivery or uptake by a subset of cells [5], further increasing their specificity and efficacy [6]. The successful clinical translation of therapeutic nanoparticles requires optimization of many distinct parameters including: variation in the composition of the carrier system, drug loading efficiency, surface hydrophilicity, surface charge, particle size, density of possible ligands for targeting, etc., resulting in a large number of potential variables for optimization which is impractical to achieve using a low throughput approach. More recently combinatorial approaches have been developed to precisely engineer nanoparticles and screen multiple nanoparticle characteristics simultaneously with the goal of identifying formulations with the desired physical and biochemical properties for each specific application [7]. The goal of this talk is to review our efforts in the design and optimization of polymeric nanoparticles for medical applications, which formed the foundation for the clinical translation of the first-inhuman targeted and controlled-release nanoparticles (BIND-014) for cancer therapy [8]
12 pm, Tuesday, January 15 Room: Sun Ballroom D Edward Chow, National University of Singapore
Targeted Nanomedical Approach to Screening and Enhanced Treatment of Cancer Stem Cell-Driven Tumors Even within the same tissue, cancers can vary greatly amongst patients and these variations can affect the response of the disease to conventional treatment. Understanding the underlying mechanisms by which cancer develops is important to improving screening and therapeutic options for this deadly disease. In recent years, a population of cells, identified as cancer stem cells (CSCs), has shown the potential to be integral to cancer initiation and progression. Sharing properties of self-renewal and differentiation with normal stem cells, CSCs have enhanced tumor initiating properties as well as other characteristics such as chemoresistance. In hepatic cancer, CSCs have been identified by a number of different external and internal markers in hepatic cancer cell lines and primary human hepatic tumor samples. Conflicting reports may arise from different driving oncogenes in the heterogeneous samples analyzed. Utilizing oncogene-specific mouse models of cancer, we have found that specific oncogenes may promote different identifiable characteristics in hepatic CSCs. These oncogenes may also mediate different mechanisms of CSC formation and maintenance that can be exploited when developing therapeutics. Utilizing a nanodiamond (ND) based drug-delivery platform, we have developed and evaluated targeted ND-drug complexes that can be used to identify cancer cells and overcome mechanisms of chemoresistance that are common in CSCs. Because the properties of nanodiamonds promote biocompatibility, hydrophilicity and the ability to bind a wide range of molecules, a nanodiamond drug-delivery approach allows for the development of a single versatile therapy system with the potential to treat a number of different oncogenespecific tumors. The approach presented here provides a comprehensive analysis of the fundamental mechanisms behind tumorigenesis by CSCs as well as an evaluation of a personalized targeted nanomedical approach based on the expression of specific CSC markers and oncogenes as a viable method of cancer screening and treatment.
126
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Micro/Nano Technologies 3 pm, Tuesday, January 15 Room: Sun Ballroom D Shu Takayama, University of Michigan
Microfluidic Models of the Body and Microfluidic Biomarker Analysis Many biological studies and drug assays require culture and manipulation of living cells outside of their natural environment in the body. The gap between the cellular microenvironment in vivo and in vitro, however, poses challenges for obtaining physiologically relevant responses from cellular drug screens and for drawing out the maximum functional potential from cells used therapeutically. One of the reasons for this gap is because the fluidic environment of mammalian cells in vivo is microscale, 3D, and dynamic whereas typical in vitro cultures are macroscopic, 2D, and static. This presentation will give an overview of efforts in our laboratory to develop microfluidic systems that enable spatio-temporal control of both the chemical and fluid mechanical environment of cells as well as efficient and high throughput 3D culture. The technologies and methods close the physiology gap to provide biological information otherwise unobtainable and to enhance cellular performance in therapeutic applications. One major challenge for utilization of such microfluidic models of the body once built is analysis. Although more convenient to image and sample fluids compared to animals or humans, microfluidic models still face challenges for accurate quantification of molecular biomarkers contained in small volumes of complex biofluid solutions. The talk presents some recent technologies to perform biochemical analysis of metabolic and protein biomarkers from small volume samples of microfluidic models of the body as well as from patients. Specific biomedical topics that are discussed include, in vitro fertilization on a chip, lung-on-a-chip, engineered 3D micro-tumors, and multiplexed microfluidic protein biomarker analysis.
3:30 pm, Tuesday, January 15 Room: Sun Ballroom D Salman Khetani, Colorado State University
Engineered Models of Liver Disease The liver plays a central role in several diseases, including diabetes (type 2), drug toxicity and hepatitis C. Animal studies ultimately only provide a limited view of human-relevant responses due to species-specific differences in liver functions. Human liver cells (i.e. hepatocytes) either isolated from donor organs or derived from a patient’s stem cells could potentially address this species gap; however, these cells rapidly lose their phenotypic functions when put in conventional culture systems utilizing simple extracellular matrix manipulations. The convergence of semiconductor-driven microtechnology tools with the biomedical arena now offers the opportunity to fabricate microscale tissue subunits towards improving the phenotypic stability of in vitro cultures. As with DNA microarrays, microtechnology also offers the potential to revolutionize biological assays simply through the benefits of miniaturization. We have utilized microtechnology to manipulate, optimize and mechanistically probe the interactions of hepatocytes and stroma towards improving and miniaturizing models of human liver physiology and diseases. In particular, we developed a liver model with precise microscale cyto-architecture and optimal stromal interactions that displays phenotypic stability for several weeks in vitro (micropatterned co-cultures, MPCCs). MPCCs were miniaturized into a high-throughput format and optimized for screening drug-induced liver injury using automated multiplexed imaging and other biomarkers. The toxicities and mechanisms of clinical liver toxins have been studied in MPCCs under chronic dosing regimens to assess concordance with clinical outcomes. Disease models of MPCCs are also under development for molecular investigations and the discovery of therapeutics. For instance, we have shown that aspects of glucose metabolism, important in type 2 diabetes, are retained in MPCCs and reflect the in vivo diabetic phenotype. In the future, MPCCs may find utility in the development of therapeutics, in evaluating the injury potential of chemical pollutants, in mechanistic research, and in personalized medicine for liver diseases. Continued merging of microtechnology with tissue engineering may spur the development of other organ models and their integration into the so-called “human-on-a-chip”.
SLAS2013.org
I
127
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Micro/Nano Technologies 4 pm, Tuesday, January 15 Room: Sun Ballroom D David Eddington, University of Illinois at Chicago
Microfluidic Oxygenated Substrates for Cells and Tissues My lab has designed, fabricated, and validated a suite of devices to easily and accurately regulate oxygen levels in cellular cultures and tissues within standard culture formats such as multiwell plates, Boyden chambers, and 3D cell matricies. Oxygen can be delivered or extracted to the cells via simple diffusion and is rapid due to the microscale distances separating the oxygen microchannels from the cell cultures or tissues. This oxygen can also be patterned onto anatomical regions of tissue, in gradients across a substrate, or cyclic profiles of high or low oxygen. In addition, due to the rapid equilibration time, intermittent hypoxia profiles or ischemia reperfusion studies are easy to perform in a format compatible with fluorescence microscopy for real time analysts of cell or tissue function. We are applying these devices with researchers studying topics varying from insulin release from islets under hypoxia, strokes in acute brain slice preparation, and ROS signaling pathways.
4:30 pm, Tuesday, January 15 Room: Sun Ballroom D Jie XU, Abbott Laboratories
A Bjerknes Force Based Microfluidic Platform for On-Chip Trapping, Enriching, Sorting and Manipulating Caenorhabditis Elegans Efficient manipulation of micro objects, including trapping, transporting, separating and concentrating, is the most sought-after task in lab on a chip devices. C. elegans is one of the most ubiquitous lab animals used in biomedical research, and this worm often needs to be selected, sorted or immobilized during experiments. The existing technologies for processing C. elegans include mechanical tweezers, optical and electrica sorting methods and pneumatic control. Here, we report for the first time the use of Bjerknes force, or secondary acoustic radiation force, from an array of acoustically actuated microbubbles as a novel technique to perform on-chip worm processing, which includes trapping, enrichment, size-based sorting, and motion manipulation of C. elegans. The advantage of using Bjerknes force in microfluidics is that it is a non-contact, non-electric approach. The Bjerknes force exists in the vicinity of an oscillating bubble owing to the mechanical perturbations that get scattered by the bubble. The response of an object to the Bjerknes force can be attractive or repulsive depending upon its density. In the experiment, we found that, upon application of a specific frequency, C. elegans is drawn toward an oscillating bubble and trapped around the bubble. By flowing C. elegans through an array of oscillating bubbles, we achieved enrichment of these worms by trapping them in the bubble zone. The effectiveness and efficiency of the enrichment have been quantified. For the purpose of sorting worms based on their sizes, we devised a simple mechanism: we first trap all the worms irrespective of their sizes and then gradually lower the actuation intensity. The big-sized worms are observed to escape first and then the smaller-sized worms too. Once a desired size of worms is selectively released from the trapping zone, a gentle flow can be used to push them into the collection ducts. The different sized C. elegans ranging from L1, L2, L3, L4 to the adults could be conveniently trapped and separated using this simple method. In the end we demonstrate that the swim path of single worms can be manipulated using the same oscillating microbubble array. To do so, the acoustic actuation is turned on and off with good timing so that the worm’s swimming path can be adjusted by the Bjerknes force. In summary, we demonstrated for the first time that Bjnerkes force from an array of acoustically actuated microbubbles is a viable technique to realize several important processes on C. elegans, including trapping, enrichment, size-selection and pathway manipulation. We believe that this simple and cost effective technique can be further improved and easily adapted for future lab on a chip and biomedical applications.
128
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Micro/Nano Technologies 9:30 am, Wednesday, January 16 Room: Sun Ballroom D Hang Lu, Georgia Institute of Technology; Co-Authors: Matthew Crane, Adriana San Miguel, Jeffrey Stirman, Mei Zhan, Georgia Institute of Technology
Autonomous Screening of C.elegans Using Advanced MIcrofluidics and Machine Vision Microscopy is a powerful tool widely used to investigate the biology of cells, tissues, and organisms. Combining imaging with artificially induced perturbations (e.g. mutations, siRNA treatment, or drugs) allows studying the function of genes, RNAs and proteins and can serve to identify remedies to dysfunctions in these systems. Automated screening of whole organisms through the use of a modified FACS system or multiwell-plate methods, have increased imaging and screening throughput but have lagged behind in their capacity to identify subtle phenotypes of interest, as they are low-resolution technologies. A primary obstacle is that automated screening requires equipment that can robustly handle large sample numbers and a system for extracting and interpreting high-content imaging data. Here we present a system for performing autonomous screens based on high-content quantitative morphometric features in C. elegans. The system combines a microfluidic device, computer-vision tools, and a statistical framework to classify animals. The microfluidic device allows animals expressing a fluorescent reporter to be imaged and sorted rapidly. The acquired images are processed to identify the fluorescently-labeled objects of interest using a two-stage computer-vision algorithm, and quantitative phenotypical descriptors are extracted and used to predict whether the animal has a pattern of interest. Finally, the microfluidic device sorts the identified mutants. Using this integrated system, we performed an autonomous forward screen in search for new classes of mutants affecting synaptogenesis. We screened at a sustained rate of over 100 haploid genomes per hour and identified a novel phenotype too subtle to be reliably identified by eye along with many alleles with similar phenotypes to known mutants. These genes could potentially become targets for drugs that remediate neural developmental diseases and diseases in learning and memory. We foresee applying these technologies to additional forward genetic, RNAi, or drug screens in many contexts to help find more genes and interactions than previously possible.
10 am, Wednesday, January 16 Room: Sun Ballroom D Matthew Stewart, Diagnostics For All; Co-Authors: Patrick Beattie, Paul Shaw, Diagnostics For All
Paper-Based Bovine Progesterone Tests for Improving the Productivity of Smallholder Farmers in Resource-Constrained Settings Dairy farming is an important agricultural activity in the developing world. The majority of dairy farmers in developing rural areas are smallholder farmers with an average herd size of 2-4 cows and less than 2 hectares of land. Dairy farmers can maximize milk production and income by minimizing the amount of time cows spend in an “open” (i.e., non-pregnant) state. Traditional methods for detecting estrus rely on monitoring behavioral changes of cows, however, these indicators are not readily apparent in small herds on small farms. Diagnostics For All is developing a low-cost, paper-based point-of-care test based on a competitive immunoassay for detecting progesterone levels in cows from an ear or tail-stick drop of blood. The test will enable smallholder farmers to detect when a cow is entering or exiting estrus and when to artificially inseminate cows to keep them in a milk producing state. This simple test could allow smallholder farmers to improve dairy production, reduce costs, increase income, and bolster the local economy.
SLAS2013.org
I
129
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Micro/Nano Technologies 10:30 am, Wednesday, January 16 Room: Sun Ballroom D Alexander Price, The Scripps Research Institute
Picoliter-Scale Compound Library Distribution and Assays Conventional high-throughput screening (HTS) facilities are built around an expensive and complicated robotic infrastructure for compound library maintenance and distribution in microtiter plates. This compound management and screening paradigm, which operates at the microliter-scale, also carries exorbitant costs related to large-scale compound synthesis and assay reagent consumption. We are engineering next-generation HTS strategies for femtomole-scale compound synthesis, picoliter-scale assays, and a microfluidic infrastructure that eliminates all robotics and microtiter plates in favor of a single device and instrument. We have developed a microfluidic circuit that distributes beads displaying compound into ~100-pL droplets. Each compound library member is synthesized step-wise on the surface of a bead that has been functionalized with a photolabile linker. Library beads are fed into the device via sedimentation from a capped cartridge and deposited into droplets of assay reagent. The cartridge can stochastically distribute 100,000 beads into droplets in ~2 h using 40 µL of assay reagent; 22 percent of droplets contain beads, and 81 percent of those droplets contain a single bead. Subsequent linker photolysis dispenses compound throughout the entire droplet volume in a UV dose-dependent fashion. We demonstrate this concept with a rhodamine-labeled peptide model and then measure the activity of the HIV-1 protease on a fluorogenic peptide substrate in the presence of inhibitor-bearing beads to calculate the droplet-scale assay Z-factor. By obviating the need for microtiter plates and the robotics that manage them, large-scale HTS can be “crowd-sourced” across hundreds of laboratories to accelerate small molecule discovery.
11 am, Wednesday, January 16 Room: Sun Ballroom D David Beebe, University of Wisconsin-Madison
FI NALIST
Kit-On-A-Lid-Assay: Self-Contained Microfluidic Cell-Based Assays for the Masses Cell-based assays are essential tools for drug discovery, cancer biology, and toxicology. However, the traditional cell culture process requires extensive training and assay characterization, equipment, and reagents. Traditional assays require labor intensive preparation, and large volumes of often expensive reagents. The Kit-On-A-Lid-Assay (KOALA) technology simplifies cell-based assays, lowers costs for the user, increases throughput, and reduces the barriers to performing cell-based assays. KOALA is a microfluidic cell-based assay technology that integrates all aspects of in vitro assays (fluid handling, cryopreservation, pre-packaging of cells and reagents) and operates passively, without the need for electronic or mechanical actuators. KOALA integrates two core components, namely a lid and a base. The lid contains microchannels where the cell culture is performed and bases that contain pre-packaged frozen reagents/cell suspensions and an absorbent pad. When the lid and base are brought together, the microchannels contact the reagents (e.g. staining solutions, cell suspensions), thereby initiating flow through the channel, and into the pad. The modular design of KOALA allows for a variety of lids and bases. For example, a dialysis base allows cryopreservation and thawing of cells by simply removing the base from the freezer and applying the appropriate lid. Specifically, the cryopreservation base thaws and prepares the cells by dialyzing away the cryopreservation media and replacing it with fresh media. We have observed greater than 70 percent viability for HEK293, HUVEC, 3T3, and BEAS-2B cells. The KOALA system is capable of housing channels for a variety of assays including drug screening assays, toxicology testing platforms and chemotaxis assays. To date, we have developed and tested bases that perform serial dilutions and gradient generation. We also demonstrate 60 assays within a 1x3in footprint for screening assays and high throughput applications. Traditional methods for performing 60 assays requires reagent preparation and a minimum of 60 pipette actuations for each step (e.g. washing, fixing, staining), which typically requires 15 - 30 minutes to complete. In comparison, KOALA enables 60 assays to be performed with minimal preparation and in one short step. While incubation times are the same between platforms, KOALA provides a significant reduction in time/effort by performing 60 fluid transfers in parallel in a single operation (as compared to 60 discrete pipetting operations). Overall, the KOALA simplifies cell-based assays such that anyone can perform them - the only operation is to place a lid (or series of lids) onto a base. KOALA enables prepackaging of reagents and cryopreserved cells, thereby eliminating the need for purchasing large volumes of expensive reagents. The KOALA expands the use of cellbased assays enabling labs with limited/no cell culture capabilities to perform cell-based experiments.
130
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Micro/Nano Technologies 1:30 pm, Wednesday, January 16 Room: Sun Ballroom D Sadik Esener, University of California, San Diego; Co-Authors: Inanc Ortac, Michael Benchimol, Stuart Ibsen, University of California, San Diego
Cancer Therapeutics Based on Smart Nanoparticles Nanoparticle based drug delivery can reduce the side effects of chemotherapies that are used to treat cancerous tumors. Encapsulation of therapeutic agents within nanoparticles can protect the payload from the immune system, and increase their accumulation in the tumor region while reducing the exposure to normal cells. This presentation will focus on the encapsulation of enzymes of non-human origin in nano-carriers and their delivery to tumor microenvironment to enable enzyme facilitated therapies. Means of externally targeting the nano carriers to the tumor will be discussed and illustrated with experimental results.
2 pm, Wednesday, January 16 Room: Sun Ballroom D Aydogan Ozcan, University of California, Los Angeles
Lens-Free On-Chip Microscopy and Tomography Toward Telemedicine Applications Today there are more than 5 billion cell-phone users in the world, and the majority of these cell phones are being used in the developing parts of the world. This massive volume of wireless phone communication brings an enormous cost-reduction to cell phones despite their sophisticated hardware and software capabilities. Utilizing this advanced state of the art of the cell phone technology towards pointof-care diagnostics and/or microscopic imaging applications can offer numerous opportunities to improve health care especially in the developing world where medical facilities and infrastructure are extremely limited or even do not exist. Centered on this vision, in this talk I will introduce fundamentally new imaging and detection architectures that can compensate in the digital domain for the lack of complexity of optical components by use of novel theories and numerical algorithms to address the immediate needs and requirements of Telemedicine for Global Health Problems. Specifically, I will present an on-chip cytometry and microscopy platform that utilizes cost-effective and compact components to enable digital recognition and 3D microscopic imaging of cells with sub-cellular resolution over a large field of view without the need for any lenses, bulky optical components or coherent sources such as lasers. This incoherent holographic imaging and diagnostic modality has orders of magnitude improved light collection efficiency and is robust to misalignments which eliminates potential imaging artifacts or the need for realignment, making it highly suitable for field use. Applications of this lens-free on-chip microscopy platform to high-throughput imaging and automated counting of whole blood cells, monitoring of HIV+ patients (through CD4 and CD8 T cell counting) and detection of waterborne parasites towards rapid screening of water quality will also be demonstrated. Further, I will discuss lens-free implementations of various other computational imaging modalities on the same platform such as pixel super-resolution imaging, lens free on-chip tomography, holographic opto-fluidic microscopy/tomography. Finally, I will demonstrate lens free on-chip imaging of fluorescently labeled cells over an ultra wide field of view of >8 cm2, which could be especially important for rare cell analysis (e.g., detection of circulating tumor cells), as well as for high-throughput screening of DNA/protein micro-arrays.
SLAS2013.org
I
131
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Micro/Nano Technologies 2:30 pm, Wednesday, January 16 Room: Sun Ballroom D Martin Gleeson, Genalyte
Silicon Photonic Bio-Sensing Detection Platform Genalyte has developed a revolutionary multiplex detection technology with the potential to transform the measurement of proteins and bio-molecules in the fields of research and clinical diagnostics. With the launch of its detection instrument, “Maverick”, an expansive family of lab-on-chip products will be introduced. The first of these products will be for commercial use in the autoimmune field. The system uses Silicon Photonics, a breakthrough in the semiconductor industry. Optical circuits that are phenomenally responsive to surface binding are etched using standard silicon manufacturing processes, to create a low cost, highly manufacturable sensor chip. The sensors are only 30um in diameter and so many hundreds to thousands of these optical features can be placed on a single chip. The methodology has a broad application potential and has been demonstrated to detect virus particles, proteins and nucleic acids. It provides a multiplex quantitative output that has already been validated at 128-plex, and has been demonstrated in complex serum and cell lysate. A sample, typically < 25uL in volume, is drawn via a sipper pump system into to a plastic cassette containing the sensor chip and appropriate microfluidics. The sensors are functionalized with a specific probe, typically an antibody, antigen or DNA strand depending on the target analyte. The Maverick instrument reads binding to the sensors in real-time. No labels or extensive incubation are required. Results are available in 2-15 minutes depending on analyte concentration. The accompanying Genalyte software uses binding kinetics to measure concentration, with a dynamic range up to 8 logs. All probes in the multiplexed assay are analyzed simultaneously and in real-time. Leveraging the scalable manufacturing capability of the silicon chip industry, the chips are very cost effective, which allows for a single use format ensuring a high quality control (QC). Details of mechanism of operation, examples of detection of various target analytes, sensitivity and dynamic range, along with a description of the first application of this product will be provided in the presentation.
3 pm, Wednesday, January 16 Room: Sun Ballroom D Rosaria Benedetti, SUN, University of Naples
Interactions Between Biomolecules Driven by Femtosecond UV Laser Pulses Femtosecond laser pulses have been widely used so far for micro- and even nano-machining of bio-materials and imaging of tissues for diagnostics purposes. We focus here on a different type of application of femtosecond laser pulses to bio-materials, exploiting the possibility of these pulses to efficiently trigger bio-molecule dynamics and, in a near-future prospect, to monitor the system response with high temporal resolution. Establishing a nucleic acid-protein or protein-protein stable covalent bond (crosslinking) affords access to study otherwise transient interactions between bio-molecules, what is a crucial task for all bio-sciences. Crosslinking with fs- UV lasers has been presented in the literature as a revolutionary technique to increase the otherwise low process yield of conventional methods. It is known that crosslinking induced in cells by ultrashort laser pulses has a twofold advantage over conventional methods: (i) it binds only species that are in proximity (*zero length* covalent bond) of the absorbed photons rather than favoring unspecifc bonds amongst many possible species in the cell and (ii) it should only operate until the radiation is incident on the sample, thus paving the way for time-resolved studies of transient interactions. Moreover, when combined with biochemical techniques to analyze the produced bonds, it will make feasible the dynamics characterization of transcription factors bindings on chromatin in living cells, opening the route for a real breakthrough in unveiling the essential transient steps of cell functioning. One of the basic questions about the interaction of the UV laser light with living cells is the role played by the laser intensity. In fact, while the advantages generally offered by pulsed lasers over conventional radiation sources to photoinduce crosslink are widely recognized, it is still unclear if the photon absorption by DNA bases is a single or rather two photon process. Past experiments reported linear [1] as well as nonlinear dependence of cross-link yield on the laser intensity [2], suggesting that the discrepancies may result from the possible role played by the particular system under study. We report on the femtosecond laser irradiation of human cells demonstrating the occurrence of DNA-protein crosslinking in their most native state [3]. Our results match well with the twophoton absorption, thus corroborating the mechanism based on the radical formation proposed in [4]. [1] T. Shapkina, et al, Nucleic Acid Res. vol.32, 1518 (2004).[2] C. Russmann, et al, Nucleic Acids Res. vol.25, 2478 (1997).[3] Altucci, et al, (2012), Nonlinear protein - nucleic acid crosslinking induced by femtosecond UV laser pulses in living cells. Laser Phys. Lett., 9: 234-239. doi: 10.1002/lapl.201110122[4] D. N. Nikogosyan, Int. J. Radiat. Biol. vol.57, 233 (1990). Stephen Johnson, Bristol-Myers Squibb Company; Matthew Crane, Adriana San Miguel, Jeffrey Stirman, Mei Zhan, Georgia Institute of Technology; Patrick Beattie, Paul Shaw, Diagnostics For All; Inanc Ortac, Micahel Benchimol, Stuart Ibsen, University of California, San Diego.
132
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
SLAS2013 Exhibition
Location: Florida Exhibition Hall Exhibition Schedule Sunday, January 13
4:30 - 7 pm
Monday, January 14 10 am - 6:30 pm Tuesday, January 15 10 am - 6 pm
See, hear, touch, feel and engage with the most innovative laboratory technologies and services from around the world when you explore the floor of the hands-on SLAS2013 Exhibition. Offering more than 300 multinational companies and dozens of engaging exhibitor tutorials and workshops, SLAS2013 provides the ultimate hands-on experience. Join with colleagues and network with leaders in the field, all while participating in this sales cycle kick-off event bursting with innovation, creativity and excitement.
SLAS2013.org
I
133
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Exhibitor Workshop and Tutorials Attendees may choose to attend workshops and/or tutorials hosted by SLAS2013 exhibitors. These workshops and tutorials allow conference participants the opportunity to learn about and explore solutions for the unique issues and challenges they need for another year of achievement in laboratory science and technology. These workshops and tutorials are open to all registered SLAS2013 participants. Sunday, January 13 – Exhibitor Workshop 1:30 - 4:30 pm (3 hours) PerkinElmer Room: Sun 3-4 Page 136
Monday, January 14 – Exhibitor Tutorials 12:30 - 1:15 pm (45 minutes)
12:30 - 1:45 pm (75 minutes)
2 - 2:45 pm (45 minutes)
CyBio AG Co-Sponsor: Texas A&M University Room: Sanibel 1-3 Page 136
Agilent Technologies, Inc. Room: Osceola 1-2 Page 137
ARTEL Room: Naples 2-3 Page 139
GE Healthcare Room: Tampa 2-3 Page 136
Brooks Automation Room: Sun 3-4 Page 137
ATCC Room: Osceola 3-4 Page 139
Promega Corporation Room: Osceola 3-4 Page 136
Cellular Dynamics International, Inc. Room: Destin 1-2 Page 137
Beckman Coulter Life Sciences Room: Sarasota 1-3 Page 139
Festo Corporation Room: Sarasota 1-3 Page 137
BioTek Instruments, Inc. Room: Sun 3-4 Page 139
Fluxion Biosciences Room: Sun 1-2 Page 137
ForteBio - A Division of Pall Life Sciences Room: Osceola 5-6 Page 139
Labcyte Inc. Room: Naples 2-3 Page 138
Freeslate, Inc. Room: Destin 1-2 Page 140
Lucigen Corporation Room: Osceola 5-6 Page 138
GE Healthcare Room: Tampa 2-3 Page 140
TAP Biosystems Room: Sun 5-6 Page 138
Genalyte Room: Gainesville 1-2 Page 140
Thermo Fisher Scientific Co-Sponsors: BioTek Instruments, Inc. and Spex SamplePrep LLC Room: Gainesville 1-2 Page 138
Hamamatsu Corporation Room: Sanibel 1-3 Page 140
IntelliCyt Corporation Room: Sun 5-6 Page 140 Molecular Devices, LLC Room: Osceola 1-2 Page 141 Tecan Room: Sun 1-2 Page 141
134
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Tuesday, January 15 – Exhibitor Tutorials 8 - 8:45 am (45 minutes)
12:30 - 1:15 pm (45 minutes) 12:30 - 1:45 pm (75 minutes)
2 - 2:45 pm (45 minutes)
Blackfield AG Room: Osceola 1-2 Page 141
BMG Labtech Room: Sun 1-2 Page 143
Agilent Technologies, Inc. Room: Osceola 1-2 Page 144
Agilent Technologies, Inc. Room: Gainesville 1-2 Page 145
ChanTest Corporation Room: Sun 5-6 Page 141
Gilson, Inc. Co-Sponsor: Lucigen Corporation Room: Tampa 2-3 Page 143
Beckman Coulter Life Sciences Room: Osceola 3-4 Page 144
Cellectis bioresearch, Inc. Room: Naples 2-3 Page 145
DiscoveRx Corporation Room: Naples 2-3 Page 141
Hamilton Company Room: Sun 5-6 Page 143
Brooks Automation Room: Sun 3-4 Page 144
CyBio AG Room: Osceola 3-4 Page 146
Labcyte Inc. Room: Osceola 5-6 Page 142
MaxCyte, Inc. Room: Gainesville 1-2 Page 143
Cellular Dynamics International, Inc. Room: Destin 1-2 Page 144
DiscoveRx Corporation Room: Sanibel 1-3 Page 146
PerkinElmer Room: Tampa 2-3 Page 142
Thermo Fisher Scientific Room: Sanibel 1-3 Page 143
Cisbio Bioassays Room: Sarasota 1-3 Page 144
Douglas Scientific Room: Sun 1-2 Page 146
Promega Corporation Room: Sarasota 1-3 Page 142
Labcyte Inc. Room: Naples 2-3 Page 145
Eppendorf Room: Osceola 5-6 Page 146
Reaction Biology Corporation Co-Sponsor: BellBrook Labs Room: Destin 1-2 Page 142
Tecan Room: Osceola 5-6 Page 145
Genedata AG Room: Destin 1-2 Page 146
TTP Labtech Room: Osceola 3-4 Page 142
Horizon Discovery Ltd Room: Sarasota 1-3 Page 147 Molecular Devices, LLC Room: Osceola 1-2 Page 147 PerkinElmer Room: Tampa 2-3 Page 147 Promega Corporation Room: Sun 3-4 Page 147
SLAS2013.org
I
135
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Pre-Conference Workshop:
This three-hour workshop is scheduled for Sunday, January 13, 1:30 - 4:30 pm.
Performing Translational Research and Development Using Phenotypic Assay Solutions Sponsored by: PerkinElmer Room: Sun 3-4 Phenotypic assays aim to measure functional and morphological changes in cells, tissues and whole organisms. Growing evidence indicates that using phenotypic assays favors the discovery of first-in-class therapeutic molecules compared to target-based approaches. In fact, results generated from phenotypic assays show enhanced translational therapeutic impact for given disease states. Join colleagues in a lively discussion on how phenotypic in vivo and in vitro assays can enhance biological relevance and translational impact.
Exhibitor Tutorials (45 minutes):
These 45-minute sessions are scheduled for Monday, January 14, 12:30 - 1:15 pm, and 2 - 2:40 pm and Tuesday, January 15, 8 - 8:40 am, 12:30 - 1:15 pm, and 2 - 2:45 pm. Many exhibitors provide refreshments during their sessions.
Exhibitor Tutorials (75 minutes):
These 75-minute sessions are scheduled for Monday and Tuesday, January 14 and 15, 12:30 - 1:45 pm. Many exhibitors provide refreshments during their sessions.
Monday, January 14, 12:30 - 1:15 pm (45 minutes) Application of CyBio Systems in Novel Drug Development Sponsored by: CyBio AG Co-Sponsored by Texas A&M University Room: Sanibel 1-3 Many pharmaceutical companies intensify their efforts in assay development and screening to enhance their drug discovery pipeline. This requires the use of additional instrumentation. Texas A&M, one of the US top 10 universities, and Novartis, a world leader in drug development, provides an insight into their current research and development activities and present their experiences in implementation and usage of CyBio automation systems from the point of view of their specific requirements.
Advances in Instrument Development for Faster and Efficient High Content Analysis Sponsored by: GE Healthcare Room: Tampa 2-3 Rapid acquisition without compromising on image quality is essential for successful high content screening, particularly in high well-density formats. GE Healthcare is continuing to push the boundaries of HCS by incorporating the latest advances in hardware and software technologies for optical imaging. New components and features of the IN Cell Analyzer systems that are enabling more rapid, robust and efficient hit identification and assessment are discussed.
Cell-Based Assays to Detect the Mechanism of Toxicity Sponsored by: Promega Corporation Room: Osceola 3-4 This tutorial addresses current assay technologies aimed at assessing mechanisms of toxicity. Investigating cytotoxicity in vitro is determined by measuring viable cells or dead cells remaining in culture following test compound incubation. Most assay technologies go beyond providing simple “live or dead” information to indicate whether cells have died by apoptosis or necrosis. More advanced assay methods point to which organelles (e.g., mitochondria) and cellular pathways are involved in cell death.
136
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Monday, January 14, 12:30 - 1:45 pm (75 minutes) Automating Complete Workflows using the Agilent Encore Multispan Liquid Handling System Sponsored by: Agilent Technologies, Inc. Room: Osceola 1-2 The new Encore MultiSpan Liquid Handling System from Agilent Automation Solutions delivers a significant leap forward in workflow automation by creating a new platform that unites advanced liquid handling and native integration capabilities into a single instrument. In conjunction with the new Encore Control Software, automating complete scientific workflows in screening, genomics, LC/MS etc. can be achieved in less time and with fewer resources.
Celigo® Imaging Cytometer: Applications in Cell Line Development and Tumor Spheroid Analysis Sponsored by: Brooks Automation Room: Sun 3-4 The Celigo Imaging Cytometer is a brightfield and fluorescent imager well-suited for image-based screening applications. This tutorial highlights its flexibility and ease-of-use: • Latest release of Celigo technology • Cell line development using Celigo in an automated process • Tumor spheroid analysis with Celigo as part of the development of a drug screen Speakers: Olivier Dery, Brooks Life Science Systems (USA) and David Shaw, Genentech (USA)
Application of iPS Cell-Derived Cells and a Novel Electrophysiology Platform for Neuronal and Cardiac Toxicity Evaluation and Drug Screening Sponsored by: Cellular Dynamics International, Inc. Room: Destin 1-2 Neuronal and cardiac function is critically dependent on a complex network of electrophysiology pathways and endpoints. The multi-well multielectrode array (mwMEA) platform enables analysis of neural and cardiac networks on an unprecedented scale. Here we demonstrate that the use of mwMEA with human iPS cell-derived neurons and cardiomyocytes provides a viable option for high throughput, physiologically relevant screening of compounds for unintended alterations in neuronal and cardiac function.
New Festo Technologies to Improve Your Liquid Handling Process Sponsored by: Festo Corporation Room: Sarasota 1-3 Festo presents breakthrough technologies: Liquid handling with micro dispensing, accurate control and pulsation free mixing all in a unique flexible package. Piezo technology in a modular concept form with applications in the Respiratory and gas control fields encompassing mobile devices, stationary equipment and hospital hardware. Laboratory automation where we showcase methods of movement allowing lower cost, simplicity and space saving without sacrificing speed or accuracy. Three diverse disciplines, one Festo.
The IonFlux Automated Patch Clamp System Sponsored by: Fluxion Biosciences Room: Sun 1-2 The IonFlux product line is a microfluidics based Automated Patch Clamp system that is capable of continuous flow, Giga-seal recordings, temperature control and fast solution exchange. Its unique plate structure gives it the ability to conduct high-throughput electrophysiology recordings with no need for liquid handling. This session introduces the intricate aspect of the system and focus on present and future developments in assay optimizations, software analysis and expandability.
SLAS2013.org
I
137
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Monday, January 14, 12:30 - 1:45 pm (75 minutes) continued Miniaturized and Automated Cisbio HTRF Assays With the Echo® Liquid Handler and BMG PHERAstar FS Sponsored by: Labcyte Inc. Room: Naples 2-3 Cisbio’s HTRF assays have many benefits: ease of use, time and cost savings, and amenability to high-throughput screening and miniaturization. Currently, most assays are performed in 384-well and 1536-well formats, at assay volumes of around 20 uL and 10 uL, respectively. Labcyte’s 500-series Echo® liquid handlers use acoustic energy to transfer reagents in a non-contact manner. The low volume increment of the Echo 555 (at 2.5 nL) enabled an investigation of further miniaturization of 1536-well HTRF assays to 2 uL. This drives down per-well costs and enables larger screens to be performed in a cost-effective manner. Plates are read using the BMG PHERAstar FS reader.
New Tools for High-Throughput Drug Discovery and Production: Endotoxin-Free Competent Cell Lines and Novel Methods for GPCR Structural Biology Sponsored by: Lucigen Corporation Room: Osceola 5-6 Lucigen presents new lines of competent cells capable of endotoxin-free protein production, plasmid DNA production, or phage display. These cell lines significantly decrease the cost and time associated with producing therapeutic proteins or DNA where immune-response avoidance is critical. In addition, Lucigen describes a novel fluorescent protein useful in stabilizing GPCR proteins for crystallization studies and rapid protein expression cloning technologies.
RAFT - A Novel, Rapid and Reproducible Method for Creating 3D Cell Cultures to Study Complex Cell Behavior Sponsored by: TAP Biosystems Room: Sun 5-6 • Creates complex 3D cell cultures in a simple, consistent and reproducible format. • Uses physiologically relevant collagen concentrations to create the most natural environment for cells. • Enables scientists to take complete control of their experiments by using their own cell type(s) and
selecting cell seeding density. Come hear about TAP’s new cell culture system. Lunch is provided.
Broadening the Adoption of Lab Automation for the Bench Sponsored by: Thermo Fisher Scientific Co-Sponsored by: BioTek Instruments, Inc., Spex SamplePrep LLC Room: Gainesville 1-2 A series of talks by leading instrumentation providers utilizing Thermo Scientific robotics and Momentum scheduling software in their automated workflow solutions. Focusing on approaches to automating sample preparation through to qPCR and ELISA assays. The speakers provides a perspective on the science and performance of Momentum workstations. Guest Speakers: Keith Tucker, Sales Manager Spex SamplePrep LLC Rupal Cutting, Field Applications Scientist Roche Applied Science Jason E. Greene, Senior Product Marketing Manager BioTek Instruments, Inc.
138
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Monday, January 14, 2 - 2:45 pm (45 minutes) Impact of Liquid Handling Variability on In Vitro Biochemical Assay Performance: A Look at Protein Binding and Enzyme Assay Classes Sponsored by: ARTEL Room: Naples 2-3 This presentation by Nathaniel Hentz, Ph.D., Golden Leaf Biomanufacturing Training and Education Center, N.C. State University examines how liquid handling variability can affect the performance of different classes of in vitro biochemical assays: protein binding and enzyme. Seemingly small changes in liquid addition steps were found to have large effects on inhibitor potency determinations.
Assay-Ready Tumor Cell Panels in Cancer Biology and Drug Discovery Sponsored by: ATCC Room: Osceola 3-4 Human tumor derived cell lines play key roles in understanding cancer biology and developing novel therapeutics. This tutorial introduces how validated, assay-ready tumor cell line panels provide a quick and convenient method suitable for high-throughput screening and mechanism studies. In particular, this tutorial describes the breast cancer cell line panel, which represents the major clinical manifestation of the disease and various gene-expression subtypes, and has several demonstrated applications in cell-based assays.
Quantifying the Public Health Burden of Foodborne Extraintestinal Pathogenic “Escherichia coli” Sponsored by: Beckman Coulter Life Sciences Room: Sarasota 1-3 Escherichia coli causes millions of urinary tract infections (UTIs) in the US each year. Recent investigations of UTI outbreaks have implicated contaminated poultry products as the likely exposure source. Here we report on a citywide epidemiologic investigation to quantify the prevalence of foodborne UTI (FUTIs) using whole genome sequence typing.
Synergy NEO: New Patented Hybrid HTS Plate Reader Combines Increased Sensitivity and Flexibility Sponsored by: BioTek Instruments, Inc. Room: Sun 3-4 Synergy™ NEO is an HTS multi-mode microplate reader designed specifically for today’s screening laboratories. NEO has all the features of an HTS screening instrument, including multiple parallel detectors and a dedicated bottom-reading filter-based system for live cell assays. With a load/unload plate transfer time of six seconds per plate, NEO’s optional integrated plate stacker is the fastest stacker on the market. BioTek Instruments presents multiple screening applications demonstrating the unique performance of NEO.
Rapid Identification of High Affinity Monoclonal Antibodies Using the ForteBio Octet RED384 Instrument Sponsored by: ForteBio - A Division of Pall Life Sciences Room: Osceola 5-6 ForteBio presents the development of an off-rate screening method of crude E. coli lysates containing monovalent Fab fragments obtained after phage display of the HuCAL® antibody library. After antibody selection and ELISA-based primary screening, antibodies with the required specificity are ranked according to their kinetic off-rates. The method was established on the ForteBio Octet RED384 instrument. ForteBio presents data that show good correlation of kinetic parameters determined in lysates and in purified samples.
SLAS2013.org
I
139
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Monday, January 14, 2 - 2:45 pm (45 minutes) continued A New Powder and Viscous Dosing System to Accelerate Pharmaceutical Development Sponsored by: Freeslate, Inc. Room: Destin 1-2 Manually weighing and dispensing sub-milligram to gram quantities of materials accurately and reproducibly often represents a bottleneck in the experimental workflow and ties up valuable resources. Freeslate, Inc. CM Protégé Powder Dispense System is a robust, automated powder system that was designed to enable precise, traceable and accurate weighing and dispensing of sub-milligram to gram quantities of a wide range of materials. An overview of the System and its capabilities are presented.
To Affinity and Beyond: Tools to Optimize Assay Design and Evaluation in Fragment Based Lead Discovery and Characterization With SPR-based Biosensors Sponsored by: GE Healthcare Room: Tampa 2-3 In this workshop, the basic strategy of SPR uses in FBLD, key applications in the identification of site specific binders and best practices/troubleshooting are discussed.
Silicon Photonic Bio-Sensing of Autoimmune Antibodies Sponsored by: Genalyte Room: Gainesville, 1-2 Genalyte has developed Maverick a revolutionary multiplex detection technology. The system has been used to detect virus particles, proteins and nucleic acids. All probes in the assay are analyzed simultaneously with quantitative output and results are available in 2-15 minutes. Details of mechanism of operation, examples of detection of various target analytes, sensitivity, dynamic range, along with a description of the first application of this product targeting autoimmune disease are presented.
Pushing the Limit: Very Fast Data Acquisition for CCD Based Cellular Assays Sponsored by: Hamamatsu Corporation Room: Sanibel 1-3 Hamamatsu has developed high speed imaging mode (100Hz) on our drug discovery system, the FDSS, providing very fast kinetic fluorescence and luminescence whole plate detection. Hamamatsu present its applications and data on calcium influx, member potential and cardiomyocytes assays.
Increasing the Power and Scope of Phenotypic Screening With IntelliCyt’s Multiplexed, High-Throughput Screening System and Reagent Solutions Sponsored by: IntelliCyt Corporation Room: Sun 5-6 The IntelliCyt Screening System and assay solutions are a powerful new tool for phenotypic screening using suspension assays. This platform enables robust screens to evaluate compound effects on non-adherent cell lines, primary immune system cells and molecular interactions using bead-based assays. The IntelliCyt System completes the phenotypic screening toolbox utilizing an ultra-fast, high performance and easy to use platform for cell and bead-based assays.
140
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Monday, January 14, 2 - 2:45 pm (45 minutes) continued Advanced Assays for In Vitro Toxicity Evaluation and Phenotypic Screening Sponsored by: Molecular Devices, LLC Room: Osceola 1-2 Stem-cell derived models are increasingly important for modeling diseases and predictive toxicity. High-content, high-throughput tools for cellular screening, imaging and electrophysiology offer complementary automated techniques for evaluating complex biology. Molecular Devices presents examples of novel multi-parametric assays for in vitro hepatotoxicity assessment, effects of compounds on the contraction profiles of cardiomyocytes, action potential kinetics and neuronal development. They also highlight innovative software with tools for designing customized and distributable image analysis algorithms.
Automation of Cell Biology Including 3D Cell Culture, Advanced Cell Assays and Reperfusion Studies Sponsored by: Tecan Room: Sun 1-2 Learn from Tecan, a world leader in liquid handling automation and detection, how to automate in-vitro cell-based assays for proliferation, cell toxicity, hypoxia/reperfusion, and long-term metabolic studies in a microplate format. Benefit from automated 3D cell cultures with Tecan’s Freedom EVO® liquid handling platform and Infinite® 200 PRO multimode reader in conjunction with the patent pending Gas Control Module (GCM) to simultaneously control CO2 and O2 levels.
Tuesday, January 15, 8 - 8:45 am (45 minutes) Application of High-End Functional Genomics to Uncover Novel Potential Cancer Targets Sponsored by: Blackfield AG Room: Osceola 1-2 Non-targetable oncogenes and treatment resistant tumors constitute for severe hurdles in targeted therapy. The combination of large-scale screens using genetically defined cell lines with state-of-the-art bioinformatics is an unrivaled possibility to solve these problems and to search for new vulnerabilities in various tumor entities. For non-small cell lung cancer, such a large-scale cell line screen revealed potential new vulnerabilities in subsets of genetically defined cell lines, demonstrating the strength of the platform.
ChanTest Partner in Ion Channel Drug Discovery Sponsored by: ChanTest Corporation Room: Sun 5-6 ChanTest is uniquely suited to partner with drug discovery companies. ChanTest has a large catalog of ion channels in recombinant cell lines and validated assays suitable for screening and profiling. The presentation focuses on strategic partnerships to identify novel compounds and dial out undesired ion channel interactions.
BioMAP® Systems: A Phenotypic Assay Platform for Reducing Preclinical Attrition Sponsored by: DiscoveRx Corporation Room: Naples 2-3 The BioMAP® systems platform, utilizing primary human cell-based tissue and disease models, provides a preview of in vivo drug effects. Case studies will be presented that demonstrate the utility of the platform for selection of preclinical lead compounds; identification of secondary or off-target activities; and for mechanistic understanding of preclinical (and clinical) side effects, thereby helping to reduce attrition at later more expensive stages of drug development.
SLAS2013.org
I
141
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Tuesday, January 15, 8 - 8:45 am (45 minutes) continued A Fully Automated Solution for Miniaturized RT-qPCR Enabled by the Access™ Workstation, the Echo® Liquid Handler, and LightCycler ® 1536 Sponsored by: Labcyte Inc. Room: Osceola 5-6 Widespread use of quantitative reverse transcriptase PCR (RT-qPCR) has been limited by an often laborious multi-step process. Combining one-step RT-qPCR with a streamlined workflow for generation of template from cellular material has enabled the use of higher density 384- and 1536-well microplates. Cells can be cultured, lysed, and transferred from acoustically qualified, tissue culture treated microplates, into a 384- or 1536-well PCR plate This tutorial discusses the integration of the Echo Liquid Handler from Labcyte, an acoustic, non-contact liquid transfer device, with Roche RealTime ready reagents and the LightCycler® 480 and LightCycler® 1536. Throughput is increased and volumes reduced to 500 nL/well.
Advancing Epigenetics: Novel Drug Discovery Strategies for Epigenetic Targets Sponsored by: PerkinElmer Room: Tampa 2-3 Given the increasing interest and investment in drug discovery for epigenetic targets, there is a clear need for robust methodologies to identify candidate therapeutic compounds. This tutorial will explore novel cell-based and biochemical techniques for drug discovery against histone-modifying enzymes.
Introducing GloMax® Discover: A New Integrated Detection Solution for Cell and Gene Reporter Assays Sponsored by: Promega Corporation Room: Sarasota 1-3 Learn about Promega’s new Cell and Gene Reporter Assay tool, the GloMax® Discover multi-mode detection instrument. GloMax® Discover was developed and optimized with Promega’s cutting edge reagent assays to provide scientists an integrated solution for both automated and manual workflows.
Streamlining Methyltransferase Screening and Profiling With Transzyme Assay Kits Sponsored by: Reaction Biology Corporation Co-Sponsored by: BellBrook Labs Room: Destin 1-2 This tutorial describes how BellBrook’s Transcreener EPIGEN Methyltransferase Assay and Reaction Biology’s purified HMT enzymes are being combined into fully optimized, turn-key assay kits to streamline methyltransferase screening and profiling. Reaction Biology provides examples illustrating the importance of high purity, functional enzymes and substrates and BellBrook describes the development and use of the Transzyme Methlytransferase Assay kits for emerging HMT targets such as DOT1L and NSD2.
The New Acumen® — Advanced High-Throughput Imaging to Significantly Increase Your Screening Capability Sponsored by: TTP Labtech Room: Osceola 3-4 Acumen brings new assets to the high content screening lab. Imaging and analyzing 384- or 1536-well plates in eight minutes removes the bottleneck in primary screening. With the additional 561nm laser more assays can be transferred to the screening environment, increasing productivity. The software creates open source OME-TIFF images that are simple to import to any third party image analysis software. Thus it takes advantage of existing imaging expertise without slowing down the screening.
142
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Tuesday, January 15, 12:30 - 1:15 pm (45 minutes) Enhanced Assay Development and High-Throughput Screening With New and Unique Microplate Based Technology Sponsored by: BMG Labtech Room: Sun 1-2 Just looking at specifications, most people may think that all microplate readers are the same. However, the technology found inside can separate a microplate reader from the rest. Having pioneered many technological advances during the last 20 years, BMG Labtech’s German engineers have outdone themselves with their latest advancement. Don’t waste time improving assay chemistry to work on other readers when a reader exists that can improve the assay for you.
NxSeq® Technology on the PIPETMAX® Automated Liquid Handling Platform — Making Automated Next-Generation Sequencing Prep Accessible to Any Laboratory Sponsored by: Gilson, Inc. Co-Sponsored by: Lucigen Corporation Room: Tampa 2-3 Next-generation sequencing (NGS) techniques are expanding current sequencing capabilities, but new techniques bring new challenges to modern laboratories. NGS protocols can be inefficient, complex and time consuming, leading to increased training requirements, manual preparation time, procedural errors and operational costs. The Gilson PIPETMAX 268 and Lucigen NxSeq technology combine to provide a pre-developed and validated, automated NGS prep solution that will mitigate these problems at a price and size accessible to any laboratory.
Current Trends in Cell Biology Automation Sponsored by: Hamilton Company Room: Sun 5-6 Cell Culture and maintenance along with downstream Cell Based Assays, Proteomic, and Genomic Studies can be very tedious and error prone. Hamilton through the years, has been solving these problems by providing world class automated solutions. Join us for an informative workshop to learn more about Hamilton’s automated cell biology applications.
Streamlined Receptor Screening: Ion Channels, GPCRs and Transporter Screening in Biologically Relevant Cells Using Large-Scale Transient Transfection Sponsored by: MaxCyte, Inc. Room: Gainesville 1-2 Large-scale transient transfection enables quality, highly reproducible cellular assays. MaxCyte flow electroporation has been shown to be an extremely effective and rapid means of expressing a variety of receptors in biologically relevant cells. This tutorial presents real world data for cell-based assays including complex transporter assays, sodium-gated ion channels and GPCRs. Additionally MaxCyte highlights the ability to transfect biologically relevant cells including primary cells and stem cells.
ALISSA Detection of Botulinum Neurotoxin on a Thermo Scientific Versette Automated Liquid Handler Sponsored by: Thermo Fisher Scientific Room: Sanibel 1-3 We have implemented an “Assay with a Large Immunosorbent Surface Area” (ALISSA) technology for the ultrasensitive detection of botulinum neurotoxin into a robotic micro column-based format using a Versette automated liquid handler. The multistep ALISSA procedure requires immunocapture of the toxin from a complex biological sample, multiple wash and activation steps, followed by enzymatic conversion of a fluorogenic reporter substrate by immobilized toxin molecules. Thermo Fisher Scientific discusses both assay development and instrument performance in detail.
SLAS2013.org
I
143
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Tuesday, January 15, 12:30 - 1:45 pm (75 minutes) AssayMAP Bravo — An Automated, Open Platform for Protein Sample Preparation Sponsored by: Agilent Technologies, Inc. Room: Osceola 1-2 The AssayMAP Bravo system is a 96-channel liquid handler equipped with ultra-low dead volume syringes connecting to disposable chromatography cartridges through a special syringe-probe. The liquid handler provides precise positivedisplacement flow control through the cartridges in either direction. This platform offers a new method for quantitative, highthroughput sample preparation, integrating a wide variety of common techniques on a single platform. Applications presented include Affinity chromatography, peptide mapping and complete sample preparation for N-glycan analysis.
Advanced Process and Data Management Software Sponsored by: Beckman Coulter Life Sciences Room: Osceola 3-4 SAMI Process Management and DART are new products from Beckman Coulter used to schedule and coordinate lengthy processes and manage data for a variety of automation systems. This workshop describes these products deployed on systems for monoclonal antibody production, cell culture and screening.
Automated Sample Management — Maintaining and Tracking Sample Integrity From Tubes to Plates Sponsored by: Brooks Automation Room: Sun 3-4 This tutorial focuses on how Brooks products are used to monitor and maintain sample integrity and includes a short presentation by Pierre Baillargeon (Scripps Institute, Florida). • Storage system developments to maintain sample integrity at -20°C and -80°C • Plate Auditor: monitoring sample quality and providing valuable information to aid decision making in Compound Management and HTS • Tube Auditor: detection of volume and precipitate; applications in new processes, such as biobanking
Advancements in the Use of iPS Cell-derived Cells for In Vitro Disease Modeling and Phenotypic Screening Sponsored by: Cellular Dynamics International, Inc. Room: Destin 1-2 Cell-based phenotypic screening approaches enable identification of disease modifying molecule(s) and the discovery of new therapeutic targets in a relatively rapid manor. Cellular Dynamics presents examples of the development and practical use of human iPS cell-based cell models, including cardiomyocytes and neurons, for disease modeling, drug screening and target validation.
From Protein-Protein Interaction to Cell Signaling and Epigenetics: New HTRF® Assays to Address Cell Biology Sponsored by: Cisbio Bioassays Room: Sarasota 1-3 What if conventional assays could be streamlined to investigate a broad number of targets with the same mix and read technology platform? Learn more about the way HTRF can be tailored to study protein-protein interactions, established for cell-based functional readouts such as cellular kinases, and optimized to address epigenetic targets. This tutorial reviews the latest advances in terms of HTRF assays, and showcase how researchers apply those to their screening projects.
144
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Tuesday, January 15, 12:30 - 1:45 pm (75 minutes) continued The Echo® 525 Liquid Handler: A New Platform for Accelerated Assay Assembly Sponsored by: Labcyte Inc. Room: Naples 2-3 The Echo 525 liquid handler is the newest acoustic liquid handler from Labcyte, enabling acoustic transfer for scientists who run assays from 100 nL to 10 uL. The Echo 525 transfers biochemical and genomics reagents in 25 nanoliter increments in a noncontact manner—without tips, tubing, or nozzles. Dynamic Fluid Analysis, a unique processing feature developed by Labcyte, ensures that scientists do not have to stop and calibrate their instrument before changing reagents or transfer volumes. This increases the flexibility to perform assay development and enables complete assembly of efficient microliter-scale assays. We will demonstrate a few ways in which the Echo 525 liquid handler can simplify processes in biochemical and genomic assay setup. Speaker: Joseph Barco
Making the Automation Operator’s Life Easy: A Hands-On Session for Interface Customization Sponsored by: Tecan Room: Osceola 5-6 Join Tecan for a hands-on session with the latest Freedom EVOware® software that enables custom tailoring of the operator experience. Following the correct procedure to setup the instrument is the first step toward reproducible and reliable results, run after run. Learn how to guide operators during assay setup steps and interact with them at run-time. See how to improve productivity with a live demonstration and explanation of a single workflow that implements these.
Tuesday, January 15, 2 - 2:45 pm (45 minutes) High-Throughput Solutions for Rapid and Robust ADME Assays Sponsored by: Agilent Technologies, Inc. Room: Gainsville 1-2 The need for Pharmaceutical companies to minimize late stage attrition has resulted in greater emphasis on selecting candidates with the best ADME properties early in discovery. In this tutorial you will learn about Agilent’s customizable liquid handling and automation solutions as well as the Rapidfire/mass spectrometry high-throughput platform. These innovative solutions will revolutionize your laboratory workflows from sample preparation to data acquisition so that analysts can maximize time spent analyzing assay data.
TALEN™: Next Generation Gene Customization Tools and Services for Precise Gene Editing and Cell Line Engineering Sponsored by: Cellectis bioresearch, Inc. Room: Naples 2-3 Cellectis bioresearch provides TALEN™ Solutions™ and expert Cell Line Customization Services to add genetic diversity, reporters, tags, gain and loss of function mutations to your immortalized and iPS cell lines. Cellectis bioresearch delivers stable and isogenic lines for HTS and secondary assays with the fastest turnaround time on the market. Thirteen years of expertise, next generation TALEN™ and cGPS® TI technologies, exclusive IP on homologous recombination, only from Cellectis bioresearch. Who else?™
SLAS2013.org
I
145
SLAS2013
I
Repeatable Inspiration
I
Through Scientific Education and Laboratory Technology
Tuesday, January 15, 2 - 2:45 pm (45 minutes) continued No Limits: Liquid Handling Using the CyBi-FeliX Sponsored by: CyBio AG Room: Osceola 3-4 CyBi®-FeliX allowing for automated processes from 1-384 channels without the need for manual exchanges. Due to its clever use of its 12 position deck it can fit in even the tightest of spaces, with an enviable 650 x 450 mm footprint. With CyBi®-FeliX, tracking samples or concentration calculations are a thing of the past using a workflow-centric approach. Join CyBio AG for this workshop during which they explore the capabilities of this innovative platform.
Targeting the Epigenome: Unexpected Compound Promiscuity and Target Class Cross-Reactivity Revealed Using the Industry’s Largest Bromodomain Profiling and Cell-Based Assay Platforms Sponsored by: DiscoveRx Corporation Room: Sanibel 1-3 Bromodomain containing proteins are a newly established class of druggable targets implicated as major hubs in oncology and inflammation. DiscoveRx describes inhibitor specificity across the industry’s largest panel of bromodomain assays as well as cellular potency utilizing a novel intracellular binding assay. By extending this characterization to alternate compound classes, we found that mature inhibitors for other intracellular targets have the potential for unforeseen, high affinity inhibition of these important epigenetic proteins.
Sponsored by: Douglas Scientific, LLC Room: Sun 1-2 See SLAS2013 Addendum for title and description.
Automated Chromatin Immunoprecipitation (ChIP) Assays Using the Eppendorf epMotion Sponsored by: Eppendorf Room: Osceola 5-6 Research in the Morris lab focuses on non-coding RNA-mediated epigenetic regulation of gene expression. Chromatin immunoprecipitation assays therefore represent a vital tool with which to study the epigenetic state of the genome. The Eppendorf epMotion has revolutionized the ChIP assay into an efficient and cost effective automated assay, generating comparable data to manual assays. The use of the epMotion for automated immunoprecipitation applications thus provides a platform for high throughput, highly reproducible epigenetic analysis.
One Platform for All Plate-Based Screening Genedata Screener ® Sponsored by: Genedata AG Room: Destin 1-2 Genedata demonstrates the benefits of a single-system screening platform that supports multiple technologies such as HighThroughput Screening, High-Content Screening including Cell Population, Ion Channel Screening, and Label-Free and other time-series technologies. See how raw data and results are managed on one platform to drive continual comparability, efficient data analysis and improved results. The “single-system” advantage also helps to reduce your training, infrastructure and maintenance costs.
146
I
SLAS2013.org
Short Courses: January 12-13
I
Conference: January 14-16
I
Exhibition: January 13-15
Tuesday, January 15, 2 - 2:45 pm (45 minutes) continued Endogenous Protein and Promoter Studies Now Possible Through X-MAN™ Reporter Kits Sponsored by: Horizon Discovery Ltd Room: Sarasota 1-3 Horizon and Promega have partnered to develop best-in-class X-MAN™ Reporter Kits. These kits enable functional cell-based promoter and protein assays to be carried out at the endogenous level, providing researchers greater confidence that their experimental results more accurately reflect real disease biology. We will also discuss the SyntheTx™ target identification platform which combines Horizon’s GENESIS™ gene-editing platform with in vitro phenotypic screens and high-throughput siRNA/ shRNA library screens to uncover novel targets with inherent anti-cancer activity.
Complex Cell Based Assays for Plate Reader and Cytometry Systems Sponsored by: Molecular Devices, LLC Room: Osceola 1-2 An important trend in drug discovery and development is the use of complex cell-based models offering more biologically relevant information and higher predictivity for efficacy and toxicity screening. New plate reader and cytometry systems provide additional tools for multiplexed read-outs and high-throughput analysis of important biological outputs. Molecular Devices presents several examples of advanced cell-based assays including models for testing anti-inflammatory compounds, in vitro toxicity assessment, epigenetics and stem cell differentiation.
Accelerating Cell Line Optimization and Process Development Using Automated Solutions for Protein Purification and Characterization Sponsored by: PerkinElmer Room: Tampa 2-3 LabChip® microfluidics technology enables multiple protein characterizations including purity assessment N-glycans and charge heterogeneicity with analysis time of